

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number  
**WO 00/77026 A1**

(51) International Patent Classification<sup>7</sup>: C07K 2/06,  
C07H 21/06, C12N 15/12, C12P 19/34

MD 20882 (US). KOMATSOULIS, George, A. [US/US];  
9518 Garwood Street, Silver Spring, MD 20901 (US).

(21) International Application Number: PCT/US00/14973

(74) Agents: HOOVER, Kenley, K. et al.; Human Genome  
Sciences, Inc., 9410 Key West Avenue, Rockville, MD  
20850 (US).

(22) International Filing Date: 1 June 2000 (01.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/138,630 11 June 1999 (11.06.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): HUMAN  
GENOME SCIENCES, INC. [US/US]; 9410 Key West  
Avenue, Rockville, MD 20850 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant and

(72) Inventor: ROSEN, Craig, A. [US/US]; 22400 Rolling  
Hill Road, Laytonsville, MD 20882 (US).

Published:

— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): RUBEN, Steven,  
M. [US/US]; 18528 Heritage Hills Drive, Laytonsville,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 00/77026 A1

(54) Title: 49 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

## 49 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly,

proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
5 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent  
10 medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### *Summary of the Invention*

The present invention relates to novel polynucleotides and the encoded  
15 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The  
20 invention further relates to screening methods for identifying binding partners of the polypeptides.

### *Detailed Description*

#### Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as



disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to

sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20  $\mu$ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M  $\text{NaH}_2\text{PO}_4$ ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100  $\mu$ g/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more

detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table I.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a

particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

20

### **Polynucleotides and Polypeptides of the Invention**

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

25

example, the sequence accessible through the following database accession no.

emb|CAB38095.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Castration induced

prostatic apoptosis related protein-1, (CIPAR-1) [Rattus norvegicus]". A partial

5 alignment demonstrating the observed homology is shown immediately below.

10 >emb|CAB38095.1| (AJ010750) Castration induced prostatic apoptosis related protein-1, (CIPAR-1) [Rattus norvegicus] >sp|CAB38095|CAB38095  
Castration induced prostatic apoptosis related protein-1,  
(CIPAR-1).  
Length = 298

Plus Strand HSPs:

15 Score = 501 (176.4 bits), Expect = 3.1e-47, P = 3.1e-47  
Identities = 128/310 (41%), Positives = 144/310 (46%), Frame = +2

20 Q: 257 MVYKTLFALCILTAGWRVQSLPTSAPLSVSLPTNIVPXTXIWTSSPQNTDADTASPSNGT 436  
MV K L LCI AG VQ PT L VSL T WT+S Q+T T ++ T  
S: 1 MVCKALITLCIFAAGLMVQGSPTPTLLPVSLTTRSTAPMATWTTSAQHTAMATTPVASAT 60

25 Q: 437 HNNSVLPVTASAPTSLLPKNXXXXXXXXXXXXXPGSNWEGTNTDXXXXXXXXXXXXVHLTT 616  
HN SVL TA++ TS LP + P E +TD +HL  
S: 61 HNASVLRRTAASLTSQLPHTPREAVTS----PPLKREVNSTDSPTGFSSNSSGIHLAP 116

30 Q: 617 TLEHHSXGTPEAGVAATLSQSAEPTLIXXXXXXXXXXXXXXXXXXEVFXXXXXXXXXXXX 796  
T EEHS G+PE V AT SQS PTL+ E  
S: 117 TPEEHSLGSPETSVPATGSQS----PTLLFSQGPTSASTSPATSPSEPLSASVTSNHSST 172

35 Q: 797 XXXXQXXXXXXXXXXXXXXXXXXXXXATAEPVPQERTPPTTVSGKVMCELIDNETTT 976  
Q T EPVP+EK+P T GKV+CE ETTT  
S: 173 VNNIQPTGAPMAPASPTEEHSSTPTSHVT-EPVPKEKSPQDTEPGKVICE---SETTT 228

40 Q: 977 TFPRVIMQEVEHALSSGSXXXXXXXXXXXXXFGVAAYLKIRHSSYGRLLDDHDYGS-- 1150  
F +IMQEVE+ALSSGS FG AAYLKIRHSSYGRLLDDHDYGS  
S: 229 PF--LIMQEVENALSSGSIAAITVTVIAVLLVFGAAAYLKIRHSSYGRLLDDHDYGS 286

Q: 1151 WGNYNPLYDDS 1186  
WGNYNPLYDDS  
S: 287 WGNYNPLYDDS 298

The segment of emb|CAB38095.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 109. Based on the structural similarity, these

homologous polypeptides are expected to share at least some biological activities.

45 Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 110 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_total\_fetus\_Nb2HF8\_9w and to a lesser extent in Primary Dendritic Cells, lib 1; normalized infant brain cDNA; Colon Normal II;  
10 Dendritic cells, pooled; Primary Dendritic cells,frac 2; NCI\_CGAP\_Co3;  
NCI\_CGAP\_Kid3; Palate normal; Hodgkin's Lymphoma I; NCI\_CGAP\_CLL1;  
NCI\_CGAP\_Gas4; NCI\_CGAP\_Pan1; NCI\_CGAP\_Kid11; CD40 activated monocyte dendritic cells; Human Pineal Gland; Human Whole Brain, re-excision; Healing groin wound, 6.5 hours post incision; KMH2;  
15 Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Pancreas Tumor;  
NCI\_CGAP\_CLL1; NCI\_CGAP\_Kid3; Soares\_NhHMPu\_S1; Soares\_testis\_NHT;  
Soares\_NFL\_T\_GBC\_S1; Colon Tumor; Human Placenta; NCI\_CGAP\_Pr22; Colon Normal III; Human Osteoclastoma and Human 8 Week Whole Embryo.

The tissue distribution in dendritic cells indicates the protein product of this  
20 clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell  
25 lineages, including blood stem cells. This gene product is involved in the regulation



of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for

5 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders,

10 such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful

15 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases

20 and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some

25 cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal

muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The protein is useful in modulating cellular responses to hormonal or growth factors. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2430 of SEQ ID NO:11, b is an integer of 15 to 2444, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 2

5       The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA34461.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0741 protein [Homo sapiens]". A partial alignment demonstrating the observed homology is shown  
10 immediately below.

>dbj|BAA34461.1| (AB018284) KIAA0741 protein [Homo sapiens]  
15 IF-2. >sp|O60841|IF2P\_HUMAN PROBABLE TRANSLATION INITIATION FACTOR

Length = 1220

Plus Strand HSPs:

20       Score = 2216 (780.1 bits), Expect = 5.6e-229, P = 5.6e-229  
Identities = 437/437 (100%), Positives = 437/437 (100%), Frame = +2

25       Q:    11 KDEFEEERAKAIIVEFAQQGLNAALFYENKDPRTFVSLVPTSHTGDMGSLIYLLVELTQ 190  
          KDEFEEERAKAIIVEFAQQGLNAALFYENKDPRTFVSLVPTSHTGDMGSLIYLLVELTQ  
      S:    784 KDEFEEERAKAIIVEFAQQGLNAALFYENKDPRTFVSLVPTSHTGDMGSLIYLLVELTQ 843  
30       Q:    191 TMLSKRLAHCEELRAQVMEVKALPGMGTTIDVILINGRLKEGDTIIVPGVEGPIVTQIRG 370  
          TMLSKRLAHCEELRAQVMEVKALPGMGTTIDVILINGRLKEGDTIIVPGVEGPIVTQIRG  
      S:    844 TMLSKRLAHCEELRAQVMEVKALPGMGTTIDVILINGRLKEGDTIIVPGVEGPIVTQIRG 903  
35       Q:    371 LLLPPPMKELRVKNQYKHKVEEAAQGVKILGKDLEKTLAGLPLLVAEKDEIPVLKDEL 550  
          LLLPPPMKELRVKNQYKHKVEEAAQGVKILGKDLEKTLAGLPLLVAEKDEIPVLKDEL  
      S:    904 LLLPPPMKELRVKNQYKHKVEEAAQGVKILGKDLEKTLAGLPLLVAEKDEIPVLKDEL 963  
40       Q:    551 IHEHKQTLNAIKLEEKGVYVQASTLGSLEALLEFLKTSEVPYAGINIGPVHKKDVMKASV 730  
          IHEHKQTLNAIKLEEKGVYVQASTLGSLEALLEFLKTSEVPYAGINIGPVHKKDVMKASV  
      S:    964 IHEHKQTLNAIKLEEKGVYVQASTLGSLEALLEFLKTSEVPYAGINIGPVHKKDVMKASV 1023  
      Q:    731 MLEHDPQYAVILAFDVRIERDAQEMADSLGVRIFFSAEIIYHLFDAFTKYRQDYKKQKQEE 910  
          MLEHDPQYAVILAFDVRIERDAQEMADSLGVRIFFSAEIIYHLFDAFTKYRQDYKKQKQEE  
      S:    1024 MLEHDPQYAVILAFDVRIERDAQEMADSLGVRIFFSAEIIYHLFDAFTKYRQDYKKQKQEE 1083  
      Q:    911 FKHIAVFPCKIKILPQYIFNSRDPIMGVTVAGQVKGQTPMCPVSKNFVDIGIVTSIEI 1090

FKHIAVFPCKIKILPQYIFNSRDPVIMGVTVAGQVKQGTPMCVPSKNFVDIGIVTSIEI  
 S: 1084 FKHIAVFPCKIKILPQYIFNSRDPVIMGVTVAGQVKQGTPMCVPSKNFVDIGIVTSIEI 1143  
 Q: 1091 NHKQVDVARKGQEVCKIEPIPGESPKMFGRRHFEATDILVSKISRQSIDALKDWFRDEM 1270  
 5 NHKQVDVARKGQEVCKIEPIPGESPKMFGRRHFEATDILVSKISRQSIDALKDWFRDEM  
 S: 1144 NHKQVDVARKGQEVCKIEPIPGESPKMFGRRHFEATDILVSKISRQSIDALKDWFRDEM 1203  
 Q: 1271 KSDWQLIVELKKVFEII 1321  
 KSDWQLIVELKKVFEII  
 10 S: 1204 KSDWQLIVELKKVFEII 1220

The segment of dbjBAA34461.11 that is shown as "S" above is set out in the  
 sequence listing as SEQ ID NO. 111. Based on the structural similarity, these  
 homologous polypeptides are expected to share at least some biological activities.

15 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 112 which  
 20 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

Contact of cells with supernatant expressing the product of this gene has been  
 shown to increase the permeability of the plasma membrane of renal mesangial cells  
 to calcium. Thus it is likely that the product of this gene is involved in a signal  
 25 transduction pathway that is initiated when the product binds a receptor on the surface  
 of the plasma membrane of renal cells, and to a lesser extent, other cells and tissue  
 cell types (i.e., immune and hematopoietic cells, etc.), in addition to other cell-lines or  
 tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but  
 are not limited to, activating renal cells. Binding of a ligand to a receptor is known to  
 30 alter intracellular levels of small molecules, such as calcium, potassium and sodium,  
 as well as alter pH and membrane potential. Alterations in small molecule

concentration can be measured to identify supernatants which bind to receptors of a particular cell.

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene muscle 937209 and to a lesser extent in Stratagene

5 ovarian cancer (#937219); Soares\_pregnant\_uterus\_NbHPU; Spleen, Chronic lymphocytic leukemia; T cell helper II; Morton Fetal Cochlea; Stromal cell TF274; Stratagene HeLa cell s3 937216; Soares melanocyte 2NbHM; Soares\_multiple\_sclerosis\_2NbHMSP; prostate-edited; Human Adult Heart, re-excision; Smooth Muscle- HASTE normalized; NTERA2 + retinoic acid, 14 days;

10 Jurkat T-Cell, S phase; Human Heart; 12 Week Old Early Stage Human; Human Substantia Nigra; Colon Tumor II; Monocyte activated; Human Testes; Stratagene fibroblast (#937212); Keratinocyte; Soares fetal liver spleen 1NFLS; Jurkat Cells, cyclohexamide treated, subtraction; Human Rejected Kidney, 704 re-excision; Human Striatum Depression, re-rescue; Human Adult Spleen, fractionII; Crohn's Disease;

15 Human Adult Heart, subtracted; Human Adult Heart; CD34+cells, II, FRACTION 2; Smooth muscle, control, re-excision; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Raji Cells, cyclohexamide treated; Mesangial cell, frac 2; Human Whole Brain, re-excision; Apoptotic T-cell, re-excision; Synovial hypoxia-RSF subtracted; Synovial hypoxia; Myeloid Progenitor Cell Line; Spleen metastatic melanoma; Spinal Cord, re-

20 excision; Human Prostate; H. Kidney Medulla, re-excision; T-Cell PHA 16 hrs; Human Bone Marrow, re-excision; KMH2; Monocyte activated, re-excision; L428; Apoptotic T-cell; Human Activated T-Cells; Human umbilical vein endothelial cells, IL-4 induced; Bone Marrow Stromal Cell, untreated; Rejected Kidney, lib 4; Human T-Cell Lymphoma; Human Placenta; Adipocytes; Dendritic cells, pooled; Primary

25 Dendritic cells, frac 2; Human Fetal Lung III; human tonsils; Human Adult

Pulmonary, re-excision; Endothelial cells-control; CD34 depleted Buffy Coat (Cord Blood), re-excision; Anergic T-cell; Human Amygdala and Hodgkin's Lymphoma II.

The tissue distribution in immune cells and tissue cell types indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the

protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1707 of SEQ ID NO:12, b is an integer of 15 to 1721, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 3

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Resting T-Cell Library,II; Spleen, Chronic lymphocytic leukemia.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 62 as residues: Lys-18 to Pro-23. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1284 of SEQ ID NO:13, b is an integer of 15 to 1298, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA17596.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "hypothetical protein [Synechocystis sp.]". A partial alignment demonstrating the observed homology is shown immediately below.

20 >dbj|BAA17596.1| hypothetical protein [Synechocystis sp.]  
 >pir|S77262|S77262  
 hypothetical protein slr0876 - Synechocystis sp. (strain PCC 6803) >sp|P73556|P73556 HYPOTHETICAL 45.3 KD PROTEIN.  
 Length = 409

25 Plus Strand HSPs:

Score = 1026 (361.2 bits), Expect = 7.2e-103, P = 7.2e-103  
 Identities = 187/395 (47%), Positives = 274/395 (69%), Frame = +1

30 Q: 220 AARNHYEVLVLGGSGGITMAARMKRKVGAEENVAIPEPSEHFYQPIWTLVGAGAKQLSS 399  
 +A NH +++V+GGG+ GIT+AA++ ++ ++AIVEP ++H+YQP WTLVG GA +  
 S: 2 SALNH-QIIVVGGGAAGITVAAQLLKQPKLDLAIVEPCDKHYYPATLVGGGAFAMED 60

35 Q: 400 SGRPTASVIPSGVEWIKARVTELNPDKNCIHTDDDEKISYRYLIIALGIQLDYERIKGLP 579



+ P IP SG + W I K A V + P + N C + D + S Y Y L + + G I Q + + + I L  
 S: 61 TIRPEQDCIPSGAKWIKASVASFDPENNCITLQDGRSLSYEYLVVCPGIQINWHLIPRLQ 120  
 5 Q: 580 EGF AHPKIGSNYSVKTVEKTWRALQDFKEGNAIFTFPNTPVKCAGAPQKIMYLSEAYFRK 759  
 E + S N Y + T W + L Q + F K G N A + F T F P T P + K C A G A P Q K I M Y L + + F R K  
 S: 121 ESLGKNGVTSNYDRRYAPYTWELLQNFKGGNALFTFPATPIKCAGAPQKIMYLADETFRK 180  
 10 Q: 760 TGKRSKANIIFNTSLGAIFGVKKYADALQEIIQERNLTVNYKKNLIEVRADKQEAVFENL 939  
 G R K N I + + + G I F G + Y + + L + + + + + N + V Y N L + + + E A F  
 S: 181 NGVREKTNITYGVAVGKIFGIPGYCESLEKVAACKNIDVRYHHNLKAINPNAKEATFT-- 238  
 15 Q: 940 DKPGETQV-ISYEMLHVTTPMSPPDVLKTSPPA-DAAGWVDVDKETLQHRYPNVFGIGD 1113  
 G + T + V + Y + + + H V T P P M S P D + K S P + A + A G W V D V D K T L Q H R Y N V F G I G D  
 S: 239 -VNGKTEVTLPYDIIHVTTPMSAPDFIKNSPLAAEAGGWVDVDKFTLQHNRYDNVFSGLD 297  
 Q: 1114 CTNLPSTKTAATAAAQSGILDRTISVIMKNQTPTKKYDGYTSCPLVTGYNRVILAEPDYK 1293  
 + + L P T S + T A A A V Q + + + + + P + + Y G Y T C P L V T G Y + I + A E F D Y  
 S: 298 ASSLPSTRTAAAVRKQAPVVATNLLGLLNSKKPSAEYGGYTCCPLVTGYGKTIMAEFDY 357  
 20 Q: 1294 AEPLTFPFDQSKERLSMYLMKADLMPFLYWNMMLRG 1404  
 + P + P F D + + E R S M + L + K + + P + L Y W N M L + G  
 S: 358 GQPKSSFPFDPTQERWSMWLVKRYVLPWLYWNRLKG 394

The segment of dbj|BAA17596.1| that is shown as "S" above is set out in the  
 25 sequence listing as SEQ ID NO. 113. Based on the structural similarity, these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein.

30 Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 114 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 35 tissues/cDNA libraries: Epithelial-TNF $\alpha$  and INF induced and to a lesser extent in  
 Activated T-cells, 24 hrs, re-excision; Monocyte activated; Primary Dendritic Cells,  
 lib 1; Soares fetal liver spleen 1NFLS; Stratagene lung (#937210); Colon Normal III;  
 Keratinocyte; Macrophage-oxLDL; T cell helper II; H Macrophage (GM-CSF

- treated), re-excision; Human OB MG63 control fraction I; T-Cell PHA 16 hrs;  
 Human Pancreas Tumor; Macrophage (GM-CSF treated); Normal colon; Human  
 Endometrial Tumor; Soares infant brain 1NIB; Human Colon, subtraction; Human  
 OB MG63 treated (10 nM E2) fraction I; Activated T-cells; Human T-cell
- 5 lymphoma, re-excision; Soares retina N2b4HR; STROMAL -OSTEOCLASTOMA;  
 Soares\_pregnant\_uterus\_NbHPU; Synovial hypoxia-RSF subtracted; Prostate BPH;  
 NCI\_CGAP\_Co3; NCI\_CGAP\_GCB1; Monocyte activated, re-excision; Human  
 Pancreas Tumor, Reexcision; Olfactory epithelium, nasalcavity; Human Placenta (re-  
 excision); Human Activated T-Cells, re-excision; Ulcerative Colitis; Bone Marrow
- 10 Stromal Cell, untreated; Hepatocellular Tumor, re-excision; Stratagene liver  
 (#937224); NCI\_CGAP\_Co9; Human Fetal Lung III; Human Adult Pulmonary, re-  
 excision; Human pancreatic islet; Hodgkin's Lymphoma II; Activated T-  
 cell(12h)/Thiouridine-re-excision; Jurkat Cells, cyclohexamide treated, subtraction;  
 Human Activated T-Cells (II); Human Infant Adrenal Gland, subtracted; Kidney
- 15 Cortex; Spleen/normal; Cheek Carcinoma; Colon Normal; Activated T-Cells, 24 hrs.;  
 Colon, tumour; Bone marrow stroma, treated; CD34+cells, II, FRACTION 2; Normal  
 lung; Resting T-Cell; Larynx carcinoma III; stomach cancer (human); Human OB  
 HOS treated (10 nM E2) fraction I; Human Adult Pulmonary; HUMAN STOMACH;  
 Human Thyroid; Early Stage Human Lung, subtracted; Smooth Muscle- HASTE
- 20 normalized; Human pancreatic islet; Hepatocellular Tumor, re-excision; Synovial IL-  
 1/TNF stimulated; Human endometrial stromal cells-treated with progesterone;  
 Human Osteoclastoma, re-excision; Human Adult Small Intestine; Human  
 Neutrophil; Human Chronic Synovitis; Human Prostate; Human Thymus;  
 NCI\_CGAP\_Br3; NCI\_CGAP\_Co8; NCI\_CGAP\_Co9; NCI\_CGAP\_Kid3;
- 25 NCI\_CGAP\_Lar1; NCI\_CGAP\_Pr11; 12 Week Old Early Stage Human, II; HUMAN  
 JURKAT MEMBRANE BOUND POLYSOMES; T-Cell PHA 24 hrs;

Soares\_NhHMPu\_S1; Human Chondrosarcoma; Soares\_fetal\_heart\_NbHH19W;  
 Soares breast 2NbHBst; Human Adrenal Gland Tumor; Human promyelocyte;  
 Human pancreatic islet; Jia bone marrow stroma; STRATAGENE Human skeletal  
 muscle cDNA library, cat. #936215.; Soares\_NFL\_T\_GBC\_S1;  
 5 Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_parathyroid\_tumor\_NbHPA;  
 Soares\_NhHMPu\_S1; Macrophage-oxLDL, re-excision; Pancreas Islet Cell Tumor;  
 Colon Tumor; Human T-Cell Lymphoma; Colon Normal II; Human Testes Tumor;  
 Colon Tumor II; Dendritic cells, pooled; Primary Dendritic cells, frac 2;  
 Soares\_multiple\_sclerosis\_2NbHMSP; Human Placenta; human tonsils; Endothelial  
 10 cells-control; NCI\_CGAP\_Brn23; Pancreatic Islet; Soares\_fetal\_heart\_NbHH19W;  
 Human Osteoclastoma; Smooth muscle, control; HUMAN B CELL LYMPHOMA;  
 Human Bone Marrow, treated; T Cell helper I; Human Testes; Osteoblasts and  
 Stratagene pancreas (#937208).

Preferred polypeptides of the present invention comprise immunogenic  
 15 epitopes shown in SEQ ID NO: 63 as residues: Pro-76 to Phe-81, Gln-95 to Pro-102,  
 Leu-121 to Ile-128, Asp-131 to Ser-137, Thr-174 to Trp-179, Arg-217 to Lys-224,  
 Val-257 to Asn-262, Asn-277 to Glu-283, His-325 to Asn-330, Lys-365 to Thr-377,  
 Pro-404 to Arg-411. Polynucleotides encoding said polypeptides are also  
 encompassed by the invention.

20 The secreted protein can also be used to determine biological activity, to raise  
 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
 that modulate their interactions, and as nutritional supplements. It may also have a  
 very wide range of biological activities. Representative uses are described in the  
 "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15,  
 25 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the  
 following activities: cytokine, cell proliferation/differentiation modulating activity or

induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1719 of SEQ ID NO:14, b is an integer of 15 to 1733, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 5

5 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gbAAC13686.11 (all information available through the recited accession number is incorporated herein by reference; for example, Mol. Cell. Biochem. 183, 103-110  
10 (1998)) which is described therein as "sarcosin [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

>gb|AAC13686.1| (AF056929) sarcosin [Homo sapiens] >sp|060662|060662  
SARCOSIN.

15

Length = 596

Plus Strand HSPs:

20

Score = 1810 (637.2 bits), Expect = 1.6e-310, Sum P(3) = 1.6e-310  
Identities = 349/366 (95%), Positives = 354/366 (96%), Frame = +1

25

Q: 808 LKATQTSRKKIKVLKDAFAGKLPRTLAKMPRKTGAGEVNGDVGDEDLPGYLNDIPRHGM 987  
+K+ +KKIKVLKDAFAGKLP +K KTGAGEVNGDVGDEDLPGYLNDIPRHGM  
S: 232 IKSNDLQKKIKVLKDAFAGKLPEP-SKNAARTGAGEVNGDVGDEDLPGYLNDIPRHGM 290

30

Q: 988 FVKDLILLVNDTAAVAYDPTENECYLTALAEQIPRNHSSIVTQQNQIYVVGGLYVDEENK 1167  
FVK LILLVNDTAAVAYDPTENECYLTALAEQIPRNHSSIVTQQNQIYVVGGLYVDE+NK  
S: 291 FVKGLILLVNDTAAVAYDPTENECYLTALAEQIPRNHSSIVTQQNQIYVVGGLYVDEKNK 350

Q: 1168 DQPLQSYFFQLDSIASEWVGLPPLPSARCLFGLGEVDDKIYVVGAKDLQTEASLDSVLCY 1347  
QPLQSYFFQLDSIASEWVGLPPLPSARCLFGLGEVDDKIYVVGAKDLQTEASLDSVLCY  
S: 351 VQPLQSYFFQLDSIASEWVGLPPLPSARCLFGLGEVDDKIYVVGAKDLQTEASLDSVLCY 410

35

Q: 1348 DPVAAKWNEVKKLPKIKVYGHNVISHKGMICYLGGKTDDKKCTNRVFIENPKKGDWKDLAP 1527  
DPVAAKWNEVKKLPKIKVYGHNVISHKGMICYLGGKTDDKKCTNRVFIENPKKGDWKDLAP  
S: 411 DPVAAKWNEVKKLPKIKVYGHNVISHKGMICYLGGKTDDKKCTNRVFIENPKKGDWKDLAP 470

40

Q: 1528 MKIPRSMFGVAVHKGKIVAGGVTEDEGLSASVEAFDLTTNKWDVMTFEPQERSISLVSL 1707  
MKIPRSMFGVAVHKGKIVAGGVTEDEGLSASVEAFDLTTNKWDVMTFEPQERSISLVSL  
S: 471 MKIPRSMFGVAVHKGKIVAGGVTEDEGLSASVEAFDLTTNKWDVMTFEPQERSISLVSL 530

Q: 1708 AGSLYAIGGFAMIQLESKEFAPTEVNDIWKYEDDKKEWAGMLKEIRYASGASCLATRLNL 1887  
AGSLYAIGGFAMIQLESKEFAPTEVNDIWKYEDDKKEWAGMLKEIRYASGASCLATRLNL

S: 531 AGSLYAIGGFAMIQLESKEFAPTEVNDIWKYEDDKKEWAGMLKEIRYASGASCLATRLNL 590  
 Q: 1888 FKLSKL 1905  
     FKLSKL  
 5 S: 591 FKLSKL 596

The segment of gblAAC13686.1 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 115. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

10 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 116 which

15 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene muscle 937209 and to a lesser extent in Human Quadriceps; Soares\_fetal\_lung\_NbHL19W; Soares\_fetal\_heart\_NbHH19W; Human

20 Soleus; STRATAGENE Human skeletal muscle cDNA library, cat. #936215.; 12 Week Old Early Stage Human, II; Nine Week Old Early Stage Human; NCI\_CGAP\_Alv1; 12 Week Old Early Stage Human; 12 Week Early Stage Human II, Reexcision; NCI\_CGAP\_Kid6; STRATAGENE Human skeletal muscle cDNA library, cat. #936215.; Stratagene muscle 937209; Soares\_NhHMPu\_S1; Human

25 Testes, Reexcision; Human fetal heart, Lambda ZAP Express; Soares\_fetal\_heart\_NbHH19W; Soares\_total\_fetus\_Nb2HF8\_9w; Larynx tumor; Human Gastrocnemius; Human Fetal Bone; Human Heart; NCI\_CGAP\_Lu5; Soares\_fetal\_liver\_spleen\_INFLS\_S1; Human Fetal Heart; Human 8 Week Whole Embryo; HM3; Human heart cDNA (YNakamura) and NCI\_CGAP\_Pr22.

The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

The secreted protein can also be used to determine biological activity, to raise  
5 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the  
10 following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or  
15 nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative  
20 diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
25 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2484 of SEQ ID NO:15, b is an integer of 15 to 2498, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 6

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Human 8 Week Whole Embryo; Soares placenta Nb2HP; Human Chondrosarcoma; Hodgkin's Lymphoma II; Nine Week Old Early Stage Human; Soares\_parathyroid\_tumor\_NbHPA; Human Testes, Reexcision; Soares retina N2b4HR; Temporal cortex-Alzheimer, subtracted; Soares\_testis\_NHT; Soares\_parathyroid\_tumor\_NbHPA; NCI\_CGAP\_GCB1; Frontal lobe,dementia,re-excision; Human Thyroid; Human T-cell lymphoma,re-excision; T-Cell PHA 16 hrs; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Lei2; Soares\_NFL\_T\_GBC\_S1; Stromal cell TF274; Soares adult brain N2b5HB55Y; Human Adrenal Gland Tumor; Pancreas Islet Cell Tumor; Human Osteoclastoma; H. Frontal cortex,epileptic,re-excision; Soares\_pregnant\_uterus\_NbHPU; Human Lung Cancer, subtracted; Thyroid Normal (SDCA2 No); H. Striatum Depression, sub;



- Activated T-cells; Papillary serous cystic neoplasm of low malignant potential (ovary); Soares\_pregnant\_uterus\_NbHPU; Human Normal Breast; B Cell lymphoma; Human Hypothalamus, schizophrenia, re-excision; Hepatocellular Tumor; pBMC stimulated w/ poly I/C; H Female Bladder, Adult; H. Kidney Cortex, subtracted;
- 5 Healing groin wound, 7.5 hours post incision; Pancreas normal PCA4 No; Synovial hypoxia; Soares\_pregnant\_uterus\_NbHPU; Spinal Cord, re-excision; Human Prostate; Soares\_parathyroid\_tumor\_NbHPA; Human Bone Marrow, re-excision; Gessler Wilms tumor; Human promyelocyte; Human fetal brain (TFujiwara); NCI\_CGAP\_HN4; NCI\_CGAP\_Pr12; Soares\_pregnant\_uterus\_NbHPU; Stratagene
- 10 fibroblast (#937212); Stratagene hNT neuron (#937233); normalized infant brain cDNA; Human Umbilical Vein Endothelial Cells, uninduced; Human Pancreas Tumor; Human Hippocampus; Synovial Fibroblasts (control); Human Whole Six Week Old Embryo; NTERA2, control; NCI\_CGAP\_GCB1; Hepatocellular Tumor, re-excision; NCI\_CGAP\_GCB1; Soares breast 3NbHBst; NCI\_CGAP\_Pr12;
- 15 NCI\_CGAP\_Thy1; Human Amygdala; Human Bone Marrow, treated; Human Testes; Keratinocyte; Soares\_fetal\_heart\_NbHH19W; Stratagene fibroblast (#937212); T cell helper II and Soares\_multiple\_sclerosis\_2NbHMSP.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 65 as residues: Ser-31 to Lys-39. Polynucleotides

20 encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3337 of SEQ ID NO:16, b is an integer of 15 to 3351, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a

5 + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA24858.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0428 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

15 >dbj|BAA24858.1| (AB007888) KIAA0428 [Homo sapiens] >sp|O43311|O43311  
KIAA0428.  
Length = 370

20 Minus Strand HSPs:

Score = 728 (256.3 bits), Expect = 2.1e-70, P = 2.1e-70  
Identities = 143/205 (69%), Positives = 143/205 (69%), Frame = -1

25 Q: 4044 RTDRLEVCREYQRGNCNRGENDCRFAHPADSTMIDTNDNTVTVCMYIKGRCSREKCKYF 3865  
RTDRLEVCREYQRGNCNRGENDCRFAHPADSTMIDTNDNTVTVCMYIKGRCSREKCKYF  
S: 178 RTDRLEVCREYQRGNCNRGENDCRFAHPADSTMIDTNDNTVTVCMYIKGRCSREKCKYF 237

30 Q: 3864 HPPAHLQAKIKXXXXXXXXXXXXXXXXXXXXXXXXXVLPPLPKRPALEKTNGATAVFNT 3685  
HPPAHLQAKIK VLPPLPKRPALEKTNGATAVFNT  
S: 238 HPPAHLQAKIAAQYQVNQAAAAQAAATAAAMGIPQAVLPPLPKRPALEKTNGATAVFNT 297

35 Q: 3684 GIFQYQQALANMQLQQHTAFLPP VPMVHG 3505  
GIFQYQQALANMQLQQHTAFLPP VPMVHG  
S: 298 GIFQYQQALANMQLQQHTAFLPP-----VPMVHGATPATVSAATTSATSVPF 345

Q: 3504 XXXXXNQIPIISAHLTSHKYVTQM 3430  
NQIPIISAHLTSHKYVTQM  
S: 346 ATATANQIPIISAHLTSHKYVTQM 370

The segment of dbj|BAA24858.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 117. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

5 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 118 which  
10 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Primary Dendritic Cells, lib 1 and to a lesser extent in Soares melanocyte 2NbHM; Soares placenta Nb2HP; Hodgkin's Lymphoma II;  
15 Soares\_pregnant\_uterus\_NbHPU; Soares\_pregnant\_uterus\_NbHPU; Colon Normal III; Human Eosinophils; Spleen, Chronic lymphocytic leukemia; B Cell lymphoma; Soares\_fetal\_heart\_NbHH19W; NCI\_CGAP\_GCB1; Healing groin wound, 6.5 hours post incision; Apoptotic T-cell; Endothelial cells-control;  
Soares\_pregnant\_uterus\_NbHPU; Soares\_senescent\_fibroblasts\_NbHSF; HUMAN  
20 STOMACH; pBMC stimulated w/ poly I/C; T-Cell PHA 16 hrs; human ovarian cancer; T-Cell PHA 24 hrs; NTERA2, control; NCI\_CGAP\_GCB1; Hepatocellular Tumor, re-excision; Human Gall Bladder; Human T-Cell Lymphoma; Human Substantia Nigra; Soares breast 3NbHBst; Adipocytes; Human Fetal Heart; Human Adult Pulmonary, re-excision; Human Bone Marrow, treated;  
25 Soares\_pregnant\_uterus\_NbHPU; Human Thymus; Human kidney Cortex, subtracted; Human Eosinophils; Human Adult Skeletal Muscle; Palate carcinoma;

- Rectum normal; Pharynx Carcinoma; Osteoclastoma-normalized B; Larynx Tumor;  
CD34+ cell, I, frac II; Soares\_multiple\_sclerosis\_2NbHMSP; CD34+cells, II,  
FRACTION 2; Human Leukocytes; LNCAP untreated; Human Gall Bladder, fraction  
II; Human Adult Spleen; Human Cardiomyopathy, subtracted; Human Fetal Spleen;  
5 Healing Abdomen wound, 70&90 min post incision; Activated T-cells; HSA 172  
Cells; Mesangial cell, frac 2; Healing groin wound - zero hr post-incision (control);  
Pancreas Tumor PCA4 Tu; Human Hypothalamus, schizophrenia, re-excision; Human  
Synovium; Soares\_fetal\_lung\_NbHL19W; H Female Bladder, Adult; Human  
Stomach, re-excision; Human Adipose Tissue, re-excision; Human Osteosarcoma;  
10 Human Osteoclastoma, re-excision; Jurkat T-cell G1 phase; Brain Frontal Cortex, re-  
excision; Stratagene endothelial cell 937223; Spinal Cord, re-excision; Mo7e Cell  
Line GM-CSF treated (1ng/ml); Human Bone Marrow, re-excision; KMH2; 12 Week  
Old Early Stage Human, II; Human Osteoblasts II; HUMAN JURKAT MEMBRANE  
BOUND POLYSOMES; Human Heart; Human umbilical vein endothelial cells, IL-4  
15 induced; Human Activated Monocytes; Human Chondrosarcoma; Epithelial-TNF $\alpha$   
and INF induced; Ovarian Tumor 10-3-95; Human Ovarian Cancer Reexcision;  
Resting T-Cell Library, II; 12 Week Old Early Stage Human;  
Soares\_multiple\_sclerosis\_2NbHMSP; Colon Carcinoma; Colon Tumor II; Normal  
colon; Neutrophils control, re-excision; Human Osteoclastoma; Anergic T-cell;  
20 Human Microvascular Endothelial Cells, fract. A; Smooth muscle, control; Monocyte  
activated; HUMAN B CELL LYMPHOMA; Bone Marrow Cell Line (RS4,11);  
Stratagene colon (#937204); Stratagene fibroblast (#937212); H. Frontal  
cortex, epileptic, re-excision; Human Endometrial Tumor;  
Soares\_fetal\_lung\_NbHL19W; neutrophils control; Nine Week Old Early Stage  
25 Human and Soares fetal liver spleen INFLS.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
5 general formula of a-b, where a is any integer between 1 to 4030 of SEQ ID NO:17, b is an integer of 15 to 4044, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### 10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Hypothalamus, Schizophrenia and to a lesser extent in Human Prostate; Temporal cortex-Alzheimer, subtracted; T-Cell PHA 24 hrs; Hepatocellular Tumor, re-excision; Resting T-Cell Library, II; Larynx tumor; H.  
15 Frontal Cortex, Epileptic; Human (Caco-2) cell line, adenocarcinoma, colon, remake; Human Adult Pulmonary; Brain-medulloblastoma; Soares retina N2b4HR; Brain Frontal Cortex, re-excision; T-Cell PHA 16 hrs; KMH2; Human Thymus; Human umbilical vein endothelial cells, IL-4 induced; Stratagene endothelial cell 937223; Adipocytes; Dendritic cells, pooled; Soares melanocyte 2NbHM; Human  
20 Osteoclastoma; H. Frontal cortex, epileptic, re-excision; Hodgkin's Lymphoma II; Nine Week Old Early Stage Human; Human Cerebellum and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2235 of SEQ ID NO:18, b  
5 is an integer of 15 to 2249, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 9**

10 It has been discovered that this gene is expressed primarily in Adipocytes.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1631 of SEQ ID NO:19, b is an integer of 15 to 1645, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

It has been discovered that this gene is expressed primarily in Human Ovary.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 939 of SEQ ID NO:20, b is an integer of 15 to 953, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 11

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene HeLa cell s3 937216 and to a lesser extent in Soares placenta Nb2HP; CD34+cells, II; Human Osteoclastoma; Human Endometrial Tumor; Osteoblasts; Keratinocyte; Stratagene pancreas (#937208); Human Fetal Muscle; H. Umbilical Vein Endothelial Cells, IL4 induced; Jurkat Cells; H. Striatum Depression, subt; Healing Abdomen wound, 70&90 min post incision; Human Prostate Cancer, Stage C fraction; pBMC stimulated w/ poly I/C; Stratagene colon (#937204); Human Osteoclastoma, re-excision; Pancreas normal PCA4 No; KMH2; Stratagene fetal spleen (#937205); Soares\_total\_fetus\_Nb2HF8\_9w; Human Pancreas Tumor, Reexcision; Human Adrenal Gland Tumor; PC3 Prostate cell line; NCI\_CGAP\_Co8; NCI\_CGAP\_Pan1; NCI\_CGAP\_Lym12; Soares\_senescent\_fibroblasts\_NbHSF; CHME Cell Line, untreated; 12 Week Old Early Stage Human; Human T-Cell Lymphoma; NCI\_CGAP\_Co9; Colon Normal II; Adipocytes; Soares\_fetal\_lung\_NbHL19W; Human Placenta; Human Testes;

25



Soares\_fetal\_lung\_NbHL19W; Human 8 Week Whole Embryo; Soares fetal liver spleen 1NFLS and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 865 of SEQ ID NO:21, b is an integer of 15 to 879, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Macrophage-oxLDL, re-excision; Soares placenta Nb2HP; Soares\_pregnant\_uterus\_NbHPU; HUMAN B CELL LYMPHOMA; Osteoblasts; Activated T-cells; H Macrophage (GM-CSF treated), re-excision; Smooth muscle, control; Keratinocyte; Soares\_fetal\_heart\_NbHH19W; Primary Dendritic Cells, lib 1; Activated T-Cells, 8 hrs.; Stratagene endothelial cell 937223; Human Fetal Brain; Macrophage (GM-CSF treated); Soares melanocyte 2NbHM; Endothelial cells-control; Soares\_parathyroid\_tumor\_NbHPA; Smooth Muscle- HASTE normalized; Human Prostate Cancer, Stage C fraction; Synovial hypoxia-RSF subtracted; Jurkat T-cell G1 phase; Stratagene lung (#937210); Smooth muscle,

- serum treated; Human Osteoclastoma; Stratagene colon (#937204);  
Soares\_fetal\_lung\_NbHL19W; Cem Cells, cyclohexamide treated, subtra; Human  
ovary tumor cell OV350721; Brain Amygdala Depression; Human Prostate,  
subtracted; Human OB HOS control fraction I; Human Colon; Human Aortic  
5 Endothelium; Smooth Muscle Serum Treated, Norm; Supt Cells, cyclohexamide  
treated; Resting T-Cell, re-excision; Raji Cells, cyclohexamide treated; HEL cell line;  
Stratagene placenta (#937225); human corpus colosum; Stratagene HeLa cell s3  
937216; Stratagene endothelial cell 937223; Human endometrial stromal cells-treated  
with progesterone; Human Adipose Tissue, re-excision; Stratagene neuroepithelium  
10 (#937231); Synovial hypoxia; Jurkat T-Cell, S phase; wilm's tumor; Human Thymus;  
Apoptotic T-cell; Stratagene fetal spleen (#937205); Human Pancreas Tumor;  
Macrophage-oxLDL; NTERA2, control; Smooth muscle, serum induced, re-exc; 12  
Week Old Early Stage Human; Human T-Cell Lymphoma; Human Substantia Nigra;  
Colon Normal II; Endothelial-induced; Human Microvascular Endothelial Cells, fract.  
15 A; CD34 positive cells (Cord Blood); Human Bone Marrow, treated; Spleen, Chronic  
lymphocytic leukemia; Hodgkin's Lymphoma II; Stratagene hNT neuron (#937233);  
T cell helper II; Soares\_fetal\_liver\_spleen\_INFLS\_S1; Human Kidney Cortex -  
unamplified; CAMA1Ee Cell Line; Supt cells, cyclohexamide treated, differentially  
expressed; Human Cardiomyopathy, diff exp; Brain, normal; Human Bone Marrow;  
20 Soares\_multiple\_sclerosis\_2NbHMSP; H. Adipose Tissue; H Umbilical Vein  
Endothelial Cells, frac A, re-excision; Human Pituitary, re-excision; Human (Caco-2)  
cell line, adenocarcinoma, colon, remake; Resting T-Cell; H. Striatum Depression,  
subt; Human Gall Bladder, fraction II; Human Adult Spleen; Human (HCC) cell line  
liver (mouse) metastasis, remake; Soares\_pregnant\_uterus\_NbHPU; Human Fetal  
25 Bone; human colon cancer; Aorta endothelial cells + TNF-a; Human Primary Breast  
Cancer; Salivary Gland; Human T-cell lymphoma, re-excision; HSA 172 Cells;

- Human Skin Tumor; Cem cells cyclohexamide treated; CD34 positive cells (cord blood),re-ex; Messangial cell, frac 2; Human Tonsils, Lib 2; Human Hypothalamus,schizophrenia, re-excision; Human Colon-Cancer,re-excision; Human Umbilical Vein, Endo. remake; H Female Bladder, Adult; Amniotic Cells - Primary
- 5 Culture; Human Fetal Epithelium (Skin); Stratagene endothelial cell 937223; Stratagene ovarian cancer (#937219); Human Stomach,re-excision; LNCAP prostate cell line; Human Osteoclastoma, re-excision; Myeloid Progenitor Cell Line; Spleen metastatic melanoma; H. Lymph node breast Cancer; Human Adult Small Intestine; Human Prostate; H. Kidney Medulla, re-excision; Breast Cancer Cell line,
- 10 angiogenic; KMH2; Human Umbilical Vein Endothelial Cells, uninduced; Human Activated T-Cells; T-Cell PHA 24 hrs; Liver, Hepatoma; Human Activated Monocytes; Human Chondrosarcoma; Soares adult brain N2b5HB55Y; Epithelial-TNF $\alpha$  and INF induced; Bone Marrow Stromal Cell, untreated; Human Thymus Stromal Cells; Human Adrenal Gland Tumor; Fetal Liver, subtraction II;
- 15 Hepatocellular Tumor, re-excision; PC3 Prostate cell line; Colon Carcinoma; Brain frontal cortex; Early Stage Human Brain; Adipocytes; Human Testes Tumor; Colon Tumor II; Normal colon; Human Fetal Lung III; Human Neutrophil, Activated; Human Adult Pulmonary,re-excision; Activated T-Cell (12hs)/Thiouridine labelledEco; Colon Normal III; Human Amygdala; T Cell helper I; Neutrophils IL-1
- 20 and LPS induced; Human Testes; Human Endometrial Tumor and Soares\_multiple\_sclerosis\_2NbHMSP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of

25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 338 of SEQ ID NO:22, b is an integer of 15 to 352, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 13

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gblAAC26082.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "GPR39 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```
>gb|AAC26082.1| (AF034633) GPR39 [Homo sapiens] >sp|O43194|GP39_HUMAN
PUTATIVE
```

```
G PROTEIN-COUPLED RECEPTOR GPR39.
Length = 453
```

```
Minus Strand HSPs:
```

```
Score = 752 (264.7 bits), Expect = 7.6e-74, P = 7.6e-74
Identities = 149/167 (89%), Positives = 149/167 (89%), Frame = -1
```

```
Q: 1629 LIVVTLAVCWMPNQIRRIMAAAKPKHDWTRSYFRAYMILLPFSETFFYLSSVINPLLYTV 1450
      LIVVTLAVCWMPNQIRRIMAAAKPKHDWTRSYFRAYMILLPFSETFFYLSSVINPLLYTV
S: 287 LIVVTLAVCWMPNQIRRIMAAAKPKHDWTRSYFRAYMILLPFSETFFYLSSVINPLLYTV 346

Q: 1449 SSQQFRRVFVQVLCRLSLQHANHEKRLRVHAHSTTDSARFVQRPLLFASRRQSSARTE 1270
      SSQQFRRVFVQVLCRLSLQHANHEKRLRVHAHSTTDSARFVQRPLLFASRRQSSARTE
S: 347 SSQQFRRVFVQVLCRLSLQHANHEKRLRVHAHSTTDSARFVQRPLLFASRRQSSARTE 406

Q: 1269 KIFLSTFQSEAXXXXXXXXXXXXXXXXXXGAKPANSAAENGFEHEV 1129
      KIFLSTFQSEA                      GAKPANSAAENGFEHEV
S: 407 KIFLSTFQSEAEPSKSKSLSLSELEPNAGAKPANSAAENGFEHEV 453
```

The segment of gb|AAC26082.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 119. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

Such activities are known in the art, some of which are described elsewhere herein.

- 5 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 120 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
10 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Stratagene ovarian cancer (#937219); Soares ovary tumor NbHOT; H. Kidney Cortex, subtracted; Stratagene neuroepithelium NT2RAM1 937234; Gessler Wilms tumor;  
15 Soares\_NbHFB; Human Fetal Kidney, Reexcision; Human Cerebellum, subtracted; Papillary serous cystic neoplasm of low malignant potential (ovary); NTERA2 + retinoic acid, 14 days; Human Manic Depression Tissue; Human Infant Brain; H. Kidney Medulla, re-excision; 12 Week Old Early Stage Human, II; NCI\_CGAP\_Br2; NCI\_CGAP\_Ov2; NCI\_CGAP\_Kid6; NCI\_CGAP\_Ov26; Human Umbilical Vein  
20 Endothelial Cells, uninduced; Human Adrenal Gland Tumor; Stratagene pancreas (#937208); Stratagene endothelial cell 937223; Pancreas Islet Cell Tumor; PC3 Prostate cell line; NCI\_CGAP\_AA1; Human Ovarian Cancer Reexcision; Soares\_testis\_NHT; Soares\_NFL\_T\_GBC\_S1; Soares\_total\_fetus\_Nb2HF8\_9w; Stratagene hNT neuron (#937233); Stratagene ovarian cancer (#937219); Endothelial-  
25 induced; Human Bone Marrow, treated and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1942 of SEQ ID NO:23, b is an integer of 15 to 1956, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 14

It has been discovered that this gene is expressed primarily in PC3 Prostate cell line.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 561 of SEQ ID NO:24, b is an integer of 15 to 575, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Endometrial Tumor and to a lesser extent in Human Placenta; Keratinocyte; Human Fetal Brain, normalized AC5002; Human Infant Adrenal Gland, subtracted; Smooth Muscle Serum Treated, Norm; NTERA2 + retinoic acid, 14 days; H. Lymph node breast Cancer; Mo7e Cell Line GM-CSF treated (1ng/ml); 12 Week Old Early Stage Human, II; Human Pancreas Tumor; Ulcerative Colitis; PERM TF274; CHME Cell Line, treated 5 hrs; Resting T-Cell Library, II; Brain frontal cortex; Soares melanocyte 2NbHM; Soares\_multiple\_sclerosis\_2NbHMSP; Human Microvascular Endothelial Cells, fract. A; Monocyte activated; Human Cerebellum; Soares fetal liver spleen 1NFLS and Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 535 of SEQ ID NO:25, b is an integer of 15 to 549, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 16

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5 gblAAD13780.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "ldlBp [Mus musculus]". A partial alignment demonstrating the observed homology is shown immediately below.

```

10  >gb|AAD13780.1| (AF109377) ldlBp [Mus musculus] >sp|AAD13780|AAD13780
    ldlBp.
        Length = 980

    Plus Strand HSPs:
15  Score = 402 (141.5 bits), Expect = 1.3e-35, P = 1.3e-35
    Identities = 93/174 (53%), Positives = 110/174 (63%), Frame = +2

20  Q:   2 KIRLPAQPSWYVQSFLFSLCQEINRVGGHALPKVTLQEMLKSCMVQVVAAYEKLSEEKQI 181
      KIRLP QPSWYVQSFLFSLCQE+NRVGGHALPKVTLQEML++CM QV+AAAYE+L+EE QI
    S:  732 KIRLPTQPSWYVQSFLFSLCQEVNRVGGHALPKVTLQEMLQETCMAQVIAAYEQLTEENQI 791

25  Q:  182 KKEGAFPVTQNRALQLLYDLRYLKQPPSPGCSEXXXXXXXXXXXXXEN---QLAPRSSTF 352
      KKEGAFP+TQNRALQLLYDLRYL  SS G E  E  +L  F
    S:  792 KKEGAFPMTQNRALQLLYDLRYLTMVLSSKG--EEVKSGRSKADSRMEKMTERLEALIDPF 850

30  Q:  353 NSQ--EPH---NILPLAS-SQIRFGLPLSMTSTRKAKSTRNIETKAQVVPARS 499
      +   PH  N+  L  + + FGL+  +   ST N +  ++P A S
    S:  851 DLDVFTPHLNSNLNRLVQRTSVLFGVLVTGTENQFASRSSTFNSQEPHNILPLASS 905
  
```

- 30 The segment of gblAAD13780.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 121. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.
- 35 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 122 which



corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene muscle 937209 and to a lesser extent in Bone Marrow Stromal Cell, untreated; Human Cerebellum; Smooth muscle control 2; Human Prostate, subtracted; Human Fetal Brain; Frontal lobe, dementia, re-excision; Cem cells cyclohexamide treated; STROMAL -OSTEOCLASTOMA; Human Adipose Tissue, re-excision; Soares\_pregnant\_uterus\_NbHPU; H. Meningioma, M1; H. Lymph node breast Cancer; Human Prostate; Human Hypothalamus, Schizophrenia; Hemangiopericytoma; Human Adrenal Gland Tumor; Human T-Cell Lymphoma; Adipocytes; Human Testes Tumor; Human Fetal Lung III; human tonsils; Human Fetal Heart; Endothelial-induced; NCI\_CGAP\_GCB1; Activated T-Cell (12hs)/Thiouridine labelled Eco; Endothelial cells-control; Colon Normal III; Anergic T-cell; Soares\_fetal\_lung\_NbHL19W; Soares\_multiple\_sclerosis\_2NbHMSP; Human Amygdala; Spleen, Chronic lymphocytic leukemia; Soares placenta Nb2HP and Soares fetal liver spleen INFLS.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 75 as residues: Asp-16 to Gln-27. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 695 of SEQ ID NO:26, b is an integer of 15 to 709, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 17

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Smooth muscle, IL1b induced; Glioblastoma; Soares infant brain 1NIB and to a lesser extent in Soares retina N2b4HR; H. Lymph node breast  
10 Cancer; NCI\_CGAP\_GCB1; Epithelial-TNF $\alpha$  and INF induced; Human placenta cDNA (TFujiwara); Soares\_parathyroid\_tumor\_NbHPA; CHME Cell Line, treated 5 hrs; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Keratinocyte; Nine Week Old Early Stage Human; Soares fetal liver spleen 1NFLS; Colon Epithelium; Hemangiopericytoma; Human Kidney Tumor; H. Epididymus, caput & corpus; Mesangial cell, frac 2;  
15 NTERA2 + retinoic acid, 14 days; H. Kidney Medulla, re-excision; Apoptotic T-cell; NCI\_CGAP\_Ov2; Human umbilical vein endothelial cells, IL-4 induced; Human Chondrosarcoma; Liver HepG2 cell line.; NCI\_CGAP\_GCB1; Human Testes Tumor, re-excision; Human Gall Bladder; 12 Week Old Early Stage Human; Colon Normal II; Human Placenta; Human Placenta; Human Osteoclastoma; Smooth muscle, control  
20 and Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1211 of SEQ ID NO:27, b is an integer of 15 to 1225, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA20489.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "peptide/histidine transporter [Rattus norvegicus]". A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >dbj|BAA20489.1| (AB000280) peptide/histidine transporter [Rattus
    norvegicus]
    >sp|009014|009014 PEPTIDE/HISTIDINE TRANSPORTER.
    Length = 572
20  Plus Strand HSPs:
    Score = 1538 (541.4 bits), Expect = 1.3e-159, Sum P(2) = 1.3e-159
    Identities = 303/385 (78%), Positives = 324/385 (84%), Frame = +3
25  Q: 330 RRFFNWFYWSINLGAILSLGGIAYIQQNVSFVTGYAIP TVCVGLAFVXFLCGQSVFITKP 509
    RRFFNWFYWSINLGAILSLGGIAYIQQNVSF+TGY IPTVCV +AF+ FLCGQSVFITKP
    S: 193 RRFFNWFYWSINLGAILSLGGIAYIQQNVSF LTGYLIPTVCVAIAFLVFLCGQSVFITKP 252
30  Q: 510 PDGSAFTDMFKILTYSCCSQKRSGERQSN GEGIGVVFQSSKQSLFDSCCKMSHGPPFTEEK 689
    PDGSAFTDMF+ILTYSCCSQ R G+R+S GEG+GVVFQSSK SLFDSCCKMS GGPFFE+K
    S: 253 PDGSAFTDMFRILTYSCCSQ-RGGQRRS-GEGLGVVFQSSKHS LFDSCCKMSRGGPFTEDEK 310
35  Q: 690 VEDVKALVKIVPVFLALIPYWTVYFQM QTTYVLQSLHLRIPEISNITTTPTHTLPAAWLTM 869
    VEDVKALVKIVPVFLALIPYWTVYFQM QTTYVLQSLHL+IPEIS+ITTT HTLPAAWLTM
    S: 311 VEDVKALVKIVPVFLALIPYWTVYFQM QTTYVLQSLHLK IPEISSITTTHTLPAAWLTM 370
40  Q: 870 FDAXXXXXXXXXXXXXXXXXXILRRHGLLPSSLKRIAVGMFFVMCSAFAAGILESKRLNLVK 1049
    FDA +LRRHGLLPSSLKRIAVGMFFV CSAFAAGILESKRL+LVK
    S: 371 FDAVLILLIPLKDKLVDPVLRHGLLPSSLKRIAVGMFFV TCSAFAAGILESKRLDLVK 430
  
```

Q: 1050 EKTINQITIGNVVYHAADLSLWWQVPQYLLIGISEIFASIAGLEFAYSAPKSMQSAIMXX 1229  
 EKTINQITIG VVYHAADL +WWQ+PQY+LIGISEIFASIAGLEFAYSAPKSMQSAIM  
 S: 431 EKTINQITIGVVYHAADLPIWWQIPQYVLIGISEIFASIAGLEFAYSAPKSMQSAIMGL 490  
 5 Q: 1230 XXXXXXXXXXXXXXXXXXXXXXXXKAIGWMSSHTDFGNINGCYLNYYFFLLAAIQGATLLFL 1409  
 +KAIGWMSSHTDFGNIN C+L+YYFFLLAAIQGATLLFL  
 S: 491 FFFSGIGSFVGSGLLALVSLKAIGWMSSHTDFGNINSCHLHYFFLLAAIQGATLLFL 550  
 10 Q: 1410 IISVKYDHRDHQSRANGVPTSRR 1484  
 I+SVKYD QR+R +G S R  
 S: 551 IVSVKYDR----QRARTDGGTASTR 571

The segment of dbj|BAA20489.1| that is shown as "S" above is set out in the  
 15 sequence listing as SEQ ID NO. 123. Based on the structural similarity, these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein.

20 Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 124 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 25 tissues/cDNA libraries: Human Osteoclastoma and to a lesser extent in Human  
 Endometrial Tumor; NCI\_CGAP\_GCB1; Soares\_pregnant\_uterus\_NbHPU; Soares  
 fetal liver spleen 1NFLS; Morton Fetal Cochlea; Hepatocellular Tumor; Stratagene  
 ovarian cancer (#937219); Soares\_fetal\_heart\_NbHH19W; Hemangiopericytoma;  
 CHME Cell Line, treated 5 hrs; Smooth muscle, serum induced, re-exc;  
 30 NCI\_CGAP\_Lu5; Soares\_NhHMPu\_S1; Soares\_testis\_NHT;  
 Soares\_pineal\_gland\_N3HPG; Stratagene lung carcinoma 937218; Activated T-  
 cell(12h)/Thiouridine-re-excision; Soares infant brain 1NIB; Spleen/normal; Human  
 Fetal Brain; Human colon carcinoma (HCC) cell line, remake; Human Pancreatic

- Carcinoma; HUMAN STOMACH; Pancreatic Islet; Smooth Muscle Serum Treated, Norm; Human Thyroid; Human Tonsils, Lib 2; Apoptotic T-cell, re-excision; B Cell lymphoma; Morton Fetal; Human Chronic Synovitis; T-Cell PHA 16 hrs; Human Fetal Dura Mater; Human Adult Testes, Large Inserts, Reexcision;
- 5 Soares\_NhHMPu\_S1; Stratagene HeLa cell s3 937216; Merkel Cells; Pancreatic Islet; Soares\_senescent\_fibroblasts\_NbHSF; Human Ovary; Human Activated Monocytes; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human adult testis, large inserts; Stratagene lung (#937210); Macrophage-oxLDL, re-excision; Resting T-Cell Library,II; Colon Normal II; Adipocytes; Dendritic cells, pooled; Human Fetal Lung
- 10 III; Human pancreatic islet; NCI\_CGAP\_Co3; NCI\_CGAP\_GC4; NCI\_CGAP\_Kid6; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_heart\_NbHH19W; Soares\_pregnant\_uterus\_NbHPU; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; b4HB3MA Cot8-HAP-Ft and Primary Dendritic Cells, lib 1.

- Many polynucleotide sequences, such as EST sequences, are publicly
- 15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
- 20 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2113 of SEQ ID NO:28, b is an integer of 15 to 2127, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5 gblAAD00107.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Tic [Homo sapiens]".

A partial alignment demonstrating the observed homology is shown immediately below.

```

10 >gb|AAD00107.1| Tic [Homo sapiens] >sp|AAD00107|AAD00107 Tic.
    Length = 1056

    Plus Strand HSPs:

15 Score = 710 (249.9 bits), Expect = 2.6e-102, Sum P(2) = 2.6e-102
    Identities = 145/202 (71%), Positives = 147/202 (72%), Frame = +2

    Q: 185 QEAHVFLRTADWRLYLFXATAKEMSSWIARINLAAATHSAPFFPAAVGSQRRFVRPIL 364
        ++ HVFQLRTADWRLYLF A TAKEMSSWIARINLAAATHSAPFFPAAVGSQRRFVRPIL
20 S: 855 KKPHVFLRTADWRLYLFQAPTAKEMSSWIARINLAAATHSAPFFPAAVGSQRRFVRPIL 914

    Q: 365 PVGPAQSSLEEQRSHENCXXXXXXXXXXQXXXXXXXXXXXXXXXXXXXXXXXXXKTR 544
        PVGPAQSSLEEQRSHENC Q KTR
25 S: 915 PVGPAQSSLEEQRSHENCDAADLLDLQRNLPERRGRGRELEEHRLRKEYLEYEKTR 974

    Q: 545 YETVQLLVARLHCPDLDLWEEQLGREAGGTREXXXXXXXXXXXXXQDEAPTTAKV 724
        YETVQLLVARLHCPDLDLWEEQLGREAGGTRE QDEAPTTAKV
    S: 975 YETVQLLVARLHCPDLDLWEEQLGREAGGTREPKLSLKKSHSSPSLHQDEAPTTAKV 1034

30 Q: 725 KRNISERRTYRKIIPKRNRNQL 790
        KRNISERRTYRKIIPKRNRNQL
    S: 1035 KRNISERRTYRKIIPKRNRNQL 1056
  
```

- The segment of gblAAD00107.1| that is shown as "S" above is set out in the
- 35 sequence listing as SEQ ID NO. 125. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 126 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- 5           It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_fetal\_heart\_NbHH19W and to a lesser extent in Activated T-Cells, 12 hrs, subtracted; Human Primary Breast Cancer Reexcision; Soares fetal liver spleen 1NFLS; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Colon Carcinoma; human tonsils; Human Colon, differential expression;
- 10       Soares\_parathyroid\_tumor\_NbHPA; Human Fetal Dura Mater; Soares breast 2NbHBst; Human Eosinophils; breast lymph node CDNA library; Colon Normal II; Anergic T-cell; Activated T-cell(12h)/Thiouridine-re-excision; Primary Dendritic Cells, lib 1; Human Colon, subtraction; NCI\_CGAP\_Co8; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co16; NCI\_CGAP\_Kid5; NCI\_CGAP\_Lym12; Fetal Heart, re-excision;
- 15       Dendritic Cells From CD34 Cells; Human Osteosarcoma; Jurkat T-cell G1 phase; Soares\_NFL\_T\_GBC\_S1; Soares\_NSF\_F8\_9W\_OT\_PA\_P\_S1; Soares\_pregnant\_uterus\_NbHPU; Monocyte activated, re-excision; Ulcerative Colitis; Human Thymus; Human Thymus Stromal Cells; Stratagene liver (#937224); Soares breast 3NbHBst; Dendritic cells, pooled; Human Testes, Reexcision; Human
- 20       Fetal Heart; NCI\_CGAP\_Pr12; Human Bone Marrow, treated; Neutrophils IL-1 and LPS induced; Bone Marrow Cell Line (RS4,11); NCI\_CGAP\_Pan1; H. Frontal cortex,epileptic,re-excision; Human Endometrial Tumor; Soares\_NhHMPu\_S1; Hodgkin's Lymphoma II; Keratinocyte; T cell helper II; NCI\_CGAP\_GCB1 and NCI\_CGAP\_Kid3.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 78 as residues: Gln-21 to Trp-30. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2317 of SEQ ID NO:29, b is an integer of 15 to 2331, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Human Endometrial Tumor; NCI\_CGAP\_GCB1; Human 8 Week Whole Embryo;  
20 Soares\_senescent\_fibroblasts\_NbHSF; Human Adrenal Gland Tumor; NCI\_CGAP\_Br2; NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid5; CHME Cell Line,untreated; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_parathyroid\_tumor\_NbHPA; normalized infant brain cDNA; Human Fetal Kidney, Reexcision; Soares fetal liver spleen 1NFLS; Larynx carcinoma IV; Pharynx carcinoma; Human Colon; Amniotic Cells -  
25 TNF induced; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Soares\_multiple\_sclerosis\_2NbHMSP; Soares\_placenta\_8to9weeks\_2NbHP8to9W;



- H. Whole Brain #2, re-excision; HEL cell line; Human endometrial stromal cells-treated with estradiol; Glioblastoma; Jurkat T-cell G1 phase; Human Infant Brain; Human Uterine Cancer; Human Rhabdomyosarcoma; CHME Cell Line, treated 5 hrs; HTCDL1; Human retina cDNA Tsp509I-cleaved sublibrary; NCI\_CGAP\_AA1;
- 5 NCI\_CGAP\_Co3; NCI\_CGAP\_GC2; NCI\_CGAP\_Ov2; NTERA2, control; Human Liver, normal; HTCDL1; Liver HepG2 cell line.;
- Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene cDNA library Human heart, cat#936208; Human Fetal Lung III; Human Testes, Reexcision; human tonsils; Activated T-Cell (12hs)/Thiouridine labelled Eco;
- 10 Human Amygdala; HUMAN B CELL LYMPHOMA; Human Testes; Activated T-cell(12h)/Thiouridine-re-excision; Soares\_pregnant\_uterus\_NbHPU and T cell helper II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

15 related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

20 general formula of a-b, where a is any integer between 1 to 2404 of SEQ ID NO:30, b is an integer of 15 to 2418, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Whole Six Week Old Embryo; Human Fetal Heart; Human Testes.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
- 10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2206 of SEQ ID NO:31, b is an integer of 15 to 2220, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a
- 15 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in
- 20 Morton Fetal Cochlea; Soares\_multiple\_sclerosis\_2NbHMSP; Soares infant brain 1NIB; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Stratagene liver (#937224); Soares\_pregnant\_uterus\_NbHPU; Nine Week Old Early Stage Human; Soares\_fetal\_lung\_NbHL19W; Human Cardiomyopathy, subtracted; Human Adult Pulmonary; H. Atrophic Endometrium; NTERA2 + retinoic acid, 14 days; Smooth
- 25 muscle, serum induced, re-exc; 12 Week Old Early Stage Human; Adipocytes; Human

Fetal Heart; Human Testes; NCI\_CGAP\_GCB1; H. Frontal cortex, epileptic, re-excision and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 967 of SEQ ID NO:32, b is an integer of 15 to 981, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: normalized infant brain cDNA; Soares melanocyte 2NbHM and to a lesser extent in Human Neutrophils, Activated, re-excision; Heart; normalized infant brain cDNA; Human endometrial stromal cells; NCI\_CGAP\_GCB1; Resting T-Cell Library, II; Human T-Cell Lymphoma; Human Testes; Soares placenta Nb2HP; Soares fetal liver spleen 1NFLS; Human Prostate BPH, re-excision; HL-60, RA 4h, Subtracted; Human Lung; B Cell lymphoma; Hepatocellular Tumor, re-excision; Salivary Gland, Lib 2; Human Brain, Striatum; Human adult (K.Okubo); NCI\_CGAP\_Co8; NCI\_CGAP\_Co9; NCI\_CGAP\_GC4; Soares\_NhHMPu\_S1; Soares\_testis\_NHT; Soares\_NSF\_F8\_9W\_OT\_PA\_P\_S1; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Stratagene schizo brain S11; Monocyte

activated, re-excision; Human Thymus; Epithelial-TNF $\alpha$  and INF induced;  
Soares\_NhHMPu\_S1; Human Placenta; Human Testes Tumor; Human Synovial  
Sarcoma; Human Testes, Reexcision; Human Neutrophil, Activated; Activated T-Cell  
(12hs)/Thiouridine labelledEco; Human Microvascular Endothelial Cells, fract. A;  
5 Bone Marrow Cell Line (RS4,11); H. Frontal cortex,epileptic,re-excision; Activated  
T-cell(12h)/Thiouridine-re-excision; Human 8 Week Whole Embryo and Soares  
infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:33 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 2188 of SEQ ID NO:33, b  
is an integer of 15 to 2202, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a  
+ 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The computer algorithm BLASTX has been used to determine that the  
translation product of this gene shares sequence homology with, as a non-limiting  
example, the sequence accessible through the following database accession no.  
gb|AAB49034.1| (all information available through the recited accession number is  
25 incorporated herein by reference) which is described therein as "I alternatively spliced

product using exon 13A [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

5  >gb|AAB49034.1| alternatively spliced product using exon 13A [Homo
    sapiens]
    >sp|P78525|P78525 MYB PROTO-ONCOGENE PROTEIN (C-MYB).
    Length = 666

10  Plus Strand HSPs:

    Score = 154 (54.2 bits), Expect = 2.1e-13, Sum P(2) = 2.1e-13
    Identities = 33/44 (75%), Positives = 35/44 (79%), Frame = +3

15  Q:  447 FVFLVETGFHHVVGQAGFELLTSGDPPALASQVAGITDVNHCAKP 578
    .      F FLVETGF HVGQAG ELLTSGD PA ASQ A IT V+H A+P
    S:  608 FEFLVETGFLHVGQAGLELLTSGDLPASASQSARITGVSHRARP 651

    Score = 100 (35.2 bits), Expect = 2.1e-13, Sum P(2) = 2.1e-13
    Identities = 21/41 (51%), Positives = 23/41 (56%), Frame = +1

20  Q:  325 GVQWRDLGSLQPPPPGFKRSSMPQPPEQLGLQAPATVPS*F 447
    .      GVQW D GSLQP PPGFKR S   P   + P   P+ F
    S:  568 GVQWHDFGSLQPLPPGFKRFSLSLPRSWDYRHPPPRPANF 608

    Score = 49 (17.2 bits), Expect = 3.9e-08, Sum P(2) = 3.9e-08
    Identities = 9/12 (75%), Positives = 9/12 (75%), Frame = +2

25  Q:  413 DYRHLPQCPANF 448
    .      DYRH P  PANF
    S:  597 DYRHPPPRPANF 608

30

```

The segments of gb|AAB49034.1| that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 127, SEQ ID NO. 129 and SEQ ID NO. 131.

Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 128, SEQ ID NO. 130 and/or SEQ ID NO. 132 which correspond to the "Q" sequences in the alignment

shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Human Testes.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1153 of SEQ ID NO:34, b is an integer of 15 to 1167, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Testes and to a lesser extent in Soares\_testis\_NHT; Soares placenta Nb2HP; Morton Fetal Cochlea; NCI\_CGAP\_GCB1;  
20 Soares\_fetal\_heart\_NbHH19W; Human Fetal Lung III; Soares fetal liver spleen 1NFLS; Saos2 Cells, Vitamin D3 Treated; H Umbilical Vein Endothelial Cells, frac A, re-excision; Soares\_multiple\_sclerosis\_2NbHMSP; Human Cerebellum, subtracted; H. Atrophic Endometrium; Human Skin Tumor; Human Pineal Gland; Human Umbilical Vein, Endo. remake; Human Frontal Cortex, Schizophrenia;  
25 Clontech human aorta polyA+ mRNA (#6572); NCI\_CGAP\_Lu5; NCI\_CGAP\_Co10; Monocyte activated, re-excision; Stromal cell TF274; Human

Ovary; Human umbilical vein endothelial cells, IL-4 induced; Synovial Fibroblasts (control); Colon Tumor II; Normal colon; Human Neutrophil, Activated; Human Bone Marrow, treated; Bone Marrow Cell Line (RS4,11); Keratinocyte; Nine Week Old Early Stage Human and Soares\_multiple\_sclerosis\_2NbHMSP.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2102 of SEQ ID NO:35, b is an integer of 15 to 2116, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a  
15 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 26

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Apoptotic T-cell, re-excision; Activated T-Cell  
20 (12hs)/Thiouridine labelledEco.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2043 of SEQ ID NO:36, b is an integer of 15 to 2057, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 27

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-Cells, 12 hrs, re-excision and to a lesser extent in Human adult testis, large inserts; Activated T-Cells, 12 hrs.; Human Adult Testes, Large Inserts, Reexcision; Human Adipose; Soares\_testis\_NHT; Ulcerative Colitis; Human Thymus; Primary Dendritic cells, frac 2; Human Testes, Reexcision; human tonsils; Human Bone Marrow, treated; Human Testes; Human Cerebellum and Primary Dendritic Cells, lib 1.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 86 as residues: Leu-78 to Phe-84, Asp-102 to Ala-113. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1215 of SEQ ID NO:37, b



is an integer of 15 to 1229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 28

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. emb|CAA17573.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Zinc Finger Protein ZFP47 LIKE [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >emb|CAA17573.1| (AL021997) dJ874C20.1 (Zinc Finger Protein ZFP47 LIKE)
    [Homo sapiens] >sp|O60817|O60817 DJ874C20.1 (ZINC FINGER PROTEIN
    ZFP47 LIKE) (FRAGMENT).
    Length = 252
20  Plus Strand HSPs:
    Score = 279 (98.2 bits), Expect = 3.1e-23, P = 3.1e-23
    Identities = 50/91 (54%), Positives = 72/91 (79%), Frame = +2
25  Q: 1022 NLGPESACRHFWSFRYHEATGPLETISQLQKLCHQWL RPEIHSKEQILEMLVLEQFLSIL 1201
    +LG E + F FRY EA GP E +S+L++LC QWL+PE+HSKEQILE+LVLEQFL+IL
    S: 39 DLGSEGSRRERFRGFRYPEAAGPREALSRLRELCRQWLQPEMHSKEQILELLVLEQFLTIL 98
30  Q: 1202 PKETQNWVQKHHHPQNVKQALVLVEFLQREPD 1294
    P Q+WV++ HP++ ++ +VL+E+L+R+ D
    S: 99 PGNLQSWVREQHPESGEEVVVLLLEYLERQLD 129

```

The segment of emb|CAA17573.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 133. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 134 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Placenta; human tonsils.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1623 of SEQ ID NO:38, b is an integer of 15 to 1637, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.  
25 emblCAA02413.11 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Homo sapiens

protein". A partial alignment demonstrating the observed homology is shown immediately below.

```

5  >emb|CAA02413.1| unnamed protein product [unidentified] >emb|CAA82638.1|
    1-acyl-glycerol-3-phosphate acyltransferase (putative) [Zea
    mays]

    >pir|S52645|S52645 probable 1-acyl-glycerol-3-phosphate
    acyltransferase - maize >sp|Q41745|Q41745
    1-ACYL-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (PUTATIVE).
10    Length = 374

    Plus Strand HSPs:

15    Score = 343 (120.7 bits), Expect = 9.0e-36, Sum P(2) = 9.0e-36
    Identities = 83/240 (34%), Positives = 132/240 (55%), Frame = +1

    Q:  379 GSKV-LAKKELAYVPIIGWMWYFTENVFCSRKWEQDRKTVATSLQHRLDYPEKYFFLIHC 555
        GS + + KK ++P+IGW +F E +F R W +D KT+ LQ L+D+P ++ +
    S:  112 GSTLAVMKRSSKFLPVIGWSMWFAEYLFLEERSWARDEKTLKWGLQRLKDFPRPFWLALFV 171
20

    Q:  556 EGTRFTEKKHEISMQVARAKGLPRLKHLLPRTKGFATVRSRLRNVS AVYDCTLNF-RN 732
        EGTRFT K + + A ++GLP ++ L+PRTKGF V +R+ V A+YD T+ ++
    S:  172 EGTRFTPAKLLAAQEYAAASQGLPAPRNVLIPRTKGFVSAVSIMRDFVPAIYDTTVIVPKD 231
25

    Q:  733 NENPTLLGVLNGRKYHADLYVRRXXXXXXXXXXXXCSAWLHKLYQEKDAFQEEYYRTGTF 912
        + PT+L +L G+ + ++R S W ++ KDA +++ TGTF
    S:  232 SPQPTMLRILKGQSSVIHVRMKRHAMSEMPKSDDEDVSKWCKDIFVAKDALLDKHLATGTF 291
30

    Q:  913 PETPMVPPRRPW-TLVNWLFWASLVLY---PFFQF--LVSMIRSGSSLTLASFILVFFVA 1074
        E + P RP +L+ LFW+ L+L+ FF++ L+S R G + T A LV V
    S:  292 DEE-IRPIGRPVKSLLVTLFWSCLLLFGAIEFFKWTQLLSTWR-GVAFTAAGMALVTGVM 349

    Q:  1075 SV 1080
        V
35    S:  350 HV 351

```

The segment of emb|CAA02413.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 135. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

40 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 136 which

corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Thymus and to a lesser extent in Ulcerative Colitis;
- 5 Bone marrow; Colon Normal III; Rejected Kidney, lib 4; Human Colon, re-excision; Hodgkin's Lymphoma II; Soares breast 3NbHBst; Stratagene lung (#937210); Soares ovary tumor NbHOT; Colon Tumor; Spleen, Chronic lymphocytic leukemia; human tonsils; Human Bone Marrow, treated; Colon Normal II; breast lymph node CDNA library; Soares breast 2NbHBst; Normal colon; Human Colon, subtraction; Human
  - 10 Colon; Human Testes Tumor; Human Thymus; Human Bone Marrow, re-excision; Colon Tumor II; Human Pancreas Tumor; Tongue Tumour; Weizmann Olfactory Epithelium; Human Adrenal Gland Tumor; Stomach cancer (human), re-excision; Larynx carcinoma III; Human Tonsils, Lib 2; Soares fetal liver spleen 1NFLS; Human Adult Lymph Node, subtracted; Thyroid Thyroiditis; Sinus piniformis
  - 15 Tumour; Aryepiglottis Normal; Human Adult Spleen; Spleen metastatic melanoma; Colon, normal; HUMAN TONSILS, FRACTION 2; Human Normal Breast; Colon Carcinoma; Soares placenta Nb2HP; Human colon cancer, metatized to liver, subtraction; Human Adult Spleen, fractionII; Palate carcinoma; Breast Lymph node cDNA library; Human Osteosarcoma; Human Chondrosarcoma; Human T-Cell
  - 20 Lymphoma; Tongue carcinoma; Human B Cell 8866; Merkel Cells; Human Adipose; Stratagene liver (#937224); human colon cancer, metastatic to liver, differentially expressed; Crohn's Disease; Rectum normal; Larynx Normal; Human Adult Pulmonary, re-excision; Human Adult Lymph Node; Human Colon, differential expression; Human Adult Small Intestine; Larynx carcinoma IV; Colon Normal;
  - 25 Human Bone Marrow; Human Colon Cancer, subtracted; Human epithelioid sarcoma; Weizmann Olfactory; Human Gall Bladder, fraction II; stomach cancer (human);

- Human Adult Pulmonary; Human Pancreatic Carcinoma; Human Skin Tumor;  
 Pancreas Tumor PCA4 Tu; Human Colon Cancer, re-excision; wilm's tumor; Human  
 Liver, normal; Stratagene hNT neuron (#937233); Soares infant brain 1NIB; Human  
 skin Tumor, subtracted; Activated T-Cell; Human Corpus Colosum; Human Adult  
 5 Spleen, subtracted; Human Esophagus, Cancer; Siebber Polyposis; Mammary Gland;  
 Raji cells, cyclohexamide treated, differentially expressed; Human Spleen;  
 Pericardium; Lung Mesothelium; Larynx carcinoma II; Stomach, normal; Rectum  
 tumour; Pharynx Carcinoma; Larynx Carcinoma; Colon Tumor; Larynx Tumour;  
 Stomach Normal; Thyroid Normal (SDCA2 No); Human Fetal Liver, mixed 10 & 14  
 10 week; Human Placenta, subtracted; Human Tonsils, lib 1; Tongue Normal; Nasal  
 polyps; Raji cells, cyclohexamide treated, subtracted; Human Prostate BPH, re-  
 excision; Human White Fat; Human 7 Weeks Old Embryo, subtracted;  
 Soares\_placenta\_8to9weeks\_2NbHP8to9W; L1 Cell line; H. Epididymus, caput &  
 corpus; H. Epididymus, cauda; Salivary Gland; Human T-cell lymphoma, re-excision;  
 15 Resting T-Cell, re-excision; Cem cells cyclohexamide treated; Raji Cells,  
 cyclohexamide treated; STROMAL -OSTEOCLASTOMA; Hepatocellular Tumor;  
 Human Stomach, re-excision; Human endometrial stromal cells-treated with  
 progesterone; Salivary Gland, Lib 2; Human Uterine Cancer; Human Activated T-  
 Cells; Bone Marrow Stromal Cell, untreated; Fetal Liver, subtraction II; Human Gall  
 20 Bladder; NCI\_CGAP\_Lu25; NCI\_CGAP\_Brn23; 12 Week Early Stage Human II,  
 Reexcision; Human Placenta; Soares\_fetal\_heart\_NbHH19W; NCI\_CGAP\_Co12;  
 Soares\_testis\_NHT and Soares\_pregnant\_uterus\_NbHPU.

Preferred polypeptides of the present invention comprise immunogenic  
 epitopes shown in SEQ ID NO: 88 as residues: Arg-60 to Ala-69, Ala-93 to Cys-99.

- 25 Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1626 of SEQ ID NO:39, b is an integer of 15 to 1640, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 30

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Monocyte activated and to a lesser extent in Primary Dendritic Cells, lib 1; Monocyte activated, re-excision; Bone marrow; Human Bone Marrow, treated; Dendritic cells, pooled; Palate normal; Macrophage (GM-CSF treated); Salivary Gland, Lib 2; Macrophage-oxLDL; Fetal Heart; Primary Dendritic cells, frac 2; Human Fetal Heart; Human Adult Pulmonary, re-excision; Human Bone Marrow, re-excision; H Macrophage (GM-CSF treated), re-excision; Colon Carcinoma; Macrophage-oxLDL, re-excision; Colon Tumor II; Palate carcinoma; Human Lung; Colon Tumor; Human Adult Small Intestine; Soares fetal liver spleen INFLS; Human Leukocytes; NCI\_CGAP\_Lu5; Human adult small intestine, re-excision; pBMC stimulated w/ poly I/C; Liver, Hepatoma; Ulcerative Colitis; Human T-Cell Lymphoma; Normal colon; Sinus piniformis Tumour; Larynx carcinoma IV; Larynx Carcinoma; Nasal polyps; Hep G2 Cells, PCR library; NCI\_CGAP\_Lym5;

- CD40 activated monocyte dendritic cells; Salivary Gland; Human Activated T-Cells, re-excision; Fetal Liver, subtraction II; Spleen, Chronic lymphocytic leukemia; Hodgkin's Lymphoma II; Thyroid Normal (SDCA2 No); Stomach Tumour; Normal trachea; Tongue Normal; Salivary Gland, Lib 3; Weizmann Olfactory Epithelium;
- 5 Human (HCC) cell line liver (mouse) metastasis, remake; NCI\_CGAP\_Gas4; Human Osteosarcoma; NCI\_CGAP\_Br1.1; NCI\_CGAP\_Gas4; NCI\_CGAP\_Pan1; Human Eosinophils; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human Activated Macrophage (LPS); Human Leukocyte, control #2; H. Leukocytes, normalized cot > 500A; H. Leukocytes, normalized cot 50A3; Larynx normal #10 261-273; Cheek
- 10 Carcinoma; Larynx Normal; Pharynx Carcinoma; Human Bone Marrow; Colon, tumour; Larynx tumor; Colon, normal; Human Gall Bladder, fraction II; Human colon carcinoma (HCC) cell line, remake; Human Colon Carcinoma (HCC) cell line; Human Adult Pulmonary; NCI\_CGAP\_Ut3; NCI\_CGAP\_Gas4; NCI\_CGAP\_Kid8; NCI\_CGAP\_Lym6; NCI\_CGAP\_Pan1; NCI\_CGAP\_Brn35; NCI\_CGAP\_Lym12;
- 15 Fetal Heart, re-excision; Human Fetal Bone; human colon cancer; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co14; NCI\_CGAP\_Lym12; CD34 depleted Buffy Coat (Cord Blood); TF-1 Cell Line GM-CSF Treated; NCI\_CGAP\_Br2; NCI\_CGAP\_Co3; NCI\_CGAP\_Co9; NCI\_CGAP\_GC3; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co11; NCI\_CGAP\_Lei2; NCI\_CGAP\_Mel3; Human Pancreas Tumor; Gessler Wilms
- 20 tumor; Human promyelocyte; 12 Week Old Early Stage Human; Colon Normal II; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Neutrophils control, re-excision; Human Placenta; human tonsils; Human Neutrophil, Activated; CD34 positive cells (Cord Blood); NCI\_CGAP\_Co9; T cell helper II; Soares placenta Nb2HP and NCI\_CGAP\_Kid5.
- 25 When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene

activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Antibodies that bind polypeptides of the invention are encompassed by the invention, particularly antibodies that inhibit activity.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:40, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. pirlJU0033IJU0033 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "hypothetical L1



protein (third intron of gene TS) - human". A partial alignment demonstrating the observed homology is shown immediately below.

```

5  >pir|JU0033|JU0033 hypothetical L1 protein (third intron of gene TS) -
    human
      Length = 562

      Plus Strand HSPs:

10  Score = 165 (58.1 bits), Expect = 3.5e-08, P = 3.5e-08
      Identities = 31/51 (60%), Positives = 37/51 (72%), Frame = +2

      Q: 1388 FKLYYKAIVTKTTTWYQNRVVDQWNRTKASEI-----MTFMQPTKKKK 1519
          FKLYYKA VTKT WYWYQNR++DQWNRT+ SEI          + F +P K K+
15  S: 364 FKLYYKATVTKTVWYQNRHIDQWNRTPESEITPHIYNYLIFDKPEKNKQ 414
  
```

The segment of pirJU0033|JU0033 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 137. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

20 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 138 which

25 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in human tonsils.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

30 related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1510 of SEQ ID NO:41, b is an integer of 15 to 1524, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a

5 + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gblAAB02291.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "reverse transcriptase [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

15

```
>gb|AAB02291.1| reverse transcriptase [Homo sapiens]
      Length = 361
```

20

Minus Strand HSPs:

```
Score = 200 (70.4 bits), Expect = 1.3e-12, P = 1.3e-12
Identities = 43/100 (43%), Positives = 55/100 (55%), Frame = -3
```

25

```
Q:  325 FNK*CWDWTAKCKRMMFDSDFTSYTKVSKILMAQRPYVIAKTIKFLEENIGVNLHDLG 146
      FNK CW+ W A CK++ D   T YTK+ S+ +       V KTIK +EEN+G+ + D+G
S:  18  FNKWCWENWLAICKKLDPFLTPYTKINSRWIKDLN--VRLKTIKTIEENLGITIQDIG 75
```

30

```
Q:  145 FGSGLDATPKA*ATKEKCRYI*LHKNLKLCLVLRDITKEV 26
      G  F+  TPKA ATK K   L K   C  K TT  V
S:  76  MGKDFMSKTPRAMATKARIDKWDLIKLSFCTAKQTIRV 115
```

The segment of gblAAB02291.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 139. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

35 Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 140 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Pancreas Tumor and to a lesser extent in Adipocytes, re-excision; Human Colon Cancer, re-excision; Human Osteosarcoma;  
10 Synovial Fibroblasts (II1/TNF), subT; Apoptotic T-cell; Human Ovary; 12 Week Old Early Stage Human; Human Testes Tumor; human tonsils; Activated T-Cell (12hs)/Thiouridine labelled Eco; Smooth muscle, control; Spleen, Chronic lymphocytic leukemia; Human fetal heart, Lambda ZAP Express;  
Soares\_multiple\_sclerosis\_2NbHMSP; Activated T-cell(12h)/Thiouridine-re-  
15 excision; Nine Week Old Early Stage Human and T cell helper II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1453 of SEQ ID NO:42, b is an integer of 15 to 1467, where both a and b correspond to the positions of  
25 nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-cell(12h)/Thiouridine-re-excision and to a lesser extent in Soares infant brain 1NIB; Osteoblasts; Human Cerebellum; Soares fetal liver spleen 1NFLS; Soares\_multiple\_sclerosis\_2NbHMSP; Soares\_testis\_NHT; Soares\_NFL\_T\_GBC\_S1; Cem cells cyclohexamide treated; Human Adipose Tissue, re-excision; Human Hippocampus; NCI\_CGAP\_Lu5; normalized infant brain cDNA; HL-60, RA 4h, Subtracted; Human Lung; Early Stage Human Lung, subtracted; H.
- 10 Whole Brain #2, re-excision; Alzheimers, spongy change; Myeloid Progenitor Cell Line; Spinal Cord, re-excision; Human Thymus; Apoptotic T-cell; Human Adrenal Gland Tumor; CHME Cell Line, treated 5 hrs; Human Fetal Lung III; Anergic T-cell; Monocyte activated; Human Testes; H. Frontal cortex, epileptic, re-excision; NCI\_CGAP\_Co3; NCI\_CGAP\_GC3; NCI\_CGAP\_Kid5;
- 15 Soares\_parathyroid\_tumor\_NbHPA; Soares\_multiple\_sclerosis\_2NbHMSP and b4HB3MA-Cot51.5-HAP-Ft.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 92 as residues: Pro-61 to Asn-72. Polynucleotides encoding said polypeptides are also encompassed by the invention.

- 20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
- 25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1626 of SEQ ID NO:43, b is an integer of 15 to 1640, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

5

### FEATURES OF PROTEIN ENCODED BY GENE NO: 34

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 emb|CAA73251.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Pro-Pol-dUTPase polyprotein [Mus musculus]". A partial alignment demonstrating the observed homology is shown immediately below.

15 >emb|CAA73251.1| Pro-Pol-dUTPase polyprotein [Mus musculus]  
>sp|O02711|O02711  
fibulin PRO-POL-DUTPASE POLYPROTEIN (FRAGMENT). >gb|AAB26708.1|  
gene homolog [mice, Peptide Partial, 78 aa] [Mus sp.] {SUB  
20 380-457}  
Length = 1182  
Minus Strand HSPs:  
25 Score = 258 (90.8 bits), Expect = 6.4e-18, P = 6.4e-18  
Identities = 74/167 (44%), Positives = 91/167 (54%), Frame = -3  
Q: 466 LPQR---PFTRVTTD\*RKGNQTQFRDY\*FLGTQNAVAYQSK\*VL-TVVR\*\*MK----- 317  
LPQR PFTRVT KGN QTFR G++ + K V+  
30 S: 26 LPQRDLRPFTRVTVHWGKGNQTFRGLLDTGSELTLPDPPKRCGPPVKVGAYGGQVIN 85  
Q: 316 -CLAQVHLTVDPPIVQWAYFVXIISVPE\*ILGTDILDYQSSHIGFLTQLIRVILIVRAKW 140  
L V LTV P+ + V IS VPE I+G DIL WQ+SHIG L +R I++ +AKW  
S: 86 GVLTDVRLTVGPVGPRTHPVVISPVPECIIGDILRNWQNSHIGSLNCRVRAIMVGRAKW 145  
35 Q: 139 KPLELTLPTKILSQKQYHI-SRIKELNVTIKRLERNRVVIPIIS\*FN 2  
PLEL LP KI++QKQY I I E+ TIK L+ VV+P S FN  
S: 146 IPLELPLPKKIVNQKQYCIPGEIAEITATIKDLKDAGVVVPTTSPFN 192

The segment of embICA73251.11 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 141. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

- 5 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 142 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
10 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Activated T-cell(12h)/Thiouridine-re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15 related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
20 general formula of a-b, where a is any integer between 1 to 1615 of SEQ ID NO:44, b is an integer of 15 to 1629, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 35

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5 gb|AAB96869.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "similar to Leucine-rich transmembrane proteins; 44% similarity to U42767 (PID:g1736918) [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

10  >gb|AAB96869.1| (AC004010) similar to Leucine-rich transmembrane proteins;
    44%
        similarity to U42767 (PID:g1736918) [Homo sapiens]
15  >sp|O43354|O43354 BAC CLONE GS099H08, COMPLETE SEQUENCE.
        Length = 522

    Plus Strand HSPs:

20  Score = 664 (233.7 bits), Expect = 1.7e-64, P = 1.7e-64
    Identities = 132/144 (91%), Positives = 132/144 (91%), Frame = +2

    Q:   23 TINVSNFTVSRSHAHEAFNTAFTTLAACVASIVLVLLYLYLTPCPCKCKTKRQKNMLHQS 202
        TINVSNFTVSRSHAHEAFNTAFTTLAACVASIVLVLLYLYLTPCPCKCKTKRQKNMLHQS
25  S:   379 TINVSNFTVSRSHAHEAFNTAFTTLAACVASIVLVLLYLYLTPCPCKCKTKRQKNMLHQS 438

    Q:   203 NAHSSILSPGPASDASADERKAGAGKRVVFLEPLKDTAAGQNGKVRFPSEAVIAEGILK 382
        NAHSSILSPGPASDASADERKAGAGKRVVFLEPLKDTAAGQNGKVRFPSEAVIAEGILK
30  S:   439 NAHSSILSPGPASDASADERKAGAGKRVVFLEPLKDTAAGQNGKVRFPSEAVIAEGILK 498

    Q:   383 STRGKXXXXXXXXXXXXTPFVAST 454
        STRGK                      TPFVAST
    S:   499 STRGKSDSDSVNSVFS DTPFVAST 522
  
```

- The segment of gb|AAB96869.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 143. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 144 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- 5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: CHME Cell Line, treated 5 hrs and to a lesser extent in Human aorta polyA+ (TFujiwara); NCI\_CGAP\_Lu5; Human Osteoclastoma, re-excision; 12 Week Old Early Stage Human, II; Lymph node, abnorm. cell line (ATCC #7225); PCR, pBMC I/C treated; Human Uterus, normal; stomach cancer (human); H Female
- 10 Bladder, Adult; Stratagene ovarian cancer (#937219); Jurkat T-cell G1 phase; Human umbilical vein endothelial cells, IL-4 induced; Human retina cDNA randomly primed sublibrary; NCI\_CGAP\_AA1; NCI\_CGAP\_GCB1; Human Thymus Stromal Cells; Ovarian Tumor 10-3-95; Smooth muscle, serum induced, re-exc; Human Testes Tumor; Bone marrow; Soares\_parathyroid\_tumor\_NbHPA;
- 15 Soares\_senescent\_fibroblasts\_NbHSF; Human Osteoclastoma; Human Bone Marrow, treated; H. Frontal cortex, epileptic, re-excision; neutrophils control; Nine Week Old Early Stage Human and T cell helper II.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
- 20 related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
- 25 general formula of a-b, where a is any integer between 1 to 1401 of SEQ ID NO:45, b is an integer of 15 to 1415, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 36

5 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. emb|CAA24033.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "URF 3 (NADH  
10 dehydrogenase subunit) [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

>emb|CAA24033.1| URF 3 (NADH dehydrogenase subunit) [Homo sapiens]
>gb|AAB58950.1| protein 3 [Homo sapiens] >pir|A00422|DNHUN3
15 NADH
    dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 3 - human
    mitochondrion (SGC1) >sp|P03897|NU3M_HUMAN NADH-UBIQUINONE
    OXIDOREDUCTASE CHAIN 3 (EC 1.6.5.3).
    Length = 115
20
    Plus Strand HSPs:
    Score = 188 (66.2 bits), Expect = 3.4e-14, P = 3.4e-14
    Identities = 42/88 (47%), Positives = 46/88 (52%), Frame = +2
25
    Q: 77 NGYIEKSTPYECGFDPISPARVPFSIKFFLVAIXXXXXXXXXXXXXXXXXXXXXXXXX 256
        NGY+EKSTPYECGFDP+SPARVPFS+KFFLVAI
    S: 28 NGYMEKSTPYECGFDPMSPARVPFSMKFFLVAITFLLFDLEIALLLPLPWALQTTNLPLM 87
30
    Q: 257 VMXXXXXXXXXXXXXXYE*LQKGLD*TE 340
        VM YE LQKGLD TE
    S: 88 VMSSLLLIILALSLAYEWLQKGLDWTE 115
  
```

The segment of emb|CAA24033.1| that is shown as "S" above is set out in the  
35 sequence listing as SEQ ID NO. 145. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 146 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Primary Dendritic Cells, lib 1; L428; Keratinocyte; Hodgkin's Lymphoma I; H. Ovarian  
10 Tumor, II, OV5232; Human Thymus Stromal Cells; Human Eosinophils; Primary Dendritic cells, frac 2; Human Bone Marrow, treated; Hodgkin's Lymphoma II; H. Leukocytes, normalized cot 500 A; Nasal polyps; Human Adult Spleen; Human Lung; Human Tonsils, Lib 2; Human Synovium; pBMC stimulated w/ poly I/C; Healing groin wound, 7.5 hours post incision; Apoptotic T-cell; Human Osteoblasts  
15 II; Human Heart; Liver, Hepatoma; Human Adipose; Rejected Kidney, lib 4; Ovarian Tumor 10-3-95; NTERA2, control; Human Liver, normal; Macrophage-oxLDL, re-excision; Human T-Cell Lymphoma; Human Placenta; H Macrophage (GM-CSF treated), re-excision; Dendritic cells, pooled; human tonsils; CD34 depleted Buffy Coat (Cord Blood), re-excision; Spleen, Chronic lymphocytic leukemia; T Cell helper  
20 I; Human Testes and Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 358 of SEQ ID NO:46, b is an integer of 15 to 372, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 37

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA12974.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "SHPS-1 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >dbj|BAA12974.1| SHPS-1 [Homo sapiens] >emb|CAA71403.1| SIRP-alpha1 [Homo
    sapiens] >pir|JC5287|JC5287 SHP substrate-1 protein - human
    >sp|P78324|P78324 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR
20  TYPE
    SUBSTRATE 1 PRECURSOR (SHP SUBSTRATE-1) (INHIBITORY RECEPTOR
    SHPS-1) (SHPS-1) (SIGNAL- REGULATORY PROTEIN ALPHA-1)
    (SIRP-ALPHA1). >emb|CAB38874.1| (AL034562) dJ684024.1 (SHP
25  1,
    substrate 1, SHPS-1, MYD-1 antigen, Signal_regulatory protein
    SIRP-alpha1)) [Homo sapiens] {SUB 146-503}
    Length = 503

    Plus Strand HSPs:
30  Score = 263 (92.6 bits), Expect = 1.0e-18, P = 1.0e-18
    Identities = 59/131 (45%), Positives = 80/131 (61%), Frame = +3

    Q: 234 EPDLWIIQPQELVLGTTGDTVFLNCTVLGDGPPGPIRWFQAGLSREAIYNFGGISHPKA 413
        E +L +IQP + V    G++ L+CTV    P GPI+WF+GAG +RE IYN    P+
35  S: 31 EEELQVIQPDKSVSVAAGESAILHCTVTSLIPVGPIQWFRGAGPARELIYNQKEGHFPRV 90

    Q: 414 TAVQAS----NNDFSILLQNVSSDAGTYTCVKFQR-KPNRQYLSGQGTSLKVKAKSTSS 578
        T V S    N DFSI + N++ DAGTYTCVKF++ P+ ++ SG GT L V+AK +
40  S: 91 TTVSESTKRENMDFSISISNITPADAGTYTCVKFRKGSPTDEFKSGAGTELSVRAKPS-- 148
  
```

Q: 579 KEAEFTSEPATEMSP 623  
A S PA +P  
S: 149 --APVVSGPAARATP 161

- 5 The segment of dbj|BAA12974.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 147. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have  
10 been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 148 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- 15 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Dendritic cells, pooled and to a lesser extent in H. Epididymus, caput & corpus; pBMC stimulated w/ poly I/C; Human Activated Monocytes; H Macrophage (GM-CSF treated), re-excision and Human Adult Pulmonary, re-excision.

- 20 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 96 as residues: Ser-32 to Thr-43. Polynucleotides encoding said polypeptides are also encompassed by the invention.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2769 of SEQ ID NO:47, b is an integer of 15 to 2783, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 38

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares fetal liver spleen 1NFLS; Early Stage Human Brain; Soares\_fetal\_heart\_NbHH19W; Soares\_NhHMPu\_S1; Soares melanocyte 2NbHM; Soares\_multiple\_sclerosis\_2NbHMSP; Human Fetal Lung III; Soares ovary tumor NbHOT; Soares\_total\_fetus\_Nb2HF8\_9w; Human Adult Pulmonary; Human Fetal Spleen; Human Osteoclastoma, re-excision; wilm's tumor; HUMAN JURKAT

MEMBRANE BOUND POLYSOMES; Human Fetal Dura Mater; Human Hypothalmus,Schizophrenia; Human Rhabdomyosarcoma; Human Osteoclastoma; Soares\_parathyroid\_tumor\_NbHPA; Spleen, Chronic lymphocytic leukemia and Primary Dendritic Cells, lib 1.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 97 as residues: Arg-32 to Trp-42. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 685 of SEQ ID NO:48, b is an integer of 15 to 699, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 39

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Brain Frontal Cortex, re-excision and to a lesser extent in Human Lung Cancer, re-excision; Human Colon Cancer, re-excision; Healing Abdomen wound, 70&90 min post incision; Healing groin wound - zero hr post-incision (control); Stomach cancer (human), re-excision; Spinal Cord, re-excision; Human Fetal Heart, subtracted; HUMAN STOMACH; Smooth muscle, control, re-excision; Human Fetal Bone; Human Hypothalamus, schizophrenia, re-excision; Human Stomach, re-excision; Macrophage-oxLDL, re-excision; Human Substantia Nigra; Hodgkin's Lymphoma I; Human adult small intestine, re-excision; Human Adipose Tissue, re-excision; Synovial hypoxia; Myeloid Progenitor Cell Line; Human Heart; Human Placenta; Human Fetal Heart and Hodgkin's Lymphoma II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1154 of SEQ ID NO:49, b is an integer of 15 to 1168, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49; and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 40

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 emb|CAA76830.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "atopy related autoantigen CALC [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

15 >emb|CAA76830.1| atopy related autoantigen CALC [Homo sapiens]  
 >sp|O75785|O75785 ATOPY RELATED AUTOANTIGEN CALC (FRAGMENT).  
 Length = 313

20 Plus Strand HSPs:

Score = 438 (154.2 bits), Expect = 1.5e-40, P = 1.5e-40  
 Identities = 84/86 (97%), Positives = 84/86 (97%), Frame = +1

25 Q: 265 LFSVTMQQVARTVAKVELSDHVCDDVVFALFDCDNGELSNKEFVSIMKQRLMRGLEKPKD 444  
 L VTMQQVARTVAKVELSDHVCDDVVFALFDCDNGELSNKEFVSIMKQRLMRGLEKPKD  
 S: 228 LDKVTMQQVARTVAKVELSDHVCDDVVFALFDCDNGELSNKEFVSIMKQRLMRGLEKPKD 287

Q: 445 MGFTRLMQAMWKCAQETAWDFALPKQ 522  
 MGFTRLMQAMWKCAQETAWDFALPKQ

30 S: 288 MGFTRLMQAMWKCAQETAWDFALPKQ 313

The segment of emb|CAA76830.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 149. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

35 Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 150 which  
 5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares\_fetal\_heart\_NbHH19W; Stratagene lung (#937210); Soares infant brain  
 10 1NIB; Soares ovary tumor NbHOT; NCI\_CGAP\_GCB1; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; NCI\_CGAP\_Kid3; NCI\_CGAP\_Kid6; H. Kidney Medulla, re-excision; Soares\_senescent\_fibroblasts\_NbHSF; Soares\_testis\_NHT; Soares melanocyte 2NbHM; Soares\_pregnant\_uterus\_NbHPU; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Brain, striatum, re-excision; Human  
 15 fetal heart, Lambda ZAP Express; NCI\_CGAP\_Co8; NCI\_CGAP\_Ew1; NCI\_CGAP\_GC2; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co11; NCI\_CGAP\_Co12; NCI\_CGAP\_Kid5; Thyroid Tumour; Human Gastrocnemius; Liver Normal Met5No; HUMAN TONSILS, FRACTION 2; NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid3; NCI\_CGAP\_Brn25; Papillary serous cystic neoplasm of low malignant potential  
 20 (ovary); Human Quadriceps; Soares adult brain N2b4HB55Y; Human Hypothalamus, schizophrenia, re-excision; Human epidermal keratinocyte; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Stratagene cat#937212 (1992); Hepatocellular Tumor, re-excision; Hepatocellular Tumor; Alzheimers, spongy change; Human Whole Brain #2 - Oligo dT > 1.5Kb; HL-60, PMA 4H, re-excision; Stratagene NT2  
 25 neuronal precursor 937230; KMH2; Human Brain, Striatum; Monocyte activated, re-excision; Infant brain, Bento Soares; Soares\_fetal\_heart\_NbHH19W; Human



Pancreas Tumor, Reexcision; Human Hippocampus; Liver, Hepatoma; Soares breast  
2NbHBst; Human Whole Six Week Old Embryo; Gessler Wilms tumor;  
Soares\_fetal\_heart\_NbHH19W; Soares\_fetal\_liver\_spleen\_INFLS\_S1; Macrophage-  
oxLDL, re-excision; Adipocytes; Bone marrow; Human Microvascular Endothelial  
5 Cells, fract. A; HUMAN B CELL LYMPHOMA; Human 8 Week Whole Embryo;  
Soares\_fetal\_lung\_NbHL19W; Soares\_pineal\_gland\_N3HPG and  
Soares\_senescent\_fibroblasts\_NbHSF.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 99 as residues: Pro-7 to Pro-17, Cys-57 to Asn-65,  
10 Leu-80 to Asp-85. Polynucleotides encoding said polypeptides are also encompassed  
by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:50 and may have been publicly available prior to conception of  
15 the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 1411 of SEQ ID NO:50, b  
20 is an integer of 15 to 1425, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a  
+ 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 41

25 The computer algorithm BLASTX has been used to determine that the  
translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no.

gb|AAB65482.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "endomembrane protein EMP70 precursor isolog [*Arabidopsis thaliana*]". A partial alignment

5 demonstrating the observed homology is shown immediately below.

```

>gb|AAB65482.1| endomembrane protein EMP70 precursor isolog [Arabidopsis
  thaliana] >sp|O04091|O04091 ENDOMEMBRANE PROTEIN EMP70
PRECUSOR
10      ISOLOG.
      Length = 589

      Plus Strand HSPs:

15      Score = 1358 (478.0 bits), Expect = 5.5e-150, Sum P(2) = 5.5e-150
      Identities = 259/537 (48%), Positives = 363/537 (67%), Frame = +2

Q:   92 TFHFHSVWGQKKSISHYHET--LGEALQGVLEFSGLDIKFKDDVMPATYCEIDLKKEK 265
      T++++S+  + S ++ H+  LGE L G EL  S + IKF +V  + C ++LD+ K
20  S:   53 TYNYYSLPFCRPSGNNVHKWGGLGEVLGGNELIDSEIAIKFMKNVERSVICPLELDEAKV 112

Q:   266 DAFVYAIKNHYWYQMYIDDLPIWGIVGEA--DENGED--YYLWYKKLEIGFNGNRIVDV 433
      F AI++ YW++ ++  +  VGE  D+N E+  + L+T+K + + +N ++I+ V
25  S:   113 KHFKDAIESSYWFEFFMGMPHVCCFVGELHPDKNSENGKHVLYTHKNIVVKYNKDQIIHV 172

Q:   434 NLTSEGVKVLVPNTKIQMSYVKKWKSVDKFDKYLDPSPFFQHRIHWFSIFNSFMMV 613
      NLT +   L   K+ ++YSV+W ++V F  RFD YLD FF+H+IHWFSIFNSFMMV
30  S:   173 NLTQDNPRPLEAGKKMDLTYSVQWIPTNVTFARRFDVYLDYPFFEHQIHWFSIFNSFMMV 232

Q:   614 IFLVGLVSMILMRTLKDYARYSKEEE--MDDMDRDLGDEYGWKQVHGDVFRPSSHPLIFS 790
      IFL GLVSMILMRTL R DYA+Y++E++ ++ ++RD+ +E GWK VHGDVFRP+S ++ S
35  S:   233 IFLTGLVSMILMRTLNDYARYAREDDLESLELDVSEESGWKLVHGDVFRPASSLVLLS 292

Q:   791 SLIGSGCQIFAVSLIVIVAMIEDLYTERGSMLSTAIFVYAATSPVNGYFGGSLYARQGG 970
      +++G+G Q+  + L+VI++A++ LY  RG++++T I  YA TS V+GY  G +Y+R GG
40  S:   293 AVVGTGAQLALLVLLVILMAIVGTLVGRGAIVTTTFIVCYALTSFVSGYVSGGMYRSRSG 352

Q:   971 RRWIKQMFIGAFLIPAMVCGTAFFINFIAIYYHASRAIPFGTMVAVCCICFFVILPLNLV 1150
      + WIK M + A L P +  G  F +N IAI+Y +  AIPFGTMV V  I  F+  PL L+
45  S:   353 KHWIKCMVLTASLPFLCFGIGFLLNTIAIFYGSLAAIPFGTMVVVFVIWGFISFPLALL 412

Q:   1151 GTILGRNLSGQPNFPCRVNAVPRPIPEKKWFMEPAVIVCLGGILPFGSIFIEMFYFTSF 1330
      GT++GRN SG PN PCRV  +PRPIPEKKW++ P+V+  +GG+LPFGSIFIEMFYF+FTSF
50  S:   413 GTVVGRNWSGAPNNPCRVKTIPRPIPEKKWYLTSPSVSLMGLLPFGSIFIEMFYFVFTSF 472

Q:   1331 WAYKIYVYVYGFMMXXXXXXXXXXXXXXXXXXXXXFLNAEDYRWQWTSFLSAASTAIXXXXX 1510
      W YK+YVYVYGF+  YFLNAE+Y WQWTSF SAASTA+
S:   473 WNYKVYVYVYGFMLLVFVILVIVTVCVTIVGTYFLNAENYHWQWTSFFSAASTAVYVYLY 532

Q:   1511 XXXXXXXXXXXXXGLFQTSFYFGYMAVFTALGIMCGAIGYMGTSFAVRKIYTNVKID 1681
      G FQTSFYFGY  +F  LGI+CGA+GY+G++ FVR+IY N+K D

```

S: 533 SIYYYYVTKMSGFFQTSFYFGYTMMFCLGLGILCGAVGYLGSNLFVRRIRYRNIKCD 589

The segment of gblAAB65482.11 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 151. Based on the structural similarity, these

- 5 homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

- 10 Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 152 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Nine Week
- 15 Old Early Stage Human; Soares\_testis\_NHT; Rejected Kidney, lib 4; Human Testes Tumor; Human Endometrial Tumor; Primary Dendritic Cells, lib 1; prostate-edited; Soares\_total\_fetus\_Nb2HF8\_9w; Human Pancreas Tumor, Reexcision; CHME Cell Line, treated 5 hrs; Normal colon; Soares melanocyte 2NbHM; 12 Week Early Stage Human II, Reexcision; Human Testes, Reexcision; Human Adult Pulmonary, re-
- 20 excision; Human 8 Week Whole Embryo; Stomach, normal; Colon Normal; Liver Tumour Met 5 Tu; Tongue carcinoma; Human Tonsil, Lib 3; Human Adult Spleen; Aorta endothelial cells + TNF-a; Human Thyroid; Human Lung; Human Tonsils, Lib 2; Stomach cancer (human), re-excision; Human Colon Cancer, re-excision; H Female Bladder, Adult; Healing groin wound, 7.5 hours post incision;
- 25 Soares\_pregnant\_uterus\_NbHPU; Human Osteoclastoma, re-excision; Synovial hypoxia; Stratagene colon (#937204); Myeloid Progenitor Cell Line; Healing groin wound, 6.5 hours post incision; Synovial Fibroblasts (II1/TNF), subt; wilm's tumor;

Brain Frontal Cortex, re-excision; Human Adult Small Intestine; Human Prostate; H.  
 Kidney Medulla, re-excision; T-Cell PHA 16 hrs; Human Umbilical Vein,  
 Reexcision; L428; 12 Week Old Early Stage Human, II; Human Uterine Cancer;  
 Atrium cDNA library Human heart; Gessler Wilms tumor; STRATAGENE Human  
 5 skeletal muscle cDNA library, cat. #936215.; Stratagene fetal retina 937202; Human  
 umbilical vein endothelial cells, IL-4 induced; Human Chondrosarcoma; Ulcerative  
 Colitis; Human Thymus Stromal Cells; Human Adrenal Gland Tumor; NTERA2,  
 control; Smooth muscle, serum induced, re-exc; Human Gall Bladder; Human Ovarian  
 Cancer Reexcision; Resting T-Cell Library, II; Human T-Cell Lymphoma; Colon  
 10 Carcinoma; Human Placenta; NCI\_CGAP\_Pr4.1; Primary Dendritic cells, frac 2;  
 Human Fetal Lung III; Colon Normal III; Human Osteoclastoma; Human Amygdala;  
 Human Microvascular Endothelial Cells, fract. A; Smooth muscle, control; HUMAN  
 B CELL LYMPHOMA; Human Bone Marrow, treated; Human Testes;  
 NCI\_CGAP\_Lym5; H. Frontal cortex, epileptic, re-excision and Activated T-  
 15 cell(12h)/Thiouridine-re-excision.

Preferred polypeptides of the present invention comprise immunogenic  
 epitopes shown in SEQ ID NO: 100 as residues: Arg-24 to Trp-44, Leu-87 to Ser-93,  
 Arg-119 to Trp-125, Pro-206 to Lys-211, Glu-280 to Trp-286. Polynucleotides  
 encoding said polypeptides are also encompassed by the invention.

20 . Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 related to SEQ ID NO:51 and may have been publicly available prior to conception of  
 the present invention. Preferably, such related polynucleotides are specifically  
 excluded from the scope of the present invention. To list every related sequence  
 25 would be cumbersome. Accordingly, preferably excluded from the present invention  
 are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 2522 of SEQ ID NO:51, b is an integer of 15 to 2536, where both a and b correspond to the positions of nucleotide-residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 42

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_parathyroid\_tumor\_NbHPA; Soares infant brain 1NIB and to a lesser extent in normalized infant brain cDNA; NCI\_CGAP\_Kid11; Human Prostate Cancer, Stage B2 fraction; Human Adult Pulmonary; Human Pancreatic Carcinoma; wilm's tumor; Pancreas Islet Cell Tumor; Soares\_pregnant\_uterus\_NbHPU and Soares\_parathyroid\_tumor\_NbHPA.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 101 as residues: Ser-20 to Asp-25. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1357 of SEQ ID NO:52, b is an integer of 15 to 1371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adult Pulmonary, re-excision; Soares ovary tumor

- 5 NbHOT and to a lesser extent in Human Adult Pulmonary; Stratagene lung (#937210); Human Fetal Lung III; Kidney Pyramids; Human Tonsil, Lib 3; NCI\_CGAP\_Ut3; NCI\_CGAP\_Kid5; NCI\_CGAP\_Ov2 and Human Endometrial Tumor.

- Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 102 as residues: Pro-28 to Ser-35. Polynucleotides encoding said polypeptides are also encompassed by the invention.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1865 of SEQ ID NO:53, b is an integer of 15 to 1879, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 44**

- 25 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no.

gb|AAC51271.1| (all information available through the recited accession number is

incorporated herein by reference) which is described therein as "putative p150 [Homo

sapiens]". A partial alignment demonstrating the observed homology is shown

5 immediately below.

>gb|AAC51271.1| putative p150 [Homo sapiens] >sp|O00370|O00370 PUTATIVE  
P150.

Length = 1275

10

Minus Strand HSPs:

Score = 220 (77.4 bits), Expect = 2.0e-17, Sum P(2) = 2.0e-17

Identities = 71/194 (36%), Positives = 105/194 (54%), Frame = -3

15

Q: 849 LDPYFTPY---NSKYMLDLDVK---LKPLEENTGKNHCNLWLKDFLDLTALKAQPRNEQM 688

LDP+ TPY NS+++ DL+VK +K LEEN G ++ +GKDF+ KA +++

S: 949 LDPFLTPYTKINSRWIKDLNVKPKTIKTLEENLGITIQDIGVGKDFMSKTPKAMATKDKI 1008

20

Q: 687 ERTDFIKISSSVLQK-TLLRE\*KDNPETGRKPLQG\*WTDSEVTPRIYF\*KLSVLNNKKTQ 511

++ D IK+ S K T +R + P T K +D + RIY +L + KKT

S: 1009 DKWDLIKLSFCTAKETTIRVNRQ-PTTWEKIFATYSSDKGLISRIYN-ELKQIYKKKTN 1066

25

Q: 510 ITQLIMGKRFKQTXHQRFSIKDDQYY\*-----SLG----QCKLISQYNFTCTRIAI 370

I K++ + ++ FS K+D Y SL Q K +Y+ T R+AI

S: 1067 --NPI--KKWAKDMNRHFS-KEDIYAAKHKMKCSSSLAIREMQIKTTMRYHLTPVRMAI 1121

Q: 369 IKKTNNKSW\*GCGETGNLIH 307

IKK+ NN+ W GCGE G L+H

30

S: 1122 IKKSGNNRCWRGCGEIGTLVH 1142

The segment of gb|AAC51271.1| that is shown as "S" above is set out in the

sequence listing as SEQ ID NO. 153. Based on the structural similarity, these

homologous polypeptides are expected to share at least some biological activities.

35 Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have

been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 154 which

corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Spleen/normal; Human Thymus Stromal Cells; Soares infant

5 brain 1NIB and to a lesser extent in Soares\_fetal\_lung\_NbHL19W;

Soares\_parathyroid\_tumor\_NbHPA and Soares\_fetal\_lung\_NbHL19W.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 103 as residues: Lys-21 to Gln-29. Polynucleotides encoding said polypeptides are also encompassed by the invention.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 993 of SEQ ID NO:54, b is an integer of 15 to 1007, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a  
20 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
25 example, the sequence accessible through the following database accession no. gb|AAC39926.1| (all information available through the recited accession number is



incorporated herein by reference) which is described therein as "zinc finger DNA binding protein 89 kDa [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below:

```

5   >gb|AAC39926.1| (AF039019) zinc finger DNA binding protein 89 kDa [Homo
      sapiens] >sp|O43591|O43591 ZINC FINGER DNA BINDING PROTEIN 89
      KDA.
      Length = 794

10   Plus Strand HSPs:
      Score = 2077 (731.1 bits), Expect = 3.1e-214, P = 3.1e-214
      Identities = 409/419 (97%), Positives = 409/419 (97%), Frame = +3

15   Q:  807 SHLEDASGEIHPKLVKKINSKRSLKQPLEQNQTISPLSTYEESKVS KYAFELVDKQAL 986
      SHLEDASGEIHPKLVKKINSKRSLKQPLEQNQTISPLSTYEESKVS KYAFELVDKQAL
      S:  376 SHLEDASGEIHPKLVKKINSKRSLKQPLEQNQTISPLSTYEESKVS KYAFELVDKQAL 435

20   Q:  987 LDSEGNADIDQVDNLQEGPSKPVHSSSTNYDDAMQFLKKKRYLQAASTTSREYALNVGTIA 1166
      LDSEGNADIDQVDNLQEGPSKPVHSSSTNYDDAMQFLKKKRYLQAAS SREYALNVGTIA
      S:  436 LDSEGNADIDQVDNLQEGPSKPVHSSSTNYDDAMQFLKKKRYLQAASNNSREYALNVGTIA 495

25   Q:  1167 SQPSVTQA AVASVIDESTTASILESQALNVEIKSNHDKNVIPDEVLTLLDHYS HKANGQ 1346
      SQPSVTQA AVASVIDESTTASILESQALNVEIKSNHDKNVIPDEVLTLLDHYS HKANGQ
      S:  496 SQPSVTQA AVASVIDESTTASILESQALNVEIKSNHDKNVIPDEVLTLLDHYS HKANGQ 555

30   Q:  1347 HEISFSVADTEVTSSISINSSEVPEVTPSENVGXXXXXXXXXDKANMLQEYSKFLQ QALDR 1526
      HEISFSVADTEVTSSISINSSEVPEVTPSENVG DKANMLQEYSKFLQ QALDR
      S:  556 HEISFSVADTEVTSSISINSSEVPEVTPSENVGSSSQASSSDKANMLQEYSKFLQ QALDR 615

35   Q:  1527 TSQNDAYLNSPSLNFVTDNQTLPNQPAFSSIDKQVYATMPINSFRSGMNSPLRTTPDKSH 1706
      TSQNDAYLNSPSLNFVTDNQTLPNQPAFSSIDKQVYATMPINSFRSGMNSPLRTTPDKSH
      S:  616 TSQNDAYLNSPSLNFVTDNQTLPNQPAFSSIDKQVYATMPINSFRSGMNSPLRTTPDKSH 675

40   Q:  1707 FGLIVGDSQHSFPFSGDET NHASATSTQDFLDQVTSQKKA EAQPVHQAYQMSSFEQPFRA 1886
      FGLIVGDSQHSFPFSGDET NHASATSTQDFLDQVTSQKKA EAQPVHQAYQMSSFEQPFRA
      S:  676 FGLIVGDSQHSFPFSGDET NHASATSTQDFLDQVTSQKKA EAQPVHQAYQMSSFEQPFRA 735

      Q:  1887 PYHGSRAGIATQFSTANGQVNLRGPGTSAEFSEFPLVNVNDNRAGMTSSPDATTGQTFG 2063
      PYHGSRAGIATQFSTANGQVNLRGPGTSAEFSEFPLVNVNDNRAGMTSSPDATTGQTFG
      S:  736 PYHGSRAGIATQFSTANGQVNLRGPGTSAEFSEFPLVNVNDNRAGMTSSPDATTGQTFG 794

```

The segment of gb|AAC39926.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 155. Based on the structural similarity, these

45 homologous polypeptides are expected to share at least some biological activities.

Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 156 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: 12 Week Old Early Stage Human, II; Soares melanocyte 2NbHM; Spleen, Chronic lymphocytic leukemia and to a lesser extent in Weizmann  
10 Olfactory Epithelium; H. Whole Brain #2, re-excision; Stratagene muscle 937209; NTERA2 + retinoic acid, 14 days; Synovial hypoxia-RSF subtracted; T-Cell PHA 16 hrs; Human Rhabdomyosarcoma; Human Thymus; Synovial Fibroblasts (control); Colon Tumor; Human Substantia Nigra; Anergic T-cell; HUMAN B CELL LYMPHOMA; Nine Week Old Early Stage Human; Soares placenta Nb2HP and  
15 Soares fetal liver spleen 1NFLS.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 104 as residues: Ser-18 to Asn-23, Leu-34 to Ile-39. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly  
20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
25 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2068 of SEQ ID NO:55, b

is an integer of 15 to 2082, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA77671.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "cytochrome c oxidase subunit 3 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```
15 >dbj|BAA77671.1| cytochrome c oxidase subunit 3 [Homo sapiens]
    >gb|AAB58949.1|
        cytochrome oxidase subunit 3 [Homo sapiens] {SUB 1-260}
        Length = 261

20 Plus Strand HSPs:

    Score = 843 (296.8 bits), Expect = 1.6e-83, P = 1.6e-83
    Identities = 165/203 (81%), Positives = 168/203 (82%), Frame = +3

25 Q:      9 RDVTRESTYQGHHTPPVQKGLRYGIILFITSEVXXXXXXXXXXHSSLAPTPQLGGHWPP 188
    RDVTRESTYQGHHTPPVQKGLRYG+ILFITSEV          YHSSLAPTPQLGGHWPP
    S:     59 RDVTRESTYQGHHTPPVQKGLRYGMILFITSEVFFAGFFWAFYHSSLAPTPQLGGHWPP 118

    Q:    189 TGITPLNPLEVPLLNTSVLLASGVSI*AHHSLIENNRNXXXXXXXXXXXXXXXXXXXXA 368
    TGITPLNPLEVPLLNTSVLLASGVSI AHHSL+ENNRN          A
30 S:    119 TGITPLNPLEVPLLNTSVLLASGVSIWAHHSLENNRNQMIQALLITILGLYFTLLQA 178

    Q:    369 SEYFESPFTISDGIYGSTFFVATGFHGLHVIIGSTFLTICFIRQLIFHFTSKHHFGFEAA 548
    SEYFESPFTISDGIYGSTFFVATGFHGLHVIIGSTFLTICFIRQL+FHFTSKHHFGFEAA
    S:    179 SEYFESPFTISDGIYGSTFFVATGFHGLHVIIGSTFLTICFIRQLMFHFTSKHHFGFEAA 238

35 Q:    549 A*YWHFVDVV*LFLYVSIY**GS 617
    A YWHFVDVV LFLYVSIY GS
    S:    239 AWYWHFVDVVWLFYVSIYWGWS 261
```

The segment of dbj|BAA77671.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 157. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

- 5 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 158 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
10 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in HUMAN B CELL LYMPHOMA.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15 related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
20 general formula of a-b, where a is any integer between 1 to 623 of SEQ ID NO:56, b is an integer of 15 to 637, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5 gb|AAC67415.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "similar to Arabidopsis thaliana male sterility protein 2 (SW:Q08891) [Caenorhabditis elegans]".

A partial alignment demonstrating the observed homology is shown immediately below.

10

```
>gb|AAC67415.1| (AF098505) similar to Arabidopsis thaliana male sterility
protein 2 (SW:Q08891) [Caenorhabditis elegans]
>sp|AAC67415|AAC67415 Y71H10A.2 protein.
Length = 536
```

15

Plus Strand HSPs:

Score = 181 (63.7 bits), Expect = 2.2e-12, P = 2.2e-12

20

Identities = 40/139 (28%), Positives = 74/139 (53%), Frame = +2

```
Q: 17 KLMNRLRLTVSMLEYFINRSWEWSTYNTMLMSELSPEQQRVFNFDVRQLNWLEYIENYV 196
KL +++ + + L +F R W ++ +++P DQ+ +NFDVRQ++W Y+ +YV
S: 380 KLYSKVWKMIETLHFFTTTRGWSFNARGLPEFFEKMT PADQKEYNFDVRQVDWNSYLFDYV 439
```

25

```
Q: 197 LGVKKYLLKEDMAGIPKAKQRLKRLRNHLYFNTALFLIAWRLLIARSQMARN---VWF- 364
+G+KK+LLKE++ + +++ L ++R I A+ + I R WF
S: 440 MGIKKFLLKENLENLNRSAHLLKMR-IRRQVIAAIVYAGFISTIGRKWKKTQYLTWFG 498
```

30

```
Q: 365 -FIVSFCYKFLSYFRASSTLK 424
+ ++ Y +S FR LK
S: 499 AMLATYTYTEVS-FRRHIPLK 518
```

- The segment of gb|AAC67415.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 159. Based on the structural similarity, these
- 35 homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 160 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Soares\_NhHMPu\_S1; Bone marrow; Soares infant brain 1NIB; Soares\_testis\_NHT; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human umbilical vein endothelial cells, IL-4 induced; NCI\_CGAP\_CLL1; Ovarian Tumor 10-3-95; Human Testes and Bone  
10 Marrow Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 712 of SEQ ID NO:57, b is an integer of 15 to 726, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 48**

It has been discovered that this gene is expressed primarily in the following  
25 tissues/cDNA libraries: Soares\_multiple\_sclerosis\_2NbHMSP; Human Osteosarcoma; Primary Dendritic cells,frac 2; Primary Dendritic Cells, lib 1 and to a

lesser extent in Soares\_fetal\_heart\_NbHH19W; Human Eosinophils; Cem cells  
cyclohexamide treated; NCI\_CGAP\_GCB1; Human Umbilical Vein Endothelial  
Cells, uninduced; Spinal cord; Soares\_parathyroid\_tumor\_NbHPA; Stratagene NT2  
neuronal precursor 937230; Human Testes Tumor, re-excision; Hodgkin's Lymphoma  
5 II; NCI\_CGAP\_Br2 and Activated T-cell(12h)/Thiouridine-re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:58 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 209 of SEQ ID NO:58, b  
is an integer of 15 to 223, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a  
+ 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 49

It has been discovered that this gene is expressed primarily in the following  
20 tissues/cDNA libraries: Soares ovary tumor NbHOT and to a lesser extent in  
normalized infant brain cDNA; H. cerebellum, Enzyme subtracted; Human Infant  
Brain; Soares\_testis\_NHT; Stratagene colon (#937204); Human Substantia Nigra;  
Soares\_fetal\_lung\_NbHL19W; Nine Week Old Early Stage Human; Soares placenta  
Nb2HP; Soares infant brain 1NIB; Soares\_NhHMPu\_S1; NCI\_CGAP\_Pr11; Larynx  
25 Carcinoma; Human Fetal Brain, random primed; NCI\_CGAP\_Co8; Hep G2 Cells,  
PCR library; Human Normal Breast; human corpus colosum; Synovial hypoxia-RSF

- subtracted; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Brain, Striatum;  
Human Umbilical Vein Endothelial Cells, uninduced; Spinal cord;  
Hemangiopericytoma; Bone Marrow Stromal Cell, untreated; Soares breast 2NbHBst;  
Adipocytes; Human Fetal Lung III; Soares\_senescent\_fibroblasts\_NbHSF;
- 5 Endothelial-induced; Human Adult Pulmonary, re-excision; Human Microvascular  
Endothelial Cells, fract. A; Smooth muscle, control and Monocyte activated.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of

10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1917 of SEQ ID NO:59, b

15 is an integer of 15 to 1931, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.



Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HPBDE33	PTA-181 06/07/99	pBluescript SK-	11	2444	1215	2435	257	257	60	1	20	21	310
2	HTEEC19	PTA-181 06/07/99	Uni-ZAP XR	12	1721	1	1721	72	72	61	1	24	25	30
3	HTWFO43	PTA-181 06/07/99	pSport1	13	1298	1	1298	193	193	62	1	20	21	30
4	HMCZ04	PTA-181 06/07/99	Uni-ZAP XR	14	1733	406	1670	106	106	63	1	25	26	450
5	HBODV76	PTA-181 06/07/99	pSport1	15	2498	1	2498	303	303	64	1			8
6	HTNBJ15	PTA-181 06/07/99	pBluescript SK-	16	3351	1511	2764	1737	1737	65	1	22	23	51
7	HBMQ74	PTA-181 06/07/99	pBluescript	17	4044	1563	3480		1815	66	1			20
8	HOUEF84	PTA-181 06/07/99	Uni-ZAP XR	18	2249	1	2249	83	83	67	1	24	25	32

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
9	HOUGS36	PTA-181 06/07/99	Uni-ZAP XR	19	1645	1	1645	295	295	68	1	20	21	70
10	HOVBE81	PTA-181 06/07/99	pSport1	20	953	1	953	172	172	69	1	20	21	32
11	HPFCI36	PTA-181 06/07/99	Uni-ZAP XR	21	879	1	879	94	94	70	1	18	19	19
12	HPFDI37	PTA-181 06/07/99	Uni-ZAP XR	22	352	1	352	38	38	71	1			17
13	HPJAN76	PTA-181 06/07/99	Uni-ZAP XR	23	1956	70	1953	275	275	72	1			18
14	HPJBU43	PTA-181 06/07/99	Uni-ZAP XR	24	575	1	575		242	73	1			17
15	HPQAJ25	PTA-181 06/07/99	Lambda ZAP II	25	549	1	549	85	85	74	1	35	36	39
16	HPRCD35	PTA-181 06/07/99	Uni-ZAP XR	26	709	1	689		265	75	1	18	19	35
17	HSHCE85	PTA-181 06/07/99	Uni-ZAP XR	27	1225	1	1225	263	263	76	1	19	20	36
18	HLHDL69	PTA-181 06/07/99	Uni-ZAP XR	28	2127	364	2127	433	433	77	1	20	21	38

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
19	HT4SB81	PTA-181 06/07/99	Uni-ZAP XR	29	2331	962	2320	1171	1171	78	1	13	14	35
20	HATEI22	PTA-181 06/07/99	Uni-ZAP XR	30	2418	2100	2394	2203	2203	79	1	33	34	41
21	HTEDX05	PTA-181 06/07/99	Uni-ZAP XR	31	2220	1	2220	65	65	80	1	18	19	20
22	HTEGS11	PTA-181 06/07/99	Uni-ZAP XR	32	981	1	981		173	81	1			7
23	HTEHS91	PTA-181 06/07/99	Uni-ZAP XR	33	2202	1	2186	343	343	82	1	18	19	66
24	HTEHW80	PTA-181 06/07/99	Uni-ZAP XR	34	1167	1	1167		96	83	1	12	13	29
25	HTEKM46	PTA-181 06/07/99	Uni-ZAP XR	35	2116	1	2116	171	171	84	1	24	25	38
26	HTGFM31	PTA-181 06/07/99	Uni-ZAP XR	36	2057	1	2057	73	73	85	1	30	31	38
27	HTLAF81	PTA-181 06/07/99	Uni-ZAP XR	37	1229	1	1229		195	86	1	15	16	190
28	HTOAO58	PTA-181 06/07/99	Uni-ZAP XR	38	1637	1	1637	157	157	87	1	13	14	34

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HTOEV16	PTA-181 06/07/99	Uni-ZAP XR	39	1640	1	1640	201	201	88	1	45	46	118
30	HTOHQ05	PTA-181 06/07/99	Uni-ZAP XR	40	1860	1	1860	198	198	89	1	19	20	54
31	HTOJP25	PTA-181 06/07/99	Uni-ZAP XR	41	1524	1	1524	268	268	90	1	19	20	33
32	HTPCO75	PTA-181 06/07/99	Uni-ZAP XR	42	1467	1	1467		73	91	1	23	24	40
33	HTXJE12	PTA-181 06/07/99	Uni-ZAP XR	43	1640	1	1640	204	204	92	1	22	23	83
34	HTXKK76	PTA-181 06/07/99	Uni-ZAP XR	44	1629	1	1629	54	54	93	1	26	27	52
35	HUSIK45	PTA-181 06/07/99	pSport1	45	1415	1	1415	204	204	94	1	20	21	33
36	HWBAK71	PTA-181 06/07/99	pCMVSPORT 3.0	46	372	1	372	260	260	95	1	15	16	17
37	HWBCN81	PTA-181 06/07/99	pCMVSPORT 3.0	47	2783	1	2783	615	615	96	1	32	33	60
38	HWTBC75	PTA-181 06/07/99	Uni-ZAP XR	48	699	1	699	228	228	97	1	32	33	44

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
39	HYBAP75	PTA-181 06/07/99	Uni-ZAP XR	49	1168	1	1168		166	98	1	27	28	37
40	H6EEO05	PTA-181 06/07/99	Uni-ZAP XR	50	1425	1	1397	190	190	99	1	35	36	111
41	HABJV67	PTA-181 06/07/99	pCMVSPORT 3.0	51	2536	1	2536	605	605	100	1	19	20	359
42	HAPBU86	PTA-181 06/07/99	Uni-ZAP XR	52	1371	255	1348	403	403	101	1	23	24	35
43	HAPQU71	PTA-181 06/07/99	Uni-ZAP XR	53	1879	1264	1807	1324	1324	102	1	20	21	53
44	HBDAB91	PTA-181 06/07/99	pSPORT1	54	1007	320	1007	671	671	103	1	19	20	29
45	HBJEL21	PTA-181 06/07/99	Uni-ZAP XR	55	2082	1	2082	48	48	104	1	21	22	45
46	HBJIG20	PTA-181 06/07/99	Uni-ZAP XR	56	637	1	637		321	105	1	16	17	77
47	HBMUH74	PTA-181 06/07/99	Uni-ZAP XR	57	726	1	726	344	344	106	1	22	23	28
48	HCABP33	PTA-181 06/07/99	Uni-ZAP XR	58	223	1	223	9	9	107	1	29	30	37

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
49	HE9AE05	PTA-181 06/07/99	Uni-ZAP XR	59	1931	476	1931	654	654	108	1	17	18	18

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially-homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is

identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted



translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

5 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

10 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate  
15 sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a  
20 deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

25 The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly

produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the  
5 mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification , such as multiple histidine residues, or an additional sequence for stability during recombinant production.

10 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40  
15 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained  
20 in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA  
25 contained in ATCC deposit Z are also encompassed by the invention.

#### Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

### Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA  
5 sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential  
10 properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide  
15 coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of  
20 these nucleic acid molecules (e.g., those fragments described herein).

Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or  
25 alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence

shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
5 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
10 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
15 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
20 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by  
25 converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to

calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

- 5            If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent
- 10 identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using
- 15 the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.
- 20            For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number
- 25 of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly

matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject



sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said

5 global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

10 If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the

15 query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from

20 the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity

25 score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10  
5 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100  
10 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not  
15 matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter  
20 the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host  
25 (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500

nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function.

For example, site-directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the  
10 protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic  
15 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,  
20 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino  
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory

sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

10 A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and  
15 still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or  
20 fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

## 25 Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in  
5 a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,  
10 and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger  
15 or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the  
20 invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500,  
25 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the

complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.

Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the



mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a

polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

- 5           The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

10  
15  
20

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

25

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10 of the invention.

### Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,

that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a

carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or

5 intradermal injection of emulsions containing about 100  $\mu$ g of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid

10 surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the

15 polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins

20 may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4- polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the

25 immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO

96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>-nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in

its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

#### Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM,



IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, 5 single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding 10 fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino 15 acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, 20 trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 25 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in  
5 contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in  
10 terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described  
15 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%,  
20 less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific  
25 antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides

which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention

may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described

supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

5           The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as  
10       well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the  
15       receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.  
20       58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al.,  
25       Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);

Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques,

including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone,

including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).

F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies,



including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve,

antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,

5 Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP

10 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods

15 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the

25 human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.

The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a

selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the

nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John

Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes

from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used.

As described *supra*, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

#### Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the

antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently



purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

15 In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

20 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region

E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the

5 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate

10 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,

15 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which

20 possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell

25 line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science

260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci.*

USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS

89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins

consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., *Nature* 331:84-86 (1988)). The polypeptides of the present invention fused or conjugated to an antibody having

5 disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A

10 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

15 identify antagonists of hIL-5. (See, Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995)).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the

20 tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which

25 corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., *Cell* 37:767 (1984)) and the "flag" tag.



The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include

paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and  
5 puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-  
10 dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological  
15 response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth  
20 factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g.,  
25 angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports  
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Aron et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,  
10 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can  
25 be used as a therapeutic.

### Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular  
5 marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and  
10 include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual  
15 disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

### 20 Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent  
25 assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays,

complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-

fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human  
5 antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For  
10 further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable  
15 compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the  
20 well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs  
25 known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al,

eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

#### 15      Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment

and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).

Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.



It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

#### Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217

(1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY  
5 (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters  
10 operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the  
15 antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

20 Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

25 In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be

accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which

facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy.

Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No.

5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection  
5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,  
10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth.  
15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and  
20 expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be  
25 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

10 In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the

therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

10

#### Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),

25

construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion  
5 or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route,  
10 including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical  
15 compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material,  
20 including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et  
25 al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein



and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, 5 *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and 10 Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose 15 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic 20 acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating 25 with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g.,

Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such  
5 compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term  
10 "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline  
15 solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired,  
20 can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as  
25 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect,

diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody

assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

5           One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which  
10 specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that  
15 detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

20           It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially  
25 accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of

Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In

yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

### Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.



In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by  
5 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of  
10 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

15 In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of  
20 bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

25 The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip

sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

- 5 Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting  
10 surface-bound anti-antigen antibody.

### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a  
15 second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

20 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics  
25 of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the

polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for

example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

- 5           Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available.
- 10          As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)
- 15           Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

- 20           The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

- 25           The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate,

such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate  
5 promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding  
10 portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin  
15 resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178));  
20 insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-  
9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,  
25 pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech,

Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph,  
5 pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated  
10 transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

15 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most  
20 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical  
25 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,

insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolism pathway is the oxidation of methanol to formaldehyde using  $O_2$ . This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for  $O_2$ . Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1*

regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and  
5 J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

10 Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like,  
15 including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the  
20 yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding  
25 sequence), and/or to include genetic material (e.g., heterologous polynucleotide



sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids,  $\alpha$ -methyl amino

acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random

positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

- One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein
- 5 (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules.
- 10 Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl
- 15 group containing polymer is achieved.

- The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific
- 20 embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

- Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides
- 25 corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and

fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another  
5 specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional  
10 embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the  
15 invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example,  
20 liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the  
25 invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the

invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper

polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different

5 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide

10 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are

15 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

20 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-

25 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent  
5 Number 5,478,925, which is herein incorporated by reference in its entirety).  
Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by  
10 reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,  
15 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic  
20 engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are  
25 generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic



polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described  
5 herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

10

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

15

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

20

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids  
25 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled  
5 flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.  
10 This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to  
15 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

20 Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins  
25 University Welch Medical Library) .) Assuming 1 megabase mapping resolution and

one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

- 5 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide  
10 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

- Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using  
15 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

- Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the  
20 measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

- In still another embodiment, the invention includes a kit for analyzing samples  
25 for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe

containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand  
5 containing a 31'-mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present  
10 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the  
15 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard  
20 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

25 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the

polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose

derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)).

5 Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is  
10 involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia  
15 cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb  
20 proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of  
25 hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.



The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.

In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

10 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a  
15 unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological  
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR  
25 Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an

identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene

expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.

In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:

The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
Masson Publishing Inc. (1982).)

- Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells  
5 or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a  
10 predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
- 15 Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair  
20 proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune  
25 response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can  
5 activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also  
10 be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

#### 15 **Gene Therapy Methods**

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present  
20 invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

25 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a

polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; 5 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters 10 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, 15 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the 20 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, 25 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye,

gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.



The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter-infusion, and so-called "gene guns". These delivery methods are known in the art.

5       The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant  
10   invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15   84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20       Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25   available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to

produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.

- 5 The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated.
- 10 SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
- 15 then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980);
- 20 Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports  
5 on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622,  
10 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding  
15 polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

20 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by  
25 reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation,

the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which  
5 include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can  
10 be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for  
15 many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt  
20 to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.,  
25 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein

incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found

in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper  
5 viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its  
10 genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO  
15 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

20 Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting  
25 sequence will be sufficiently near the 5' end of the desired endogenous

polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR.

Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

10 The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, 15 topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The 20 promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor 25 alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth



factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

- 5 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.
- 10 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available
- 15 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the
- 20 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting

25 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
5 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
10 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
15 Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
20 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise  
25 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of

polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

### **Immune Activity**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases, disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present

invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used

to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the

present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction  
5 of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an  
10 immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation  
15 and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis,  
20 cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

#### **Hyperproliferative Disorders**

25 A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders,

and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other  
5 cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may  
10 be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can  
15 be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral),  
20 lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:  
25 hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's

Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or  
5 protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

10 Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a  
15 recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference).  
20 In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule,  
25 chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the



beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing  
5 expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the  
10 normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any  
15 other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA  
20 delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in  
25 the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes

needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell  
5 proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or  
10 disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of  
15 the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of  
20 the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a  
25 mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for

producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

5           A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings  
10       provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

          In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing  
15       cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

          The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or  
20       hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

          It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and  
25       therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies,

fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  
5  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be  
10 achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,  
15 Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce  
20 apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).  
25 Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the

activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such thereapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present

invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

5           **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular  
10 abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome,  
15 levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart  
20 disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular  
25 septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous),

pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

- 5           Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include
- 10   paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

- Heart valve disease include aortic valve insufficiency, aortic valve stenosis,
- 15   hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

- Myocardial diseases include alcoholic cardiomyopathy, congestive
- 20   cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

- Myocardial ischemias include coronary disease, such as angina pectoris,
- 25   coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive  
5 diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion,  
10 Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary  
15 aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

20 Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural  
25 hematoma, subaraxhnoid hemorrhage, cerebral infarction, cerebral ischemia



(including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

### Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which

5 neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes

10 pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995);

15 Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have

20 accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or

25 antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the

invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor.

5 Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma;

10 Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

15 Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes

20 of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions; besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artherosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted

above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

5           Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity  
10   macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

          Thus, within one aspect of the present invention methods are provided for  
15   treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain  
20   pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of diseases, disorders, and/or conditions can result in corneal neovascularization,  
25   including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and

Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared  
5 for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within  
10 preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic  
15 response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance.  
20 The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly  
25 after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed

between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a

patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

5           Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,  
10           pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

          Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for  
15           example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations,  
20           hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma, fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth  
25           control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence



such as cat scratch disease (*Rochela minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

10 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in

15  
20  
25

order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

5        Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate  
10        including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

      Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten  
15        oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum  
20        (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

      A wide variety of other anti-angiogenic factors may also be utilized within the  
25        context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells),

(Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L- 3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 5 3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin 10 (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomaleate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312- 15 316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxyaminolimidazole; and metalloproteinase inhibitors such as BB94.

#### Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis 20 that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular 25 cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast

cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

10 Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia  
15 (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited  
20 to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal  
25 cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary

carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, 5 craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, 10 and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and 15 immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic 20 shock, cachexia and anorexia.

#### **Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists 25 or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing,

and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye  
5 tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and  
10 antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and  
15 to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,  
20 epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the  
25 appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or



agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the

invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

5           The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins  
10   known in the art).

          In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the  
15   invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

20

#### Neurological Diseases

          Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not  
25   limited to, nervous system injuries, and diseases, disorders, and/or conditions which

result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human-mammalian patients) according to the invention, include but are not limited to, the following lesions of

5 either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the

10 nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated

15 with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6)

20 lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar

25 degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus

erythematosis, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture;

(2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary  
Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

### Infectious Disease

5           A polypeptide or polynucleotide and/or agonist or antagonist of the present  
invention can be used to treat, prevent, and/or diagnose infectious agents. For  
example, by increasing the immune response, particularly increasing the proliferation  
and differentiation of B and/or T cells, infectious diseases may be treated, prevented,  
and/or diagnosed. The immune response may be increased by either enhancing an  
10   existing immune response, or by initiating a new immune response. Alternatively,  
polypeptide or polynucleotide and/or agonist or antagonist of the present invention  
may also directly inhibit the infectious agent, without necessarily eliciting an immune  
response.

          Viruses are one example of an infectious agent that can cause disease or  
15   symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or  
polypeptide and/or agonist or antagonist of the present invention. Examples of  
viruses, include, but are not limited to Examples of viruses, include, but are not  
limited to the following DNA and RNA viruses and viral families: Arbovirus,  
Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae,  
20   Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae  
(Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes  
Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae),  
Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma  
virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or  
25   Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus),  
and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a

variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis,

5 opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or

10 diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available

15 hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide

20 and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia

25 (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic

- E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter,
- 5 Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal
- 10 families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease,
- 15 Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.
- 20 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.
- 25 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or



antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### **Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects,

trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs  
5 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the  
10 present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel  
15 syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to  
20 proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral  
25 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease,

Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

## 5 Chemotaxis

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as  
10 inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection,  
15 hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can  
20 be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the  
25 present invention could be used as an inhibitor of chemotaxis.

**Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The  
5 binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the  
10 polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can  
15 be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed  
20 polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving  
25 competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and retransfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or

more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF),  
5 insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-  
10 derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a  
15 decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H]  
20 thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is  
25 measured by liquid scintillation chromatography which measures the incorporation of

3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention



experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### 15 **Targeted Delivery**

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for

delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific  
5 destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of  
10 toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic  
15 effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the  
20 methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

## 25 Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or

the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present

invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein.

Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The

5 peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

10 This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the  
15 invention.

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the  
20 complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).  
25 Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for

example, in Okano, *Neurochem.*, 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or

a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.

- 5 Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible
- 10 or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the
- 15 metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest.

However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a

- 20 sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the
- 25 hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be).

One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end,  
5 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,  
10 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,  
15 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,  
20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,  
25 2-fluoroarabinose, xylulose, and hexose.



In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

10 The oligonucleotide is a 2-0-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are

15 commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

20 While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published

25 October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs

corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases:

5 5' -UG-3' . The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, *Nature*, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or

prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

## **Other Activities**

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

5       The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may  
10   be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair  
15   loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs  
20   before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the  
25   present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

#### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous  
5 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of  
10 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide  
sequence which is at least 95% identical to a sequence of at least about 500  
20 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a  
nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ  
ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of  
the First Amino Acid of the Signal Peptide and ending with the nucleotide at about  
25 the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X  
in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
5 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which  
10 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of  
20 at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

25 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at

least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
5 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
10 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and  
15 determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence  
20 selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

25 A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic



acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least

95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise  
5 a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
10 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the  
15 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the  
20 Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
25 sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino  
10 acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence  
15 at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence  
20 at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence  
25 at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1

and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at

least 10 contiguous amino acids in a sequence selected from the group consisting of:  
an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in  
Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA  
clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit  
5 with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences  
is performed by comparing the amino acid sequence determined from a polypeptide  
molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a  
10 biological sample which method comprises a step of detecting polypeptide molecules  
in said sample, if any, comprising an amino acid sequence that is at least 90%  
identical to a sequence of at least 10 contiguous amino acids in a sequence selected  
from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is  
any integer as defined in Table 1; and a complete amino acid sequence of a secreted  
15 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in  
Table 1 and contained in the deposit with the ATCC Deposit Number shown for said  
cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell  
type of a biological sample, which method comprises a step of detecting polypeptide  
20 molecules comprising an amino acid sequence in a panel of at least two amino acid  
sequences, wherein at least one sequence in said panel is at least 90% identical to a  
sequence of at least 10 contiguous amino acids in a sequence selected from the above  
group.

Also preferred is a method for diagnosing in a subject a pathological condition  
25 associated with abnormal structure or expression of a gene encoding a secreted  
protein identified in Table 1, which method comprises a step of detecting in a

biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone

identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred  
 5 embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides  
 10 comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences  
 15 referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HPBDE33	11	853660	H95104, AA514321, AA524472, AA865884, AA995890, AA649884, AA448357, AA478455, AA644380, AA448215, AA759333, AA780275, AA912175, Z40511, Z44658
4	HMCAZ04	14	867910	T64005, T64084, T74688, T74801, T86387, T90950, T85836, T95375, R13065, R40496, R50203, R40496, N50841, N58703, W96028, AA056968, AA057016, AA100857, AA133917,



				AA253283, AA280758, AA281439, AA468902, AA527252, AA639665, AA576059, AA885922, AA911904, D82662, D82703, AI097457, W94661, AA643646, AA643688, AA481324, AA486109, AA486172, C75117, AA664347, AA669130, AA703984, AA838720, AA948547, T27349
6	HTNBJ15	16	853916	T90793, R10265, R10264, R21407, R32179, R32228, R68686, R68741, R79633, R79827, H15739, H40220, H40793, R94269, H58305, H58695, H63252, H63329, H78607, H78662, H80484, N34916, N57882, W04585, W31833, W33186, W37252, AA001417, AA001476, AA044024, AA058969, AA111864, AA149278, AA149304, AA156432, AA251881, AA459353, AA631419, AA669088, AA669116, AA689254, AA730992, AA856892, AA888623, AA976147, AA976169, D80081, N87651, N87946, AA044200, AA083679, AA436984, AA437254, AA633999, AA678955, AA719387, AA860723, AA905274, AA906416, AI051914, AI092296, D20797, Z40781, AA694450
7	HBMQC74	17	864382	R27887, R71361, R71441, R71454, R73760, H68816, H85514, H96323, N20943, N24245, N24739, N27812, N28410, N31913, N38893, N42698, W19517, W47448, N90798, AA009581, AA024840, AA024880, AA026834, AA027016, AA037850, AA037851, AA039261, AA043509, AA043706, AA044330, AA044759, AA045660, AA057150, AA065134, AA121932, AA121933, AA215753, AA236137, AA262820, AA262821
13	HPJAN76	23	854893	R11723, R14544, R17696, R20352, R41205, R43737, R41205, R43737, H06707, H06756, H17189, H17965, AA075743, AA082074, AA084248, AA084249, AA102212, AA173383, AA173739, AA419229, AA419214, AA613995, AA574173, AA827444, AA834860, AI054234, AA075710, AA496806, AA626797, AA665640, AA706146, AA775244, AA780222, AA970361, AI018769
18	HLHDL69	28	855906	T60023, R00439, R54281, H65908, H73031, W40166, W45294, W53019, AA009923, AA046897, AA076314, AA076486, AA234173, AA827338, AA973851, AA453971, AA644330, AA721966, AA732750, AA772486, AI033131
19	HT4SB81	29	858154	T73129, T66974, R71992, R71993, H25285, N63815, N94173, W74312, W79246, W87803, W87904, W90715, W90716, AA026934, AA040327, AA040306, AA424782, AA522766, H67298, AA737522, AA745803, AA759291, AA889930, AA890661, AI088944, AI089449, AI250834
20	HATEI22	30	858585	T75035, R21138, R43650, R46733, R43650, R46733, H16773, H16882, R96518, R96563, N40824, W00616, W46979, W47080, AA027114, AA552138, AA558424, AA564697, AA574224, AA741538, AA746222, AA760625, AA768148, AA829787, AA829945, AA838157, AA960941,

				AA988314, W22559, AA190209, D11952, AA449343, AA449602, AA585377, AA724234, AA844390, Z17889, AI038229, AI056257, F12705, F10313
40	H6EEO05	50	865424	T57104, T57172, T90491, R09214, R09324, R13771, R14023, R41944, R41944, R69536, H14086, R87736, R87799, H72498, H72897, H95812, N24082, N31376, N54187, N58476, N78065, N93684, W52817, W67600, W67599, AA001233, AA001647, AA031269, AA031394, AA032200, AA032267, AA037880, AA037879, AA069357, AA227367, AA235634, AA250785, AA553821, AA580477, AA747793, AA748673, AA811284, AA814465, AA864442, AA872759, AA917754, AA932962, AA954674, AA983287, AA989138, AA995470, N55702, AA411123, AA487552, AA634485, AA634537, AA665921, AA676905, AA716132, AA775542, AA889751, AA907067, T03435, AI016960, AI022147, AI079252, AI040689, AI081505, AI084955, D29420, F13715, AA702164, AI240972, AI278789, AI369176
42	HAPBU86	52	864890	T77303, R20876, R38187, R42056, R42056, W56173, AA030021, W63595, AA706707, AA782399, AI027420, AI031732, AI091586, F13277, F10875, AI262985
43	HAPQU71	53	864781	AA459527, AA525222, AA459296, AA477819, AA482434, AA482607, AA634679, AA434062, AA781487, AI276354, AI301537
44	HBDAB91	54	864374	R45349, R45349, N75825, W07319, AA782398
49	HE9AE05	59	863257	T79877, R37596, R53207, R76384, R76723, N79081, W21601, W52046, AA121168, AA121192, AA464380, AA533774, AA393959, AA400926, AA479037, AA477520, AA478754, Z40557, Z44730, AI304836

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

- 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
- 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 5 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ 10 and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the 15 other, antisense.

Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et 20 al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for 25 instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention

does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional  
5 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample  
10 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ  
15 ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular  
20 Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection  
25 agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for

bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the  
5 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and  
the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the  
desired cDNA using the deposited cDNA plasmid as a template. The polymerase  
chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction  
mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is  
10 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25  
pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR  
(denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation  
at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated  
thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and  
15 the DNA band with expected molecular weight is excised and purified. The PCR  
product is verified to be the selected sequence by subcloning and sequencing the  
DNA product.

Several methods are available for the identification of the 5' or 3' non-coding  
portions of a gene which may not be present in the deposited clone. These methods  
20 include but are not limited to, filter probing, clone enrichment using specific probes,  
and protocols similar or identical to 5' and 3' "RACE" protocols which are well  
known in the art. For instance, a method similar to 5' RACE is available for  
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et  
al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a  
population of RNA presumably containing full-length gene RNA transcripts. A

primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

- 5           This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order  
10 to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

- This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is  
15 used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

20   **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

25   **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with  $P^{32}$  using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

10 Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films  
15 developed according to standard procedures.

#### **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This  
20 primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios,  
25 Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose



gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

5           A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product  
10 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning  
15 sites.

          The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which  
20 expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

          Clones containing the desired constructs are grown overnight (O/N) in liquid  
25 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The

cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

- 5        Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
- 10    QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

- Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then
- 15    washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

- The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-
- 20    NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50
- 25    mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

- 5 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.
- 10 DNA can be inserted into the pHEa by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or
- 15 *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

20 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 25 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield

of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

5       The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10       The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles,  
15       the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential  
20       filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a  
25       stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are  
5 equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the  
10 polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS  
15 contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus**

#### **Expression System**

20 In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40")  
25 is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak

Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5 Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-  
10 39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does  
15 not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

20 The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and  
25 optionally, can be dephosphorylated using calf intestinal phosphatase, using routine

procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with-T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue

5 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

10 Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a  
15 microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is  
20 then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life  
25 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of

a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then  
5 resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's  
10 medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  
15 uCi of  $^{35}\text{S}$ -methionine and 5 uCi  $^{35}\text{S}$ -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
20 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
25 mediates the initiation of transcription of mRNA, a protein coding sequence, and



signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers,

the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

5           Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,  
10   with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

          Specifically, the plasmid pC6, for example, is digested with appropriate  
15   restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

          A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.  
20   Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

          The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment  
then is digested with appropriate restriction enzymes and again purified on a 1%  
25   agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG

domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

## Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCACCGTGC  
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
5 CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
ACGGCGTGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
10 ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG  
15 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

20 The antibodies of the present invention can be prepared by a variety of  
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
expressing a polypeptide of the present invention is administered to an animal to  
induce the production of sera containing polyclonal antibodies. In a preferred  
method, a preparation of the secreted protein is prepared and purified to render it  
25 substantially free of natural contaminants. Such a preparation is then introduced into  
an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells,

and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of  
5 further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub>  
10 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced  
15 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson  
20 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

**Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution  
5 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered  
10 Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x  
15 Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods  
20 described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem  
I to each well. As a control, one plate of vector DNA lacking an insert should be  
25 transfected with each set of transfections.



Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in  
10 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130 mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
15 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
20 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
25 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 $\text{H}_2\text{O}$ ; 99.65 mg/ml of L-

Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
5 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
10 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end  
15 of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
20 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
25 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

**Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the  
5 Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six  
10 members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in  
15 tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are  
20 generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-  
25 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS GAS(elements) or ISRE</u>
	<u>IFN family</u>					
5	IFN-a/B	+	+	-	-	1,2,3 ISRE
	IFN-g		+	+	-	1 GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3
	<u>gp130 family</u>					
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3 GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3
	OnM(Pleiotrophic)	?	+	+	?	1,3
	LIF(Pleiotrophic)	?	+	+	?	1,3
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3
	IL-12(Pleiotrophic)	+	-	+	+	1,3
	<u>g-C family</u>					
	IL-2 (lymphocytes)	-	+	-	+	1,3,5 GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6 GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5 GAS
	IL-9 (lymphocytes)	-	+	-	+	5 GAS
	IL-13 (lymphocyte)	-	+	?	?	6 GAS
	IL-15	?	+	?	+	5 GAS
25	<u>gp140 family</u>					
	IL-3 (myeloid)	-	-	+	-	5 GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5 GAS
	GM-CSF (myeloid)	-	-	+	-	5 GAS
30	<u>Growth hormone family</u>					
	GH	?	-	+	-	5
	PRL	?	+/-	+	-	1,3,5
	EPO	?	-	+	-	5 GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>					
	EGF	?	+	+	-	1,3 GAS (IRF1)
	PDGF	?	+	+	-	1,3
	CSF-1	?	+	+	-	1,3 GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCTCCCGAAATGATTTCCTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCTCCCGAAATGATTTCCTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
25 AGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-

2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

5 **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP  
10 activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate  
15 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing  
20 concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in  
25 RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life



Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentacin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul

samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
5 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
10 stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells..  
15 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct  
20 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

25 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM

KCl, 375  $\mu$ M  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2$ , and 675  $\mu$ M  $\text{CaCl}_2$ . Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

- 5 The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400  $\mu$ g/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400  $\mu$ g/ml G418 for couple of passages.

These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200  $\mu$ l cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

Add 50  $\mu$ l of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

**Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl

phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

- 5           The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

- 10           5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

- Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.
- 15

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

- 20           PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.
- 25

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

20

#### **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

25

apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded,  
5 causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants  
10 produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based  
15 strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
20 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in  
25 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
5 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTA  
TTCCAGAAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

10

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

15

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

20

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

25

**Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

- 5           Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- Cool the samples to room temperature for 15 minutes. Empty the dispenser  
10       and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at  
15       each time and start the second set 10 minutes later.

          Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5



21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small  
5 molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane  
potential. These alterations can be measured in an assay to identify supernatants  
which bind to receptors of a particular cell. Although the following protocol  
describes an assay for calcium, this protocol can easily be modified to detect changes

in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small

5 molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for  
10 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four  
15 times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are  
20 washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as  
25 fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an  
5 extracellular signaling event which has resulted in an increase in the intracellular  $\text{Ca}^{++}$  concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

10 The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is  
15 unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include  
20 receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine  
25 kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the

following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from

5 Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or

10 calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen

15 Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20

20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is

25 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane

bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4  
5 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by  
10 determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

15 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2+</sub> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the  
20 components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction  
25 mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for  
5 one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of  
10 tyrosine kinase activity.

**Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine  
15 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,  
20 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are  
25 then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against

Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

5           A431 cells are seeded at 20,000/well in a 96-well Loprodyn filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

10           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
15           procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

20    **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
25    is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for

30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre  
5 Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al.,  
10 Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated  
15 according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

20 Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et  
25 al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical



Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

5

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).  
5 Interpolate the concentration of the polypeptide in the sample using the standard curve.

**Example 23: Formulation**

10 The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or  
15 antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of  
20 delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about  
25 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01

mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable

polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

5           Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric  
10   acid (EP 133,988).

          Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)).  
15   Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small  
20   (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

          In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see Langer, supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).  
25

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar

alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will  
5 be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container  
10 having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml  
15 vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the  
20 invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

25 The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the

Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either

concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through  
5 separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like  
10 molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No.  
15 WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904),  
20 DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms  
25 CD154, CD70, and CD153.



In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™,

KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, 5 DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic 10 *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with 15 GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another 20 specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent 25 an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered  
5 in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered  
10 with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-  
15 sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other  
20 immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™  
25 (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNE™ (sirolimus). In a specific

embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations.

5 Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation  
10 therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-  
15 inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone,  
20 guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to,  
25 antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-

FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate);  
5 hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g.,  
10 dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another  
15 embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are  
20 administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3,  
25 IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, 5 FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

10 **Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the 15 invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering 20 to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on 25 administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising  
5 administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of  
10 decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation  
15 of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a  
20 subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed  
25 to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS,



penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge.

- 5 The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

- 10 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine  
15 sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene  
20 of interest properly inserted.

- The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.  
25 The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the

polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary  
5 phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the  
10 supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to  
15 construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an  
20 Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-  
25 digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120  $\mu\text{g/ml}$ . 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960  $\mu\text{F}$  and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter

or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al.,  
5 *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial  
10 space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the  
15 cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those  
20 skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies  
25 techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies

have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the

condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
5 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
10 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
15 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

20 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15  $\mu$ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
25 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.



The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

5    **Example 29: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a  
10    specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of  
15    transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci.,  
20    USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent  
25    stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of

such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
5 enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their  
10 cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory  
15 sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the  
20 endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science  
25 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific

inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

----- Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening  
5 may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse  
10 transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding  
15 strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given  
20 integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

25 Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of

polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

5    **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by  
10   reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express  
15   polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be  
20   used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

25       In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically

engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

10 **Example 31: Production of an Antibody**

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing XXX are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of XXX protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for protein XXX are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with XXX polypeptide or, more preferably, with a secreted XXX polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine

serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the XXX polypeptide.

Alternatively, additional antibodies capable of binding to XXX polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the XXX protein-specific antibody can be blocked by XXX. Such antibodies comprise anti-idiotypic antibodies to the XXX protein-specific antibody and are used to immunize an animal to induce formation of further XXX protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein.

(See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed

Against XXX From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against XXX to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody



fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification

with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

**Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective

ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse  
5 (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and  
10 various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and  
15 proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

20 Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are  
25 compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

**Example 33: T Cell Proliferation Assay**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then  
10 washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4$ /well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium  
15 alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored  $-20$  degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5  $\mu\text{Ci}$  of  $^3\text{H}$ -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of  
20 proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to

measure the IL-12 release as follows. Dendritic cells ( $10^6/\text{ml}$ ) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or

activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

20

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the

25



cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $H_2O_2$  produced by the macrophages, a standard curve of a  $H_2O_2$  solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### Example 35: Biological Effects of Polypeptides of the Invention

#### Astrocyte and Neuronal Assays:

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite

outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

#### Fibroblast and endothelial cell assays:

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA

medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity

reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

5           It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J.  
10   Neuroscience, 1990).

          Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential  
15   effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium  
20   containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

25           Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are

proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*.

Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10       **Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2.5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16  
15       units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is  
20       determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25       test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

5           For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight.

10   After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is

15   subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al. In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

          The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the

20   invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

25           HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6

mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4-degrees C for 2-h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After  
5 counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV  
10 fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

#### **Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the  
20 invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours  
25 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25

ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1%  
5 FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at  $37^\circ\text{C}$  in a humidified chamber with 5%  $\text{CO}_2$  to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by  
10 counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

#### **Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**


Nitric oxide released by the vascular endothelium is believed to be a mediator of  
20 vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a  
25 positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after



reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C.

The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of  
5 endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a  
10 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Cord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an  
15 additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control.  $\beta$ -estradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also  
20 utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine

extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one

femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.*, *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.*, *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

**Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the  
5 ability of polypeptides of the invention to affect the blood pressure in spontaneously  
hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900  
mg/kg) of the polypeptides of the invention are administered to 13-14 week old  
spontaneously hypertensive rats (SHR). Data are expressed as the mean  $\pm$  SEM.  
Statistical analysis are performed with a paired t-test and statistical significance is defined  
10 as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the  
invention. However, one skilled in the art could easily modify the exemplified studies to  
test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
invention.

15

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor  
VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of  
20 polypeptides of the invention, during the skin ischemia, is studied using in situ  
hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- 25 c) Normal wounds

The experimental protocol includes:

a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

c) Topical treatment with a polypeptide of the invention of the excisional wounds  
5 (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 47: Peripheral Arterial Disease Model**

15 Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

20 b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.

c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention  
25 and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 48: Ischemic Myocardial Disease Model**

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.
- c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25

**Example 49: Rat Corneal Wound Healing Model**



This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- 5        b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
- 10       e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15    invention.

**Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

20        A.        *Diabetic db+/db+ Mouse Model.*

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is  
25    dependent on formation of granulation tissue and re-epithelialization rather than

contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal  
5 heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375  
10 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,  
15 *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of*  
20 *Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All  
25 manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional

Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of  
5 wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following  
10 wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of  
15 surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses,  
20 from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral  
25 buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by  
5 establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

10

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the  
15 healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

20

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

25

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon

cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

#### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

5        Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*  
10 *libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of  
15 wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the  
20 testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement  
25 on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a

calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups  
5 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

10 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing  
15 the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

20

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the  
25 healing process and the morphologic appearance of the repaired skin is improved by

treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

5        The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10    **Example 51: Lymphadema Animal Model**

or        The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system  
15    in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

      Prior to beginning surgery, blood sample is drawn for protein concentration  
20    analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The  
25    intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's



Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are  
5 used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2  
10 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ  
15 Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which  
20 typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are  
25 evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

- 5           Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema  
10 software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

- Limb Weight Comparison: After drawing blood, the animal is prepared for tissue  
15 collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

- Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped  
20 into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
25 invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression  
by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently

washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

- 5 Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are  
10 aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

- Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-  
15 1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

- Then add 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with  
20 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  
25  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M

NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10

**Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation**

This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low

level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL-3, and then contacted with the compound that is  
5 being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one  
10 hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one  
15 hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine  
20 is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with  
25 TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

**Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM.

Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin  
5 receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with  
10 fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products are tested with appropriate negative controls in  
15 the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$ ) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA.  
20 Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACSscan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or  
25 antagonists and fragments and variants thereof.



If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

**Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-

assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

10        Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5  $\mu$ g/ml hEGF, 5mg/ml insulin, 1 $\mu$ g/ml hFGF, 50mg/ml gentamycin, 50  $\mu$ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50 $\mu$ g/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

20        On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNF $\alpha$  is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or  
25        supernatants and incubate at 37C/5% CO $_2$  until day 5.

Transfer 60 $\mu$ l from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100  $\mu$ l in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10 $\mu$ l). Return plates to incubator for 3 to 4 hours. Then measure

5 fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100  $\mu$ l/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

10 On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200  $\mu$ l/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50  $\mu$ l/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make

15 dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100  $\mu$ l/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

20 Add 100  $\mu$ l/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or

25 smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product

of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vascularogenesis, both of the blood  
5 vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in  
10 the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,  
15 rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb  
20 angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or  
25 described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

5    **Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in  
10    both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on  
15    endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an  
inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is  
20    removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are  
aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++  
25    and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA

and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue

Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration.

Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free  
5 medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with  
10 GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to  
15 each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell  
20 growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional  
25 to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the

output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

**Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

5        This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine  
10    production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These  
15    include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

20        Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is  
25    adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is



added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 µg/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 µg/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1 µC of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, U.S. provisional application No. 60/138,630 is hereby incorporated by reference in its entirety.

421

Applicant's or agent's file reference number	PS559PCT	International application no.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>100</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>07 June 1999</u>	Accession Number <u>PTA-181</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer <u>Sonya D. Barnes</u> <u>PCT/Internat'l Appl Processing Div</u> <u>(703) 306-3665</u>	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer
--	--

**ATCC Deposit No. PTA-181**  
**Page No. 2**

#### **CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

#### **NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

#### **AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

#### **FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

#### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-181****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group
- 5 consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a
  - 10 polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
  - 20 having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

5

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

10

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

20

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

5 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

20 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

25 (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
- (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:



(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

5

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

10 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

15 (a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

20

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

25 (c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 49 Human Secreted Proteins

<130> PS559PCT

<140> Unassigned

<141> 2000-06-01

<150> 60/138,630

<151> 1999-06-11

<160> 160

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccccaaatct	tctgacaaaa	ctcacacatg	cccacogtgc	ccagcacctg	60
aattcgaggg	tgcacogtca	gtcttctctt	tcccccaaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcaagg	tctccaacaa	agccctccca	accccatcg	360
agaaaacat	ctccaaagcc	aaagggcagc	cccagagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggtctct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctc	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaagagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86  
<212> DNA  
<213> Homo sapiens

<400> 3  
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaaatat ctgccatctc aattag 86

<210> 4  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 4  
gcggcaagct ttttgcaaag cctaggc 27

<210> 5  
<211> 271  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctcgagattt cccccgaaatc tagattttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gcccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6  
<211> 32  
<212> DNA  
<213> Homo sapiens

<400> 6  
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 7  
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
<211> 12  
<212> DNA  
<213> Homo sapiens

<400> 8  
ggggactttc cc

12

<210> 9  
<211> 73  
<212> DNA  
<213> Homo sapiens

<400> 9  
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg  
ccatctcaat tag

60  
73

<210> 10  
<211> 256  
<212> DNA  
<213> Homo sapiens

<400> 10  
ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct  
caattagtca gcaaccatag tcccggccct aactccggcc atcccgcccc taactccggc  
cagttccggc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga  
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg  
cttttgcaaa aagctt

60  
120  
180  
240  
256

<210> 11  
<211> 2444  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (1655)  
<223> n equals a,t,g, or c

<400> 11  
ggcgaggcg gaggcgccc cgggctcggg cggctgggat ggagcagaag agcgcgga  
ccggagggca cgcagctgac ggagctgcgc tgcgttcgcc tcgtttgcct cgcgccctcc  
actggagctg ttcgcgcctc cgggctccca ccgcagccca cccggcagag gagtgcgtac  
cagcgcccag tgcgctctgt cagtcgcgaa actccttgcc gcccgccccg ggctgggcac  
caaataccag gctaccatgg tctacaagac tctcttcgct ctttgcatct taactgcagg  
atggagggtg cagagtcctgc ctacatcagc tcctttgtct gtttctcttc cgacaaacat  
tgtaccamcg accamcatct ggactagctc tccacaaaac actgatgcag acactgcctc  
cccatccaac ggcactcaca acaactcggg gctcccagtt acagcatcag cccaacatc  
tctgcttcct aagaacattt ccatagagtc cagagaagag gagatcacca gccaggttc  
gaattgggaa ggcacaaaca cagacccctc acctctcggg ttctcgtcaa caagcgtg  
agtccactta acaaccaagt tggaggaaca cagctygggc actcctgaag caggcgtggc  
agctacactg tcgcagtcgc ctgctgagcc tcccacactc atctccctc aagctccagc  
ctcatcacc ccatccctat caacctcacc acctgaggtc ttttctgcct ccgttactac  
caaccatagc tccactgtga ccagcaccca acccaactgga gctccaactg caccagagtc  
cccgacagag gagtccagct ctgaccacac acccaacttca catgccacag ctgagccagt  
acccaggag aaaacacccc caacaactgt gtcaggcaaa gtgatgtgtg agctcataga

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960

catggagacc	accaccacct	ttcccagggt	gatcatgcag	gaagtagaac	atgcattaag	1020
ttcaggcagc	atcgccgcca	ttaccgtgac	agtcattgcc	gtgggtgctgc	tgggtgtttgg	1080
agttgcagcc	tacctaaaaa	tcaggcattc	ctcctatgga	agacttttgg	acgaccatga	1140
ctacgggtcc	tggggaaact	acaacaaccc	tctgtacgat	gactcctaac	aatggaatat	1200
ggcctgggat	gaggattaac	tgttctttat	ttataagtgc	ttatccagta	gaattaataa	1260
gtacctgatg	cgattgaac	gacaatctta	agccctgttt	tgttggtatg	gttgtttttg	1320
ttttcctccc	tctcctctgg	ctgtacaac	ttcccttttc	tggtagaaga	agaaccattc	1380
tttaaagggt	agtggaggct	gatttgcagc	tgaagtgggc	cagccttgca	ccagccaggc	1440
cagaccacca	tgggtgaaggc	ttctttcccc	actgcaggac	ccactttgag	aaggaccgag	1500
gargargatt	tgggttggttt	tgttaggggt	tactttcagg	ggaacatttc	atttgtgtta	1560
tttcttaaac	ttctatttag	gaaattacat	taagtattaa	tgaggggaaa	ggaaatgagc	1620
tctacgagga	tttcaccctg	catgggagag	agcanggttt	tctcagattc	ctttttaatc	1680
tctatttatc	tggttgtttc	tgacaggatg	ctgcctgctt	ggctctacaa	gctggaaagc	1740
agcttcttag	ctgcctaatt	aatgaaagat	gaaaatagga	agtgccttgg	agggggccag	1800
caggtcacgg	ggcagaatct	ctcagggttg	tgtgggatct	cagtgtgccc	ctacctgttc	1860
tcccctccag	gccacctgtc	tctgtaaagg	atgtctgtct	tgttcaaaag	gcagctggga	1920
tcccagccca	caagtgatca	gcagagttgc	atttccaaag	aaaaaggcta	tgagatgagc	1980
tgagttatag	agagaaaagg	agaggcatgt	acggtgtggg	gaagtggaaag	agaagctggc	2040
ggggggagaag	gaggctaacc	tgcactgagt	acttcattag	gacaagtgag	aatcagctat	2100
tgataatggc	cagagatatc	cacagcttgg	aggagcccag	agaccgtttg	ctttataccc	2160
acacagcaac	tgggtccactg	ctttactgtc	tgttggtata	tggctgtaaa	atgtttaaaa	2220
acaaaacaaa	acaaaaaaga	ggcactagtc	tatctgcaat	tactcaacga	ggcattttca	2280
taggaacacg	actatgatta	atccatttat	tcttcccaca	cacttacctt	actaagtctt	2340
tgctttaata	aatgagcaac	cctgggtata	gtcttaaaat	tctgcacaat	aaattttgag	2400
aaagaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaagggg	gggg		2444

&lt;210&gt; 12

&lt;211&gt; 1721

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

ggcacgagca	aaagatgaat	ttgaggagcg	agcaaaggct	attattgtag	aatttgcaca	60
gcagggtttg	aatgctgctt	tgtttttatga	gaataaagat	ccccgcactt	ttgtgtcttt	120
ggtacctacc	tctgcacata	ctgggtgatgg	catgggaagt	ctgatctacc	ttcttgtaga	180
gttaactcag	accatgttga	gcaagagact	tgcacactgt	gaagagctga	gagcacagg	240
gatggagggt	aaagctctcc	cggggatggg	caccactata	gatgtcatct	tgatcaatgg	300
gcgtttgaag	gaaggagata	caatcattgt	gcctggagta	gaagggccca	ttgtaactca	360
gattcgaggc	ctcctgttac	ctcctcctat	gaaggaatta	cgagtgaaga	accagtatga	420
aaagcataaa	gaagtagaag	cagctcaggg	ggtaaagatt	cttggaaaag	acctggagaa	480
aacattggct	ggtttaccct	tccttgtggc	ttataaagaa	gatgaaatcc	ctgttcttaa	540
agatgaattg	atccatgagt	taaagcagac	actaaatgct	atcaaattag	aagaaaaagg	600
agtctatgtc	caggcatcta	cactgggttc	tttggaagct	ctactggaat	ttctgaaaac	660
atcagaagtg	ccctatgcag	gaattaacat	tggcccagtg	cataaaaaag	atgttatgaa	720
ggcttcagtg	atgttggaac	atgacctca	gtatgcagta	attttggcct	tcgatgtgag	780
aattgaacga	gatgcacaag	aaatggctga	tagtttagga	gttagaattt	ttagtgcaga	840
aattatttat	catttatttg	atgcctttac	aaaatataga	caagactaca	agaaacagaa	900
acaagaagaa	tttaagcaca	tagcagtatt	tccctgcaag	ataaaaatcc	tccctcagta	960
catttttaat	tctcgagatc	cgatagtgat	gggggtgacg	gtggaagcag	gtcagggtgaa	1020
acaggggaca	cccatgtgtg	tcccaagcaa	aaattttggt	gacatcgga	tagtaacaag	1080
tattgaaata	aaccataaac	aagtggatgt	tgcaaaaaaa	ggacaagaag	tttgtgtaaa	1140
aatagaacct	atccctgggtg	agtcacccaa	aatgttttga	agacattttg	aagctacaga	1200
tattcttgtt	agtaagatca	gccggcagtc	cattgatgca	ctcaaagact	ggttcagaga	1260

tgaaatgcag	aagagtgcact	ggcagcttat	tgtggagctg	aagaaagtat	ttgaaatcat	1320
ctaatttttt	cacatggagc	aggaactgga	gtaaatgcaa	tactgtgttg	taatatccca	1380
acaaaaatca	gacaaaaaat	ggaacagacg	tatttggaca	ctgatggact	taagtatgga	1440
aggaagaaaa	ataggtgtat	aaaatgtttt	ccatgagaaa	ccaagaaact	tacactgggt	1500
tgacagtggg	cagttacatg	tccccacagt	tccaatgtgc	ctgttcactc	acctctccct	1560
tcccaaccct	tctctacttg	gctgctgttt	taaagtgtgc	ccttcccca	atttggattt	1620
ttattacaga	tctaaagctc	tttcgatttt	atactgatta	aatcagtact	gcagtatttg	1680
attaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a		1721

&lt;210&gt; 13

&lt;211&gt; 1298

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (319)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 13

gcctcatccc	tttttttcag	tatgtgcaac	gtatagagaa	acagtttctt	ttgtatgcct	60
actggatagg	cttaggaatt	ttgtcttctg	ttgggcttgg	aacagggctg	cacacctttc	120
tgctttatct	ggtaagaata	atttatttta	ataagcaaaa	atgatatttc	ctatcttttt	180
attggtgctt	ttatgtcaga	agtaaaaatt	ctaagatttg	ttttaattac	ctttgtgttt	240
tgtaagcatt	ctgacctccc	aatcagtgtc	ttaagtgtga	cttagagtgc	tgtttkgttt	300
tcctttaggg	ttagtattna	aaaagcaaa	agaaaaaccc	agttaagcaa	ataaggttgt	360
ttatttaa	tagtttagcg	tggaagggtt	ttcttttctt	tctagattta	attgcttaag	420
caattgttat	tttaataaat	gaagtccatt	taaatatgca	aaattccatg	tgagaaatgt	480
cttcccttac	atcctctaac	atcatttaca	tacttggata	tttattttgg	tattcttggt	540
gaatgtaatt	gatggagtat	taacatgtag	aactaaatgc	tttcttgagt	cctttgaacc	600
aaagtataaa	aagtgtccct	tctgggctgg	gcgtgggtgg	tcacgcctgt	aatcccagca	660
ctttgggagg	ccaaggcggg	cagatcatga	ggtctggaga	tcgagaccat	cctggctaac	720
atggtgaaac	cctgtctcta	ctaaaaatac	aaaaaattag	ccggacgtgg	tggcgggtgc	780
ctgtagtccc	acatactcag	gatgctgagg	caggagaatg	gcctgaaccc	gggaggcgga	840
gcttccagt	agtggagatg	gcgccactgc	actccarct	gggcgacaga	gcaagactcy	900
gtctcaaaaa	aaaaaaaaaa	aaaaaagtgc	cccttctgaa	aaatattctt	ttactagtgg	960
aaataagaga	gaatggccag	gcgcagtggc	tcacacctgt	aatcccagca	ctttgggagg	1020
ccgaggcarg	ggatcacaaa	ggycaggaga	tcgagaccat	cctggctaac	atggkgaaac	1080
cccgtctcta	ctaaatatac	aaaaaaaaatc	agccgarctt	agtggcaggc	gcctgtagtc	1140
ccagctactc	gggaggctga	ggcaggagag	tgatgtgaac	ctgggagggtg	gagcttgcag	1200
tgagccgaga	tcacgccact	gcactccaac	ctgggcgaca	gagcaagact	ccgtctcaaa	1260
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	agggcggc			1298

&lt;210&gt; 14

&lt;211&gt; 1733

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1730)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 14

cccacgcgtc	cgccaggcct	tgagacccag	aagggagcga	agggttttgc	tgcgccaacg	60
cagtgaccga	agctccgctc	acgcccggcc	tgatcctgcc	tgaagatggg	gccactggtg	120
gctgtggtat	cagggccccg	tgcccagctc	tttgctcgcc	tgctcaggct	gggcactcag	180
caggtcggcc	cccttcagct	gcacaccggg	gccagccatg	cggccaggaa	ccattatgag	240
gtgctggtgc	tgggtggggg	cagtggcgga	atcaccatgg	ctgcccgcag	gaagaggaaa	300
gtgggtgcag	agaatgtggc	cattgttgag	cccagtgaga	gacatttcta	ccagccaatc	360
tggacactgg	tgggtgctgg	tgccaaacaa	ttgtcctcat	ctggtcgtcc	cacggcaagt	420
gtgattccat	ctggtgtaga	atggatcaaa	gctagagtga	ctgagttgaa	cccagacaag	480
aactgcattc	acacagatga	cgacgagaag	atctcctacc	gatatcttat	tattgtcttc	540
ggaatccagc	tggactatga	gaagattaaa	ggcctacctg	aaggtttcgc	tcatcccaaa	600
atagggtcga	attattcagt	taagactgta	gagaagacat	ggaaagctct	gcaggacttc	660
aaagagggca	atgccatctt	caccttccca	aatactccag	tgaagtgtgc	tggagccccct	720
cagaagatca	tgtacttatc	agaagcctac	ttcaggaaga	caggggaagcg	atccaaggcc	780
aatatcattt	tcaacacttc	tcttgagacc	attttcgggg	ttaagaagta	tgcatatgcc	840
ctgcaggaga	tcacccagga	gcggaacctc	actgttaact	acaagaaaaa	cctcattgaa	900
gtccgagccg	ataaacaaga	ggctgtatct	gagaacctgg	acaaccagg	agagacccaa	960
gtgatttcat	atgaaatgct	tcattgtcac	cctccaatga	gcccaccaga	tgctctcaag	1020
accagtcctg	tggctgatgc	tgctgggtgg	gtggatgtgg	ataaagaaac	tctgcaacac	1080
aggaggtacc	caaagtgtgt	tgggattggg	gactgcacca	accttcctac	gtcaaagacc	1140
gctgctgcag	tagctgcccc	gtcaggaata	cttgatagga	caattttctgt	aattatgaag	1200
aatcaaacac	caacaaagaa	gtatgatggc	tacacatcat	gtccactggg	gaccggctac	1260
aaccgtgtga	ttcttgctga	gtttgactac	aaagcagagc	cgctagaaac	cttccccctt	1320
gatcaaaagc	aagagcgcct	ttccatgtat	ctcatgaaag	ctgacctgat	gcctttctctg	1380
tattggaata	tgatgctaag	gggttactgg	ggaggaccag	cgtttctgcg	caagtgtgtt	1440
catctaggta	tgagttaagg	atggctcagc	cttggtctcat	cttgatggc	ttctgggcca	1500
aaactgcagt	cactgaatga	ccaagagcag	cacgaaggac	ttggaacctc	tccttgtaaa	1560
gagttccttg	atgggtaatg	gtgaccaaag	gcctcccttt	tcagtacctt	tgaacagcaa	1620
ccatgtgggc	tactcatgat	gggcttgatt	ctttgggaat	aataaaatga	aataatactt	1680
ttattttctg	aataaaagtt	tgctactgaa	aaaaaaacct	ccgggggggn	ccg	1733

&lt;210&gt; 15

&lt;211&gt; 2498

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ccacgcgtcc	gggtgtgctgc	aaggagctaa	ggccttcagt	gtccccttcc	ttaccaggt	60
ttctcacaga	atggattccc	agcgggaact	tgagaggaa	ctgcggcttt	accaatccac	120
ccttcttcag	gatggctctaa	aagatctcct	ggatgagaaa	aaattcatcg	attgcaccct	180
aaaagcagg	gacaaaagtc	ttccttgcca	cagattgatt	ttgtcagctt	gtagtcttta	240
cttccttgag	tactttttat	ctgaaattga	tgaggcgaaa	aaaaaggagg	tagtgctaga	300
caatgtggat	cctgctatac	ttgatttaat	catcaaatac	ctgtactctg	ccagtattga	360
tctcaatgac	ggaaatgtgc	aagatatttt	tgcatctggc	agccgctttc	agatcccctc	420
agtgtttact	gtctgcgttt	cttatcttca	gaaaagactt	gctcctggta	actgctcctg	480
gtaactgtct	agccatccca	agattaggac	ttcttcttga	ctgcccagaga	ctcgccattt	540
ctgcccgtga	atttgtgtct	gatcgctttg	tacagatttg	taaggaagag	gacttttatgc	600
aactgtctcc	acaggaactg	atctcagtc	tttcaaatga	cagcctaaat	gtagaaaaag	660
aagaagcagt	atttgaggca	gtgatgaaat	gggtgcgaac	agacaaggaa	aacagggtta	720
aaaaccttag	tgaggtgttt	gattgtatcc	gttttcgcct	tatgacagaa	aaatatttta	780
aggatcatgt	tgagaaagat	gatataatta	aaagcaacc	agacctccag	aaaaaaaatc	840
aaagttctaa	aagatgcttt	cgcaggcaaa	ctcccaagaa	ccctagcaaa	aatgccgcga	900



aagactgggg	ctggtgaggt	gaatggtgat	gttgggtgat	aagatttact	tcctgggttac	960
ctgaatgaca	ttcccaggca	tggaaatgttt	gtaaaagacc	tcatacctctt	ggttaatgac	1020
acagcagcag	tggcttatga	ccccacggaa	aatgaatgct	accttactgc	actggctgag	1080
cagattccca	gaaatcattc	cagcattggt	accagcaaaa	atcagatata	tgtggtagga	1140
ggactatatg	tggatgaaga	aaataaggat	caacctctac	agtcatactt	cttccagctc	1200
gatagcatag	catctgaatg	ggttggactt	ccacctctgc	cttcagccag	gtgtctatct	1260
ggtctgggag	aggtggatga	taaaatctat	gtagttgcag	gcaaagacct	tcaaacagag	1320
gcttcgctgg	attcagatatt	atgctatgat	cctgtggctg	caaaatggaa	cgaagtaaaa	1380
aaactcccta	tcaaagtcta	tggccataat	gtgatttcac	ataaagggat	gatataattgt	1440
ctaggaggaa	agacagatga	caaaaaatgt	acaaacaggg	tgtttatctt	caaccccaaa	1500
aaaggagatt	ggaaagatct	ggctccaatg	aaaattcctc	gttccatggt	tggagtagca	1560
gtccataaag	gcaaaattgt	gattgcagga	ggtgtcactg	aagatggtct	ttcagcttca	1620
gttgaagctt	ttgaccttac	aacaaataaa	tgggatgtaa	tgaccgaatt	tccccaagaa	1680
agaagctcca	tcagtttggt	cagcctggct	ggatctctgt	atgcaattgg	tggttttgct	1740
atgattcaac	tggagtctaa	agaatttgca	cccactgaag	tcaatgacat	atggaagtat	1800
gaagatgata	aaaaagaatg	ggctgggatg	ttgaaggaaa	tacgttatgc	ttcaggagct	1860
agttgcctag	caacacgttt	aaatctcttc	aaactgtcta	aactgtgaac	aaggtgacaa	1920
aacataatag	attgggaggt	ggtttgtttg	gtgaatgggg	ctttaattta	ttctgttttt	1980
taaaagcttg	tacagacact	catgtagaaa	ttattcaaga	agttattgtc	taagagatga	2040
gcagtaggta	agaaaacctc	agtcattgac	tcttcaatgt	aatgatcaga	gtttaaaacc	2100
attttcta	aataaattaa	atcttcagtt	gaacaaatta	ttttgtgaat	ctgtttcact	2160
caatggattg	taaagaaggc	tcctaaattt	gagttgtttg	ctaatacttt	catttgcac	2220
attagggtat	ccttaaaactg	attttctatt	acaattggaa	gtggagaata	tgtgcatcta	2280
cactaaaaaa	atgtttaaga	tatcaaaaac	ctctcctcgt	gcttcaaaat	gacaggaatc	2340
ctgtgcatta	tactaagaat	tacatgccat	aagatgactt	cagaaatcct	acttcagaag	2400
tgtataaat	ggatggggaa	atcgtttgat	ggggaaaagt	ctcttgtaag	taaaagtagt	2460
caaattcaaa	tggcaaaaaa	aaaaaaaaaa	aaaaaagg			2498

&lt;210&gt; 16

&lt;211&gt; 3351

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3250)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3251)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3272)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3282)

&lt;223&gt; n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3323)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3335)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3341)  
 <223> n equals a,t,g, or c

<400> 16  
 gcaggaaagt gcatctatca taagtgtgca aattgatgaa ttctaaaatc tttattgtac 60  
 ctgttttagca cmtagattga cactgaacat aactaacaac cagaaatctc cgtgtactcc 120  
 cttcctgtaa ctaccctgc gcccgacca atcactctct tctaacagca taactttgtg 180  
 tgactagctt ttttaatgta aaagaatgaa atctacagca tgtattcatt tgcattggc 240  
 ttctgccacc caacattata tttgtgggat tcrtttgtac agttgcatat tagtttgag 300  
 atccctcact ctcatctcta tatggtatta tattgcataa acgtaccaca ctttatccaa 360  
 ctactgttaa atatttgtgc attttctact tgggggtgat ttcaaatagt gctgctatga 420  
 acattctgt aaatgtcttt tgggtgaacat atgcaacaca tatatgcgtt gttgttgggt 480  
 cccaggagg gcatctctgg gtcataaaca atgcgtgtgt tcaggtttag tacagtataa 540  
 tgccaaacag gtttccaaag tgtttgtgcc actttacata cctgccatta ttgaaaaaga 600  
 gttctgtttg ctccacattg tcaccaatac ttgatatttt ctgctttttt tttcttttaa 660  
 accgtactag tgggtgtgca gtgatattgc aatgtgggtt taatttgcatt cttccttggt 720  
 acaacctga ttactgtaag ccacttggaa atgtgattta aattcatata aagatatagt 780  
 agcaaaacgc atactagggt actttcgtat ccagaaagtt tagatagaat gatttctatg 840  
 taagctttta ctgtgtagtc tgagtccatg aatattgatt acaaaaaaca catctgtagg 900  
 tgagttacaa tacctcactt ataattcmaa attcatgttg tgttagctca atatttttca 960  
 aataattttt gcatgcaatt ttcaccttct ttctgagtag tttcagggtat tttgtatgggt 1020  
 tccagcagtc agttagggtg ccattgtttg gaagcacaca tccacgtatc tgcaccatga 1080  
 tgatatgaca crcccatacc ccccatctca cattttgtca gaagtgcata gttatcacta 1140  
 actttgccag tagaaatgta ctcccaatct cccacggact tatcttgaat aatctctcca 1200  
 ctgaagcata acagggtttg aattctgtta gaatagttgt ttttactatc ttttaatttt 1260  
 atacaaattt caaagttacg taatactttt atttaaaaag tgaaacaaag cttttcctct 1320  
 cccttaccga catgttagtc cagcagaggg ggaaagcatt ggmcccaggc caaaatcata 1380  
 aacgctttca attaactaat aataattgct ggcattgttc cattaaatat tcttgtctca 1440  
 ttatctctgg ttgctttatc aaacctatag gtcactgaag cccacttttg agacaaagac 1500  
 tatttctccc ccaaaagtca agggaaatat aaaaaatgaa attagtgtat aagaatagaa 1560  
 gtcaattaat acawtcattt tgtcttaatt atttaaagtc cagttttttc cctccagcaa 1620  
 acctgaaaat acactatcct ccagctatca gaattatatt gagatctact cacatttatg 1680  
 atgatgttca gagattctca ttgggaagga aaaggcacac gctgcggcgg tcttgcattga 1740  
 ctctgttgtt gtggaaattc aatttgttca ttgtgttttg ggctctctgg gtggtcaggg 1800  
 ctgggctctg ggtccttggc aattcctcag gttcccagca ctccaaagcc aagctcacct 1860  
 cctcatcaca caccctacag gagaagcatt aggggtgtcc actacgtggg tttcatagct 1920  
 gtggaaaagc caaaggggag actcctgaag aaaggcgggt aagactgtga agagcgggtc 1980  
 aggaagatga gcacagcact gctactcctg tgggcacagg gacagcatgt ctccagccag 2040  
 ygccaccttg ttttaatacat gggaactcac tgaaattcat tctgtatttt gcccgcaag 2100  
 ttttaaagmt ttcattccaca gtcaggaatt aaacttatac caatgagagc ctcacacatt 2160  
 caaggatgta ctaagcacta caggcctcac agaaacagag atcccatctt ggagttttca 2220  
 gtaccacatg ggagataaag ggttttgaac atgaaatgac aaaaacaaca gcaagaagaa 2280

aattcttgtc	ctttttcatt	actatcagac	tcaaataaat	gtcttggctc	ttacattaca	2340
ttcattcttc	aaccattgtg	gtctggcttc	cacttccctc	acttcaccaa	catggctctg	2400
ccaaaggaag	cccgtgatct	ctaggccatc	actttaattg	atctytctac	aacattttatc	2460
ctgggtgtta	agccctcctt	acaacattct	tctctctttg	tttttatagc	tccatctctc	2520
ctgcttcttt	aacttgataa	tgcatacttg	atttttctat	ttgttatttc	ataaaccaat	2580
taatacacag	ataaaatgac	tgtatatcaa	accatgtttg	tatagaaaaa	atggattttg	2640
gatgcctctc	atatgtaatt	agttctatta	aacatattaa	ttgtattgtt	taatttgtca	2700
ggtttttgac	agaattttgt	ttacaagtaa	taaaaatfff	atctccaatt	ttcaataaaa	2760
aaaaaaaaaa	aaaactcgag	ggggggcccg	gtacccaatt	cgccctatag	tgagtctgat	2820
tacaattcac	ttggcgtcgt	tttacaacct	cgtgactggg	aaaaccctgg	cgttaccgaa	2880
cttaatcgcc	ttgcagcaca	tccccctttc	gccagctggc	gtaatagcga	agaggcccg	2940
accgatcgcc	cttcccaaca	gttgccgagc	ctgaatggcg	aatggcaaat	tgtaagcggt	3000
aatattttgt	taaaattcgc	gttaaatttt	tgtaaataca	agctcatttt	ttaaccaata	3060
ggccgaaatc	ggcaaaatcc	cttataaatc	aaaagaatag	accgagatag	ggttgagtgt	3120
tgtccagttt	ggaacaagag	tccactatta	aagaacgtgg	actccaacgt	caaagggcga	3180
aaaaccgcta	tcagggcgat	ggcccaactac	ggtgaacat	caccctaat	caagtttttt	3240
gggggtcgan	ngtgccgtaa	agcactaaat	cngaacccta	angggagccc	cccgatttag	3300
agccttgacc	ggggaaagcc	cgncgaacgt	ggctnagaaa	ngaaagggaa	g	3351

&lt;210&gt; 17

&lt;211&gt; 4044

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

cgaacagaca	gacttgaggt	atgtcgagag	taccaacgtg	gcaattgcaa	ccgaggagaa	60
aatgattgtc	ggtttgctca	tctgtctgac	agcacaatga	ttgacaccaa	tgacaacaca	120
gtcactgtgt	gtatggatta	catcaaaggg	agatgctctc	gggaaaagtg	caaatacttt	180
catccccctg	cacatttgca	agccaagatc	aaggctgccc	aataccaggt	caaccaggt	240
gcagctgcac	aggctgcagc	caccgcagct	gcatgggaa	ttctcaagc	tgtacttccc	300
ccattaccaa	agaggcctgc	tcttgaaaaa	accaacggtg	ccaccgcagt	ctttaacact	360
ggatattttc	aataccaaca	ggctctagcc	aacatgcagt	tacaacagca	tacagcattt	420
ctcccaccag	gctcaatatt	gtgcatgaca	cccgctacaa	gtgtgttcc	catggtgcac	480
gggtgctacg	cagccactgt	gtccgcagca	acaacatctg	ccacaagtg	tcccttcgct	540
gcaacagcca	cagccaacca	gatacccata	atatctgccc	aacatctgac	tagccacaag	600
tatgttacct	agatgtagaa	ttttcatcac	taacaataca	tgctaaagag	gaaaggacag	660
tgtgcttgg	tagagtaaag	gacgaggtca	ttagccatat	tgtatatatc	gtcaagcaac	720
acacacaaaa	gttcctcagc	cacaagacat	ccacatattg	catgttaacc	agaagaaaag	780
acaacatttt	ccggaaatcc	actgcacact	gttgcttata	cactttgtac	atttaattga	840
tatttgtgct	gaggtgatat	tctgtcttaa	aagaacaaca	ttgtctttct	tttctagcac	900
agagttatgc	attcaaagat	gcatacctag	ttagtttccy	atatattcat	gccatcttga	960
aaagacagac	tatggtgtaa	ccatgattct	attatgtatt	ggtacgtctg	tagaccaaga	1020
tataattttt	taaaaataag	tttatttctt	tcaagggtta	caaataacaa	aggtgcacct	1080
tgtattttaa	attgccatta	tagatgagag	cgtgcatgca	cagtcatttt	tgtttaagag	1140
taatattttt	aatgtaatag	attgtaagac	gtggtgaggg	agggatctga	cagagatgaa	1200
tgtgccaaag	aaaaccacaa	ctgtgtatat	tttaaagcac	atcatggctt	taagtaccat	1260
ggtgttaagg	attctcatga	agtgccatag	actgtacatc	aaattagagt	attatttctt	1320
cagtggttatt	gttttcagag	ccacattttg	ttgcatattt	gctagtacta	atcagtcaaa	1380
gggcaccatt	cttttttttt	ttttttgaaa	ccaaagctgt	ctcagaaatg	gccaatftaa	1440
ctttacagta	acaatagaca	gcacaacaca	aactctctca	atacagataa	actcacacat	1500
actggagata	tatatataat	agatatatat	aaaattattt	taatgcattg	tagtgtaata	1560
tttatgcata	ctatactgta	taacatgtta	ttcaaaaggg	attgccattt	ctgagacaca	1620
gtaacaaaaa	aatgaggaaa	ttattttgct	tctattttata	gcctctgtca	aaagtcacaaa	1680

gactataaat	gctttgcaaa	aatgggtttca	cgtttgctta	aatgcttcat	cacagtcaca	1740
ttcaaaatag	tgactctaaa	caaagaagaa	agcagcactg	tcatcagatg	catgataaac	1800
caaaatatga	aaatgggaaa	tgtttaatta	acctagtaat	tgggtgggtt	aagtacatgg	1860
gtgaatttta	tatgtgattt	ttgttttggt	ttgttttggt	cagattaact	gcttatagcc	1920
ttagaaagcc	ttttacaaaa	taaaaaaaaa	aatagatgtg	cattcagttt	ttaagaatgg	1980
aatcatccaa	aggaattcct	ttttttgagg	tttggtatgt	gcagctagta	aaggatattt	2040
ttgctctgtt	cagcagttct	aaaaattgct	gaagtagggg	ccaggctact	ggtagttata	2100
gtatggaatg	ggagaagtga	aagttcagtt	atagaacttt	ccatacttcc	aagtttactg	2160
caagttttta	tgcttgagag	agatgccttc	taataataaga	ctgatgtgtt	gattttactg	2220
attgtactgt	acatctatta	aagccttaga	ttattacatt	acgggttgga	acccatacca	2280
atgtaatttc	aatcgtgtta	agaaagtaat	ggtgacttca	catgttattg	tagttagtta	2340
cattatagaa	tattacttat	ttttcttggt	aaaatgtagt	ttttcatttc	ctacatttat	2400
tagattttca	ttttctatta	acaattgaat	accatttcag	tttatagact	tgttttatta	2460
gattttacca	atgaattttt	caaaatacaa	aaaaaagtag	tttttccttc	ataacatact	2520
cagttttgaa	ttacatgtag	tgtcacatga	atattcgtat	tgtaactaa	atgatttata	2580
ttttactgat	ttaatattac	agtgtgaaga	tgtcagtcac	tgtagttct	tgtctagttt	2640
tcattaaaag	aacaaagatc	ttttatatgg	atatcttata	aatatataat	cattgctaag	2700
taagaagtta	agttgttgct	atcgcaacaa	tcctggcaga	caattgagta	atattttgat	2760
gatttatttt	gtttgttaatt	agttattata	agaagatcta	gacccatgat	attagaataa	2820
aatttatttt	ctactgtatc	catttcaaatt	gttaaaatat	tgtttaatat	ttttgaaatc	2880
cctgagtatc	aggccttggt	ataaataagc	tgcataatca	ataaatagaa	caagggactt	2940
tttgttgata	atccaaatc	tcaaagttaa	cgtaatgaaa	attatagcgt	gtgtgcaaac	3000
tcttgagggt	tgattatgct	gcaatttagc	atgttggaac	gtctagggag	aagggtgact	3060
ttttgcactt	ctgtatatag	tcaaaagaga	gaaacctgta	taatagtaag	atcttatttt	3120
gaataaaaac	gtctataatt	acaaggagtt	ttgttaaggc	taatacaatg	acagactgag	3180
caaaattgct	tgcaaaagtg	gcacagagtt	agcactccat	accccttcaa	acatgttgct	3240
ttgctttctt	gtggacagct	tgtagtttgc	caggattttt	tcagctggaa	agatacgcca	3300
tcctttcaaa	ccctcatgac	tgacaaaaac	tccatggggc	caaactctgc	tgaagatcat	3360
taccaaaaat	agcaggtaact	tctaccatta	agggtgaaatc	atggatcaga	tattccttac	3420
atttttcaaa	actactgcat	gtttaaaact	tcaacaaaaa	aagagagaaa	gaactatact	3480
aagaacatat	attattcaga	tcagtttctg	ccaatttcag	tggtttattg	ttcacaaaaa	3540
aatcttcaaa	acaagtattg	actttcacaa	aattttaaatc	ataaacaggc	aaaccaaaca	3600
gcacactgta	gctatagttg	ttatgtgatt	gttttttaatt	tgctgtagga	tcctgttctt	3660
tcagcagggtg	aaaaataaaa	cgagtttcaa	atttcattgg	tttaattttc	aactcagaag	3720
cactcaaaaa	tgcaaaatgt	gataatgggc	acttgtttaa	aagaattagt	gtatccagcc	3780
ttcactccag	ctggttaaaa	atgttgcaact	tatcagcaac	cctaccactt	tgcatctgct	3840
gaaaggacaa	atgtgcttgg	ktttactatt	atgtaatcac	aacttacttt	ctgctttag	3900
ttgcttaaaa	ttatgtattt	tgtcttgggc	tgcaatttgt	tttatgctta	ttttattatt	3960
actgcagtag	ttgaccttgc	tgtatggaaa	aataaagtga	aattgcccta	ataaaacttc	4020
tctttcttaa	gtaaaaaaag	ggaa				4044

&lt;210&gt; 18

&lt;211&gt; 2249

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ggcacgagcg	atcatgaatt	tttgcgtgga	accaagcttt	tggtttataa	attgatcagt	60
aaaattattg	atgtaaaaac	caatgtacag	tgcattccac	aactgtttat	gttttagcatt	120
gcacgtactc	acttttctgt	atgatgtggg	cagctcagta	aatcttcaga	gaaaaatctg	180
actcagtcac	gtcagggatc	ctgaaagctg	cagatggcac	aaagaccttt	tacaagtgc	240
ctggcttgat	cactgcacac	gccatccctg	gtacctgagg	cagaagacac	atcttgtgct	300
tccttagtca	tcaggttcat	cacttcgaag	catagaagct	gtagactgac	cccgtaaca	360

gaaggggtcat	ttaagacagt	gctgatcact	cttaccatgg	aatatttagct	tttgctgggtg	420
ggaacattag	cttcctagtc	accaaataac	tgtatgtggg	ataaaactga	accttgaact	480
gcctcataaa	atgactttat	atcttaggac	atgggaagaa	cagaagacag	agcatgctct	540
tttaagtctg	ataacatggg	ttcaagccca	gccccagcc	tttcttacca	atcaaggact	600
cagaactgaa	ggcaattatt	tcttttggtg	gacttggaat	ctccgtttgt	ctacactgtc	660
ctcttcacag	tggagtcttt	ttatctcaga	cctacagatt	gtttttatat	ttgttgtcac	720
agtgtgacaa	ttttttgtac	agtcgggttt	aaggctctct	ctgccattag	agccagtagg	780
ttacagctat	tgatgtaact	atagctgcaa	tttttgtgca	ggactgagaa	acacagtgca	840
ttattttattg	cggaaatcatt	gctgctaaat	aactactgtc	tgtttattta	acacaacaat	900
tgaatgcctg	aagaagttgc	agtggcttta	ttatatgtga	atgcatctgt	ttctcctcac	960
gaattgtttt	actgctgcat	tttttgtttt	taaaattaaa	ctgcagtgtt	tcctggaatg	1020
taaatttagc	tttgcttaat	agtaaaataa	gtgagccatc	ttgaacactt	taagtttata	1080
ctatataatt	tcttaatgaa	cattggcaaa	tagagttagct	aagagattga	caagcacatt	1140
acgttttagat	aagcatgtga	tgacagaagt	gattcaagca	agtgaatccc	tgacattttg	1200
aggatctcac	attagacacc	aacaaattaa	agctccaaaa	ttattttatt	tttatgtgtt	1260
cctcacttta	gaaacgtcta	ctgcatatta	ctggatattt	gtataactat	acacttacct	1320
atctttacatt	gtgtttttaa	tttagttaaa	acttaaccgt	agaagtctgt	tcaaacgcga	1380
aaggctctgc	tttgtttgtt	ttaaatacat	ttattttatt	agaaaggatg	atattttcatt	1440
ggggaatagt	ttctttcatt	tgggggctat	gtgtttcaat	aacattcact	tggaatcagc	1500
tgaaagctgt	aatatgtctt	tgaaatgagc	catgataaat	tacaaacaag	agaaatgaga	1560
acttacagga	ttgcttgaaa	ttattgtggg	tattatctgt	ttaccagaga	tactaaatat	1620
tagttttaat	tatgcatctc	tttgaacatc	ataaacacac	tttgggtgtg	gtaacagtat	1680
tttaagcatt	tttgttcact	tttaaggact	atttgttttag	tgcatcttac	aaactataaa	1740
tcttaattgg	tatatatttg	aatggtcgtg	taaatttttg	ccttatatat	catgaaaata	1800
gtcataactt	aatttctttt	cctgaaattc	actgtaaaac	attcaggggt	cctaccattt	1860
ctgttcagga	aatcttgtag	tttattgttg	ttatttaaca	gtatttaagt	gatttttcta	1920
tatttcattt	taactttatt	tgtgaatagt	gattgtggca	tgtttggggg	gttattttta	1980
tatttcacga	tactaaaatt	ttatttttaa	aaaattctgg	aagaaacaga	ttcatgtgta	2040
atggtgaata	ttggaccact	actgcttttc	acatttgtaa	attgggttta	tgttaaacct	2100
tgtagcctaa	caaactgctg	ttctttctaa	ctgacagaca	tgtattaata	ttgtactttg	2160
aaggttataa	atatgtggaa	attccttcat	tttgttttga	aattttataat	aacaaaatct	2220
ccatgttgtt	aaaaaaaaa	aaaaaaaaa				2249

&lt;210&gt; 19

&lt;211&gt; 1645

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

ggcacgagct	aagtaatcaa	ttgaggttat	tccaaccaaa	cattttaaatt	atccttatta	60
agtgtccacc	agtgagtgg	actaagtgtg	acatactgtg	cacaatcctt	gctctcaaga	120
aacatgaaca	gcatagctag	gaagaaaagt	tgagaggagc	accagggcat	aagcagattc	180
gcactgcaag	ataaagcaaa	aagaagataa	gtgccaaagta	ccagatggaa	tgaaatcatg	240
ttccttttgc	tctcttgccc	agcctaagaa	gacaggccag	gggagtttgt	gatcatggta	300
cagaaatgga	ggctattgct	caatttgctc	actctgcccc	atcgggtcaa	attgctattc	360
aaaatgtgcc	ttactcccta	ttttgtattt	agagtcttgg	attcttattt	gaaacttggc	420
agctttggaa	gctgtcttat	atcttgttct	gctttaagac	tttctactgc	aagtacatat	480
tcaggctttg	tttgccagtt	tttttgattg	tgtggttgaa	tgccatccct	ggaaagatgt	540
acttttgagc	tagtatgaag	tcaatgagct	gccttcagca	ttcatgaaga	ggttctgaag	600
ttctgttttc	aaggcttttg	acatgtcagc	gtgtgtaaat	ctagtctgat	gccaagatgc	660
cttatgccaa	tgggttcctt	ttgatttttg	tatgcatgat	tttcttctgt	catattaacc	720
tgttgccatt	aaaagaaaca	gaaaattata	agatcatgta	atataacata	ggttctagcc	780
acaaataaca	ttagtactgt	atcacacac	tagtggattt	tggtttgtta	gaatttttaa	840

ctgtcttggc	ttttttttaa	tatcctttct	aaaactgtgt	attcaactcc	tgatttttca	900
ttcaacccat	gatgatgctt	cctgactgct	cagctggaat	ctggatttgc	cttctttcat	960
tcagcacact	tctgaagcag	tggcaggtct	tgtggggaat	tttgggggta	gcagattcaa	1020
atltggcagg	accctgggga	cattaatcaa	ttggaaaata	tcaatgagca	aatcatttct	1080
cagataaaaat	ggttcaatta	aaaatgatat	tgaactgaaa	aaaacaaaac	gttaccaaac	1140
taaaaatgtg	tacaattcat	aggctccacg	atacgtttat	tttgtttcta	tgtacttttt	1200
aggcttgatc	ttaccatcct	tataatttaa	ataaattggca	ataacttata	acttgttgta	1260
atgataatga	gttcaccttt	actacttact	ccctgaccca	tgttggtggc	ctctccagt	1320
ccttcctcgc	ttttattatg	taccacacagc	agcctaatac	acagccctgt	ggccagcagc	1380
ttccacaata	tttggtgtgg	aaaatactga	ttgatatttt	gggtgaaaaa	ttgtaactta	1440
atggtacttt	atatcattat	taaacataca	taataatttca	aatattaaat	aattgcaatg	1500
ttctcagat	aaaaacacgt	ctatccaacc	tggccattgg	aagtaagaga	aaacttccca	1560
cagaaaactc	ttaatatatt	atttttgttg	ctggtgttgt	ctgtttccaa	tgtttattct	1620
tttgtccaaa	aaaaaaaaaa	aaaaa				1645

&lt;210&gt; 20

&lt;211&gt; 953

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ccacgcgtcc	ggaggatttc	tcttcctgtt	atatagcctt	ttgcttcccc	ctttcctcat	60
tccagctgat	accccgagaa	aaaactcagc	cataacatga	ttatgttgct	taagtaagtc	120
catggtcttt	ttcagtctct	taagttcctg	tctacacagt	tttttcacag	gatgcacttg	180
atatggttgt	gtgttacagg	tttattcata	tcagctactg	aaatacatgc	tgtgtgtaca	240
tataataggt	acattgtctc	tgtttattga	acttataaaa	taataataaa	cagctgaata	300
aggaaagtaa	tgtaagtgtt	gttaagtaaa	ggactttgtt	gaagaagaac	ttcagttttt	360
aacaaaaaaa	tgggagccag	aagaaggcgg	ctggagtaaa	tggttctctc	atatgtggag	420
taaagcaaac	aaaaatatgt	tttcttatat	gtggagtaaa	gaaaacaaaa	agccatttaa	480
agagtcttga	tgtttgagat	taaggggttg	atggtttgtt	cttccttttt	gtccatagtt	540
ttttcagagt	gataattttt	aattcccatc	gtcagtaatt	aaagaaagtg	atatttttta	600
cactttttta	aaaagcttca	gtatttcatg	ttaacctgtg	ctaggtttta	ctgaaagggt	660
tgggattttt	tagttgtttt	ttggggggtg	gataatatta	aacgtaagac	tgaatttggc	720
cagctgaatc	taattagggtc	aataagttgc	attatttcat	ctctgaatta	tgaaaataat	780
ttgaaatttt	ttttcttata	tttcaggcct	ttttatgggt	atcatgagaa	ggaaagacac	840
tttatgaaga	tctatcttta	caatcctaca	atggtgaaaa	ggtacaaaga	taaatgaaac	900
caaaatatga	ataactatca	ttgaagtatt	ttaataataa	aaaaaaaaaa	aaa	953

&lt;210&gt; 21

&lt;211&gt; 879

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

ggcacgagaa	actacaaatt	ttaaatagta	tatttccagg	gataggttgt	cctgttcctc	60
gaattccagc	tgaggccaat	ccttttagcag	atcatgtctc	tgctactcga	atcttgtgtg	120
gagcccttgt	ctttcctact	attgctacaa	tagttggtaa	attgatgttc	agtagtggtta	180
actctaattt	acaaaggaca	atcttgggtg	gaattgcgtt	tgttgccata	aaaggagcat	240
ttaaagttta	cttcaaacag	cagcaatatt	tacgacaggc	acaccgaaa	attctgaatt	300
atccagaaca	agaagaagca	taaaactgac	ttctggttgt	tctgcagttc	tctcatcctt	360
atgaatctgt	tgtgtgtgtt	tgattccatc	attaatgcac	ttgtggagac	ttgtgataag	420
ctgctgctcc	tatatttttt	aagaaatata	ataaagcact	tagggcaggg	gaaatcatct	480

cggtaatcat	ggaacctaa	gatgtgattt	gttttcattg	tttgtatgta	ctacttttat	540
ggcagtcata	tgaaccatta	tcttagcatg	gtaaacctgg	gttttgttca	tattttctcc	600
agacagaaat	gcaaagatca	aactgtgcaa	atattaaaaa	aatgcacatg	ctgtttttatt	660
caaatgcctc	ttttgtacat	gttcatgttt	agtgttttct	cagaatcagc	aactcaaggt	720
actatgagga	tttttctcac	tgacataatt	tgattacata	ctaaataaga	ggatatgtta	780
atatgaggaa	atgtaaatta	aattagttat	aaataaataa	ccaaaaatgt	atgtaaacat	840
tcaaatgatt	atctgaaaaa	aaaaaaaaaa	aaaaaaaaaa			879

&lt;210&gt; 22

&lt;211&gt; 352

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ggcacgagca	aggactggca	gcaggggaagc	cctgtgcatg	tgtgccctgg	gaaagctctg	60
cttgattctg	caaagctggc	atcctcttta	aggaagccct	aggacaggcc	aaatggagct	120
cttgtccaag	gggtcatttc	tgtcttgaca	gatcgaaggt	gccttggaat	atggaatcac	180
aagtgatgac	atcttctggc	tgaaggaatc	ccctggaaaa	acgtaaggcc	tgcgctgct	240
tgggtggggtc	ctctttttgt	tcaccagagt	gagcactgga	cccttagagc	ctgtgctggt	300
gctgggctcc	tggggctttc	tttccggttt	acccaaaaaa	aaaaaaaaaa	aa	352

&lt;210&gt; 23

&lt;211&gt; 1956

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1362)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 23

tttttttttt	tttttttttt	tttttttcac	caatgaaaac	atttttttta	aattaacaga	60
catcaactgg	tataaatata	ctgtctaaag	catttaaatg	tctttcttta	acacagccaa	120
ctccccggg	tttgaaacag	tggttaaattc	tctcttgctt	gtggcaaaag	aagctgtcaa	180
gtccaacact	gaaaaattgg	taccatttcc	tggccagtaa	gcacagaaca	gaggggctaa	240
atattttatg	gttttattya	tttactgtgt	tctcatgctg	tgtttttctt	ttctctgtct	300
ctccctctctg	ctcgtgtctg	cccagggctg	attgttgtga	cattggccgt	atgctggatg	360
cccaaccaga	ttcggaggat	catggctgcg	gccaaaccca	agcacgactg	gacgaggctc	420
tacttccggg	cgtacatgat	cctcctcccc	ttctcggaga	cgtttttcta	cctcagctcg	480
gtcatcaacc	cgctcctgta	cacgggtgtc	tgcgagcagt	ttcggcgggt	gttcgtgcag	540
gtgctgtgct	gcgcctgtc	gctgcagcac	gccaaaccag	agaagcgctt	gcgcgtacat	600
gcgcactcca	ccaccgacag	cgcccgcttt	gtgcagcgcc	cgttgctctt	cgctccccgg	660
cgccagtcct	ctgcaaggag	aactgagaag	attttcttaa	gcacttttca	gagcgaggcc	720
gagccccagt	ctaagtccca	gtcattgagt	ctcgagtcac	tagagcccaa	ctcaggcgcg	780
aaaccagcca	attctgctgc	agagaatgg	tttcaggagc	atgaagtttg	aatgtcaagc	840
gagggagcct	tgagtgggaa	ctggccctcc	agccctaaga	aaacgtcact	ctcactctgc	900
agtctcaaac	tatgccccca	tcagggatgg	aatggacact	ggaggcttta	caaaaggcag	960
atgccacact	cagtgacttc	taaggactga	ctctgccagc	ctggccttga	ctccggttac	1020
acagacatgg	gggtgaactt	tcactccacc	tccttccttc	aagtacatac	tgaaaattca	1080
gtcargctga	atattttcag	aatgctttac	cgagctcttt	cattatttgc	acaggaacaa	1140
aagagaacac	ggactcccg	tccctaccca	gaataaaaag	acaccagaa	gaaactcact	1200

cagggaggtg	gggggttggg	ggcgagggct	ggaagaacaa	tgcaggaggg	ggtggcatct	1260
ccttcagctt	cagcagtgtg	cogagaagag	ggctaatttg	aggaacagga	tggtaggtgcg	1320
gagccctgcc	tgagggccga	ggcagaactt	ccccctttct	tnggccttgg	cccgttacia	1380
agaggggtgt	tgcagcagct	gatgcaaaact	gagttcagtt	tccctgggga	gcagaaggac	1440
tggtagcccg	cagaggcgat	gagacaggcc	gctgatgatg	cacaggactt	gcggtacatg	1500
atcccgccac	tttgctccat	cacttctttc	tgacacatgt	cttgaacggt	caccgtgcaa	1560
ttcacaaatga	actcggggga	ggagcagtcg	ttgttcagct	ggaattcttc	acactggtag	1620
cactggattt	gcagcgcaaa	gcctggaagc	aagaacaatc	cgcaaaaagt	tgccgcgatg	1680
cctaggaccc	acattctccc	ggagtcccg	ggccgggaga	gggcaagcgc	atcagaggag	1740
gcgacagcag	cggaggctgc	cccggctgca	gcccgtgtgg	ctgccgaggc	tgctggggcc	1800
cgcgtgctg	ccgcggagac	gacggctcgt	gcttagagga	gccgcaggtg	ccgctcgcgg	1860
agcctgcac	gcccgcgctc	gggctcccg	ctgcccgtct	ctgctcctcc	cgctcgcgct	1920
cccgggccga	gcaccgcgcc	tccggacggc	acgagc			1956

&lt;210&gt; 24

&lt;211&gt; 575

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

ggcacgaggc	tttttttagct	caagagtttg	ttattacccc	ccttctgaag	cttacttcca	60
tcaattcctc	aaactcattc	tgtgtccatt	tttgtgccct	tactagagag	gatctgggat	120
aatttgagg	agaagaggca	ttctggtttt	ttaaattttc	agcatttttg	cacggttttt	180
tctcatctt	agtggattta	tctacctttg	tactttgagg	ctgatgacct	gtggatgaga	240
ttctgtgtgg	gggtcctttt	tgtcgatgtt	gatgttattg	ctttctgttt	gttaggtatt	300
ctaacaggca	ggcccctctg	ctgcaggtct	gctgcagttt	gctggaggtc	cactgcagac	360
cctatttgcc	tgggtatcac	cagcagaggc	tgcaaacag	caaagattgc	tgctgtctcc	420
ttctctgga	agtttctgcc	cagaggggca	tggacctgat	gccagctgga	gctctcctgt	480
ataggtgtct	gtcaactcct	gttgggagg	ctctcccaat	caggaggcat	ggaggtcagg	540
gaccacttg	aggagcagtc	tgtctcttag	cagag			575

&lt;210&gt; 25

&lt;211&gt; 549

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

ctacatagcg	aacaagatct	tttcagagt	gtgtttctaa	aagagcatgt	acaaaagtgg	60
cctgtggaca	tttaggcctg	ggtgatgcat	ttgctcttcc	tgtttggtgc	aatgtatcaa	120
tgtagagttg	ctctgttttc	ttcaactgta	tttattgctg	catttctcag	cataaactta	180
tcccattgta	ttttttataa	ataaatattt	tttttaaatg	ttctctacag	aagattttaa	240
tcaacaaaaa	gatataaaat	tgcaaaagg	gctcagtcac	aaccatgatt	atcaaggaag	300
caaagcttct	ggttccaaat	ttggtaatct	gctacccatg	ttaagtttcc	agtttttatc	360
tggttgccct	tcagtttagg	gaccactggc	ccagaacaca	cattactggc	ttagataccg	420
gcctgacata	ggaaagagag	tggtagggtg	aagagagtca	ttctctgcag	gctcagagat	480
gtgtaggcac	aagggactcc	cgctatgtag	ggaatcgata	tcaagcctta	tcgataccgt	540
cgacctga						549

&lt;210&gt; 26

&lt;211&gt; 709

&lt;212&gt; DNA



&lt;213&gt; Homo sapiens

&lt;400&gt; 26

caagatccga	ctccctgcac	agccgtcctg	gtatgtacag	tccttcctgt	ttagtttatg	60
ccaggaaatt	aatcggttg	gaggccatgc	cttgccaaag	gtgacattac	aggagatgct	120
gaaaagctgt	atggttcaag	tagtagctgc	ctatgagaaa	ctctccgaag	aaaaacagat	180
taagaaagaa	ggtgcatttc	cagtcaccca	gaaccgggcg	ctgcagctgc	tttatgatct	240
gcgttacctc	aaacagcaac	cttcacgcgc	tgggtgcagc	gaacttcttg	ttcctgtttt	300
gggattggtg	actggtacag	agaatcagct	cgcccccccg	agcagtacgt	tcaactccca	360
agaaccccat	aacatcctgc	cactggcatc	cagtcagatc	aggtttgac	ttctcccact	420
gagcatgaca	agcactcgaa	aggctaaatc	aaccagaaac	atcgaaacaa	aagctcaggt	480
tgtccccccg	gcacgctcca	cagctggtga	cccagacgtt	cctggctcct	tggttcagaca	540
gcttgctcag	gaagaagaca	acacgtctgc	accttcatta	ttcaaaactg	gctggctctc	600
tagtatgact	aagtaacatg	gcaacacatc	tgtctctccc	taaataaata	ctaccacatt	660
atttcttcta	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		709

&lt;210&gt; 27

&lt;211&gt; 1225

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

ggcacgagcc	cgcgccccgg	ctgacgggga	agggtcagc	accccgggca	caaagctagg	60
aagggtggga	cacagtgaag	gtgggaggag	gaggggctg	ggggcaacca	ggcgccgtgg	120
agctgccgct	cgctgccccg	ggcaggggca	caggcttcat	ccagtgaata	ctagagggat	180
cgaacagttg	caaccaaggc	aatgtcttac	tacctcagct	cagaaaacca	cctggaccca	240
gggcccattc	acatgcgaga	aaatgggcag	ctgcacatgg	tcaatctggc	tctggatggg	300
gtcaggagta	gcctgcagaa	gccaaaggcct	ttcagactgt	tccccaagg	cttttctgtg	360
gagctttgca	tgaacaggga	agacgacact	gcacggaaag	agaagactga	tcatttcac	420
ttcacatata	cccagagagg	gaatcttcgg	tactccgcca	aatccctctt	cagccttgtc	480
ctgggtttca	tctccgacaa	tgtggatcac	attgattccc	ttattggctt	tcctgagcag	540
attgctgaaa	agctgttctc	tgtgctgaa	gccagacaga	aattcactga	gccagggtgca	600
gggctgaggg	ctttacagaa	attcactgag	gcctatggaa	gtttggtgct	ttgctccctg	660
tgtttgcgaa	acaggtatct	cgtgatttca	gaaaagcttg	aggagattaa	gtctttccgg	720
gagctgacct	gcctggatct	ttcctgttgc	aagcttggag	atgagcatga	acttctagaa	780
catctacca	atgaagccct	gtctagtgt	actcagctcc	acctgaagga	taattgttta	840
tctgatgctg	gggtgcggaa	gatgacagca	ccagttcgag	tgatgaaaag	aggccttgag	900
aatctaacat	tattagactt	atcatgtaac	cctgagatca	cagatgcagg	cattggatac	960
ctcttttctt	ttaggaaact	aaactgctta	gatatctctg	ggacagggct	caaggacatc	1020
aaaaccgtca	agcacaagct	ccagaccac	ataggccttg	ttcactccaa	agtgcctttg	1080
aaggaatttg	atcatagtaa	ctgcaagaca	gagggctggg	ctgaccagat	cgttctgcag	1140
tgggagcgtg	tgactgcgga	agctgtgaag	ccacgggaga	cctcggagcc	tagagcagca	1200
gctcagcgct	tctatgggaa	gcggt				1225

&lt;210&gt; 28

&lt;211&gt; 2127

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (72)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (141)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (294)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (303)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1938)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2045)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2117)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2121)

<223> n equals a,t,g, or c

<400> 28

attctacagc	agaatatact	tggaaaaact	caagtttttc	cacatacttg	gaaaaactct	60
ctagcatttg	tnngaattta	gtgtaattaa	gtgaaaccta	cctagcaact	gtagtaatta	120
aaagcgtggg	gtgtgctttt	ngttgagatc	cgtgaatggt	tctgtaaaca	caattttgat	180
tgtgttgcg	ttcttaaagg	ttgtgatgac	aacggtaatt	ttaaccactt	gaccgtatat	240
cgtttttcatc	cttgaagact	gtcatatatt	tccaagtgtc	tttcctccct	ggtnatTTta	300
ggntaaagat	cgaggtcgg	aagccaccta	ggagattttt	taattgggtt	tattggagca	360
ttaacctggg	agcgatcctg	tcgttaggtg	gcattgccta	tattcagcag	aacgtcagct	420
ttgtcactgg	ttatgcgatc	cccactgtct	gcgtcggcct	tgcttttggtg	gycttctct	480
gtggccagag	cgttttcatc	accaagcctc	ctgatggcag	tgctttcacc	gayatgttca	540
agatactgac	gtattcctgc	tgttcccaga	agcgaagtgg	agagcgccag	agtaatgggtg	600
aaggcattgg	agtcctttcag	caatcttcta	aacaaagtct	gtttgattca	tgtaatgtgt	660
ctcatgggtg	gccatttaca	gaagagaaag	tggaaagtgt	gaaagctctg	gtcaagattg	720
tcccgtgttt	cttggccttg	ataccttact	ggacagtgtg	tttccaaatg	cagacaacat	780
atgttttaca	gagtcttcat	ttgaggattc	cagaaatttc	aaatattaca	accactcctc	840
acacgctccc	tgcagcctgg	ctgaccatgt	ttgatgctgt	gctcatcctc	ctgctcatcc	900
ctctgaagga	caaactgggc	gatcccatTT	tgagaagaca	tggcctgctc	ccatcctccc	960

tgaagaggat	cgccgtgggc	atgttctttg	tcatgtgtctc	rgccttttgc	gcaggaattt	1020
tggagagtaa	aaggctgaac	cttgtaaag	agaaaacat	taatcagacc	atcggcaacg	1080
tctgtctacca	tgctgccgat	ctgtcgtgt	ggtggcaggt	gccgcagtac	ttgctgattg	1140
ggatcagcga	gatccttgca	agtatcgag	gcctggaatt	tgataactca	gctgccccca	1200
agtccatgca	gagtgccata	atgggcttgt	tctttttctt	ctctggcgctc	gggtcgttcg	1260
tgggttctgg	actgctggca	ctgggtgtcta	tcaaagccat	cggatggatg	agcagtcaca	1320
cagacttttg	taatattaac	ggctgctatt	tgaactatta	ctttttcctt	ctggctgcta	1380
ttcaaggagc	tacctcctg	cttttcctca	ttatttctgt	gaaatatgac	catcatcgag	1440
accatcagcg	atcaagagcc	aatggcgtgc	ccaccagcag	gagggcctga	ccttcctgag	1500
gccatgtgcg	gtttctgagg	ctgacatgtc	agtaactgac	tggggtgcac	tgagaacagg	1560
caagacttta	aattcccata	aaatgtctga	cttcaactgaa	acttgcattg	tgcttgatt	1620
gatttcttct	ttccctctat	ccaaaggagc	ttggtaaagt	ccttactgca	gcgtgtctcc	1680
tggcacgctg	ggccctccgg	gaggagagct	gcagatttcg	agtatgtcgc	ttgtcattca	1740
aggtctctgt	gaatcctcta	gctgggttcc	cttttttaca	gaaactcaca	aatggagatt	1800
gcaaagtctt	ggggaactcc	acgtgttagt	tggcatccca	gtttcttaaa	caaatagtat	1860
cacctgcttc	ccatagccat	atctcactgt	aaaaaaaaaa	attaataaac	tgttacttat	1920
atttaagaaa	gtgaggantt	tttttttttt	taaagataaa	agcatggtca	gatgctgcaa	1980
ggattttaca	taaatgccat	atttatgggt	tccttcctga	gaacaatctt	gctcttgcca	2040
tgaanttgaa	aaggctggta	gtaaacacat	ttcatctgct	gcttcaaaaa	gtacggggct	2100
ttttggccca	aaagccntcc	ntacggg				2127

&lt;210&gt; 29

&lt;211&gt; 2331

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (121)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 29

gcggcaagaa	gacgccatgg	ggcaagcgtg	gctggaagat	gttccacacc	ttactgcgag	60
ggatgggttct	ctacttcctg	aaggagagaag	accactgtct	ggagggggag	agcttggtgg	120
ngcagatgggt	ggatgagccc	gtgggggtgc	accactcgct	ggccaccccc	gtcacgcatt	180
acaccaagaa	gccacgctmt	tccagctgcg	cacggctgac	tggcgccctct	acctcttccm	240
ggcasccact	gccaaaggaga	tgagctcctg	gatcgcgcg	atcaacttgg	ctgcggccac	300
ccactccgcg	ccgcccttcc	ccgccgctgt	gggctcccag	cgcagattcg	tgcgggccat	360
cctgcccgtg	ggccccgccc	agagctccct	ggaggagcag	catcgatccc	acgagaactg	420
cctggacgct	gccgcggacg	acctgctgga	tctacagagg	aacctgccgg	agcggcgggg	480
ccgtggccgc	gagctggagg	agcaccgcct	gcggaaggag	tacctggagt	acgagaaaac	540
ccgctacgag	acctacgtgc	agctgctggg	ggcccgcctg	cactgcccct	ctgatgctct	600
ggacctgtgg	gaggagcagc	tggggaggga	agctggaggc	actcgggagc	ccaagctcag	660
cctgaagaag	tcccactcga	gcccgtccct	gcaccaggat	gaggctccca	ccacggccaa	720
ggtgaagcgc	aacatctcag	agcgcagaac	ctaccggaag	atcatcccta	agcggaaaccg	780
caatcagctg	tgaagccagc	accacctcag	agacactgtt	ccctgctcca	gggtagacct	840
gagatgaacc	tccttgagg	agacttattt	caatgagtcc	accatgacgg	atgaggcacc	900
tcctttccct	gctgaaggac	aaaccttggt	tccctgtggc	cctcattctt	gtgctccctg	960
aagcttttct	aattattgctg	tgctccccac	cacccccatg	gcagtccctc	cgcagcccca	1020
gtccctggcc	acgcccagg	gaagaggggag	gtgaggactt	gactttcctc	ccagagctca	1080
gcccattgtca	ccctccaggc	cccagaatcc	agagtggcct	catttccctag	acttgctgag	1140
aactcagcac	ttgtttgaga	accagtgtt	atgtggtgtg	cccttggtt	ctgggggaga	1200
gcttggggca	gcagaggccc	ctgggcagcc	cagccagggg	agccacagcc	ccgaggatgg	1260

tcttgctctg	ggaattaggt	gaccttcctg	gggaggcccc	aggagagtga	atcagggact	1320
cttgagaaat	tcctaaccag	cctcctgtga	cccaggaggc	agggctcgta	aggtcctgcc	1380
cactgagggg	acagccttct	gggcaggggc	ctcggggggc	ttcaagggct	ctgcacggct	1440
gtggggccct	gtgcctttgt	ctccttgtgt	ctcctttccc	ccgaagtaga	tgaacagtc	1500
tcacataccc	aactgctcat	caacagagca	gagctgatgg	catgagtrag	ggctgggcgg	1560
ggtggggcct	ccagagcttt	gcagggaacc	ctggaaccct	aggaacaagg	agcctttgtt	1620
ccaacagagc	agagaaggag	gttctctatg	ttcagaccac	tggagaggat	agagaggtaa	1680
aaggtggcga	cagtttccct	taggggtctg	cctggcagga	gccacagctc	aggagagtgt	1740
tgagggatgg	gacggaggct	ggcgaccagg	cgaggcctag	gccaggctcg	ggagactttt	1800
ctgtgctcct	ttctacacat	gccttaaacc	ttccttcctg	tggggtgcct	ggacccttc	1860
cccattctctg	gcagctcaga	gggtctctgc	tgctctcccc	tgggaaatcc	cctcatcctg	1920
ccctctggct	gcctcccagc	tgggcttggt	ctctgaggga	ggttccggag	actcatggac	1980
ttggggctct	gcctgtagga	aggaggctgg	gccggaggga	ccagccacca	ttgtctctgt	2040
tcagccaagt	gtgcaagtag	gctgcccggc	aagagggggc	ctctgctacc	cgctgctgcc	2100
tgccggctga	cacactgcct	ccccagcctt	cctgctaggc	caccctcttc	ccttcccatg	2160
cttgtaacca	gctctggggc	ttgcacctcc	acaaagtaag	gttggccctt	ggaggccatg	2220
tttgggtctc	cggccagggc	ctagggctag	gccatgcacc	caatgggtgc	acaataaata	2280
acaggtcaac	aaaaaaaaaa	aaaaaaaaara	aaaaaaaaaaa	aaaaagtcga	c	2331

&lt;210&gt; 30

&lt;211&gt; 2418

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (138)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (171)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 30

gctcgtgccg	ctgttgaccc	cactgagcag	tgctaagtgt	tggtttagtg	gatgttcgtg	60
gaattgctga	cccatccaag	ggcgtccttt	ggagccagtg	gagcctgccg	gcgcatactra	120
ggggcagaaat	gctgctanca	cttgaatctg	ggatctcgcc	ttattctcaa	ntagcaaggc	180
atctcgacaa	gcattggtcta	rgtctgggtg	ccagcttgcc	artacctgag	ccggctgggt	240
catctgcctc	tgagggaccg	tcctcaccga	gctcctgcat	cccttgagt	ttgatcagga	300
ggcgccaca	gcattgttct	cgctctgaa	tgatgcttct	ttctgtgttg	gagcctggcg	360
aagttgtgtt	ttcaagccct	ttactttttt	tttccaagt	gggtaggagc	ttttggcagt	420
gtttacttta	cctagatggc	ttatataatc	cagtaagaga	tgcaaagata	aaattgctgc	480
ggttggttaca	gaagcatggc	ggcctccaga	ctgaccatt	ggttgccctt	tagattttgt	540
aaggatgcgg	tgctggggag	gtggtgcttc	cctacccctt	agaaatgctg	ccttccaact	600
accactctcc	cagatgtgac	ccttgcgatt	atttcctctg	aggtttgagg	atgaagataa	660
gttgaggga	aagagagtaa	ctaatagggg	atgaaatata	gcagaagcta	gaagaaagcg	720
gtgaggtgag	agagatgcat	ctgcacgttt	tcttcaacag	caccaggtga	ttcagcatat	780
tcctaattac	ctttcactat	tcgtgtatat	aagatcgttt	acttgcataa	tatatcatca	840
at ttgacata	ttcttaaaac	tagaggtgtg	gagaagcaca	gcaataggaa	gtctctccac	900
aaactagggg	aacacaaatg	gggtcattca	cggtcctgga	ctgtcactat	gtggctgtca	960
cgtgaagtgc	tggtgttgat	ttccatttca	gccagtgggt	agctgataag	ccagtgccag	1020
catccagcat	gagcagatgt	cggggagact	gggaagtctc	cagcgttact	gctctccttc	1080

ccttcacgat	aagccagtgc	cagcatccag	cgtgagcaga	cgtcggggag	actgggaagt	1140
ctccgatgtt	actgcctgcc	ttcctttcgt	gtgaggggct	gcacttgctt	ttccttgat	1200
ctgttagtgg	acgaggtcct	ccaaggaagt	gctttgcaca	ctttctttgc	tcctttttac	1260
agtctttgtc	tttgcagcaa	gcaaatgaaa	ttaagccact	ttgggataat	gaacattcag	1320
tataattcta	ctttgtctca	ttttggatct	cactgttgct	tttataaaaa	tggcacattt	1380
tacaaagttag	tttatcttta	ttatactttc	tgctggagag	tgcttgaaa	taaaatgtga	1440
gagtattctg	gtactctgtg	ttccagatgc	atgaaattgg	gtgaggaata	acccctagtc	1500
tggaaatcttt	gtgaagcata	gggttattgc	aaggcaaatg	ggaactaaca	catcttgcca	1560
tttgaatcag	ggtctccagt	ttctagaaaa	ggcagacact	ggttgggacc	aaagtctcca	1620
tggcacatga	ctgaagactg	gtggtcgtgt	gtgtgaggag	tccacrgaag	cctcggggag	1680
gtggagctgc	tccttcatt	ccgtcaggac	gtgatctgaa	aacatgtaga	gaagatgagt	1740
tgaggacagc	tttctaagg	caatgtgatg	tccttgcttt	cttatttctc	tttctctgcg	1800
ttgttagttt	tgaagagtgg	aggagctagg	ggctccagaa	agaatcttac	acatgtgttg	1860
aagacattga	tgtcataggg	agcggggagc	tgcatccct	tctgggctgt	tactgctaaa	1920
tctcagtatg	aacagaccag	gcggaaagct	tggtggccaa	gcagtctgtg	tgctcccccg	1980
ctgatggaga	acgttgctgt	gttcacaata	ggcctcatg	ggtgtagccg	catggcagac	2040
ccatggctgg	cgcagctgcc	tggtgcctgc	tgcttcagct	aactgctgct	ctgttaactg	2100
ttctattctg	atactacgcg	tggtgttttt	tacaacaggt	atgtttttgt	ttcagaaata	2160
tgatttgcct	ttctcatatt	ttttgcaaat	tgatttgtca	acatgggtca	tttaaagtcc	2220
tgatgaacc	ataacctgct	gtggtacctt	tgatcatgtt	tgattctgta	ttctttatct	2280
cagtgtggca	tatgtgcccc	tctgtatctt	ttgagaagtg	cggaaatagg	tgcttctacc	2340
acctgttctt	aatgtaacag	taaaagtttt	cacatttttc	tcagaaaaaa	aaaaaaaaaa	2400
aaaaaaaaaa	aactcgag					2418

&lt;210&gt; 31

&lt;211&gt; 2220

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

gaattcggca	cgagagaaaa	tccaactgag	tttcggccta	agagtactct	tgagggtcaa	60
ttgaatgaat	ccatgtttct	tctcagttct	cgtcctactc	ccagaactag	cactgcagtg	120
gaagtaagtc	ctggtgagga	tatgactcac	tgttcaccac	agaagacttc	tcctctgacc	180
aagattacaa	gtggacacct	gagtcagcag	gacctggaat	cccagatgag	agagcttatc	240
tacacggact	cagatcttgt	tgtaaccccc	attatcgaca	atccaaagat	aatgaaacag	300
ccaccagtta	aatttgactg	aaaaatattg	catctaccaa	catattcagt	ggataagtta	360
ttattttctga	aagatcaaga	ttggaatgac	tttttgcaac	aagtgtgctc	gcagatcgac	420
tccactgaga	gagcatgggg	gcctcccgag	ccaagctgaa	tctcctttgc	tatttgtgcg	480
tggtggctgg	tcaccaggag	gtggccacca	ggctcctcca	ttccccctg	ttccaattgc	540
taatccagca	tttgcgata	gctccaaact	gggatatacg	ggccaagggt	gctcacgtga	600
ttggtttact	ggcttcgcac	acaactgagc	tccaggaaaa	tacacctgtt	gttgaggcaa	660
ttgttctctt	aactgaatta	attagggaaa	acttcaggaa	cagcaaatta	aaacagtgcc	720
ttttaccaac	ccttggggag	ctgatctatc	ttgtagccac	ccaggaagaa	aaaaaaaaaga	780
accctagaga	gtgtcgggct	gttcccttg	ctgcatacac	agtgctaata	aggtgccttc	840
gggaagggga	agagcgtgtt	gtgaatcaca	tggcagcaaa	aattattgaa	aatgtctgta	900
ccaccttttc	tgctcagtc	cagggtctta	ttacaggaga	aataggaccc	attttgtggt	960
acctattcag	acactccact	gctgattctc	ttaggataac	agcagtatcg	gccttggtga	1020
gaatcactcg	ccattctctc	actgccttcc	agaatgttat	tgaaaagggtg	ggactgaact	1080
cagtaataaa	ctccctggcc	tctgccatct	gcaaagtcca	gcagtacatg	ttgaccttat	1140
tcgtgcccac	gtgtcctgtg	gggattcatc	ttcaaagact	aatccaagaa	aagggttttg	1200
tctccacaat	tatccgttta	cttgacagcc	cctcaacatg	cattagagca	aaagccttcc	1260
tggttcttct	atataatttg	atttataacc	gtgagatgtt	gctgctcagt	tgccaagcaa	1320
gactggtgat	gtacatcgag	agagacagca	gaaagaccac	tccaggcaag	gagcagcaaa	1380

gtggcaatga	atacctgtcc	aaatgcctgg	atcttctcat	ctgtcacatt	gtgcaggagc	1440
tgccacgaat	cctgggtgac	attcttaact	ccttggttaa	tgtttctgga	cgtaaaccac	1500
catcaacagt	tcaagtga	cagctgaagt	tgtgtctccc	cctgatgcct	gtagtgcttc	1560
acctcgtaac	ttcacaggta	tttcgacctc	aagttgtgac	agaagagttt	cttttcagct	1620
atggaactat	tcttagtcat	attaaatctg	tagactcagg	agaaacgaac	atagatggag	1680
ccataggact	gacagcatca	gaagaattta	tcaagatcac	attgtcagct	tttgaagcaa	1740
taatacagta	tcctatttta	ttgaaagact	atcgctccac	ggttgttgac	tatatactgc	1800
cacccttggg	gtccttgggt	caaagccaaa	atgtggagtg	gagactcttt	agcttgcggt	1860
tgctctcaga	aaccacatct	ctactcgtga	accaggagtt	tggggatggc	aaggagaagg	1920
ccagtgttga	ttctgacagc	aatcttctgg	ctctcattcg	agatgtctta	cttccccagt	1980
atgagcacat	tcttttagaa	cctgaccag	taccagcata	tgctctgaaa	ctgctagtgc	2040
cgatgactga	acacaaccca	actttcaca	ggtactggaa	gttcaaattt	ctttttcttg	2100
tgctctacct	ctaaaaatga	ttttatgtgt	tgtgaaaatg	ttattaaaga	tgagattcca	2160
aaagaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2220

&lt;210&gt; 32

&lt;211&gt; 981

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

ggcagagct	cgtgccggtg	ctctccagac	ctcctctcta	aactgcttca	ttgacctaa	60
tactctctt	caatcccacc	tttgttacgt	tgaatccct	catttatatt	cttctcaaaa	120
tgccattat	ccaaatgcag	aacctctgca	tctccaagcc	agttatgctg	aatttgtaa	180
acttagacac	ccttgacaac	tgactccta	ctgtaggctc	ctgtgcatac	tgctgtcttc	240
tgtgggggat	ggagagggtta	gtgtgatgag	gtggtgtctg	cccaggaggt	ttctttcaaa	300
catcatggcc	tcccatccaa	tcaacatcat	caaattacat	gtgtaataca	ggctctgtgc	360
catgggggaa	atgaatcatt	tagctaggcc	aggatctagt	gaaagccaca	gagtttaaaa	420
ccatgaaaga	agttgaaggc	agcattccct	agctctgtga	cttgtgacct	tatttgaa	480
ttcaggattt	gggtgtcaca	aaggattgtc	cctaattcct	ggccctgggg	tcttccag	540
gagctggttt	aatactctga	gaatgagcag	ggagatccag	agaatgaatc	cctgaccgca	600
tcacctaaac	tgtcttccaa	acatgagaca	aagctgactg	ttcacactga	ttgccagca	660
cataccgtct	tgccagtttc	ttcttttctc	ccagtctcct	gttcatecat	tctgttctcc	720
cttgggggtg	gaatctatga	tggaggttac	tggggaaaca	gctcagcaga	tttttgaga	780
ccaaaccaaa	ggctctcata	ggaaatttat	ctgttttaaa	acattgcttc	cttctggct	840
ctgctaaatt	gaatgctcat	tgtttgttgt	tgttgttttt	taattcta	gttcaaaatc	900
ctgcgtgctg	tatgaatcta	gaaagcctta	atttactacc	aagaaataaa	gcaatatgtt	960
cgtaaaaaaa	aaaaaaaaaa	a				981

&lt;210&gt; 33

&lt;211&gt; 2202

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

ggcagagct	taaaagcaat	ggtgaaagga	taacctcgat	gatgtaaata	cacccaaaga	60
tactgttcta	caaaaagtag	ggtgtggacg	caaacctgtg	acagcagagg	gggacgactt	120
cacactcact	gcctcatgtg	gcccctttcc	cagtggcagc	tggtgacact	aacgattgct	180
actcggttca	cttgcccaga	tgtcttcata	tgatgagcaa	ggccagaagc	aaggctagat	240
tcgaagtttc	tgacaccatt	tccagtttgc	acaaaagtca	gtattttatc	ttaaagtggc	300
ttgatttcca	atagctgaac	ttgggcagaa	aacagcaggc	caatgttcc	atgtggttcc	360
tttgtgtgtg	tttttgtttg	gggtgggggc	aagtacaggg	taattcatga	gcaagacatt	420

tcaactgctgt	cgaagtctct	gggatccccg	tgtgggtctg	agatggcctg	ggaaggacct	480
tgtggacaat	ggttttatct	gttctttttg	tcaactgttaa	tttctgggct	gctgagggttc	540
tagaatagaa	gggctgccaa	atgaggtttg	ctgcaggagg	aaagtttaat	ccccattcc	600
aaaagtccag	gccaaatggg	gggcttagcc	tctttgaaaa	gttctgcctt	gccccacag	660
gtgggcacat	cctgtgtctc	attcaccatg	atgcttcctg	agggtgttct	agaagcccgt	720
tccccagtgg	ctgtatccag	cctttccttg	catcatcttc	ctcttgaagg	tgaggaagtg	780
aaaactacag	acctccccg	gacagccac	tctctatcac	gagcctaacc	cgcgaggagg	840
ggaagagaca	tccattcgag	aactgaagcg	gcctccggga	tgaggtcaga	ggccccacct	900
gattttcctg	gtggtggtat	ccaaaatctt	cagtaactag	gaaggaaacc	agggtctcat	960
ggtttaaaag	agtttgaagc	aggaatgttg	cattgacgc	ctttaaaact	acctttttgc	1020
tgttgggagg	agtcgggggc	gagccttagc	agctgcaccg	ccatcccat	gctggttggt	1080
gctgccctgc	ctctcggtgc	gggtgttgct	tcagcccaga	gccagagggc	tggtgtccgg	1140
gtcctccaca	ggtgaccccg	gtggacacac	gcgttcccat	cctggcctcc	gtctctgctt	1200
ttccacttct	acctgcgtgt	gggtttgccc	cctgtctatc	ggttgtgtga	gtgtcgcaga	1260
cctttccaga	gctccgggtc	actctttcca	aacaggcctc	cctgtcggtg	gcactgcact	1320
cctagaacct	tcagtttcta	cgatggtttg	tttggctcct	ttgaaccacc	ccaaagaact	1380
caacatggca	aagcaaatgg	taaaagcttc	ccgactgttc	tactttgggt	ccgcgcgaag	1440
ccccactcac	gtgtgatctg	tggtgcccct	ctcgggtggt	ccaggcgatc	cagccatgcc	1500
ccctgcccct	ctgcccagat	gcttcagggg	cccggctttt	caggcttgcc	ctcaccagcg	1560
gccgtcagcc	gacactcagg	gatgtagcta	acaccactcc	gccagtgtct	tcagtaggaa	1620
gagctgaggc	tgccctgggag	gcccggggcg	accggaaaaag	ggctctctca	agttctgaaa	1680
agagaatctg	ccaccagatc	gaatttcgac	ccctgagctt	gttcggacgt	atggtccaaa	1740
ttcagattaa	ggtggtcacc	caacccgaga	tgccacacag	ggccttctgc	agagaaaatg	1800
tccccccacc	ggccatctgc	agccagggtg	gtgccacacg	gcagccttcc	cgaaacatag	1860
tatggatttt	aaaaatgtgt	ttatttttgt	ttctcaacca	ctttataacg	tattttttta	1920
atttattttg	taatgtcttg	ttttgaagta	ttgtgtctat	ccttgttata	cttccactg	1980
tttttatcac	tgattttatt	ttgtgaaagt	tgtacactaa	tgttctatgt	caaaatcaaa	2040
aagtatttaa	atggaaatac	tagttctatt	taatgtgggt	atggaaccag	ctggaaacac	2100
aaaacaaaca	gtgattgtac	agcaggctgg	gccaggagg	tcaggttcat	tttgttacat	2160
atgcaataaa	ctcacgactt	taaaaaaaaa	aaaaaaaaaa	gg		2202

&lt;210&gt; 34

&lt;211&gt; 1167

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

ggcacgagtg	tgtttgtatt	taattagtaa	agatgttcat	ctcaccccat	tatatcatga	60
tgtacttgat	gccaacatgg	cttataactc	ataatgttaa	ccttgatcat	ttagttaagg	120
tagtgtttgc	cagggtttctt	cactataaag	ttaatatatt	tccattttcca	tactattttc	180
tttgaaagtg	agtcattgta	attccatacc	acaacccaaa	ggacaggatt	aatctctatc	240
tcctagagag	gagtgctctac	atatattctt	tagaattctt	tttttttttt	ttttgagatg	300
gagtccttgct	ctgtcaccca	ggctggagtg	caatggcggtg	atctcggctc	actgcaacct	360
ccacctcccc	ggttcaagcg	atcctccatg	cctcagcctc	ctgagcagct	aggattacag	420
gcacctgcca	cagtgcccg	ctaatttttg	tatttttagt	agagacaggg	tttcatcatg	480
ttggccaggc	tggtttcgaa	ctcctgacct	cagggtgatcc	gcctgccttg	gcatctcagg	540
ttgctgggat	tacagacgtg	aatcactgcg	ccaagcctga	aattcttcta	taagataaat	600
ttctcccttt	atcacttaag	tatttattca	ataatactta	tatcattatg	gactcatgga	660
tatttatttt	actctctgaa	ttataatcca	ataactcac	tgttttgttg	gttttttttg	720
gtttttttgt	ttttgttttt	gtttttttgc	tgaaattgtt	ccagcttttg	ccactgggga	780
actctttcca	attgcctctg	gtgtcctttt	gacctctctc	ctacttttat	aattttcttt	840
tttttttttt	tttttttttt	tagcactata	agatgttcca	gactcgtctt	gcgttttccc	900
tcctttaatt	ggaaatggta	tttagaaact	aagatttgtg	aactggtcat	gcttggtgtt	960

actgtggtgt	cactatgtgt	taggctgttc	ttgtattgct	ataaagaaac	acctggccag	1020
gtgccgtggc	tcatgcctgt	aatcccagca	ctttgggagg	ccgaggcagg	tgatcatga	1080
ggccaagaga	tcgagatcat	gctggccaac	atgggtgaaac	cctgactcta	ctaaaaatac	1140
aaaaaaaaaa	aaaaaaaaaa	aaaaaaa				1167

&lt;210&gt; 35

&lt;211&gt; 2116

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

ggcagagcc	tgattctaca	ctgggaagtt	aggggtagaa	gcacacagga	gcccagcact	60
tacagccagt	ggccctgggg	gtctcctcca	gctccacctc	atgacacccc	gtgctgctgc	120
gtgactgctc	ctggtgccaa	ggccaccgct	gccatgagtc	tgaatggcta	atgctgagat	180
tagcagggcc	tcccttctac	tggcctgtcc	tcctggctct	cctccctttt	gcctcttctg	240
gatttcaggt	cagtttgaaa	gtgggtggct	gtctcagctc	cctgtgagct	tccatttcca	300
gtctacgcta	cggaaagtcag	agagctcaga	cacaaatccc	tcccaatggc	aaaggtgcta	360
tagctgcaac	ttcctctgca	gtgaccgggt	gggcagtaat	ctgtattagc	agaattcctc	420
tcatgccagc	accagctggg	ggaggagagg	gtagtgcctg	ggcattctgc	tttgggaaga	480
aaaaggacaa	tcaaaaccaa	gtgaaatcca	accaccatgg	tgtaccaaac	aggtggagtg	540
ggctgcaaag	tccttaaac	tctcaacagg	agaagtagct	ccattttgcg	ggcaattatt	600
ttctgcttga	aattagctgt	tctcaccaag	aatggactgc	atactaaatc	aattgtcca	660
ctgaggctgc	cataagcttc	atgaagcaaa	gaatgattca	ttcttctaaa	gctgtgattt	720
cctatttgct	cacaagccat	tgcaggggaa	atcctcatct	ttccactca	ctgctacact	780
cactgtgatg	tgtttataga	ccttcgggga	ccacacctcc	tccagctgtc	tgccttactc	840
gaaaattaga	cccagcttgt	cctgacttcc	tagtagccag	aaagtcttcc	acaagatcca	900
gccgcatgat	acggagtaca	cacataaatg	tgaaaacaaa	cccctccatc	ctttccact	960
gtaaatcaac	agcacatgcc	ctctgtgtct	gacaattcct	ctcaaagaca	gtggctccag	1020
cagaggaaat	taaggctggg	gcaggtgccc	cagaagctga	gtcatccggg	atgactgggtg	1080
gccctgaagt	cccgccaca	gaaggacggc	catgggagcc	tggcacactg	ccccttgggtg	1140
gcacaaatcc	tgagcaagcc	atgccctaac	cttaaacaaag	gacctaggac	tgttttctct	1200
cccacagcct	ctgagaactt	gccctttctc	tcccaatgtg	atttgtaaac	aattctccta	1260
cccagcctca	agtaaataatc	agagttaagc	tggtttcata	cacctagtgtg	acagtaaaaca	1320
tcttagagga	cactttcaat	ccacccacac	tgcagetcag	tccatctgca	caaagagaag	1380
accccccccc	cacccccatc	gcggtccaac	ttgggggtac	atagatggaa	aggcagcagt	1440
agtcagcagg	tcaactctgt	ctgaaagagg	tccatggcaa	tgtaaatacc	aatctactgg	1500
caaccacaaa	gcaccacat	agacaggcac	tgcaaggaat	ggagggtttg	aagaagcagg	1560
tcttgatgga	gttttaaaaga	cacaaaacct	ccttcctttc	aggggtcaagg	gtttgtgat	1620
tccgctactc	tgatgtggaa	ttcaaagaga	tggataatta	tcaccttttc	taagtgtgtg	1680
tttcataat	caggtccccg	tgettatcca	catccacact	ccccttctct	cacaaagtcc	1740
tacttgtctc	ctgggagccc	ctgcacgcct	cccctctctg	aatctctgcg	aatttttact	1800
tataaaacag	taacaactct	ctcaagggtca	tcaaaaatgg	cagaacagtg	ttcccccatc	1860
tctgaaaaat	atgaatgtga	gaaacggttt	catactgctg	agagaattta	taagacttaa	1920
gcagaagaat	cttcagatcc	cccatcccc	agagattttt	gcaaatgagc	cagcccagcc	1980
acaaaaatgt	atgcaaactt	gaagataaaa	tggaaattaa	atatgtttta	aagagaagca	2040
ggctttggaa	aaatgaggat	tttaataaaa	acagaaatta	cgacaatatt	tctaccacaa	2100
aaaaaaaaaa	aaaaaa					2116

&lt;210&gt; 36

&lt;211&gt; 2057

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



&lt;400&gt; 36

ggcacgagca	gggaagtaca	gtccttttcta	tgtgtctgca	aggaggactc	acatcttttg	60
tgagcagcac	tgatgcctgc	tgcaacctgg	catccccctt	cctgtctcct	ttctttcctg	120
gtctgtgcag	tagtaggggtg	tattagtcca	tttttgcaact	gcaataaagg	catacctgag	180
attgggtaat	ttataaagaa	aagagggttta	attggcttat	ggttctgcag	gctgtacagg	240
tttctgcttc	tggagaggcc	tcaggaaact	tacaatcatg	gcagaagggtg	aaggggaaac	300
aggcacatct	ccacatggct	ggcaagaaaa	gggaagagca	aagggagagg	tgctacacac	360
ttttaaacia	ccagatctca	tgagaactct	atcatgagaa	cagtaagggg	gaagtctgcc	420
cccattgatc	agtcgccttc	caccaggccc	ctcctccaac	actggggatt	tgggtgggga	480
cacagagcca	aaccatatca	taggggatag	gacccctctt	atctggtttc	tttgctaccg	540
taattaatcc	atccttatag	gttcaattct	aaacctcgaa	gacattagta	tttccattg	600
cccttgggat	acaaactatt	tcccttgga	cataaggctc	tctccttatt	agacaccacc	660
ctcccatgta	tgccagcctc	tctcatactc	caggaggtaa	aaagctctca	cttctgcctg	720
gaataatcat	gacccctggc	cacccctctc	agttgccagg	ccactctctc	tggcctttga	780
aactgtactc	gcatgtcctg	gcctatccac	ccaaactaaa	gcatgactg	cctgttcctt	840
tcctttgacc	acttatcaca	atttatttat	ttatttattt	ttgtacattt	gcttaatgtc	900
tttttccctc	cctggactgt	tggttcaccg	tggttttcgc	agggcctggg	gcatagcagg	960
ggctcagtc	tatttttttg	atgaatgaac	aaacctcgaa	gatgctacat	ctgactctat	1020
atcttcattt	tatccttttc	gtatttctta	ttacctctaa	tttctcttcc	ctgcacccat	1080
ttctatttat	ttcatcccag	tttacctct	gctgccagat	taattttcct	aatgcacagg	1140
ctctatcata	tcagagttt	ctcattgcta	catatgacta	atttgccaat	atttttgcac	1200
atcagaatgt	gtatcacttt	gaggctgggt	ctgtgtttgt	tttagtttag	gaaaagctgt	1260
tcagattgtc	tgtaaatccg	tatggggatc	tttgcatagg	attttaagc	agccacacat	1320
cttgtaaaaa	atgtataaga	ttaattttct	atgttagggc	catttgtttt	caccaattcc	1380
atagagctcc	aatgtgtaaa	agaagacact	gatctaactc	ttgtgttaaa	tatttagtaa	1440
ctcatttatc	tggagaaaag	caaaacaaaa	caaaaataca	aggaataaaa	atcactggga	1500
gtgcttttca	ttcactgaat	aatgagtttt	gcaaggagca	cgtggatggg	gacattatat	1560
cttttacatc	tttattttct	gtttcttttt	tgactcctta	tcagtgaatt	tatcttattt	1620
tatactttta	ctttctattt	ctttcttgac	tctttgttgg	tgaattggta	gcaagagact	1680
tactgtctga	tcagaacttt	gaatcttcct	gcctctcttt	ctttgagggt	gacagggata	1740
aagataatta	agatagcgct	tgggtgtgat	gacactggaa	gacaggctgg	gtcagggcct	1800
gtagtagaga	cttccccctt	ctattgaatg	ttaatctgaa	agtgaatctg	aaagcagatg	1860
gtcatgaact	acccagggtc	tccattaagc	ccatgaagtt	tattttaaaa	ctcttaaaat	1920
agattgagat	tcaaattgag	attcatgtct	attttttaaa	cattgtgtct	taacaaagta	1980
gatgttcagt	catacagtt	ggcaaatgtt	ctaaggaaa	atgtttacca	tgctaagtta	2040
aaaaaaaaaa	aaaaaaa					2057

&lt;210&gt; 37

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

ggcacgagct	gggggtggggc	tgagaagtcc	atgtaccgcc	agactatggg	gagtgaccat	60
agggtatgac	cattatctct	ttgtaagtaa	gtcaatactg	ttccccacag	atgaaacctc	120
agagcataga	aacccatgga	ttagcaggaa	atgtcactga	gtccattaca	ggtcagggat	180
cactgaaaaa	tgtctattgt	cttcgattga	cactgctccc	tgcttctcca	gctgctctgc	240
atttgaggag	aagccctgtg	tgctccagc	tggttgccaag	gcagttaatt	aaacaaccgg	300
tccgcctgat	gttcaccaag	gtgaagctgg	agcagggtgct	gaaaggccca	gaggaagccc	360
tcgtgacctg	cagacaagtg	ctgaggctgt	ggcagaccct	gtacagcttc	tcccagctgg	420
gaggcctaga	aaaggatggc	agcttcgggtg	agggcctcac	catgaagaag	cagagtggca	480
tgcacctgac	tttgctgat	gcccattgat	cagactctgg	ctcccggcgg	gcttcgtcca	540

tcgccgcctc	ccggctggag	gaggccatgt	cagagctgac	tatgccctct	tcggctcctga	600
agcaggggccc	catgcagctg	tggaccacgc	tggaaacagat	ctggctgcag	gctgctgagc	660
tgttcatgga	gcagcagcac	ctcaaggaag	caggtttctg	cacaggaggc	ggcgggcctc	720
ttccccactt	ctcactcagt	actctatatg	cggggccggc	tggctgaggt	gaagggcaac	780
ctggaggagg	ccaagcagct	gtacaaggag	gcgctcacgg	tgaacccaga	tggcgtgcgc	840
atcatgcata	gcctgggtct	gatgctgagt	cggctggcca	caagagcttg	gcccagaagg	900
tgcttcgtga	tgccgtggag	aggcagagta	cgtgccacga	ggcgtggcag	ggcctgggcg	960
aggtgctgca	ggcccagggc	cagaacgagg	ctgccgttga	ctgcttcctc	accgcccttg	1020
agctggaggc	cagcagccct	gtactgccct	tctccatcat	ccccagagag	ctctgacgac	1080
gctgcagccg	cagggaggga	ggggctggcc	agagggagag	gcagcaggga	acgtgggtca	1140
gggtggggca	acagtggcat	caggtgcggg	gcctcaggga	aatacatctt	tagtgaacgc	1200
caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				1229

&lt;210&gt; 38

&lt;211&gt; 1637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

ggcacgagct	cgtgccgtga	catttgtata	tatgtaaagg	aagaccatct	gtaaattttt	60
ccagttaaag	taaacaaaaa	atttaatacg	caagtacaaa	cctgtgcagt	gccctttata	120
agtctttcga	agaagtacta	cacctgcca	catcaaagt	tgatgatctg	cttgcttagc	180
gggaggggcat	ttgcttactt	tttctcta	tactttactt	ctactctgat	cttgctgtct	240
cagttctcct	accagcattg	atacagtata	aaaggggaata	ttaagagttc	catttagtaa	300
aaggcttcaa	tctaaatgag	atgaagggat	atagaaactg	tttttctct	gactaaagaa	360
aaatgattgg	gatgatctgt	taaagtttcg	agaaactcaa	ataggcccta	tttgccaata	420
taggacagga	aaccacaga	ttaagtattg	gataatctca	aagctccttt	tggccaattg	480
gtgccagttt	tctcaccac	caatctttcc	tcaactgtta	aaaaaaaaaa	caggaaatac	540
attgattgac	atttgtcttc	tcttagctgt	gctttgtttc	aaagttgaaa	aacaaagaaa	600
aggagagaaa	cttacctcct	gagtaatcta	atcatgaatg	ttctaattct	tggcagttga	660
ttttaaagaa	gaagccagac	aggaactttt	ctcttcattt	tcctctacca	ataaatagca	720
agtaaataatg	tgtcatgtga	ttttcttctt	gacatgtact	tttcttctgc	tctccctcag	780
tgctcttggg	aagaacaatt	cattgatttg	gtaccaacct	gatgcacct	gatttgtcaa	840
aggtggtacc	aggtgggtgt	cagtgtcaca	tacaagagta	aaactgttcc	tagagcaaat	900
ggcgatgaga	gcgtgaacg	cggattcatg	ctcaagcccc	cagatggggg	ctatgtggga	960
gactagtggg	tctgtgaaag	agaactccag	tcagagtaag	aaatacagca	caaaaataga	1020
gaatcttggg	cctgagagcg	cttgaggga	cttctggagc	ttcggttatc	atgaagcaac	1080
cggaccgctt	gagactatca	gccaacttca	gaaattgtgc	catcagtggc	tgaggccaga	1140
gatccactca	aaagagcaga	tcttggaat	gctgggtgta	gagcagttcc	tgagcattct	1200
gcccaggag	accagaact	gggtgcagaa	gcacatcca	cagaatgtca	aacaggctct	1260
ggtcctggg	gaattcttgc	agagggagcc	tgatggaaca	aagaatgagg	taagaagaaa	1320
gattgcttac	atgtacaatg	aagtaggata	aaagtggata	tatcagaatg	gaggagttat	1380
cagagaatta	gacagattaa	gtcgctcttc	tggtgtcct	ttaggacagc	tagcaaggat	1440
ctgaaatgac	atacatgcat	caatagtcca	caggtttcaa	gatttctggc	agagcctttc	1500
cttgtcttag	agaaaataaa	tgcattttgt	cttctctagg	gccaggggtga	attgatgggtg	1560
gtgggcctag	tctggcatgg	gcaaggacaa	gagttgagtt	cttaaaaaaa	aaaaaaaaaa	1620
aaaaaaaaaa	aaaaaa					1637

&lt;210&gt; 39

&lt;211&gt; 1640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1639)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 39

ggcacgagct	gacttacagc	tcttataaac	tagtggcaat	ttctgaaccc	agccggctcc	60
atctcagctt	ctggtttcta	agtccatgtg	ccaaaggctg	ccaggaagga	gacgccttcc	120
tgagtcctgg	atctttcttc	cttctggaaa	tctttgactg	tgggtagtta	tttatttctg	180
aataagagcg	tccacgcata	atggacctcg	cgggactgct	gaagtctcag	ttcctgtgcc	240
acctggtctt	ctgctacgtc	tttattgcct	cagggtcaat	catcaacacc	attcagctct	300
tactctcct	cctctggccc	attaacaagc	agctcttccg	gaagatcaac	tgcagactgt	360
cctattgcat	ctcaagccgg	ctccaaggtc	ctggccaaga	aagagctggc	ctatgtccca	420
attatcggct	ggatgtggtg	cttcaccgag	atggtcttct	gttcgcgcaa	gtgggagcag	480
gatcgcaaga	cggttgccac	cagtttgtag	cacctccggg	actaccccca	gaagtatttt	540
ttcctgattc	actgtgaggg	cacacgggtc	acggagaaga	agcatgagat	cagcatgcag	600
gtggcccggg	ccaaggggct	gcctcgccct	aagcatcacc	tgttgccacg	aaccaagggc	660
ttcgccatca	ccgtgaggag	cttgagaaat	gtagtttcag	ctgtatatga	ctgtacactc	720
aatttcagaa	ataatgaaaa	tccaacactg	ctgggagtcc	taaaacgaaa	gaaataccat	780
gcagatttgt	atgttaggag	gatcccactg	gaagacatcc	ctgaagacga	tgacgagtgc	840
tcggcctggc	tgcacaagct	ctaccaggag	aaggatgcct	ttcaggagga	gtactacagg	900
acgggcacct	tcccagagac	gcccattggtg	ccccccgggc	ggccctggac	cctcgtgaac	960
tggtgttttt	gggcctcgct	ggtgctctac	cctttcttcc	agttcctggg	cagcatgata	1020
aggagcgggt	cttccttgac	gctggccagc	ttcatcctcg	tcttctttgt	ggcctccgtg	1080
ggagtctgat	ggatgattgg	tgtgacggaa	attgacaagg	gctcttccca	cggcaactct	1140
gacagcaagc	agaaactgaa	tgactgactc	agggagggtg	caccatccga	agggaaacct	1200
ggggaactgg	tggcctctgc	atatcctcct	tagtgggaca	cggtgacaaa	ggctgggtga	1260
gcccctgctg	ggcacggcgg	aagtacagac	ctctccagcc	agggagtctg	gtctcaaggc	1320
cggatgggga	ggaagatgtt	ttgtaatctt	tttttcccca	tgtgctttag	tgggctttgg	1380
ttttcttttt	gtgcgagtgt	gtgtgagaat	ggctgtgtgg	tgagtgtgaa	ctttgttctg	1440
tgatcataga	aagggtattt	taggtctcag	gggagggcag	ggctggggac	cgaaggggac	1500
aagttccctt	ttcatccttt	ggtgctgagt	tttctgtaac	ccttggttgc	cagagataaa	1560
gtgaaaagtg	ctttaggtga	gatgactaaa	ttatgcctcc	aagaaaaaaa	aattaaagtg	1620
ctaaaaaaa	aaaaaaaaa					1640

&lt;210&gt; 40

&lt;211&gt; 1860

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (821)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 40

ggcacgaggt	ccccactaa	aattaaaact	aaactgctac	ttctgtccat	tctccctggc	60
cgggtgtctt	gctgctgtgt	ggcttctgtt	agaagttcgg	aaacgaattt	ttggagagga	120
aagtcagact	aatccttcaa	gtctttttgag	aaacaggctc	tctgcattag	ctgaggggca	180
ggagtctctg	gcttgccatg	tgggtgtctga	gccatctctc	tctctctctc	tctctctctc	240
atctctcttt	ggccaggcgg	gcaggaagac	ctatgccatg	gtgtccagcc	actcagctgg	300
tcattctctg	gcttcagaac	tgggtggagtc	ccatgatgga	catgaggaga	tcattaaggt	360

aagcttagtt	cacctccaac	ttttctccct	gtcctcttcc	tccctgcacg	tatatgagaa	420
ggagcagttg	atgttggtgc	caaagggagc	ttgtggtttg	atggaaggaa	ccagacctga	480
gctgctagtt	cctggcaatc	tcctagaaat	atcttaatta	ataccaggag	actacagtct	540
gcctgttagc	aactttggtg	cagcctggcc	ccaggcaagg	ggatggactg	gatgacctta	600
ctagggggcct	atccactgac	catgttttgc	tgctaaaggt	tgtggagaca	ggtaggaggt	660
gtgtttatgg	aaaaccattt	gagtatgaca	actatagcat	gaaacatcta	aggtttgaaa	720
gcattttaca	agaaaaaaaa	ataattcaga	tcacatgtgg	agattaccat	tctcttgcac	780
tctcaaaagg	taatttttct	gtaatattaa	tagttttgta	naagtaatac	ctgtgtgtat	840
atgtggagcc	agtagaatgt	ctatatattca	cttgtaacag	gacagaaata	cagttttgaa	900
tttgatatgg	ttccgagtac	gattcttaaa	gtaaatacat	aatgagagaa	ttcttggtac	960
tgtaaaatgt	tcaggtttcc	aaaattacta	ttcctaaatt	tggtttcatg	ttttttattt	1020
tcaagtacga	aacagtgaag	attttctgaa	taatcaaaac	tgttttctct	acatctgac	1080
caggcctggg	gccacccttt	tccagaaact	gcttcccttt	tcctaaccac	tttccaactt	1140
ccactcttcc	ggctcagaat	ccccttttgt	ggccaggctg	cagacctctg	atacgtttta	1200
acattgcttt	tgaattcaag	gatctcctta	gccctgtagt	atttcccat	ttctatcaga	1260
cactgtcatg	gtgggaaatg	gaagcagtga	atatgaatta	ttttcctaaa	gaaacttgac	1320
tatgaggcca	ggcttggtgg	ctaataccta	taatccaaa	gtgctgggat	tacaggcgtg	1380
agccactgcg	cccggccaca	ttcagttctt	atcaaagaaa	taaccagac	ttaatcttga	1440
atgatacgat	tatgcccaat	attaagtaaa	aaatataaga	aaaggttatc	ttaaatagat	1500
cttaggcaaa	ataccagctg	atgaaggcat	ctgatgcctt	catctgttca	gtcatctcca	1560
aaaacagtaa	aaataaccac	tttttggttg	gcaatatgaa	atttttaaaag	gagtagaata	1620
ccaaatgata	gaaacagact	gcctgaattg	agaattttga	ttttttaaag	tgtgtttctt	1680
tctaaattgc	tgctccttaa	tttgattaat	ttaatttcag	tattatgatt	aaatctgagg	1740
cagatgagct	tacaagtatt	gaaataatta	ctaattaatc	acaaatgtga	agttatgcat	1800
gatgtaaaaa	atacaaacat	tctaattaaa	ggctttgcaa	cacaaaaaaa	aaaaaaaaaa	1860

&lt;210&gt; 41

&lt;211&gt; 1524

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

ggcacgagtt	ggttttccca	tttccctttt	tccttttccac	tgtcgaatta	taacagtttt	60
tatgtatctt	tacattgtaa	agttattaat	gttgtaatcc	ttatttgctt	gtttttatcc	120
ttattcagtg	tttatttttg	cccatctctt	gacctttgac	atttctgcat	tttgatttaa	180
attgttatag	ttaggttcca	gttggttgat	gcaatccttt	tgtctttata	taaacagttg	240
agtttatctt	atttagtctc	actgtagatg	tgtttaatct	tttccatctg	ctttttatgc	300
attcatattg	gcttttggtt	tgtttttaat	ctcttgataa	tggggctcaa	ttttcagata	360
tacttttaag	atatgtttat	gcctttattt	ctcaaattgc	ttcagaaaca	aaatagtgtc	420
tattgtgac	ttccttatcc	tcataacact	taaggatgtg	ttggcatgtt	ctgagatttt	480
tattcttggt	tattacagtt	aaatgattat	ttttctggtt	tgtggcatat	acttcaaaaa	540
caatatattat	tttctgattt	tctaacttta	tttccacaga	tcctttgcat	tgagtatctg	600
cttatctttc	acaagacagc	ttcctcattt	gtgagtcctc	gtatgagtaa	tttcagtggg	660
cagattctgt	cttcatgata	atttttttct	cctcaagaaa	gtgcacatga	gtgatacacg	720
tcctgagttc	cttttctgta	gacttcatgt	gagaccatag	cttctcatgc	tctagaattc	780
tgtcataacc	attattgatg	tataaatgac	atacaataaa	ctgcatgtgt	ttaaattatg	840
taattttaaaa	agttggcata	attatgtacc	tgtgaaatta	ttactacaat	caagataatg	900
gacatacgtg	tcacccttaa	aaagtctact	gtgccccttg	gtaatccctt	tacgtcctt	960
atcttttaggc	aaccaccagt	ctgctttctg	tcactgtcag	gaagtttaca	tttttaaaaca	1020
ctttatataa	atggagtcac	acagaatgta	ctttttttgag	gggtctgggtt	gttccactca	1080
gcataattat	tttgagatta	atctgtgttg	ttttgtatat	caatagctta	ttctttttat	1140
tgtctagtcg	tattccattg	tacggatata	acacaactca	tgtgtctgtt	cacctggata	1200
cgtggaagtt	tgggctgggtg	gaaatttggg	ctgtttccaat	actgagctgt	aacaaagctg	1260

ctacgaacat	ttatgtacaa	gccattcatt	gtacggacaa	atgcttttgt	ttctcttggg	1320
catatatcta	ggagtggagt	gatttggtca	tatggtaggt	gtatgtttaa	ctttgtaaga	1380
aattggcttc	aaactatact	acaaggctat	agtaaccaa	acaacatgg	actggtacca	1440
aaacaggtat	gtagaccaat	ggaacagaac	aaaggcctca	gaaataatga	catttatgca	1500
gccacaacaaa	aaaaaaaaaa	aaaa				1524

<210> 42  
 <211> 1467  
 <212> DNA  
 <213> Homo sapiens

<400> 42

ggcagagcc	caggtgggtt	gtcttcactt	ccttggtagt	gtcttttaat	acacaaagtt	60
ttaaattttt	atgaagtaa	atgtatctac	atcttctctt	ggttgctcat	gcttttggtg	120
ttgcatctaa	gaatccactg	ccaaatccaa	ggcatgaag	atttactcct	atgttttctt	180
ctaagaattt	tatagttttt	gctattacat	aaggctcttg	agccattaag	atctttgact	240
taacttttgt	atatgatgta	aagtcactgt	caaacatcat	tcttttgcac	ttggctgtcc	300
aggtatccca	gcattatttg	ttgaaatgcc	tacacttctt	tatattccct	tgactcctct	360
aaccaaggca	gttggacctt	tgctactacc	actgccctga	aactgctgtc	actgggttac	420
tgaggactgg	gtagcttagt	tgagtagata	atcttttggt	gtttcctcct	tgtaataatac	480
aagccttggc	ttctgtgaca	tcatactctc	ctagatttcc	ccctgtcact	gtggcttctt	540
ctcagtctct	gtccatccct	gggtgctcctg	aagggtctgt	tctcagcctt	acacacatta	600
cctgggtgat	ctcattctct	gccatgactt	cacttgccat	atatgtgctg	atcttcccca	660
aattcctatt	tctcccgacc	tttacatcta	ttttatttgc	aggtcatata	tctaataagg	720
aattgatata	cagtgtacat	gtagaactcc	tgtaattcaa	tacagaaacc	aaacagtcca	780
attaataaat	ggagaagaga	tttgaatgaa	catttttcta	aagaacatct	caagctcaag	840
atctccaga	taacttttct	ttcttcaaaa	tctgcttctg	tgtttctcta	tctgtagggtg	900
gcacagcata	catctgattt	cccaagccag	aaacctcata	gttattcttg	actccaggaa	960
gaaatattat	tgagttttta	aaaactcagc	ttattgactc	attgttttat	ataataaaat	1020
gcaacagttt	taagtgtata	tttcaatgag	ttttaataca	tttatgtact	tgtgtcacta	1080
tcctcataga	tagagacaaa	acatttctat	cacaccggca	atttcctatg	tgtcccatcc	1140
caatcaatcc	tttccccttt	gctggctcca	aacaatgact	ctttcctatc	tttttagaaa	1200
gattagaatt	gcttttctag	agttccagta	atggaatcat	acagtgtcta	agtcgtgttg	1260
tggtgctgta	acaaaatacc	tgagactggg	taatttataa	attataggaa	tttatttctc	1320
acagttctgg	atgctgaaaa	gtttatgata	aaggcactag	caggtttggg	gtctgagggc	1380
ccagtttcta	atctgaagat	gggtgcttaa	acactgtcct	cacatggtag	aaggggcaga	1440
tgggcaaaaa	aaaaaaaaaa	aaaaaa				1467

<210> 43  
 <211> 1640  
 <212> DNA  
 <213> Homo sapiens

<400> 43

ggcagagct	gacctgacct	tttccctgcc	ttcaggactt	ctgggcccag	ccctcttgcc	60
aggcatgcat	atgtgagata	tgcatatcat	gtatgtgtcc	tcttgggggtg	agacttctgc	120
acagccatgc	ctgcctctga	ccagtcactt	tttcatgttg	gggctgtagg	cctggggcag	180
gttcagagtc	tacccaagta	cctatgtatg	agcaggcagc	agcagggcat	ggccccatct	240
ctccttttag	cctctgtgtt	tcattaggca	ttcatctgc	caaccagggc	aggcccggcg	300
tctgggctct	gggaacaaat	ggggcccaca	tctggagtgc	gcaaattttg	ggggatgcgc	360
tacctgtccc	agcgggccct	gtgcctccaa	cccagagctc	cccacagacc	tggtgtaatt	420
tcacaagggc	catccctttc	cccaggcttc	cctgagggag	gcggaagttt	gaacccttat	480

gtgggggtcaa	tgggggctagg	gtagtggtat	gagggtttaa	actattttaag	gattaggagg	540
agaaagagtc	ttcaggaaac	tcttgtttca	ctggactctg	cagcctgcag	aactggggca	600
agggtaggag	ttccagtagg	ggaaggagca	ggtagactct	tcagctgcct	cagctgggac	660
tgaagacct	agctgattct	ctttcctctc	cactcctaag	aagcaatctt	ctgttcctct	720
ccttccacca	ctttttactt	tctgctatct	cccatctccc	gcttcccttc	catttccttt	780
ctagaaaacc	ctggtattta	gctcaggcca	aactgcctca	gcagaaaggt	ggccttggac	840
aaaactggtc	caagaatttg	aagtggcagt	acttgccgat	tggctctgtc	cagcaaggcc	900
tcagctgctt	gttgctgtct	ctttccctcc	cctaacagaa	gggtaccctg	gcttattcag	960
gggactcctt	agtccacact	gtgtcacctg	catgccttaa	tctttcattg	ctgggggtgtg	1020
gcttggggaga	tcctggggcca	gcccctccac	acatctccct	aagtcagagt	ggctgctggc	1080
cctggtagat	ttgacttgct	cttgccctcac	tcgacctcca	aagtgggact	gaagacagtg	1140
gtcaagagac	ttgagttcgg	gacagtaagc	caggggttaa	ggttctttcc	tttttttgaa	1200
agccaaagac	ccagtttgca	ttgtgctgct	gcattcatgg	ttagaagctt	tccatgccta	1260
ggttctaggg	aattttatctt	tctatgtgta	tatatcttca	aactttgttt	cctgggtact	1320
gggcatgtgc	ctgtctgagc	cccaggctctg	tctacacccc	accattcatt	ctgtctgtct	1380
gttccctgga	cactgcctaa	aagggtctca	agacagtgcc	ctgtgggttc	ctaggactag	1440
ggcccatcac	tggtctcttc	tgctgggaaa	tgagctttaa	aaatggctaa	ccacagcaga	1500
gggcagatgc	ttgatagatt	atcttttctt	tgctttcttg	tttctgtttt	gaaagtga	1560
tgggggttta	aattgttatt	taaactcttt	ttccaaataa	aggtttacct	ttttccccc	1620
caaaaaaaaa	aaaaaaaaaa					1640

&lt;210&gt; 44

&lt;211&gt; 1629

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

ggttaaatca	agatataata	ggatcacta	ccctgtttct	ttcaagtctt	ttgatgggtga	60
cattaagctc	tttaattctt	gagatgtggt	attgcttctg	gcttaatatc	ttagtaggga	120
gggtaagttc	taggggcttc	catttagccc	ttactattaa	aatgactctt	atcagttggg	180
tcagaaagcc	aatatgggag	ctctgccaat	agtcaagtat	gtctgttcca	agtatttatt	240
caggaaactga	ggagatamca	acaaagtagg	cccattgtac	tatgggggtcc	actgtgaggt	300
ggacttgagc	taagcatttc	atctattacc	tgaccactgt	cagcactcac	tttgactgat	360
aggccacagt	agcattttga	gtccccagga	attagtaatc	cctgaaagtc	tgggtatttc	420
cttttctcta	atccgtagtc	actctagtaa	atggcctttg	gggaagcttg	gatgaggatt	480
tacagtatgt	acttgactct	gtgggaacac	tacaggtttt	tcctcagggg	acctgggctt	540
gtaatttgac	tgggtcttag	aaattagatg	agaggtcaaa	acttttctag	tccagggttt	600
cactaccaga	gctggagttt	tttcagttgt	acagatgaaw	cyggtttggg	aggctgcttg	660
tggaaactcg	tgatgatcaat	tactgcaaaa	gatcctgggtg	ggccaagggtg	ttctgattac	720
cagtacaact	ttactgtatt	tatagtagat	ttcccacctt	gtctttgggtg	attacatgct	780
gctacttggc	ctctgttatt	ttaggatccc	gttaccctct	taaatcaggg	aaccacttta	840
gtggtggcat	ttcccattgg	catacctagg	ggttgtgaca	gagaccttag	ggactgtaaa	900
acctaaaatg	tttatctgtg	gccctttata	aataaagttt	gccaaacccat	gtctagggga	960
acagggacac	actgcaaagg	ggagcaacca	cagagctttt	caaggatgaa	gggtgatcccc	1020
tcactaatgc	atttcttttt	ttgttggtgt	ttgttttttt	tttgtttttt	tgagacagag	1080
tctcactctg	tcaccacagg	tggagtacag	tggcacgac	ttggctaact	gcaacctctg	1140
cctcctgggt	tcaagcaatt	ctcatgcctc	agctactctg	gaggctgagg	caggagaatg	1200
gcttgaaact	ggaatgggga	gcttgacagt	agccaaagtc	gtgccactgc	actcctccag	1260
tctgggagac	agagcgagac	tccgtctcaa	aaaaaaaaaa	aaaagcattc	ataaaatgaa	1320
actaagcggg	gaaaggtagg	ggagagtcac	ggctctcctc	ccagcagagt	ggaaatcttt	1380
agatggtaat	taagaaatgg	gatgaccagc	ctgggcaaca	tggcgaaacc	ctgtttttaca	1440
aaaaaatata	aaaatttagtc	aggtgtgggtg	gtgaacttct	gtgggcccag	ctaactcagg	1500
aggccaggat	gggaggatca	cttgagccca	ggagtttgag	gctgcagtga	gcagtgatgtg	1560

gacaactgca ctccaacctg ggtgagagag cgagagcctg tctcaaaaaa aaaaaaaaaa 1620  
aaactcgag 1629

<210> 45

<211> 1415

<212> DNA

<213> Homo sapiens

<400> 45

acgcgtccgc ccacgcgtcc gcacaataaa tgtgagcaat ttcactgtaa gcagatccca 60  
tgctcatgag gcatttaaca cagcttttac cactcttgct gcttgcgtyg ccagtatcgt 120  
tttggtactt ttgtacctct atctgactcc atgcccctgc aagtgtaaaa ccaagagaca 180  
gaaaaatatg ctacaccaa gcaatgccca ttcactgatt ctgagtcctg gccctgctag 240  
tgatgcctcc gctgatgaac ggaaggcagg tgcaggtaaa agagtgggtg ttttggaacc 300  
cctgaaggat actgcagcag ggcagaacgg gaaagtcagg ctctttccca gcgaggcagt 360  
gatagctgag ggcacccata agtccacgag ggggaaatct gactcagatt cagtcaattc 420  
agtgttttct gacacacctt ttgtggcgtc cacttaattt gtgcctatat ttgtatgatg 480  
tcataattta atctgttcat atttaacttt gtgtgtggtc tgcaaaataa acagcaggac 540  
agaaattgtg ttgttttgtt ctttgaaata caaccaaat ctcttaaaat gattggtagg 600  
aaatgaggta aagtacttca gttcctcaat gtgccagaga aagatggggg ttgtttccaa 660  
agtttaagtt ctatgacaca atatcttagc ttttaccact attggtaat tccagagtagg 720  
cccaaagggtg atatgactcc cattgtccct ttatttagga tattgaaaga aaaaataaac 780  
tttatgtatt agtgcctttt aaaaatagac tttgctaact tactagtacc agagtatttt 840  
taaagaaaaa cactagtgtc caatttcatt tttaaaagat gtagaaagaa gaatcaagca 900  
tcaattaatt ataaagccta aagcaaagtt agatttgggg gttattcagc caaaattacc 960  
gttttagacc agaataaata gactacactg ataaaaatgta ctggataatg ccacatccta 1020  
tatggtgtta tagaaatagt gcaaggaaag tacatttgtt tgccctgtctt ttcattttgt 1080  
acattcttcc cattctgtat tctgttaca aagatctcat tgaaaaatta aagtcacatc 1140  
aatttgttgc cataaatatg taagtgtcaa taccaaaatg tctgagtaac ttcttaaatc 1200  
cctgttctag caaactaata ttggttcatg tgcttggta tatgtaaatc ttaaattatg 1260  
tgaactatta aatagaccct actgtactgt gcttgggaca tttgaattaa tgtaaatata 1320  
tgtaactgtg gacttgatat tttgttttat ttggctattt aaaaacataa atctaaatg 1380  
tcttatgtta aaaaaaaaaa aaaaaaaaaa aaaaa 1415

<210> 46

<211> 372

<212> DNA

<213> Homo sapiens

<400> 46

acgcgtccgc ggacgcgtgg gcaacaccct cctagcctta ctactaataa ttattacatt 60  
ttgactacca caactcaacg gctacataga aaaatccacc ccttacgagt gcggcttcga 120  
ccctatatcc ccgcccgcg tccctttctc cataaaatc ttcttagtag ctattacctt 180  
cttattattt gatctagaaa ttgccctcct tttaccctca ccatgagccc tacaaacaac 240  
taacctgccca ctaatagtta tgtcatccct cttattaatc atcatcctag ccctaagtct 300  
ggcctatgag tgaactacaa aaggattaga ctgaaccgaa taaaaaaaaa aaaaaaaaaa 360  
aaaaaaaaaa aa 372

<210> 47

<211> 2783

<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

gaccacg	tcgcacaag	agagcagagg	agccccaagt	cttggggacc	acagaagatg	60
ccatgtgctc	cacgatgtcg	gccccacct	gcctggccca	cttgccctccc	tgttctctgc	120
tgctggcact	ggtccttgct	ccctcagatg	cctctgggca	gagcagcagg	aatgactggc	180
agggtctaca	gccccagggc	cccatgtctg	tggcagaagg	agctggggac	cctgaaccag	240
acctgtggat	catccagccc	caggaattgg	tgttggggac	cactggagac	actgtctttc	300
tgaactgcac	agtgtctgga	gacggtcccc	ctggacccat	caggtggttc	cagggagctg	360
gtctgagccg	ggaggccatt	tacaactttg	gaggcatctc	ccacccaag	gcgacagcgg	420
tgacggcctc	caacaatgac	ttcagcattc	ttctgcaaaa	cgtctccagt	gaggatgcag	480
gcacctatta	ctgtgtaaa	tttcagagga	aacccaacag	gcaataacctg	tctggacagg	540
gcaccagcct	gaaagtga	gcaaaatcta	cctcttccaa	agaggcagaa	ttcaccagt	600
aacctgcaac	tgagatgtct	ccaacaggcc	tcttggtgtg	gttcgcacct	gtggtcctgg	660
ggctgaaggc	aattaccttg	gctgcactcc	tactggccct	ggctacctct	cggaggagcc	720
ctgggcaaga	agatgtcaag	accacaggcc	cagcaggagc	catgaacacc	ttagcatgga	780
gcaagggtca	agagtgaagg	gtcagcccca	gagtgaaggc	cctctgagtt	ggagaggagc	840
cagggctcct	caaccatttc	cctacctcca	gtcccagcct	ctaggtgccc	ccaggcctca	900
tgacaaactc	ctagatccct	acatctggtt	ttggtccacc	tagtgaaatt	cccttctttg	960
caccgggctt	ccctctaaaa	tgtctccctt	tctctttttg	gcctgttcaa	gacctccttg	1020
cttttcagtc	cctggctcag	tctctcctca	acacccttgc	ccctgctgca	gccctttctg	1080
gtgcgccttg	cccctttccc	cacctcgcta	catccttctt	ggcctccaac	atccaactca	1140
gagtcttctt	cccaggagat	gtctgtaaga	atctctgaac	tcaaccagcc	agaccatctg	1200
tgccctccca	tctacacctt	tctccccact	ccttcttgcc	ttccttccat	ccccctcatg	1260
gctggcttgg	gcaggtataa	tattagaatg	caggttcagc	aactataaca	aagctcttaa	1320
ataacagtgg	cttaaacagg	tggaaatcaa	ccagaaagt	gaccatcagc	aggccaagca	1380
atacagagac	tccctgggat	tgagaccag	gattcactga	tctcattgct	accagggtcca	1440
ccttctaggc	agccagactg	gaaaagaagg	caggaaagg	ggagcaggac	cctccccttt	1500
aaagtgcaca	gtcaggaact	tggccacctc	acttatctct	acttggtctg	aatgtggtca	1560
catggtcaca	cctagctgca	agaaacactg	ggagatgtag	tctttatttc	tggcagcaat	1620
gcgccagct	gcaagttttc	actagagaaa	ccagatggca	gatatcagg	gataaccagt	1680
tatctccacc	acagcagcat	acagacagcc	tctcacctgc	cctgtgggac	acctgagttc	1740
aatgcccagc	tagctagcca	gcacttcttc	ccactatcac	ctcccctggg	gcagcatgat	1800
gtggggcagt	agttcccaag	atgagtgatt	ttgccccac	tggacttttg	gcaatgtcta	1860
gagatgtttt	tggttggcac	aacctggggg	gtgctaccac	catctagtgg	actgagaagc	1920
cctgacatgg	ggaagagtgt	gcctgcccag	gagtcagaca	cacctgcctt	taacctgag	1980
gcctctgcct	cctccctgtg	cacctcagt	gactaatcag	agtccttcc	catcacggaa	2040
catccaggat	actaatgtgg	acttctctgc	attgtgtaag	aaccaattca	agaccaggca	2100
cgggtggctta	tgcatgtaat	cccagcactt	tgggaggccg	aggtgggtgg	atcacctgag	2160
ttcaggagtt	tgagaccagc	ctggctaaca	tggtgaaacc	tcgtctctac	taaaaatata	2220
aaaaattagc	caggcgtggg	ggtgtgcacc	tgtaatccca	gctacttggg	aggatggggc	2280
aggagaaccg	cttgaactgg	gaggcagagg	ctgcagttag	ctgagatcgc	gccattgcac	2340
tccagcctgg	gcaacaagag	caaaactccg	tctcaaaaaa	aaaaaaaaga	accaattcaa	2400
ttctgcattt	actgagggcc	tactatgtgc	tgtgtgcact	gcgtgcactc	gatacatgta	2460
aattccctgt	tctctttcca	ggcaaacatt	tattagcact	cactatagcg	gcgagtagat	2520
gagtctagat	gtttttcatt	accacaaaca	gaaaaacagc	ttgaactaag	ccagcgacaa	2580
cagtaattta	gtctgagaat	ggaataaatt	attgaattac	cagacattag	agagggtagg	2640
gaaggtaggc	tgaatactaa	ccccacccc	aaagatatcc	atgtccta	ctctggaacc	2700
tttgactgtt	accttgtatg	gcaaaagtaa	aaataaaaa	aaaaaagaaa	acaagaaaaa	2760
aaaaaaaaaa	aaaaaaaaaa	aaa				2783

&lt;210&gt; 48

&lt;211&gt; 699



&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

ggcagcagga	aaaacccaaa	ctgagactct	taagttttgt	ttagcaatgt	gtttctggta	60
tgaacaaaac	tactgtgtca	ctgtccaggt	aggaaacaat	tctttcaact	gggttttcag	120
cataaatggg	aactgatgta	gaaggcagga	tttagccctt	ctaggcaaaa	gaaaagctca	180
gttgggtttc	acgagtgttc	ctgtgcttat	attcagtcctg	tgccctacatg	ttctcatgca	240
tgtctaacct	gatttacctc	ttacctgtaa	cctaccttat	catgtggcctt	ttaattggca	300
gtcactcgcc	atttctaagc	agatatagta	ctacctttca	gaactcacat	tggcaagtgt	360
aaaaagatga	cttaagggtga	agtgaggaca	aaatcacatt	ctgcatacta	accttttttt	420
tctcccttta	aggtgctaaa	cttgacctc	atgtccactc	agtaacaagt	attgggacgt	480
agagcacagc	ctcactcagc	tctgaaaggt	aatacagcct	gtgaggaagt	gagccagcag	540
tggcctttgc	aattgtggat	cttaagctct	gctctcagca	gatttcaggt	gtaaccattt	600
gttaactgta	ctgaaggtgt	gtcctcaaga	agaaagtgtt	caaattaaaa	aagctgctgc	660
caagtaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa			699

&lt;210&gt; 49

&lt;211&gt; 1168

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

aattcggcac	gagcacagat	agaaggagtg	gtggtatattt	taaagtgaac	tgttgcgatg	60
atatctgctt	agctttctca	tgctaattctc	tttctgtggt	ccatcttttg	aaggcctccc	120
ttccctgctg	ggcttccttg	caacacacct	aggaattgaa	atgtgctccc	ttttctgtct	180
ctctgctgtg	ctatgtcatc	gtcatctcca	ctagttcttg	gtgcctggca	agaggtggca	240
gccataggat	gttttctaaa	tgaaggagca	aatcaatgaa	gacgtgccga	ggtgcctaca	300
tctccacctc	tggtccgtct	cattgcaggc	tgtaatcggg	aggtgaagga	gattgaatgg	360
aaggcatcta	ccagcatcag	tttggttctg	acttgggttt	ctgccctgtt	catggcacag	420
agtccccacc	ccaaactcta	gttttagtag	atggctatca	attctcttgt	gcctaaattc	480
ctgccttgtc	aaccctagtg	cgctgttagc	cccccaagag	aggagcccag	caggttcttg	540
acagcagaat	ttgtcttgcc	tgtattttgt	ccactttatg	catctttgag	tccagacctg	600
tcatgagctg	tactctttaa	tctcagacac	cttggccatt	tttcagagtg	actaaatagt	660
gcctgctgcc	aggtccctgt	tttcaagctc	catggcccat	caggaaagac	catgatccct	720
ctctgacctc	ccttgtgata	gctgtatgca	atatttctag	ctgctgcttg	tcaactgttg	780
gtcaggatgt	tccctccact	taaccattgc	tgccctgaa	ttctttccta	acacttacct	840
caattcatgg	gccacctcag	ggaacatagc	tagttcaact	tcctggcacc	tgtaaaaaag	900
tttcttgaga	tggagtcttg	ctgtgttgcc	caggctgatc	tcaaaatcct	gggctcaaag	960
gatcctcctg	tcccagcctc	cagaatagct	gggattacag	gcgcatgcc	cgtgcctgg	1020
cttgaggca	cctttaacca	tgcaagccca	cagctatcat	tcttcaatct	ggtcaagtca	1080
ttagatacaa	caaatgtaat	caaacaaaac	acatggagga	gaaaataaaa	taacttactg	1140
gtataaagaa	aaaaaaaaaa	aaaaaaaaaa				1168

&lt;210&gt; 50

&lt;211&gt; 1425

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

gaattcggca	cgagttttag	tagagacagg	gtttcaccat	cttgccagg	ctggtcttga	60
agttctggcc	tcagtgatc	cacctctctc	ggcctcccaa	agtgtggaa	ttacaggcat	120

gagccactgt	ggccagccta	acttatcatt	ttcttaaatg	tgacttaaat	gcagttgaaa	180
acttgattta	tgactgagtc	gttttatccc	ctgaatcaga	gaaagcaaaa	tgaaaatccc	240
tctgctgtgc	taatgcacct	ctttcttttt	tcagtgacca	tgacgcaggt	ggccaggaca	300
gtggctaaag	tgagctcttc	agaccacgtg	tgtgatgtgg	tgtttgact	ctttgactgt	360
gatggcaatg	gcgaactgag	caataaggaa	tttgtttcca	tcatgaagca	acggctgatg	420
agaggcctgg	aaaagcccaa	agacatgggt	ttcactcgcc	tcatgcaggc	catgtggaaa	480
tgtgcacagg	aaactgcctg	ggacttcgct	ttacccaaac	agtaacccca	cactgcaaga	540
ggggacccct	ccacccccag	taccctggac	cccctccgca	gagtctcggc	agagcccttt	600
gtgctgctgc	ttctggaagt	agtcyccctt	cctcccggga	tgacctcagg	actctgtcgg	660
tttccctctt	ttacccttcc	cctccccgt	gttctgctgg	gctctgattc	tgcccaatga	720
gtatccccat	aggttctcaa	aaacatgaac	aagtctgtaa	agctcagaca	tttgtcagcc	780
tcaacagcac	cacccattca	agcatcctgt	ggataaagaa	ttcagggaac	catccacaca	840
cctgccaacc	ctgggaagca	tccagttctc	aaatcgtttt	tgctatggat	ttatactaac	900
aagaacattc	cttgacttcc	ctcctgctgg	tgttttaaag	ccacaagtag	ggaagatata	960
tggcaggcag	aaagaagtct	gtgatgataa	acaatgatga	ggatgacctc	ggcaccctac	1020
gctagtgtga	gaagcctgcg	ccccaggaag	gatctgtgtt	agtcctcggg	atggctccaa	1080
ggcctgctct	aggaaggcag	catgctcagt	gggaacacag	caagattcag	aatttaaagt	1140
agttgcttca	tggtctctgt	cactcccttt	tcttcctcgc	agcctcccta	agatgactcc	1200
agtgtgaccc	tgtgcttagt	gagcaatagt	gattgagctc	atgttccctg	caagtgccat	1260
ttcctctcca	ggatgggcct	ctaaagctga	ggcctggctc	agagcctgtt	tgccctctgt	1320
cttaacaat	tgtaaatatc	acttaaatta	taaccatttg	caataaacat	ccccaaagt	1380
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	waaaaaaaaa	aaaaaa		1425

&lt;210&gt; 51

&lt;211&gt; 2536

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

ccacgcgtcc	gcacgtatca	agataaagag	gaagttgtct	tatggatgaa	tactgttggg	60
ccctaccata	atcgtaaga	aacatataag	tacttttcac	ttccattctg	tgtgggggtca	120
aaaaaaaaagt	atcagtcatt	accatgaaac	tctgggagaa	gcacttcaag	gggttggaatt	180
ggaatttagt	ggctcgata	ttaaatttaa	agatgatgtg	atgccagcca	cttactgtga	240
aattgattta	gataaagaaa	agagagatgc	atttgatat	gccataaaaa	atcattactg	300
gtaccagatg	tacatagatg	atttaccaat	atgggggtatt	gttggtgagg	ctgatgaaaa	360
tggaagaagt	tactatcttt	ggacctataa	aaaacttgaa	ataggtttta	atggaaatcg	420
aattgttgat	gttaattctaa	ctagtgaagg	aaagggtgaaa	ctggttccaa	atactaaaat	480
ccagatgtca	tattcagtaa	aatggaaaaa	gtcagatgtg	aaatttgaa	atcgatttga	540
caaatatctt	gatccgtcct	ttttcaaca	tcggattcat	tggttttcaa	ttttcaactc	600
cttcatgatg	gtgatcttct	tggtgggctt	agtttcaatg	attttaatga	gaacattaag	660
aaaagattat	gctcgtgaca	gtaaagagga	agaaatggat	gatatggata	gagacctagg	720
agatgaatat	ggatggaaac	aggtgcatgg	agatgtat	agaccatcaa	gtcaccctact	780
gatattttcc	tctctgattg	gttctggatg	tcagatattt	gctgtgtctc	tcacgtttat	840
tattgttgca	atgatagaag	atttatatac	tgagagggga	tcaatgctca	gtacagccat	900
atttgtctat	gctgctacgt	ctccagtga	tggttatttt	ggagggaagtc	tgtatgctag	960
acaaggagga	aggagatgga	taaagcagat	gtttattggg	gcattccotta	tcccagctat	1020
gggtgtgtggc	actgccttct	tcatcaattt	catagccatt	tattaccatg	cttcaagagc	1080
cattcctttt	ggaacaatgg	tgcccggttg	ttgcatctgt	ttttttgtta	ttcttctctt	1140
aaatcttggt	ggtacaatac	ttggccgaaa	tctgtcaggt	cagcccaact	ttccttgtcg	1200
tgtcaatgct	gtgcctcgtc	ctataccgga	gaaaaaatgg	ttcatggagc	ctgcgggttat	1260
tgtttgctctg	ggtggaattt	taccttttgg	ttcaatcttt	attgaaatgt	atttcatctt	1320
cacgtctttc	tgggcatata	agatctatta	tgtctatggc	ttcatgatgc	tggtgctggg	1380
tatcctgtgc	attgtgactg	tctgtgtgac	tattgtgtgc	acatattttc	tactaaatgc	1440

agaagattac	cggtggcaat	ggacaagttt	tctctctgct	gcatcaactg	caatctatgt	1500
ttacatgtat	tccttttact	actatttttt	caaaacaaag	atgtatggct	tatttcaaac	1560
atcattttac	tttgatata	tggcgggtatt	tagcacagcc	ttggggataa	tgtgtggagc	1620
gatttggttac	atgggaacaa	gtgcctttgt	ccgaaaaatc	tataactaatg	tgaaaattga	1680
ctagagaccc	aagaaaacct	ggaactttgg	atcaatttct	ttttcatagg	ggtggaactt	1740
gcacagcaaa	aacaaacaaa	cgcaagaaga	gatttgggct	ttaacacact	gggtactttg	1800
tgggtctctc	tttcgtcgg	ggcttaaagt	aacatctatt	tccattgatc	ctaggttctt	1860
cctgactgct	ttctccaact	gttcacagca	aatgcttga	ttttatgcag	taggcattac	1920
tacagtacat	ggctaactct	cccaaaaact	agctcattaa	agatgaaata	gaccagctct	1980
cttcagtga	gaggacaaat	agttttattta	aagcatttgt	tccaataaaa	taaataagagg	2040
gaaacttggg	tgctaaaatt	acatgaatag	gaatcttctc	ggcacttagt	gtttctatgt	2100
tattgaaaaa	tgatgttcca	gaaagattac	ttttttcttc	ttatttttac	tgccattgtc	2160
gacctattgt	gggacatttt	tatatattga	atctgggttc	ttttttgact	ttttttttcc	2220
caatccaaca	gcatcctttt	ttttaaaaga	gagaattaga	aaatattaaa	tcctgcatgt	2280
aatatatctg	ctgtcatctt	agttggacca	acttcccatt	tatttatctt	aaaactatac	2340
agttacatct	taattccatc	caaagaagat	acagtttgaa	gacagaagtg	tactctctac	2400
aatgcaattt	actgtacagt	tagaaagcaa	agtgttaaat	ggagaagata	cttggttttta	2460
ttaaacattt	tgagatttag	ataaactaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2520
aaaaaaaaaa	aaaaaa					2536

&lt;210&gt; 52

&lt;211&gt; 1371

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1351)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 52

ctttgagccc	ctctcattcc	actttagcaa	tctttttggt	aagaactctt	aaagccaaaa	60
gtctgctgaa	aagatttgct	gattattagt	ttaaaaatct	tgtaacactc	agcagtgcata	120
ttttgagtc	tcccagtttc	ctgaaagtaa	tgcccagctc	tectgaatcc	tccttaatag	180
cagaaccttg	gtgattttgt	tggctcatat	gaatgcttgt	catggatatg	ttaacaattt	240
agtgtttgac	attgcttcct	ctgccacaaa	gacaatactc	tggtgacaca	tgtctagacc	300
cagcacaggc	tgtaggcccc	ggagtgcactc	aaaggagttt	ttccctcttt	cttacggttc	360
aaagggtgacc	ctggtggttg	ccagagcagt	aatgcttggt	tgatgctctt	catggctcat	420
ctgcttctca	gaacccaccc	gttgagtttg	tgggtaacca	gcaggcaggc	caaagactgg	480
tgcttttcat	ttcatccttt	agagggatga	aacagttatt	tccgtctgat	gagcattcgg	540
tagaattttt	gaagtgcgat	tttatgaagt	caaaggggac	tttacacaga	tctcgacctg	600
ctttgaaacc	tagaggtggc	cctttgattt	gtgcgtgtcc	ttgccctctg	gacaacttaa	660
tatttcaagt	aatcgaatac	caacttcctc	gccagcccac	ctgccttcog	ccccgcttgt	720
gtaacagtcc	tgttttgttg	agttgctgct	attgcactgc	cagtgcagcc	cacaccaa	780
cacaacccaa	gatactcaga	taggaagact	ccttcctctc	ccagtacttt	accaaggaa	840
ccccgccag	gaccacatg	gggccacgtg	ttggcagtg	aatcagcctg	tgcaaggctg	900
ggatctcagg	ctgatcagta	ggggccagct	ttggagccag	ccaagctgaa	tcccacactc	960
caggtctgtg	ctcaagagac	cagatggtgt	atttccaaat	gggcctctct	ggtatgggca	1020
ataggcaagc	tcctggggtc	tggttatgtg	gaagattctt	agtggatgtt	ccgcctggtt	1080
agctggttct	cttcagagaa	tataaagtga	atgcctttag	gggtagctct	gaaagagaaa	1140
cccaacaact	tcattcctag	ccatgaaagt	agcacgatca	tattgtactg	tattgttatt	1200
gtaaaatgay	tatttgccat	gtcatgagta	ggtagatgtt	ttgccacaaa	tatgaatgtg	1260
tttgtgttcc	ctgactttta	gcaatgaaga	ttgagacaat	aaatagcact	cagagaatga	1320

aaaaaaaaa aaaaaaaaaa attactgctg nccgacaagg gaattcagtg g

1371

<210> 53

<211> 1879

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> n equals a,t,g, or c

<400> 53

agacctttga	taacataacc	attagcagag	aggctcaggg	ngaggctccct	gcctcggact	60
caaagaccga	atgcacggcc	ttgtagggga	cgccccagat	tgtcagggat	kgggggatgg	120
tccttgaggt	tttgcattgt	ctcctccctc	ccacttctgc	accctttcac	cacctcgagg	180
agatttgctc	ccattagcg	aatgaaattg	atgcagtcct	acctaactcg	attccctttg	240
gcttggtggg	taggcctgca	gggcactttt	attccaaccc	ctggtcaytc	agtamtstkt	300
tactccagga	aggcacagga	tggtagctaa	agagaattag	agaatgaacc	tggckrgacg	360
gatgtcta	cctgcrcta	gctgggttgg	tcagtagaac	ctattttcag	actcaaaaac	420
catcttcaga	aagaaaaggc	ccaggggaagg	aatgtatgag	aggctctccc	agatgaggaa	480
gtgtactctc	tatgactatc	aagctcaggc	ctctcccttt	ttttaaacca	aagtctggca	540
accaagagca	gcagctccat	ggcctccttg	ccccagatca	gcctgggtca	ggggacatag	600
tgtcattgtt	tggaaactgc	agacacaagg	tgtgggtcta	tcccacttcc	tagtgctccc	660
cacattcccc	atcagggcct	cctcacgtgg	amaggktktg	tartccaggc	agttcacttg	720
cagtttccct	gtcctcatgc	ytcggggatg	ggagccmcmg	cygaactaga	gttcaggctg	780
gatacatgtg	ctcacctgct	gctcttgtct	tcctaagaga	cagagagtgg	ggcagatgga	840
ggagaagaaa	gtgaggaatg	agtagcatag	cattctgcca	aaagggcccc	agattcttaa	900
tttagcaaac	taagaagccc	aattcaaaaag	cattgtggct	aaagtctaac	gctcctctct	960
tggtagata	acaaaagccc	tccctgttgg	atcttttgaa	ataaaacgtg	caagttatcc	1020
aggctcgtag	cctgcatgct	gccaccttga	atcccagggg	gtatctgcac	ctggaatagc	1080
tctccacccc	tctctgcctc	cttactttct	gtgcaagatg	acttctctgg	ttaaacttct	1140
tctttccatc	caccacacca	ctggaatctc	tttccaaaca	tttttccatt	ttccacacaga	1200
tgggctttga	ttagctgtcc	tctctccatg	cctgcaaagc	tccagatatt	tggggaaagc	1260
tgtacccaac	tggactgccc	agtgaactgg	gatcattgag	tacagtcgag	cacacgtgtg	1320
tgmatgggtc	aaaggggtgt	gttccttctc	atcctagatg	ccttctctgt	gccttcaca	1380
gcctcctgcc	tgattacacc	actgcccccg	ccccaccctc	agccatccca	attcttctctg	1440
gccagtcgcg	tccagcctta	tctaggaag	gargagtggg	tgtagccgtg	cagcaagatt	1500
ggggcctccc	ccatccagc	ttctccacca	ttccagcaag	tcaggatata	agacartcct	1560
cccctgaccc	tcccccttgt	agatatcaat	tcccaaacag	agccaaatac	tctatatcta	1620
tagtcacagc	cctgtacagc	atttttcata	agttatatag	taaatggctc	gcatgatttg	1680
tgcttctagt	gctctcattt	ggaaatgagg	caggcttctt	ctatgaaatg	taaagaaaga	1740
aaccactttg	tatattttgt	aataccacct	ctgtggccat	gcctgccccg	cccactctgt	1800
atatatgtaa	gttaaaccgg	ggcaggggct	gtggccgtct	ttgtactctg	gtgattttta	1860
aaaattgaat	ctttgtact					1879

<210> 54

<211> 1007

<212> DNA

<213> Homo sapiens

<220>

&lt;221&gt; SITE

&lt;222&gt; (995)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 54

cggcacgagg	catatgttca	gctatatgtt	ataaaaccag	ttttcaagtg	gttgtacca	60
tgtacactcc	caccaaccca	gtatgcgagt	tctagtgtct	cacatacttg	ccaacatttg	120
gcattttcca	tcttttttac	tatagccatt	agtggtgggc	atatagtgat	atgtcagttt	180
tagttttcgg	ttttattttc	ttgtcctcca	aaccattgta	gtatctcccc	aggatagatg	240
agtgatggct	gagacctgag	acctaggcct	gttcctcaca	tgactgcacc	attttacatt	300
ctatcaatgt	atgaggtttc	cggtttctcc	acatccttac	caactcttat	tattattagt	360
cttttttatt	atagctatcc	tagtacatgt	gaagttatat	tgtgatatta	atttacactg	420
ccctaataat	taataatatt	gatcatcttt	tattgagaat	ctttgatgaa	rtgtctgttt	480
aaatcttttg	cccattatca	gttgggttat	ttgggttttt	ttattgttga	gcaactgatag	540
tttttaaaaa	tatattctgg	gtgtaacttc	actatcagtc	cattatcctt	gcaaagggtt	600
tctcccagtc	tctggattgt	cttttcattc	tcttaagagt	gtcttttgaa	gaacagaact	660
gcttattttg	atgaagtccg	ttctttccat	ttgttcattt	ctgggttggt	ctttgagtgc	720
tgtatctaag	aaatccttgc	ctaaccaaag	attacaatga	tttttctctg	tgttttcttc	780
taaaaggttta	agttttacat	ctagatctag	catgtatttt	gagttatatg	gtgtgaaata	840
tggatccaag	ttcttttatg	tttttgtttt	gttttgtttt	gtttttgctt	atggatattc	900
aatggtttcc	acaccatttg	tttaaaaata	ctaccctttc	tcaataaaaa	aaaaaaaaaa	960
agggcggcgc	ctctagagga	tccaagctta	cgtangcgtg	catgcga		1007

&lt;210&gt; 55

&lt;211&gt; 2082

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 55

ggcacgagat	tcccagggtc	ctgtttgaga	atgtggaggc	ttttgccatg	ggttttattg	60
ggctgatggg	tgccatgatt	ttcattatgt	tgtttggttc	ctgggatcat	aaaaatgttt	120
gcctcttcct	agagtaccta	ggatcattga	aaagaaaagg	gataaaaaag	cccctgcatt	180
tgtagctgct	acatagcata	caaaccatgg	cttccttgag	ggaaaagggc	cagctctggc	240
tctgggctag	ggaaaatcat	caaactggaa	gggacaggac	aagcagccac	accagcttc	300
caactccctc	ccatccaagg	acactgaggc	ccagagagat	gctcatctaa	agctggctctg	360
gaatcctggg	cccactctcg	gtcagggtgt	ctttctctcc	ctggtgactt	gaggctgtga	420
gtagagttgg	gaaaggtaaa	ggagtctgaa	ttctgctgaa	ctagtgtctt	gggacacctc	480
taggagtggg	agaaatgggc	agatttacag	gcagcatagc	tcaggacctt	gtccaatcag	540
ctgtcttgaa	cacccacttt	ggtccacggg	tcacgttcat	gttatagtca	tgagcccttg	600
ctcctccgcc	agtctagact	caaggaagca	gtggcacaaa	tctcctggct	gttgggttcc	660
atggagcaga	gagcctgaac	ccaccgggaa	accaagtcta	gacaaaacag	agctttgagg	720
tttacaccca	caacctttgt	accgtcggaa	gcagaggggtg	ccaggggatc	cactacacgc	780
tccctgggaa	gcagaggcca	gaggtgtcgc	atttagaaga	tgctcagga	gaaatacacc	840
cacctaaagt	agttctcaaa	aaaattaata	gtaagagaag	tctgaaacag	ccactggagc	900
aaaatcaaac	aatttcacct	ttatccacat	atgaagagag	caaagtttca	aagtatgctt	960
ttgaacttgt	ggataaacag	gctttactgg	actcagaagg	caatgctgac	attgatcagg	1020
ttgataattt	gcaggagggg	cccagtaaac	ctgtgcatag	tagtactaat	tatgatgatg	1080
ccatgcagtt	tttgaagaag	aagcgggtatc	ttcaagcagc	aagtaccacc	agcagggaat	1140
atgcgctgaa	tgtgggtacc	atagcttctc	agccttctgt	aacacaagca	gctgtggcaa	1200
gtgtcattga	tgaaagtacc	acggcatcca	tattagagtc	acaggcactg	aatgtggaga	1260
ttaagagtaa	tcatgacaaa	aatgttatcc	cagatgaggt	actgcagact	ctgttggatc	1320
attattccca	caaagctaata	ggacagcatg	agatattcct	cagtgttgca	gatactgaag	1380
tgacttctag	catatcaata	aattcttcag	aagtaccaga	ggtcaccca	tcagagaatg	1440

ttggatcaag	ctcccaagca	tcctcatcag	ataaagccaa	catgttgca	gaatactcca	1500
agtttctgca	gcaggctttg	gacagaacta	gccaaaatga	tgctatttg	aatagcccg	1560
gccttaactt	tgtgactgat	aaccagaccc	tcccaaata	gccagcattc	tcttccatag	1620
acaagcaggt	ctatgccacc	atgcccatca	atagctttcg	atcaggaatg	aattctccac	1680
taagaacaac	tccagataag	tcccactttg	gactaatagt	tggtgattca	cagcactcat	1740
ttcccttttc	aggtgatgag	acaaaccatg	cttctgccac	atcaacacag	gactttctgg	1800
atcaagtga	ttctcagaag	aaagctgagg	cccagcctgt	ccaccaagct	taccaaatga	1860
cttcttttga	acagcccttc	cgtgctccct	atcatggatc	aagagctgga	atagctactc	1920
tttagcac	tgccaatgga	caggtgaacc	ttcggggacc	agggacaagt	gctgaatttt	1980
cagaatttcc	cttggtgaat	gtaaatgata	atagagctgg	gatgacatct	tcacctgatg	2040
ccacaactgg	ccagactttt	ggctaaaaaa	aaaaaaaaaa	aa		2082

&lt;210&gt; 56

&lt;211&gt; 637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 56

ggcagcagcg	cgatgtaaca	cgagaaagca	cataccaagg	ccaccacaca	ccacctgtcc	60
aaaaaggcct	tgcatacggg	ataatcctat	ttattacctc	agaagttttt	ttcttcgcag	120
gatttttctg	agccttttac	cactccagcc	tagccctac	cccccaatta	ggagggcact	180
ggcccccaac	aggcatcacc	ccgctaaatc	ccctagaagt	cccaactcta	aacacatccg	240
tattactcgc	atcaggagta	tcaatcacct	gagctcacca	tagtctaata	gaaaacaacc	300
gaaaccaaat	aattcaagca	ctgctcatta	caattttact	gggtctctat	ttaccctcc	360
tacaagcctc	agagtacttc	gagtctccct	tcaccatttc	cgacggcatc	tacggctcaa	420
cattttttgt	agccacaggc	ttccacggac	ttcacgtcat	tattggctca	actttcctca	480
ctattctgct	catccgccaa	ctaataatttc	actttacatc	caaacatcac	tttggtctcg	540
aagccgcgcg	ctgatactgg	cattttgtag	atgtggtttg	actattttctg	tatgtctcca	600
tctattgatg	agggctctta	aaaaaaaaaa	aaaaaa			637

&lt;210&gt; 57

&lt;211&gt; 726

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 57

ggcagcaggg	atgacaaagc	tcatgaatcg	gcttttaaga	actgtttcca	tgttgagta	60
tttcatcaac	cggagttggg	aatggagcac	gtacaataca	gaaatgctga	tgtctgagct	120
gagtcctgaa	gaccagagag	tattcaactt	tgacgtgcgc	cagttgaact	ggttggaata	180
cattgaaaat	tatgttttgg	gagttaaaaa	atacttattg	aaagaggata	tggctgggat	240
cccaaaagca	aagcaacgct	taaaaaggct	ccgaaatatt	cactacctct	ttaatactgc	300
cctcttctct	atcgctggc	gccttctcat	tgcaagatct	cagatggctc	ggaatgtctg	360
gttcttcatt	gtaagcttct	gttataaatt	cctctcctac	tttagagcat	ccagcacgct	420
caaagtttta	gagcattttg	ccatcgcttt	ttatctggaa	cctctcagat	acctctaaaa	480
cagcaaactg	tgattctcaa	gattagaaag	taacaaggaa	tatgcccaaa	ctgtcaaatg	540
tcacctgtta	tgtattcgtc	cctattcctt	aactatgtat	ttttatttca	gtgagagaag	600
gaaagttgta	aactagccca	tagtcaccta	tattttaggg	aaaaaaatcc	aaattgtttc	660
ctaacattct	attttatgcc	cttgcgatatt	aaacgtgaaa	gtactcccaa	aaaaaaaaaa	720
aaaaaa						726

&lt;210&gt; 58

<211> 223  
 <212> DNA  
 <213> Homo sapiens

<400> 58

ggcagagat	gagatccttg	gggtccaccc	tagtctctga	cacctgggac	aggggtgctt	60
ttgctacttt	ggttggtggtc	actccccac	acctgcctgc	ctccttcacg	gactcgaagt	120
gaccttcctg	gaggaggtgg	gcagctcaga	ctccacatgc	tggtggtgcc	tgaggtctga	180
tggcctctaa	taaactgtgt	cctataaaaa	aaaaaaaaaa	aaa		223

<210> 59  
 <211> 1931  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (184)  
 <223> n equals a,t,g, or c

<400> 59

ccaggngcaa	gctttggtga	atccagtggg	ctgagtggct	ctatggatgt	ggttggttgg	60
atgtggtagg	gagtgcttag	cagaatgtgt	gtgtatctct	gaggctgtca	gggggtgggt	120
gggtgtgtgt	ctctgttgga	cctgtctctc	ctcagctctat	tcctgtcata	gatgtgggtg	180
tcctktgtag	ggaagtgcct	gtgtggtctg	tttacagtgc	agaaggcggc	tcagcagtgc	240
aatgggctga	cagccttgga	cgggagtc	gaagcctggg	ttctggttgt	agctctggcc	300
cctccctgtg	atcttcaaca	agccacttgc	tttctctcgt	cttcagtttc	ctcaactaga	360
aaatgaacag	cagctgaaat	tatgttgaag	atccttttat	acctgaaaga	gtttcttcat	420
agaaatttct	gtggtgggga	gggggcaatc	tcgkgtgtgc	tcagtatacc	taaagggttg	480
ggtgggrcgg	agtgtgtgtg	ctctgtagaa	aggcgaagg	gcagttccta	tcaggactgt	540
gtatgtctga	gcacatgtgg	ctctgtttgg	gattacgtgt	ttgtctgtga	atgtgtgtgt	600
gtgttgagg	gttgtctatt	gtgtgtggct	gtataggggtg	tctgtagatc	aagatgtgta	660
tacagctgct	tctgctattg	ctggtttggg	ggaggggact	ggaaagctga	gactgaaaat	720
caagagggaa	gaggtgagga	aggcccaccc	ctggggctgg	gcagtgtaga	cctgccaccg	780
tgtgaagaaa	aatgaaagca	cagatagcct	aagactgcac	aggcctgtgc	ccacatacct	840
tatagcacag	gccaggtgg	atcatctcat	gctaacaccc	cacatgtgct	ggtggatcca	900
ctcccatgga	tccactcaca	tgctgcaggc	atgcagttaga	ctcaccacaca	gcccactctc	960
tggacaccaa	tcctgggagg	tgggagctgg	aatggggagc	aatgagagga	gggagtgaga	1020
ctgttggtct	aggaagggtg	gtacctctcc	ctgcatcata	cccaggaact	tccagctcca	1080
aaatattggg	gtacagctca	ccacccccca	ctccgccaac	ccatttctac	ctcctctagt	1140
gcagggaccc	aagttagatg	atgagaaaat	gccaaacaaa	gggaggcaag	gacagagaag	1200
gtacctgcag	gaccacaag	gccatactg	gccccatct	gaacccacct	ctcccaccca	1260
gatcaacatc	cccccaaccc	ctgtgcccc	atcatctgga	ccccagagcc	agccctccca	1320
ctaccaccac	caccaccccc	gggtccttg	gctcaccttt	ctagaacatg	ggtacctcct	1380
ctttttgggg	gctcathtag	actgctgct	ttgctgctga	cttgcaagtgt	gactcgggcc	1440
cattgttcaa	tctctgtggc	cctgagacac	cagggaaaat	ctcccccccc	acaggacata	1500
ctagttccct	ggcaggcaag	ggcttccaac	tgaggcagtg	catgtgtggc	agagagaggc	1560
aggaagctgg	cagtggcagc	ttctgtgtct	agggaggggt	gtggctccct	ccttccctgt	1620

```

ctgggaggtt ggaggggaaga atctaggcct tagcttgccc tcctgccacc cttcccccttg      1680
tagatactgc cttaacactc cctcctctct cagctgtggc tgccaccag ccagggtttct      1740
ccgtgctcac taatttattt ccaggaaggt gtgtggaaga catgagccgt gtataatatt      1800
ttttttaaca ttttcattgc agtattgacc atcatccttg gttgtgtatc gtgtaacaca      1860
aataatgata ttaaaagcat caaacaagcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      1920
aaaaaactcg a                                                                1931

```

<210> 60  
 <211> 310  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (38)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (40)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (127)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 60  
 Met Val Tyr Lys Thr Leu Phe Ala Leu Cys Ile Leu Thr Ala Gly Trp  
   1                  5                  10                  15  
 Arg Val Gln Ser Leu Pro Thr Ser Ala Pro Leu Ser Val Ser Leu Pro  
                   20                  25                  30  
 Thr Asn Ile Val Pro Xaa Thr Xaa Ile Trp Thr Ser Ser Pro Gln Asn  
   35                  40                  45  
 Thr Asp Ala Asp Thr Ala Ser Pro Ser Asn Gly Thr His Asn Asn Ser  
   50                  55                  60  
 Val Leu Pro Val Thr Ala Ser Ala Pro Thr Ser Leu Leu Pro Lys Asn  
   65                  70                  75                  80  
 Ile Ser Ile Glu Ser Arg Glu Glu Glu Ile Thr Ser Pro Gly Ser Asn  
                   85                  90                  95  
 Trp Glu Gly Thr Asn Thr Asp Pro Ser Pro Ser Gly Phe Ser Ser Thr  
   100                  105                  110  
 Ser Gly Gly Val His Leu Thr Thr Thr Leu Glu Glu His Ser Xaa Gly  
   115                  120                  125  
 Thr Pro Glu Ala Gly Val Ala Ala Thr Leu Ser Gln Ser Ala Ala Glu



130                      135                      140  
 Pro Pro Thr Leu Ile Ser Pro Gln Ala Pro Ala Ser Ser Pro Ser Ser  
 145                      150                      155                      160  
 ----- Leu Ser Thr Ser Pro Pro Glu Val Phe Ser Ala Ser Val Thr Thr Asn -----  
                                  165                      170                      175  
 His Ser Ser Thr Val Thr Ser Thr Gln Pro Thr Gly Ala Pro Thr Ala  
                                  180                      185                      190  
 Pro Glu Ser Pro Thr Glu Glu Ser Ser Ser Asp His Thr Pro Thr Ser  
                                  195                      200                      205  
 His Ala Thr Ala Glu Pro Val Pro Gln Glu Lys Thr Pro Pro Thr Thr  
                                  210                      215                      220  
 Val Ser Gly Lys Val Met Cys Glu Leu Ile Asp Met Glu Thr Thr Thr  
 225                      230                      235                      240  
 Thr Phe Pro Arg Val Ile Met Gln Glu Val Glu His Ala Leu Ser Ser  
                                  245                      250                      255  
 Gly Ser Ile Ala Ala Ile Thr Val Thr Val Ile Ala Val Val Leu Leu  
                                  260                      265                      270  
 Val Phe Gly Val Ala Ala Tyr Leu Lys Ile Arg His Ser Ser Tyr Gly  
                                  275                      280                      285  
 Arg Leu Leu Asp Asp His Asp Tyr Gly Ser Trp Gly Asn Tyr Asn Asn  
                                  290                      295                      300  
 Pro Leu Tyr Asp Asp Ser  
 305                      310

&lt;210&gt; 61

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (31)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 61

Met Leu Leu Cys Phe Met Arg Ile Lys Ile Pro Ala Leu Leu Cys Leu  
 1                      5                      10                      15

Trp Tyr Leu Pro Leu His Ile Leu Val Met Ala Trp Glu Val Xaa  
 20                      25                      30

<210> 62  
 <211> 31  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (31)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 62  
 Met Ser Glu Val Lys Ile Leu Arg Phe Val Leu Ile Thr Phe Val Phe  
           1                  5                  10                  15  
 Cys Lys His Ser Asp Pro Pro Ile Ser Ala Leu Ser Leu Thr Xaa  
                   20                  25                  30

<210> 63  
 <211> 450  
 <212> PRT  
 <213> Homo sapiens

<400> 63  
 Met Val Pro Leu Val Ala Val Val Ser Gly Pro Arg Ala Gln Leu Phe  
           1                  5                  10                  15  
 Ala Cys Leu Leu Arg Leu Gly Thr Gln Gln Val Gly Pro Leu Gln Leu  
                   20                  25                  30  
 His Thr Gly Ala Ser His Ala Ala Arg Asn His Tyr Glu Val Leu Val  
           35                  40                  45  
 Leu Gly Gly Gly Ser Gly Gly Ile Thr Met Ala Ala Arg Met Lys Arg  
           50                  55                  60  
 Lys Val Gly Ala Glu Asn Val Ala Ile Val Glu Pro Ser Glu Arg His  
           65                  70                  75                  80  
 Phe Tyr Gln Pro Ile Trp Thr Leu Val Gly Ala Gly Ala Lys Gln Leu  
                   85                  90                  95  
 Ser Ser Ser Gly Arg Pro Thr Ala Ser Val Ile Pro Ser Gly Val Glu  
           100                  105                  110  
 Trp Ile Lys Ala Arg Val Thr Glu Leu Asn Pro Asp Lys Asn Cys Ile  
           115                  120                  125  
 His Thr Asp Asp Asp Glu Lys Ile Ser Tyr Arg Tyr Leu Ile Ile Ala  
           130                  135                  140  
 Leu Gly Ile Gln Leu Asp Tyr Glu Lys Ile Lys Gly Leu Pro Glu Gly  
           145                  150                  155                  160

Phe Ala His Pro Lys Ile Gly Ser Asn Tyr Ser Val Lys Thr Val Glu  
 165 170 175  
 Lys Thr Trp Lys Ala Leu Gln Asp Phe Lys Glu Gly Asn Ala Ile Phe  
 180 185 190  
 Thr Phe Pro Asn Thr Pro Val Lys Cys Ala Gly Ala Pro Gln Lys Ile  
 195 200 205  
 Met Tyr Leu Ser Glu Ala Tyr Phe Arg Lys Thr Gly Lys Arg Ser Lys  
 210 215 220  
 Ala Asn Ile Ile Phe Asn Thr Ser Leu Gly Ala Ile Phe Gly Val Lys  
 225 230 235 240  
 Lys Tyr Ala Asp Ala Leu Gln Glu Ile Ile Gln Glu Arg Asn Leu Thr  
 245 250 255  
 Val Asn Tyr Lys Lys Asn Leu Ile Glu Val Arg Ala Asp Lys Gln Glu  
 260 265 270  
 Ala Val Phe Glu Asn Leu Asp Lys Pro Gly Glu Thr Gln Val Ile Ser  
 275 280 285  
 Tyr Glu Met Leu His Val Thr Pro Pro Met Ser Pro Pro Asp Val Leu  
 290 295 300  
 Lys Thr Ser Pro Val Ala Asp Ala Ala Gly Trp Val Asp Val Asp Lys  
 305 310 315 320  
 Glu Thr Leu Gln His Arg Arg Tyr Pro Asn Val Phe Gly Ile Gly Asp  
 325 330 335  
 Cys Thr Asn Leu Pro Thr Ser Lys Thr Ala Ala Ala Val Ala Ala Gln  
 340 345 350  
 Ser Gly Ile Leu Asp Arg Thr Ile Ser Val Ile Met Lys Asn Gln Thr  
 355 360 365  
 Pro Thr Lys Lys Tyr Asp Gly Tyr Thr Ser Cys Pro Leu Val Thr Gly  
 370 375 380  
 Tyr Asn Arg Val Ile Leu Ala Glu Phe Asp Tyr Lys Ala Glu Pro Leu  
 385 390 395 400  
 Glu Thr Phe Pro Phe Asp Gln Ser Lys Glu Arg Leu Ser Met Tyr Leu  
 405 410 415  
 Met Lys Ala Asp Leu Met Pro Phe Leu Tyr Trp Asn Met Met Leu Arg  
 420 425 430  
 Gly Tyr Trp Gly Gly Pro Ala Phe Leu Arg Lys Leu Phe His Leu Gly  
 435 440 445

Met Ser  
450

<210> 64  
<211> 9  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (9)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 64  
Met Trp Ile Leu Leu Tyr Leu Ile Xaa  
1 5

<210> 65  
<211> 52  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (52)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 65  
Met Thr Leu Leu Leu Trp Lys Phe Asn Leu Phe Ile Val Phe Trp Ala  
1 5 10 15

Leu Trp Val Val Arg Ala Gly Leu Trp Val Leu Gly Asn Ser Ser Gly  
20 25 30

Ser Gln His Ser Lys Ala Lys Leu Thr Ser Ser Ser His Thr Leu Gln  
35 40 45

Glu Lys His Xaa  
50

<210> 66  
<211> 21  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (21)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 66

Gly Lys Cys Leu Ile Asn Leu Val Ile Gly Trp Val Lys Tyr Met Gly  
 1 5 10 15

Glu Phe Tyr Met Xaa  
 20

<210> 67  
 <211> 33  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (33)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 67  
 Met Tyr Ser Ala Phe His Asn Cys Leu Cys Leu Ala Leu His Val Leu  
 1 5 10 15

Thr Phe Leu Tyr Asp Val Gly Ser Ser Val Asn Leu Gln Arg Lys Ile  
 20 25 30

Xaa

<210> 68  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (71)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 68  
 Met Val Gln Lys Trp Arg Leu Leu Leu Asn Leu Leu Thr Leu Pro His  
 1 5 10 15

Arg Ser Lys Leu Leu Phe Lys Met Cys Leu Thr Pro Tyr Phe Val Phe  
 20 25 30

Arg Val Leu Asp Ser Tyr Leu Lys Leu Gly Ser Phe Gly Ser Cys Leu  
 35 40 45

Ile Phe Cys Ser Ala Leu Arg Leu Ser Leu Pro Ser Thr Tyr Ser Gly  
 50 55 60

Phe Val Cys Gln Phe Phe Xaa  
 65 70

<210> 69  
 <211> 33  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (33)  
 <223> Xaa ,equals any of the twenty naturally occurring L-amino acids

<400> 69  
 Met His Leu Ile Trp Leu Cys Val Thr Gly Leu Phe Ile Ser Ala Thr  
     1                    5                    10                    15  
 Glu Ile His Ala Val Cys Thr Tyr Asn Arg Tyr Ile Val Ser Ala Tyr  
                     20                    25                    30

Xaa

<210> 70  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (20)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 70  
 Met Ser Leu Leu Leu Glu Ser Cys Val Glu Pro Leu Ser Phe Leu Leu  
     1                    5                    10                    15

Leu Leu Gln Xaa  
                     20

<210> 71  
 <211> 18  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (18)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 71  
 Met Cys Ala Leu Gly Lys Leu Cys Leu Ile Leu Gln Ser Trp His Pro  
     1                    5                    10                    15

Leu Xaa

<210> 72

<211> 19

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 72

Met	Leu	Cys	Phe	Ser	Phe	Leu	Cys	Leu	Ser	Leu	Leu	Val	Ser	Ala
1				5					10				15	

Gln Gly Xaa

<210> 73

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 73

Ser	Val	Trp	Gly	Ser	Phe	Leu	Ser	Met	Leu	Met	Leu	Leu	Ser	Val
1				5					10				15	

Cys Xaa

<210> 74

<211> 40

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 74

Met	His	Leu	Leu	Phe	Leu	Phe	Val	Pro	Met	Tyr	Gln	Cys	Arg	Val	Ala
1				5					10					15	

Leu Phe Ser Ser Thr Val Phe Ile Ala Ala Phe Leu Ser Ile Asn Leu  
20 25 30

Ser His Cys Ile Phe Tyr Lys Xaa  
35 40

<210> 75

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 75

Ile Ala Trp Val Gln Arg Thr Ser Cys Ser Cys Phe Gly Ile Gly Asp  
1 5 10 15

Trp Tyr Arg Glu Ser Ala Arg Pro Pro Glu Gln Tyr Val Gln Leu Pro  
20 25 30

Arg Thr Pro Xaa  
35

<210> 76

<211> 37

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 76

Met Gly Ser Cys Thr Trp Ser Ile Trp Leu Trp Met Val Ser Gly Val  
1 5 10 15

Ala Cys Arg Ser Gln Gly Leu Ser Asp Cys Ser Pro Lys Ala Phe Leu  
20 25 30

Trp Ser Phe Ala Xaa  
35

<210> 77

<211> 39

<212> PRT

<213> Homo sapiens



<220>  
<221> SITE  
<222> (14)  
<223> Xaa equals any of the naturally occurring L-amino acids

-----  
<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 77  
Met Arg Ser Pro Leu Ser Ala Ser Ala Leu Leu Leu Trp Xaa Ser Ser  
1 5 10 15  
Val Ala Arg Ala Phe Ser Ser Pro Ser Leu Leu Met Ala Val Pro Ser  
20 25 30  
Pro Xaa Cys Ser Arg Tyr Xaa  
35

<210> 78  
<211> 36  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (36)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 78  
Met Trp Cys Ala Leu Gly Phe Trp Gly Arg Ala Trp Gly Ser Arg Gly  
1 5 10 15  
Pro Trp Ala Ala Gln Pro Gly Glu Pro Gln Pro Arg Gly Trp Ser Cys  
20 25 30  
Ser Gly Asn Xaa  
35

<210> 79  
<211> 42  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE

&lt;222&gt; (42)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 79

Met	Gly	His	Leu	Lys	Ser	Cys	Met	Asn	His	Asn	Leu	Leu	Trp	Tyr	Leu
1				5				10					15		

Cys	Thr	Cys	Leu	Ile	Leu	Tyr	Ser	Leu	Phe	Gln	Cys	Gly	Ile	Cys	Ala
			20					25					30		

Pro	Leu	Tyr	Leu	Leu	Arg	Ser	Ala	Glu	Xaa
		35				40			

&lt;210&gt; 80

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (21)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 80

Met	Asn	Pro	Cys	Phe	Phe	Ser	Val	Leu	Val	Leu	Leu	Pro	Glu	Leu	Ala
1				5				10				15			

Leu	Gln	Trp	Lys	Xaa
			20	

&lt;210&gt; 81

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (8)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 81

Phe	Val	Lys	Leu	Arg	His	Pro	Xaa
1				5			

&lt;210&gt; 82

&lt;211&gt; 67

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (67)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 82

Met Phe Leu Cys Gly Phe Phe Val Val Val Phe Val Trp Gly Gly Gly

1

5

10

15

Lys Tyr Arg Val Ile His Glu Gln Asp Ile Ser Leu Leu Ser Lys Ser

20

25

30

Leu Gly Ser Arg Cys Gly Ser Glu Met Ala Trp Glu Gly Pro Cys Gly

35

40

45

Gln Trp Phe Tyr Leu Phe Phe Leu Ser Leu Leu Ile Ser Gly Leu Leu

50

55

60

Arg Phe Xaa

65

&lt;210&gt; 83

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (30)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 83

Val Asn Leu Asp His Leu Val Lys Val Val Phe Ala Arg Phe Leu His

1

5

10

15

Tyr Lys Val Asn Ile Phe Pro Phe Pro Tyr Tyr Phe Leu Xaa

20

25

30

&lt;210&gt; 84

&lt;211&gt; 39

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (39)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 84

Met Leu Arg Leu Ala Gly Pro Pro Phe Tyr Trp Pro Val Leu Leu Ala

1

5

10

15

Leu Leu Pro Phe Ala Ser Ser Gly Phe Gln Val Ser Leu Lys Val Gly

20

25

30

Gly Cys Leu Ser Ser Leu Xaa  
35

<210> 85

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 85

Met Pro Ala Ala Thr Trp His Pro Leu Ser Cys Leu Leu Ser Phe Leu  
1 5 10 15

Val Cys Ala Val Val Gly Cys Ile Ser Pro Phe Leu His Cys Asn Lys  
20 25 30

Gly Ile Pro Glu Ile Gly Xaa  
35

<210> 86

<211> 191

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (191)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 86

Ile Ala Leu Arg Leu Thr Leu Leu Pro Ala Ser Ser Ala Ala Leu His  
1 5 10 15

Leu Arg Arg Ser Pro Val Cys Leu Gln Leu Leu Pro Arg Gln Leu Ile  
20 25 30

Lys Gln Pro Val Arg Leu Met Phe Thr Lys Val Lys Leu Glu Gln Val  
35 40 45

Leu Lys Gly Pro Glu Glu Ala Leu Val Thr Cys Arg Gln Val Leu Arg  
50 55 60

Leu Trp Gln Thr Leu Tyr Ser Phe Ser Gln Leu Gly Gly Leu Glu Lys  
65 70 75 80

Asp Gly Ser Phe Gly Glu Gly Leu Thr Met Lys Lys Gln Ser Gly Met  
85 90 95

His Leu Thr Leu Pro Asp Ala His Asp Ala Asp Ser Gly Ser Arg Arg  
 100 105 110

Ala Ser Ser Ile Ala Ala Ser Arg Leu Glu Glu Ala Met Ser Glu Leu  
 115 120 125

Thr Met Pro Ser Ser Val Leu Lys Gln Gly Pro Met Gln Leu Trp Thr  
 130 135 140

Thr Leu Glu Gln Ile Trp Leu Gln Ala Ala Glu Leu Phe Met Glu Gln  
 145 150 155 160

Gln His Leu Lys Glu Ala Gly Phe Cys Thr Gly Gly Gly Gly Pro Leu  
 165 170 175

Pro His Phe Ser Leu Ser Thr Leu Tyr Ala Gly Pro Ala Gly Xaa  
 180 185 190

<210> 87

<211> 35

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 87

Met Leu Met Ile Cys Leu Leu Ser Gly Arg Ala Phe Ala Tyr Phe Phe  
 1 5 10 15

Ser Asn Tyr Phe Thr Ser Thr Leu Ile Leu Leu Ser Gln Phe Ser Tyr  
 20 25 30

Gln His Xaa  
 35

<210> 88

<211> 119

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (119)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 88

Met Asp Leu Ala Gly Leu Leu Lys Ser Gln Phe Leu Cys His Leu Val  
 1 5 10 15

Phe Cys Tyr Val Phe Ile Ala Ser Gly Leu Ile Ile Asn Thr Ile Gln  
                   20                  25                  30

Leu Phe Thr Leu Leu Leu Trp Pro Ile Asn Lys Gln Leu Phe Arg Lys  
           35                  40                  45

Ile Asn Cys Arg Leu Ser Tyr Cys Ile Ser Ser Arg Leu Gln Gly Pro  
       50                  55                  60

Gly Gln Glu Arg Ala Gly Leu Cys Pro Asn Tyr Arg Leu Asp Val Val  
   65                  70                  75                  80

Leu His Arg Asp Gly Leu Leu Phe Ala Gln Val Gly Ala Gly Ser Gln  
                   85                  90                  95

Asp Gly Cys His Gln Phe Ala Ala Pro Pro Gly Leu Pro Arg Glu Val  
           100                  105                  110

Phe Phe Pro Asp Ser Leu Xaa  
       115

<210> 89

<211> 55

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 89

Met Trp Cys Leu Ser His Leu Ser Leu Ser Leu Ser His Leu  
   1                  5                  10                  15

Ser Leu Ala Arg Arg Ala Gly Arg Pro Met Pro Trp Cys Pro Ala Thr  
           20                  25                  30

Gln Leu Val Ile Leu Trp Leu Gln Asn Trp Trp Ser Pro Met Met Asp  
       35                  40                  45

Met Arg Arg Ser Leu Arg Xaa  
       50                  55

<210> 90

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

&lt;222&gt; (34)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 90

Met	Cys	Leu	Ile	Phe	Ser	Ile	Cys	Phe	Leu	Cys	Ile	His	Ile	Gly	Phe
1				5					10					15	

Cys	Phe	Val	Phe	Asn	Leu	Leu	Ile	Met	Gly	Leu	Asn	Phe	Gln	Ile	Tyr
			20					25					30		

Phe Xaa

&lt;210&gt; 91

&lt;211&gt; 41

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (41)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 91

Glu	Val	Lys	Cys	Ile	Tyr	Ile	Phe	Leu	Trp	Leu	Leu	Met	Leu	Leu	Val
1				5					10					15	

Leu	His	Leu	Arg	Ile	His	Cys	Gln	Ile	Gln	Gly	His	Glu	Asp	Leu	Leu
			20					25					30		

Leu	Cys	Phe	Leu	Leu	Arg	Ile	Leu	Xaa
			35				40	

&lt;210&gt; 92

&lt;211&gt; 84

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (84)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 92

Met	Tyr	Glu	Gln	Ala	Ala	Ala	Gly	His	Gly	Pro	Ile	Ser	Pro	Phe	Ser
1					5					10				15	

Leu	Cys	Val	Ser	Leu	Gly	Ile	His	Pro	Ala	Asn	Gln	Gly	Arg	Pro	Gly
				20					25				30		

Val	Trp	Ala	Leu	Gly	Thr	Asn	Gly	Ala	His	Ile	Leu	Glu	Trp	Gln	Ile
			35					40					45		

Leu Gly Asp Ala Leu Pro Val Pro Ala Gly Pro Val Pro Pro Thr Gln  
 50 55 60

Ser Ser Pro Gln Thr Trp Cys Asn Phe Thr Arg Ala Ile Pro Phe Pro  
 65 70 75 80

Arg Leu Pro Xaa

<210> 93

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 93

Met Val Thr Leu Ser Ser Leu Ile Leu Glu Met Trp Tyr Cys Phe Trp  
 1 5 10 15

Leu Asn Ile Leu Val Gly Arg Val Ser Ser Arg Gly Phe His Leu Ala  
 20 25 30

Leu Thr Ile Lys Met Thr Leu Ile Ser Trp Val Arg Lys Pro Ile Trp  
 35 40 45

Glu Leu Cys Gln Xaa  
 50

<210> 94

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 94

Met Pro Ile His Arg Phe Ser Val Leu Ala Leu Leu Val Met Pro Pro  
 1 5 10 15

Leu Met Asn Gly Arg Gln Val Gln Val Lys Glu Trp Cys Phe Trp Asn  
 20 25 30

Pro Xaa



&lt;210&gt; 95

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (18)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 95

Met	Ser	Ser	Leu	Leu	Ile	Ile	Ile	Leu	Ala	Leu	Ser	Leu	Ala	Tyr
1				5				10					15	

Glu Xaa

&lt;210&gt; 96

&lt;211&gt; 61

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (61)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 96

Met	Ser	Pro	Thr	Gly	Leu	Leu	Val	Val	Phe	Ala	Pro	Val	Val	Leu	Gly
1				5					10					15	

Leu	Lys	Ala	Ile	Thr	Leu	Ala	Ala	Leu	Leu	Ala	Leu	Ala	Thr	Ser
			20					25					30	

Arg	Arg	Ser	Pro	Gly	Gln	Glu	Asp	Val	Lys	Thr	Thr	Gly	Pro	Ala	Gly
		35					40					45			

Ala	Met	Asn	Thr	Leu	Ala	Trp	Ser	Lys	Gly	Gln	Glu	Xaa
	50					55					60	

&lt;210&gt; 97

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (45)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 97

Met Phe Ser Cys Met Ser Asn Leu Ile Tyr Leu Leu Pro Val Thr Tyr  
 1 5 10 15

Leu Ile Met Trp Leu Leu Ile Gly Ser His Ser Pro Phe Leu Ser Arg  
 20 25 30

Tyr Ser Thr Thr Phe Gln Asn Ser His Trp Gln Val Xaa  
 35 40 45

&lt;210&gt; 98

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 98

Leu Pro Phe Leu Ser Leu Cys Cys Ala Met Ser Ser Ser Ser Pro Leu  
 1 5 10 15

Val Leu Gly Ala Trp Gln Glu Val Ala Ala Ile Gly Cys Phe Leu Asn  
 20 25 30

Glu Gly Ala Asn Gln Xaa  
 35

&lt;210&gt; 99

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (112)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 99

Met Thr Glu Ser Phe Tyr Pro Leu Asn Gln Arg Lys Gln Asn Glu Asn  
 1 5 10 15

Pro Ser Ala Val Leu Met His Leu Phe Leu Phe Ser Val Thr Met Gln  
 20 25 30

Gln Val Ala Arg Thr Val Ala Lys Val Glu Leu Ser Asp His Val Cys  
 35 40 45

Asp Val Val Phe Ala Leu Phe Asp Cys Asp Gly Asn Gly Glu Leu Ser  
 50 55 60

Asn Lys Glu Phe Val Ser Ile Met Lys Gln Arg Leu Met Arg Gly Leu  
65 70 75 80

Glu Lys Pro Lys Asp Met Gly Phe Thr Arg Leu Met Gln Ala Met Trp  
85 90 95

Lys Cys Ala Gln Glu Thr Ala Trp Asp Phe Ala Leu Pro Lys Gln Xaa  
100 105 110

<210> 100

<211> 360

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (360)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 100

Met Met Val Ile Phe Leu Val Gly Leu Val Ser Met Ile Leu Met Arg  
1 5 10 15

Thr Leu Arg Lys Asp Tyr Ala Arg Tyr Ser Lys Glu Glu Glu Met Asp  
20 25 30

Asp Met Asp Arg Asp Leu Gly Asp Glu Tyr Gly Trp Lys Gln Val His  
35 40 45

Gly Asp Val Phe Arg Pro Ser Ser His Pro Leu Ile Phe Ser Ser Leu  
50 55 60

Ile Gly Ser Gly Cys Gln Ile Phe Ala Val Ser Leu Ile Val Ile Ile  
65 70 75 80

Val Ala Met Ile Glu Asp Leu Tyr Thr Glu Arg Gly Ser Met Leu Ser  
85 90 95

Thr Ala Ile Phe Val Tyr Ala Ala Thr Ser Pro Val Asn Gly Tyr Phe  
100 105 110

Gly Gly Ser Leu Tyr Ala Arg Gln Gly Gly Arg Arg Trp Ile Lys Gln  
115 120 125

Met Phe Ile Gly Ala Phe Leu Ile Pro Ala Met Val Cys Gly Thr Ala  
130 135 140

Phe Phe Ile Asn Phe Ile Ala Ile Tyr Tyr His Ala Ser Arg Ala Ile  
145 150 155 160

Pro Phe Gly Thr Met Val Ala Val Cys Cys Ile Cys Phe Phe Val Ile  
165 170 175

Leu Pro Leu Asn Leu Val Gly Thr Ile Leu Gly Arg Asn Leu Ser Gly  
180 185 190

Gln Pro Asn Phe Pro Cys Arg Val Asn Ala Val Pro Arg Pro Ile Pro  
195 200 205

Glu Lys Lys Trp Phe Met Glu Pro Ala Val Ile Val Cys Leu Gly Gly  
210 215 220

Ile Leu Pro Phe Gly Ser Ile Phe Ile Glu Met Tyr Phe Ile Phe Thr  
225 230 235 240

Ser Phe Trp Ala Tyr Lys Ile Tyr Tyr Val Tyr Gly Phe Met Met Leu  
245 250 255

Val Leu Val Ile Leu Cys Ile Val Thr Val Cys Val Thr Ile Val Cys  
260 265 270

Thr Tyr Phe Leu Leu Asn Ala Glu Asp Tyr Arg Trp Gln Trp Thr Ser  
275 280 285

Phe Leu Ser Ala Ala Ser Thr Ala Ile Tyr Val Tyr Met Tyr Ser Phe  
290 295 300

Tyr Tyr Tyr Phe Phe Lys Thr Lys Met Tyr Gly Leu Phe Gln Thr Ser  
305 310 315 320

Phe Tyr Phe Gly Tyr Met Ala Val Phe Ser Thr Ala Leu Gly Ile Met  
325 330 335

Cys Gly Ala Ile Gly Tyr Met Gly Thr Ser Ala Phe Val Arg Lys Ile  
340 345 350

Tyr Thr Asn Val Lys Ile Asp Xaa  
355 360

<210> 101  
<211> 36  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (36)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 101  
Met Leu Phe Met Ala His Leu Leu Leu Arg Thr His Pro Leu Ser Leu  
1 5 10 15

Trp Val Thr Ser Arg Gln Ala Lys Asp Trp Cys Phe Ser Phe His Pro  
                   20                  25                  30

Leu Glu Gly Xaa  
                   35

<210> 102

<211> 54

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 102

Met Gly Gln Arg Gly Val Phe Leu Leu Ile Leu Asp Ala Phe Ser Val  
   1                  5                  10                  15

Pro Ser Thr Ala Ser Cys Leu Ile Thr Pro Leu Pro Pro Pro His Pro  
                   20                  25                  30

Gln Pro Ser Gln Phe Phe Leu Ala Ser Ala Leu Gln Pro Tyr Leu Gly  
                   35                  40                  45

Lys Glu Glu Trp Val Xaa  
                   50

<210> 103

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 103

Met Lys Ser Val Leu Ser Ile Cys Ser Phe Leu Gly Cys Ala Leu Ser  
   1                  5                  10                  15

Ala Val Ser Lys Lys Ser Leu Pro Asn Gln Arg Leu Gln Xaa  
                   20                  25                  30

<210> 104

<211> 46

<212> PRT

<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (46)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 104

Met	Gly	Phe	Ile	Gly	Leu	Met	Val	Ala	Met	Ile	Phe	Ile	Met	Leu	Phe
1				5					10					15	

Gly	Ser	Trp	Asp	His	Lys	Asn	Val	Cys	Leu	Phe	Leu	Glu	Tyr	Leu	Gly
			20					25					30		

Ser	Leu	Lys	Arg	Lys	Gly	Ile	Lys	Lys	Pro	Leu	His	Leu	Xaa
	35						40						45

&lt;210&gt; 105

&lt;211&gt; 78

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (78)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 105

Leu	Leu	Ile	Thr	Ile	Leu	Leu	Gly	Leu	Tyr	Phe	Thr	Leu	Leu	Gln	Ala
1				5					10					15	

Ser	Glu	Tyr	Phe	Glu	Ser	Pro	Phe	Thr	Ile	Ser	Asp	Gly	Ile	Tyr	Gly
			20						25					30	

Ser	Thr	Phe	Phe	Val	Ala	Thr	Gly	Phe	His	Gly	Leu	His	Val	Ile	Ile
			35					40						45	

Gly	Ser	Thr	Phe	Leu	Thr	Ile	Cys	Phe	Ile	Arg	Gln	Leu	Ile	Phe	His
		50					55							60	

Phe	Thr	Ser	Lys	His	His	Phe	Gly	Phe	Glu	Ala	Ala	Ala	Xaa
	65					70							75

&lt;210&gt; 106

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 106

Met Ala Arg Asn Val Trp Phe Phe Ile Val Ser Phe Cys Tyr Lys Phe  
 1 5 10 15

Leu Ser Tyr Phe Arg Ala Ser Ser Thr Leu Lys Val Xaa  
 20 25

&lt;210&gt; 107

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 107

Met Arg Ser Leu Gly Ser Thr Leu Val Ser Asp Thr Trp Asp Arg Gly  
 1 5 10 15

Ala Phe Ala Thr Leu Val Val Val Thr Pro Pro His Leu Pro Ala Ser  
 20 25 30

Phe Thr Asp Ser Lys Xaa  
 35

&lt;210&gt; 108

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (19)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 108

Met Cys Ile Gln Leu Leu Leu Leu Leu Val Trp Gly Arg Gly Leu  
 1 5 10 15

Glu Ser Xaa

&lt;210&gt; 109

&lt;211&gt; 298

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 109

Met Val Cys Lys Ala Leu Ile Thr Leu Cys Ile Phe Ala Ala Gly Leu

62

1	5	10	15
Met Val Gln Gly Ser Pro Thr Pro Thr Leu Leu Pro Val Ser Leu Thr	20	25	30
Thr Lys Ser Thr Ala Pro Met Ala Thr Trp Thr Thr Ser Ala Gln His	35	40	45
Thr Ala Met Ala Thr Thr Pro Val Ala Ser Ala Thr His Asn Ala Ser	50	55	60
Val Leu Arg Thr Thr Ala Ala Ser Leu Thr Ser Gln Leu Pro Thr His	65	70	75
Pro Arg Glu Glu Ala Val Thr Ser Pro Pro Leu Lys Arg Glu Val Asn	85	90	95
Ser Thr Asp Ser Ser Pro Thr Gly Phe Ser Ser Asn Ser Ser Gly Ile	100	105	110
His Leu Ala Pro Thr Pro Glu Glu His Ser Leu Gly Ser Pro Glu Thr	115	120	125
Ser Val Pro Ala Thr Gly Ser Gln Ser Pro Thr Leu Leu Phe Ser Gln	130	135	140
Gly Pro Thr Ser Ala Ser Thr Ser Pro Ala Thr Ser Pro Ser Glu Pro	145	150	155
Leu Ser Ala Ser Val Thr Ser Asn His Ser Ser Thr Val Asn Asn Ile	165	170	175
Gln Pro Thr Gly Ala Pro Met Ala Pro Ala Ser Pro Thr Glu Glu His	180	185	190
Ser Ser Ser His Thr Pro Thr Ser His Val Thr Glu Pro Val Pro Lys	195	200	205
Glu Lys Ser Pro Gln Asp Thr Glu Pro Gly Lys Val Ile Cys Glu Ser	210	215	220
Glu Thr Thr Thr Pro Phe Leu Ile Met Gln Glu Val Glu Asn Ala Leu	225	230	235
Ser Ser Gly Ser Ile Ala Ala Ile Thr Val Thr Val Ile Ala Val Val	245	250	255
Leu Leu Val Phe Gly Ala Ala Ala Tyr Leu Lys Ile Arg His Ser Ser	260	265	270
Tyr Gly Arg Leu Leu Asp Asp His Asp Tyr Gly Ser Gly Ser Trp Gly	275	280	285
Asn Tyr Asn Asn Pro Leu Tyr Asp Asp Ser			



290

295

&lt;210&gt; 110

&lt;211&gt; 310

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (40)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (127)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 110

Met	Val	Tyr	Lys	Thr	Leu	Phe	Ala	Leu	Cys	Ile	Leu	Thr	Ala	Gly	Trp
1				5					10					15	

Arg	Val	Gln	Ser	Leu	Pro	Thr	Ser	Ala	Pro	Leu	Ser	Val	Ser	Leu	Pro
		20						25					30		

Thr	Asn	Ile	Val	Pro	Xaa	Thr	Xaa	Ile	Trp	Thr	Ser	Ser	Pro	Gln	Asn
	35					40						45			

Thr	Asp	Ala	Asp	Thr	Ala	Ser	Pro	Ser	Asn	Gly	Thr	His	Asn	Asn	Ser
	50					55					60				

Val	Leu	Pro	Val	Thr	Ala	Ser	Ala	Pro	Thr	Ser	Leu	Leu	Pro	Lys	Asn
	65				70					75					80

Ile	Ser	Ile	Glu	Ser	Arg	Glu	Glu	Glu	Ile	Thr	Ser	Pro	Gly	Ser	Asn
				85					90					95	

Trp	Glu	Gly	Thr	Asn	Thr	Asp	Pro	Ser	Pro	Ser	Gly	Phe	Ser	Ser	Thr
		100					105						110		

Ser	Gly	Gly	Val	His	Leu	Thr	Thr	Thr	Leu	Glu	Glu	His	Ser	Xaa	Gly
		115				120						125			

Thr	Pro	Glu	Ala	Gly	Val	Ala	Ala	Thr	Leu	Ser	Gln	Ser	Ala	Ala	Glu
	130					135					140				

Pro	Pro	Thr	Leu	Ile	Ser	Pro	Gln	Ala	Pro	Ala	Ser	Ser	Pro	Ser	Ser
	145				150				155					160	

Leu Ser Thr Ser Pro Pro Glu Val Phe Ser Ala Ser Val Thr Thr Asn  
 165 170 175  
 His Ser Ser Thr Val Thr Ser Thr Gln Pro Thr Gly Ala Pro Thr Ala  
 180 185 190  
 Pro Glu Ser Pro Thr Glu Glu Ser Ser Ser Asp His Thr Pro Thr Ser  
 195 200 205  
 His Ala Thr Ala Glu Pro Val Pro Gln Glu Lys Thr Pro Pro Thr Thr  
 210 215 220  
 Val Ser Gly Lys Val Met Cys Glu Leu Ile Asp Met Glu Thr Thr Thr  
 225 230 235 240  
 Thr Phe Pro Arg Val Ile Met Gln Glu Val Glu His Ala Leu Ser Ser  
 245 250 255  
 Gly Ser Ile Ala Ala Ile Thr Val Thr Val Ile Ala Val Val Leu Leu  
 260 265 270  
 Val Phe Gly Val Ala Ala Tyr Leu Lys Ile Arg His Ser Ser Tyr Gly  
 275 280 285  
 Arg Leu Leu Asp Asp His Asp Tyr Gly Ser Trp Gly Asn Tyr Asn Asn  
 290 295 300  
 Pro Leu Tyr Asp Asp Ser  
 305 310  
  
 <210> 111  
 <211> 437  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 111  
 Lys Asp Glu Phe Glu Glu Arg Ala Lys Ala Ile Ile Val Glu Phe Ala  
 1 5 10 15  
 Gln Gln Gly Leu Asn Ala Ala Leu Phe Tyr Glu Asn Lys Asp Pro Arg  
 20 25 30  
 Thr Phe Val Ser Leu Val Pro Thr Ser Ala His Thr Gly Asp Gly Met  
 35 40 45  
 Gly Ser Leu Ile Tyr Leu Leu Val Glu Leu Thr Gln Thr Met Leu Ser  
 50 55 60  
 Lys Arg Leu Ala His Cys Glu Glu Leu Arg Ala Gln Val Met Glu Val  
 65 70 75 80  
 Lys Ala Leu Pro Gly Met Gly Thr Thr Ile Asp Val Ile Leu Ile Asn  
 85 90 95

Gly Arg Leu Lys Glu Gly Asp Thr Ile Ile Val Pro Gly Val Glu Gly  
 100 105 110

---

Pro Ile Val Thr Gln Ile Arg Gly Leu Leu Leu Pro Pro Pro Met Lys  
 115 120 125

Glu Leu Arg Val Lys Asn Gln Tyr Glu Lys His Lys Glu Val Glu Ala  
 130 135 140

Ala Gln Gly Val Lys Ile Leu Gly Lys Asp Leu Glu Lys Thr Leu Ala  
 145 150 155 160

Gly Leu Pro Leu Leu Val Ala Tyr Lys Glu Asp Glu Ile Pro Val Leu  
 165 170 175

Lys Asp Glu Leu Ile His Glu Leu Lys Gln Thr Leu Asn Ala Ile Lys  
 180 185 190

Leu Glu Glu Lys Gly Val Tyr Val Gln Ala Ser Thr Leu Gly Ser Leu  
 195 200 205

Glu Ala Leu Leu Glu Phe Leu Lys Thr Ser Glu Val Pro Tyr Ala Gly  
 210 215 220

Ile Asn Ile Gly Pro Val His Lys Lys Asp Val Met Lys Ala Ser Val  
 225 230 235 240

Met Leu Glu His Asp Pro Gln Tyr Ala Val Ile Leu Ala Phe Asp Val  
 245 250 255

Arg Ile Glu Arg Asp Ala Gln Glu Met Ala Asp Ser Leu Gly Val Arg  
 260 265 270

Ile Phe Ser Ala Glu Ile Ile Tyr His Leu Phe Asp Ala Phe Thr Lys  
 275 280 285

Tyr Arg Gln Asp Tyr Lys Lys Gln Lys Gln Glu Glu Phe Lys His Ile  
 290 295 300

Ala Val Phe Pro Cys Lys Ile Lys Ile Leu Pro Gln Tyr Ile Phe Asn  
 305 310 315 320

Ser Arg Asp Pro Ile Val Met Gly Val Thr Val Glu Ala Gly Gln Val  
 325 330 335

Lys Gln Gly Thr Pro Met Cys Val Pro Ser Lys Asn Phe Val Asp Ile  
 340 345 350

Gly Ile Val Thr Ser Ile Glu Ile Asn His Lys Gln Val Asp Val Ala  
 355 360 365

Lys Lys Gly Gln Glu Val Cys Val Lys Ile Glu Pro Ile Pro Gly Glu  
 370 375 380

Ser Pro Lys Met Phe Gly Arg His Phe Glu Ala Thr Asp Ile Leu Val  
 385 390 395 400

Ser Lys Ile Ser Arg Gln Ser Ile Asp Ala Leu Lys Asp Trp Phe Arg  
 405 410 415

Asp Glu Met Gln Lys Ser Asp Trp Gln Leu Ile Val Glu Leu Lys Lys  
 420 425 430

Val Phe Glu Ile Ile  
 435

<210> 112

<211> 437

<212> PRT

<213> Homo sapiens

<400> 112

Lys Asp Glu Phe Glu Glu Arg Ala Lys Ala Ile Ile Val Glu Phe Ala  
 1 5 10 15

Gln Gln Gly Leu Asn Ala Ala Leu Phe Tyr Glu Asn Lys Asp Pro Arg  
 20 25 30

Thr Phe Val Ser Leu Val Pro Thr Ser Ala His Thr Gly Asp Gly Met  
 35 40 45

Gly Ser Leu Ile Tyr Leu Leu Val Glu Leu Thr Gln Thr Met Leu Ser  
 50 55 60

Lys Arg Leu Ala His Cys Glu Glu Leu Arg Ala Gln Val Met Glu Val  
 65 70 75 80

Lys Ala Leu Pro Gly Met Gly Thr Thr Ile Asp Val Ile Leu Ile Asn  
 85 90 95

Gly Arg Leu Lys Glu Gly Asp Thr Ile Ile Val Pro Gly Val Glu Gly  
 100 105 110

Pro Ile Val Thr Gln Ile Arg Gly Leu Leu Leu Pro Pro Pro Met Lys  
 115 120 125

Glu Leu Arg Val Lys Asn Gln Tyr Glu Lys His Lys Glu Val Glu Ala  
 130 135 140

Ala Gln Gly Val Lys Ile Leu Gly Lys Asp Leu Glu Lys Thr Leu Ala  
 145 150 155 160

Gly Leu Pro Leu Leu Val Ala Tyr Lys Glu Asp Glu Ile Pro Val Leu  
 165 170 175

Lys Asp Glu Leu Ile His Glu Leu Lys Gln Thr Leu Asn Ala Ile Lys

180	185	190
Leu Glu Glu Lys Gly Val Tyr Val Gln Ala Ser Thr Leu Gly Ser Leu		
195	200	205
<hr/>		
Glu Ala Leu Leu Glu Phe Leu Lys Thr Ser Glu Val Pro Tyr Ala Gly		
210	215	220
Ile Asn Ile Gly Pro Val His Lys Lys Asp Val Met Lys Ala Ser Val		
225	230	235
Met Leu Glu His Asp Pro Gln Tyr Ala Val Ile Leu Ala Phe Asp Val		
245	250	255
Arg Ile Glu Arg Asp Ala Gln Glu Met Ala Asp Ser Leu Gly Val Arg		
260	265	270
Ile Phe Ser Ala Glu Ile Ile Tyr His Leu Phe Asp Ala Phe Thr Lys		
275	280	285
Tyr Arg Gln Asp Tyr Lys Lys Gln Lys Gln Glu Glu Phe Lys His Ile		
290	295	300
Ala Val Phe Pro Cys Lys Ile Lys Ile Leu Pro Gln Tyr Ile Phe Asn		
305	310	315
Ser Arg Asp Pro Ile Val Met Gly Val Thr Val Glu Ala Gly Gln Val		
325	330	335
Lys Gln Gly Thr Pro Met Cys Val Pro Ser Lys Asn Phe Val Asp Ile		
340	345	350
Gly Ile Val Thr Ser Ile Glu Ile Asn His Lys Gln Val Asp Val Ala		
355	360	365
Lys Lys Gly Gln Glu Val Cys Val Lys Ile Glu Pro Ile Pro Gly Glu		
370	375	380
Ser Pro Lys Met Phe Gly Arg His Phe Glu Ala Thr Asp Ile Leu Val		
385	390	395
Ser Lys Ile Ser Arg Gln Ser Ile Asp Ala Leu Lys Asp Trp Phe Arg		
405	410	415
Asp Glu Met Gln Lys Ser Asp Trp Gln Leu Ile Val Glu Leu Lys Lys		
420	425	430
Val Phe Glu Ile Ile		
435		

&lt;210&gt; 113

&lt;211&gt; 393

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

Ser Ala Leu Asn His Gln Ile Ile Val Val Gly Gly Gly Ala Ala Gly  
 1 5 10 15  
 Ile Thr Val Ala Ala Gln Leu Leu Lys Gln Lys Pro Lys Leu Asp Leu  
 20 25 30  
 Ala Ile Val Glu Pro Cys Asp Lys His Tyr Tyr Gln Pro Ala Trp Thr  
 35 40 45  
 Leu Val Gly Gly Gly Ala Phe Ala Met Glu Asp Thr Ile Lys Pro Glu  
 50 55 60  
 Gln Asp Cys Ile Pro Ser Gly Ala Lys Trp Ile Lys Ala Ser Val Ala  
 65 70 75 80  
 Ser Phe Asp Pro Glu Asn Asn Cys Leu Thr Leu Gln Asp Gly Arg Ser  
 85 90 95  
 Leu Ser Tyr Glu Tyr Leu Val Val Cys Pro Gly Ile Gln Ile Asn Trp  
 100 105 110  
 His Leu Ile Pro Arg Leu Gln Glu Ser Leu Gly Lys Asn Gly Val Thr  
 115 120 125  
 Ser Asn Tyr Asp Arg Arg Tyr Ala Pro Tyr Thr Trp Glu Leu Leu Gln  
 130 135 140  
 Asn Phe Lys Gly Gly Asn Ala Leu Phe Thr Phe Pro Ala Thr Pro Ile  
 145 150 155 160  
 Lys Cys Ala Gly Ala Pro Gln Lys Ile Met Tyr Leu Ala Asp Glu Thr  
 165 170 175  
 Phe Arg Lys Asn Gly Val Arg Glu Lys Thr Asn Ile Thr Tyr Gly Val  
 180 185 190  
 Ala Val Gly Lys Ile Phe Gly Ile Pro Gly Tyr Cys Glu Ser Leu Glu  
 195 200- 205  
 Lys Val Ala Ala Lys Lys Asn Ile Asp Val Arg Tyr His His Asn Leu  
 210 215 220  
 Lys Ala Ile Asn Pro Asn Ala Lys Glu Ala Thr Phe Thr Val Asn Gly  
 225 230 235 240  
 Lys Thr Glu Val Thr Leu Pro Tyr Asp Ile Ile His Val Thr Pro Pro  
 245 250 255  
 Met Ser Ala Pro Asp Phe Ile Lys Asn Ser Pro Leu Ala Ala Glu Ala  
 260 265 270

Gly Gly Trp Val Asp Val Asp Lys Phe Thr Leu Gln His Asn Arg Tyr  
 275 280 285

Asp Asn Val Phe Ser Leu Gly Asp Ala Ser Ser Leu Pro Thr Ser Arg  
 290 295 300

Thr Ala Ala Ala Val Arg Lys Gln Ala Pro Val Val Ala Thr Asn Leu  
 305 310 315 320

Leu Gly Leu Leu Asn Ser Lys Lys Pro Ser Ala Glu Tyr Gly Gly Tyr  
 325 330 335

Thr Cys Cys Pro Leu Val Thr Gly Tyr Gly Lys Thr Ile Met Ala Glu  
 340 345 350

Phe Asp Tyr Gly Gly Gln Pro Lys Ser Ser Phe Pro Phe Asp Pro Thr  
 355 360 365

Gln Glu Arg Trp Ser Met Trp Leu Val Lys Arg Tyr Val Leu Pro Trp  
 370 375 380

Leu Tyr Trp Asn Arg Met Leu Lys Gly  
 385 390

<210> 114

<211> 395

<212> PRT

<213> Homo sapiens

<400> 114

Ala Ala Arg Asn His Tyr Glu Val Leu Val Leu Gly Gly Gly Ser Gly  
 1 5 10 15

Gly Ile Thr Met Ala Ala Arg Met Lys Arg Lys Val Gly Ala Glu Asn  
 20 25 30

Val Ala Ile Val Glu Pro Ser Glu Arg His Phe Tyr Gln Pro Ile Trp  
 35 40 45

Thr Leu Val Gly Ala Gly Ala Lys Gln Leu Ser Ser Ser Gly Arg Pro  
 50 55 60

Thr Ala Ser Val Ile Pro Ser Gly Val Glu Trp Ile Lys Ala Arg Val  
 65 70 75 80

Thr Glu Leu Asn Pro Asp Lys Asn Cys Ile His Thr Asp Asp Asp Glu  
 85 90 95

Lys Ile Ser Tyr Arg Tyr Leu Ile Ile Ala Leu Gly Ile Gln Leu Asp  
 100 105 110

Tyr Glu Lys Ile Lys Gly Leu Pro Glu Gly Phe Ala His Pro Lys Ile  
 115 120 125

Gly Ser Asn Tyr Ser Val Lys Thr Val Glu Lys Thr Trp Lys Ala Leu  
 130 135 140  
 Gln Asp Phe Lys Glu Gly Asn Ala Ile Phe Thr Phe Pro Asn Thr Pro  
 145 150 155 160  
 Val Lys Cys Ala Gly Ala Pro Gln Lys Ile Met Tyr Leu Ser Glu Ala  
 165 170 175  
 Tyr Phe Arg Lys Thr Gly Lys Arg Ser Lys Ala Asn Ile Ile Phe Asn  
 180 185 190  
 Thr Ser Leu Gly Ala Ile Phe Gly Val Lys Lys Tyr Ala Asp Ala Leu  
 195 200 205  
 Gln Glu Ile Ile Gln Glu Arg Asn Leu Thr Val Asn Tyr Lys Lys Asn  
 210 215 220  
 Leu Ile Glu Val Arg Ala Asp Lys Gln Glu Ala Val Phe Glu Asn Leu  
 225 230 235 240  
 Asp Lys Pro Gly Glu Thr Gln Val Ile Ser Tyr Glu Met Leu His Val  
 245 250 255  
 Thr Pro Pro Met Ser Pro Pro Asp Val Leu Lys Thr Ser Pro Val Ala  
 260 265 270  
 Asp Ala Ala Gly Trp Val Asp Val Asp Lys Glu Thr Leu Gln His Arg  
 275 280 285  
 Arg Tyr Pro Asn Val Phe Gly Ile Gly Asp Cys Thr Asn Leu Pro Thr  
 290 295 300  
 Ser Lys Thr Ala Ala Ala Val Ala Ala Gln Ser Gly Ile Leu Asp Arg  
 305 310 315 320  
 Thr Ile Ser Val Ile Met Lys Asn Gln Thr Pro Thr Lys Lys Tyr Asp  
 325 330 335  
 Gly Tyr Thr Ser Cys Pro Leu Val Thr Gly Tyr Asn Arg Val Ile Leu  
 340 345 350  
 Ala Glu Phe Asp Tyr Lys Ala Glu Pro Leu Glu Thr Phe Pro Phe Asp  
 355 360 365  
 Gln Ser Lys Glu Arg Leu Ser Met Tyr Leu Met Lys Ala Asp Leu Met  
 370 375 380  
 Pro Phe Leu Tyr Trp Asn Met Met Leu Arg Gly  
 385 390 395

&lt;210&gt; 115



&lt;211&gt; 365

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 115

```

Ile Lys Ser Asn Pro Asp Leu Gln Lys Lys Ile Lys Val Leu Lys Asp
 1              5              10              15

Ala Phe Ala Gly Lys Leu Pro Glu Pro Ser Lys Asn Ala Ala Lys Thr
      20              25              30

Gly Ala Gly Glu Val Asn Gly Asp Val Gly Asp Glu Asp Leu Leu Pro
      35              40              45

Gly Tyr Leu Asn Asp Ile Pro Arg His Gly Met Phe Val Lys Gly Leu
      50              55              60

Ile Leu Leu Val Asn Asp Thr Ala Ala Val Ala Tyr Asp Pro Thr Glu
      65              70              75              80

Asn Glu Cys Tyr Leu Thr Ala Leu Ala Glu Gln Ile Pro Arg Asn His
      85              90              95

Ser Ser Ile Val Thr Gln Gln Asn Gln Ile Tyr Val Val Gly Gly Leu
      100              105              110

Tyr Val Asp Glu Lys Asn Lys Val Gln Pro Leu Gln Ser Tyr Phe Phe
      115              120              125

Gln Leu Asp Ser Ile Ala Ser Glu Trp Val Gly Leu Pro Pro Leu Pro
      130              135              140

Ser Ala Arg Cys Leu Phe Gly Leu Gly Glu Val Asp Asp Lys Ile Tyr
      145              150              155              160

Val Val Ala Gly Lys Asp Leu Gln Thr Glu Ala Ser Leu Asp Ser Val
      165              170              175

Leu Cys Tyr Asp Pro Val Ala Ala Lys Trp Asn Glu Val Lys Lys Leu
      180              185              190

Pro Ile Lys Val Tyr Gly His Asn Val Ile Ser His Lys Gly Met Ile
      195              200              205

Tyr Cys Leu Gly Gly Lys Thr Asp Asp Lys Lys Cys Thr Asn Arg Val
      210              215              220

Phe Ile Phe Asn Pro Lys Lys Gly Asp Trp Lys Asp Leu Ala Pro Met
      225              230              235              240

Lys Ile Pro Arg Ser Met Phe Gly Val Ala Val His Lys Gly Lys Ile
      245              250              255

Val Ile Ala Gly Gly Val Thr Glu Asp Gly Leu Ser Ala Ser Val Glu

```

260	265	270
Ala Phe Asp Leu Thr Thr Asn Lys Trp Asp Val Met Thr Glu Phe Pro		
275	280	285
Gln Glu Arg Ser Ser Ile Ser Leu Val Ser Leu Ala Gly Ser Leu Tyr		
290	295	300
Ala Ile Gly Gly Phe Ala Met Ile Gln Leu Glu Ser Lys Glu Phe Ala		
305	310	315
Pro Thr Glu Val Asn Asp Ile Trp Lys Tyr Glu Asp Asp Lys Lys Glu		
	325	330
Trp Ala Gly Met Leu Lys Glu Ile Arg Tyr Ala Ser Gly Ala Ser Cys		
	340	345
		350
Leu Ala Thr Arg Leu Asn Leu Phe Lys Leu Ser Lys Leu		
355	360	365

&lt;210&gt; 116

&lt;211&gt; 366

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

Leu Lys Ala Thr Gln Thr Ser Arg Lys Lys Ile Lys Val Leu Lys Asp
1 5 10 15
Ala Phe Ala Gly Lys Leu Pro Arg Thr Leu Ala Lys Met Pro Arg Lys
20 25 30
Thr Gly Ala Gly Glu Val Asn Gly Asp Val Gly Asp Glu Asp Leu Leu
35 40 45
Pro Gly Tyr Leu Asn Asp Ile Pro Arg His Gly Met Phe Val Lys Asp
50 55 60
Leu Ile Leu Leu Val Asn Asp Thr Ala Ala Val Ala Tyr Asp Pro Thr
65 70 75 80
Glu Asn Glu Cys Tyr Leu Thr Ala Leu Ala Glu Gln Ile Pro Arg Asn
85 90 95
His Ser Ser Ile Val Thr Gln Gln Asn Gln Ile Tyr Val Val Gly Gly
100 105 110
Leu Tyr Val Asp Glu Glu Asn Lys Asp Gln Pro Leu Gln Ser Tyr Phe
115 120 125
Phe Gln Leu Asp Ser Ile Ala Ser Glu Trp Val Gly Leu Pro Pro Leu
130 135 140

Pro Ser Ala Arg Cys Leu Phe Gly Leu Gly Glu Val Asp Asp Lys Ile  
145 150 155 160

Tyr Val Val Ala Gly Lys Asp Leu Gln Thr Glu Ala Ser Leu Asp Ser  
165 170 175

Val Leu Cys Tyr Asp Pro Val Ala Ala Lys Trp Asn Glu Val Lys Lys  
180 185 190

Leu Pro Ile Lys Val Tyr Gly His Asn Val Ile Ser His Lys Gly Met  
195 200 205

Ile Tyr Cys Leu Gly Gly Lys Thr Asp Asp Lys Lys Cys Thr Asn Arg  
210 215 220

Val Phe Ile Phe Asn Pro Lys Lys Gly Asp Trp Lys Asp Leu Ala Pro  
225 230 235 240

Met Lys Ile Pro Arg Ser Met Phe Gly Val Ala Val His Lys Gly Lys  
245 250 255

Ile Val Ile Ala Gly Gly Val Thr Glu Asp Gly Leu Ser Ala Ser Val  
260 265 270

Glu Ala Phe Asp Leu Thr Thr Asn Lys Trp Asp Val Met Thr Glu Phe  
275 280 285

Pro Gln Glu Arg Ser Ser Ile Ser Leu Val Ser Leu Ala Gly Ser Leu  
290 295 300

Tyr Ala Ile Gly Gly Phe Ala Met Ile Gln Leu Glu Ser Lys Glu Phe  
305 310 315 320

Ala Pro Thr Glu Val Asn Asp Ile Trp Lys Tyr Glu Asp Asp Lys Lys  
325 330 335

Glu Trp Ala Gly Met Leu Lys Glu Ile Arg Tyr Ala Ser Gly Ala Ser  
340 345 350

Cys Leu Ala Thr Arg Leu Asn Leu Phe Lys Leu Ser Lys Leu  
355 360 365

<210> 117

<211> 193

<212> PRT

<213> Homo sapiens

<400> 117

Arg Thr Asp Arg Leu Glu Val Cys Arg Glu Tyr Gln Arg Gly Asn Cys  
1 5 10 15

Asn Arg Gly Glu Asn Asp Cys Arg Phe Ala His Pro Ala Asp Ser Thr  
20 25 30

Met Ile Asp Thr Asn Asp Asn Thr Val Thr Val Cys Met Asp Tyr Ile  
                   35                                  40                                  45

Lys Gly Arg Cys Ser Arg Glu Lys Cys Lys Tyr Phe His Pro Pro Ala  
                   50                                  55                                  60

His Leu Gln Ala Lys Ile Lys Ala Ala Gln Tyr Gln Val Asn Gln Ala  
                   65                                  70                                  75                                  80

Ala Ala Ala Gln Ala Ala Ala Thr Ala Ala Met Gly Ile Pro Gln  
                                   85                                  90                                  95

Ala Val Leu Pro Pro Leu Pro Lys Arg Pro Ala Leu Glu Lys Thr Asn  
                   100                                  105                                  110

Gly Ala Thr Ala Val Phe Asn Thr Gly Ile Phe Gln Tyr Gln Gln Ala  
                   115                                  120                                  125

Leu Ala Asn Met Gln Leu Gln Gln His Thr Ala Phe Leu Pro Pro Val  
                   130                                  135                                  140

Pro Met Val His Gly Ala Thr Pro Ala Thr Val Ser Ala Ala Thr Thr  
                   145                                  150                                  155                                  160

Ser Ala Thr Ser Val Pro Phe Ala Ala Thr Ala Thr Ala Asn Gln Ile  
                                   165                                  170                                  175

Pro Ile Ile Ser Ala Glu His Leu Thr Ser His Lys Tyr Val Thr Gln  
                   180                                  185                                  190

Met

&lt;210&gt; 118

&lt;211&gt; 205

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

Arg Thr Asp Arg Leu Glu Val Cys Arg Glu Tyr Gln Arg Gly Asn Cys  
                   1                                  5                                  10                                  15

Asn Arg Gly Glu Asn Asp Cys Arg Phe Ala His Pro Ala Asp Ser Thr  
                                   20                                  25                                  30

Met Ile Asp Thr Asn Asp Asn Thr Val Thr Val Cys Met Asp Tyr Ile  
                   35                                  40                                  45

Lys Gly Arg Cys Ser Arg Glu Lys Cys Lys Tyr Phe His Pro Pro Ala  
                   50                                  55                                  60

His Leu Gln Ala Lys Ile Lys Ala Ala Gln Tyr Gln Val Asn Gln Ala

75

65		70		75		80
Ala Ala Ala Gln	Ala Ala Ala Thr	Ala Ala Met Gly	Ile Pro Gln			
	85	90	95			
Ala Val Leu Pro	Pro Leu Pro Lys	Arg Pro Ala Leu	Glu Lys Thr Asn			
	100	105	110			
Gly Ala Thr Ala	Val Phe Asn Thr	Gly Ile Phe Gln	Tyr Gln Gln Ala			
	115	120	125			
Leu Ala Asn Met	Gln Leu Gln Gln	His Thr Ala Phe	Leu Pro Pro Gly			
	130	135	140			
Ser Ile Leu Cys	Met Thr Pro Ala	Thr Ser Val Val	Pro Met Val His			
	145	150	155	160		
Gly Ala Thr Pro	Ala Thr Val Ser	Ala Ala Thr Thr	Ser Ala Thr Ser			
	165	170	175			
Val Pro Phe Ala	Ala Thr Ala Thr	Ala Asn Gln Ile	Pro Ile Ile Ser			
	180	185	190			
Ala Glu His Leu	Thr Ser His Lys	Tyr Val Thr Gln	Met			
	195	200	205			

&lt;210&gt; 119

&lt;211&gt; 167

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

Leu Ile Val Val	Thr Leu Ala Val	Cys Trp Met Pro	Asn Gln Ile Arg
1	5	10	15

Arg Ile Met Ala	Ala Ala Lys Pro	Lys His Asp Trp	Thr Arg Ser Tyr
20	25	30	

Phe Arg Ala Tyr	Met Ile Leu Leu	Pro Phe Ser Glu	Thr Phe Phe Tyr
35	40	45	

Leu Ser Ser Val	Ile Asn Pro Leu	Leu Tyr Thr Val	Ser Ser Gln Gln
50	55	60	

Phe Arg Arg Val	Phe Val Gln Val	Leu Cys Cys Arg	Leu Ser Leu Gln
65	70	75	80

His Ala Asn His	Glu Lys Arg Leu	Arg Val His Ala	His Ser Thr Thr
85	90	95	

Asp Ser Ala Arg	Phe Val Gln Arg	Pro Leu Leu Phe	Ala Ser Arg Arg
100	105	110	

Gln Ser Ser Ala Arg Arg Thr Glu Lys Ile Phe Leu Ser Thr Phe Gln  
 115 120 125

Ser Glu Ala Glu Pro Gln Ser Lys Ser Gln Ser Leu Ser Leu Glu Ser  
 130 135 140

Leu Glu Pro Asn Ser Gly Ala Lys Pro Ala Asn Ser Ala Ala Glu Asn  
 145 150 155 160

Gly Phe Gln Glu His Glu Val  
 165

<210> 120

<211> 167

<212> PRT

<213> Homo sapiens

<400> 120

Leu Ile Val Val Thr Leu Ala Val Cys Trp Met Pro Asn Gln Ile Arg  
 1 5 10 15

Arg Ile Met Ala Ala Ala Lys Pro Lys His Asp Trp Thr Arg Ser Tyr  
 20 25 30

Phe Arg Ala Tyr Met Ile Leu Leu Pro Phe Ser Glu Thr Phe Phe Tyr  
 35 40 45

Leu Ser Ser Val Ile Asn Pro Leu Leu Tyr Thr Val Ser Ser Gln Gln  
 50 55 60

Phe Arg Arg Val Phe Val Gln Val Leu Cys Cys Arg Leu Ser Leu Gln  
 65 70 75 80

His Ala Asn His Glu Lys Arg Leu Arg Val His Ala His Ser Thr Thr  
 85 90 95

Asp Ser Ala Arg Phe Val Gln Arg Pro Leu Leu Phe Ala Ser Arg Arg  
 100 105 110

Gln Ser Ser Ala Arg Arg Thr Glu Lys Ile Phe Leu Ser Thr Phe Gln  
 115 120 125

Ser Glu Ala Glu Pro Gln Ser Lys Ser Gln Ser Leu Ser Leu Glu Ser  
 130 135 140

Leu Glu Pro Asn Ser Gly Ala Lys Pro Ala Asn Ser Ala Ala Glu Asn  
 145 150 155 160

Gly Phe Gln Glu His Glu Val  
 165

<210> 121

<211> 174  
 <212> PRT  
 <213> Homo sapiens

<400> 121

Lys Ile Arg Leu Pro Thr Gln Pro Ser Trp Tyr Val Gln Ser Phe Leu  
 1 5 10 15

Phe Ser Leu Cys Gln Glu Val Asn Arg Val Gly Gly His Ala Leu Pro  
 20 25 30

Lys Val Thr Leu Gln Glu Met Leu Glu Thr Cys Met Ala Gln Val Ile  
 35 40 45

Ala Ala Tyr Glu Gln Leu Thr Glu Glu Asn Gln Ile Lys Lys Glu Gly  
 50 55 60

Ala Phe Pro Met Thr Gln Asn Arg Ala Leu Gln Leu Leu Tyr Asp Leu  
 65 70 75 80

Arg Tyr Leu Thr Met Val Leu Ser Ser Lys Gly Glu Glu Val Lys Ser  
 85 90 95

Gly Arg Ser Lys Ala Asp Ser Arg Met Glu Lys Met Thr Glu Arg Leu  
 100 105 110

Glu Ala Leu Ile Asp Pro Phe Asp Leu Asp Val Phe Thr Pro His Leu  
 115 120 125

Asn Ser Asn Leu Asn Arg Leu Val Gln Arg Thr Ser Val Leu Phe Gly  
 130 135 140

Leu Val Thr Gly Thr Glu Asn Gln Phe Ala Ser Arg Ser Ser Thr Phe  
 145 150 155 160

Asn Ser Gln Glu Pro His Asn Ile Leu Pro Leu Ala Ser Ser  
 165 170

<210> 122  
 <211> 166  
 <212> PRT  
 <213> Homo sapiens

<400> 122

Lys Ile Arg Leu Pro Ala Gln Pro Ser Trp Tyr Val Gln Ser Phe Leu  
 1 5 10 15

Phe Ser Leu Cys Gln Glu Ile Asn Arg Val Gly Gly His Ala Leu Pro  
 20 25 30

Lys Val Thr Leu Gln Glu Met Leu Lys Ser Cys Met Val Gln Val Val  
 35 40 45

Ala Ala Tyr Glu Lys Leu Ser Glu Glu Lys Gln Ile Lys Lys Glu Gly  
 50 55 60

Ala Phe Pro Val Thr Gln Asn Arg Ala Leu Gln Leu Leu Tyr Asp Leu  
 65 70 75 80

Arg Tyr Leu Lys Gln Gln Pro Ser Ser Pro Gly Cys Ser Glu Leu Leu  
 85 90 95

Val Pro Val Leu Gly Leu Val Thr Gly Thr Glu Asn Gln Leu Ala Pro  
 100 105 110

Arg Ser Ser Thr Phe Asn Ser Gln Glu Pro His Asn Ile Leu Pro Leu  
 115 120 125

Ala Ser Ser Gln Ile Arg Phe Gly Leu Leu Pro Leu Ser Met Thr Ser  
 130 135 140

Thr Arg Lys Ala Lys Ser Thr Arg Asn Ile Glu Thr Lys Ala Gln Val  
 145 150 155 160

Val Pro Pro Ala Arg Ser  
 165

<210> 123  
 <211> 379  
 <212> PRT  
 <213> Homo sapiens

<400> 123  
 Arg Arg Phe Phe Asn Trp Phe Tyr Trp Ser Ile Asn Leu Gly Ala Ile  
 1 5 10 15

Leu Ser Leu Gly Gly Ile Ala Tyr Ile Gln Gln Asn Val Ser Phe Leu  
 20 25 30

Thr Gly Tyr Leu Ile Pro Thr Val Cys Val Ala Ile Ala Phe Leu Val  
 35 40 45

Phe Leu Cys Gly Gln Ser Val Phe Ile Thr Lys Pro Pro Asp Gly Ser  
 50 55 60

Ala Phe Thr Asp Met Phe Arg Ile Leu Thr Tyr Ser Cys Cys Ser Gln  
 65 70 75 80

Arg Gly Gly Gln Arg Arg Ser Gly Glu Gly Leu Gly Val Phe Gln Gln  
 85 90 95

Ser Ser Lys His Ser Leu Phe Asp Ser Cys Lys Met Ser Arg Gly Gly  
 100 105 110

Pro Phe Thr Glu Asp Lys Val Glu Asp Val Lys Ala Leu Val Lys Ile  
 115 120 125



Val Pro Val Phe Leu Ala Leu Ile Pro Tyr Trp Thr Val Tyr Phe Gln  
 130 135 140  
 Met Gln Thr Thr Tyr Val Leu Gln Ser Leu His Leu Lys Ile Pro Glu  
 145 150 155 160  
 Ile Ser Ser Ile Thr Thr Thr His His Thr Leu Pro Ala Ala Trp Leu  
 165 170 175  
 Thr Met Phe Asp Ala Val Leu Ile Leu Leu Ile Pro Leu Lys Asp  
 180 185 190  
 Lys Leu Val Asp Pro Val Leu Arg Arg His Gly Leu Leu Pro Ser Ser  
 195 200 205  
 Leu Lys Arg Ile Ala Val Gly Met Phe Phe Val Thr Cys Ser Ala Phe  
 210 215 220  
 Ala Ala Gly Ile Leu Glu Ser Lys Arg Leu Asp Leu Val Lys Glu Lys  
 225 230 235 240  
 Thr Ile Asn Gln Thr Ile Gly Gly Val Val Tyr His Ala Ala Asp Leu  
 245 250 255  
 Pro Ile Trp Trp Gln Ile Pro Gln Tyr Val Leu Ile Gly Ile Ser Glu  
 260 265 270  
 Ile Phe Ala Ser Ile Ala Gly Leu Glu Phe Ala Tyr Ser Ala Ala Pro  
 275 280 285  
 Lys Ser Met Gln Ser Ala Ile Met Gly Leu Phe Phe Phe Phe Ser Gly  
 290 295 300  
 Ile Gly Ser Phe Val Gly Ser Gly Leu Leu Ala Leu Val Ser Leu Lys  
 305 310 315 320  
 Ala Ile Gly Trp Met Ser Ser His Thr Asp Phe Gly Asn Ile Asn Ser  
 325 330 335  
 Cys His Leu His Tyr Tyr Phe Phe Leu Leu Ala Ala Ile Gln Gly Ala  
 340 345 350  
 Thr Leu Leu Leu Phe Leu Ile Val Ser Val Lys Tyr Asp Arg Gln Arg  
 355 360 365  
 Ala Arg Thr Asp Gly Gly Thr Ala Ser Thr Arg  
 370 375

&lt;210&gt; 124

&lt;211&gt; 385

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (48)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 124

Arg Arg Phe Phe Asn Trp Phe Tyr Trp Ser Ile Asn Leu Gly Ala Ile  
 1 5 10 15

Leu Ser Leu Gly Gly Ile Ala Tyr Ile Gln Gln Asn Val Ser Phe Val  
 20 25 30

Thr Gly Tyr Ala Ile Pro Thr Val Cys Val Gly Leu Ala Phe Val Xaa  
 35 40 45

Phe Leu Cys Gly Gln Ser Val Phe Ile Thr Lys Pro Pro Asp Gly Ser  
 50 55 60

Ala Phe Thr Asp Met Phe Lys Ile Leu Thr Tyr Ser Cys Cys Ser Gln  
 65 70 75 80

Lys Arg Ser Gly Glu Arg Gln Ser Asn Gly Glu Gly Ile Gly Val Phe  
 85 90 95

Gln Gln Ser Ser Lys Gln Ser Leu Phe Asp Ser Cys Lys Met Ser His  
 100 105 110

Gly Gly Pro Phe Thr Glu Glu Lys Val Glu Asp Val Lys Ala Leu Val  
 115 120 125

Lys Ile Val Pro Val Phe Leu Ala Leu Ile Pro Tyr Trp Thr Val Tyr  
 130 135 140

Phe Gln Met Gln Thr Thr Tyr Val Leu Gln Ser Leu His Leu Arg Ile  
 145 150 155 160

Pro Glu Ile Ser Asn Ile Thr Thr Thr Pro His Thr Leu Pro Ala Ala  
 165 170 175

Trp Leu Thr Met Phe Asp Ala Val Leu Ile Leu Leu Leu Ile Pro Leu  
 180 185 190

Lys Asp Lys Leu Val Asp Pro Ile Leu Arg Arg His Gly Leu Leu Pro  
 195 200 205

Ser Ser Leu Lys Arg Ile Ala Val Gly Met Phe Phe Val Met Cys Ser  
 210 215 220

Ala Phe Ala Ala Gly Ile Leu Glu Ser Lys Arg Leu Asn Leu Val Lys  
 225 230 235 240

Glu Lys Thr Ile Asn Gln Thr Ile Gly Asn Val Val Tyr His Ala Ala  
 245 250 255

Asp Leu Ser Leu Trp Trp Gln Val Pro Gln Tyr Leu Leu Ile Gly Ile  
 260 265 270

Ser Glu Ile Phe Ala Ser Ile Ala Gly Leu Glu Phe Ala Tyr Ser Ala  
 275 280 285

Ala Pro Lys Ser Met Gln Ser Ala Ile Met Gly Leu Phe Phe Phe Phe  
 290 295 300

Ser Gly Val Gly Ser Phe Val Gly Ser Gly Leu Leu Ala Leu Val Ser  
 305 310 315 320

Ile Lys Ala Ile Gly Trp Met Ser Ser His Thr Asp Phe Gly Asn Ile  
 325 330 335

Asn Gly Cys Tyr Leu Asn Tyr Tyr Phe Phe Leu Leu Ala Ala Ile Gln  
 340 345 350

Gly Ala Thr Leu Leu Leu Phe Leu Ile Ile Ser Val Lys Tyr Asp His  
 355 360 365

His Arg Asp His Gln Arg Ser Arg Ala Asn Gly Val Pro Thr Ser Arg  
 370 375 380

Arg  
 385

<210> 125

<211> 202

<212> PRT

<213> Homo sapiens

<400> 125

Lys Lys Pro His Val Phe Gln Leu Arg Thr Ala Asp Trp Arg Leu Tyr  
 1 5 10 15

Leu Phe Gln Ala Pro Thr Ala Lys Glu Met Ser Ser Trp Ile Ala Arg  
 20 25 30

Ile Asn Leu Ala Ala Ala Thr His Ser Ala Pro Pro Phe Pro Ala Ala  
 35 40 45

Val Gly Ser Gln Arg Arg Phe Val Arg Pro Ile Leu Pro Val Gly Pro  
 50 55 60

Ala Gln Ser Ser Leu Glu Glu Gln His Arg Ser His Glu Asn Cys Leu  
 65 70 75 80

Asp Ala Ala Ala Asp Asp Leu Leu Asp Leu Gln Arg Asn Leu Pro Glu  
 85 90 95

Arg Arg Gly Arg Gly Arg Glu Leu Glu Glu His Arg Leu Arg Lys Glu

100                      105                      110  
 Tyr Leu Glu Tyr Glu Lys Thr Arg Tyr Glu Thr Tyr Val Gln Leu Leu  
       115                      120                      125  
 Val Ala Arg Leu His Cys Pro Ser Asp Ala Leu Asp Leu Trp Glu Glu  
       130                      135                      140  
 Gln Leu Gly Arg Glu Ala Gly Gly Thr Arg Glu Pro Lys Leu Ser Leu  
       145                      150                      155                      160  
 Lys Lys Ser His Ser Ser Pro Ser Leu His Gln Asp Glu Ala Pro Thr  
                              165                      170                      175  
 Thr Ala Lys Val Lys Arg Asn Ile Ser Glu Arg Arg Thr Tyr Arg Lys  
                              180                      185                      190  
 Ile Ile Pro Lys Arg Asn Arg Asn Gln Leu  
                              195                      200  
  
 <210> 126  
 <211> 202  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (19)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (21)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 126  
 Gln Glu Ala His Val Phe Gln Leu Arg Thr Ala Asp Trp Arg Leu Tyr  
       1                      5                      10                      15  
 Leu Phe Xaa Ala Xaa Thr Ala Lys Glu Met Ser Ser Trp Ile Ala Arg  
                              20                      25                      30  
 Ile Asn Leu Ala Ala Ala Thr His Ser Ala Pro Pro Phe Pro Ala Ala  
                              35                      40                      45  
 Val Gly Ser Gln Arg Arg Phe Val Arg Pro Ile Leu Pro Val Gly Pro  
                              50                      55                      60  
 Ala Gln Ser Ser Leu Glu Glu Gln His Arg Ser His Glu Asn Cys Leu  
                              65                      70                      75                      80  
 Asp Ala Ala Ala Asp Asp Leu Leu Asp Leu Gln Arg Asn Leu Pro Glu  
                              85                      90                      95

Arg Arg Gly Arg Gly Arg Glu Leu Glu Glu His Arg Leu Arg Lys Glu  
 100 105 110

Tyr Leu Glu Tyr Glu Lys Thr Arg Tyr Glu Thr Tyr Val Gln Leu Leu  
 115 120 125

Val Ala Arg Leu His Cys Pro Ser Asp Ala Leu Asp Leu Trp Glu Glu  
 130 135 140

Gln Leu Gly Arg Glu Ala Gly Gly Thr Arg Glu Pro Lys Leu Ser Leu  
 145 150 155 160

Lys Lys Ser His Ser Ser Pro Ser Leu His Gln Asp Glu Ala Pro Thr  
 165 170 175

Thr Ala Lys Val Lys Arg Asn Ile Ser Glu Arg Arg Thr Tyr Arg Lys  
 180 185 190

Ile Ile Pro Lys Arg Asn Arg Asn Gln Leu  
 195 200

<210> 127

<211> 44

<212> PRT

<213> Homo sapiens

<400> 127

Phe Glu Phe Leu Val Glu Thr Gly Phe Leu His Val Gly Gln Ala Gly  
 1 5 10 15

Leu Glu Leu Leu Thr Ser Gly Asp Leu Pro Ala Ser Ala Ser Gln Ser  
 20 25 30

Ala Arg Ile Thr Gly Val Ser His Arg Ala Arg Pro  
 35 40

<210> 128

<211> 44

<212> PRT

<213> Homo sapiens

<400> 128

Phe Val Phe Leu Val Glu Thr Gly Phe His His Val Gly Gln Ala Gly  
 1 5 10 15

Phe Glu Leu Leu Thr Ser Gly Asp Pro Pro Ala Leu Ala Ser Gln Val  
 20 25 30

Ala Gly Ile Thr Asp Val Asn His Cys Ala Lys Pro  
 35 40

<210> 129  
 <211> 41  
 <212> PRT  
 <213> Homo sapiens

<400> 129  
 Gly Val Gln Trp His Asp Phe Gly Ser Leu Gln Pro Leu Pro Pro Gly  
     1                    5                    10                    15  
 Phe Lys Arg Phe Ser Cys Leu Ser Leu Pro Arg Ser Trp Asp Tyr Arg  
                     20                    25                    30  
 His Pro Pro Pro Arg Pro Ala Asn Phe  
                     35                    40

<210> 130  
 <211> 41  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (40)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 130  
 Gly Val Gln Trp Arg Asp Leu Gly Ser Leu Gln Pro Pro Pro Pro Gly  
     1                    5                    10                    15  
 Phe Lys Arg Ser Ser Met Pro Gln Pro Pro Glu Gln Leu Gly Leu Gln  
                     20                    25                    30  
 Ala Pro Ala Thr Val Pro Ser Xaa Phe  
                     35                    40

<210> 131  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 131  
 Asp Tyr Arg His Pro Pro Pro Arg Pro Ala Asn Phe  
     1                    5                    10

<210> 132  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 132

85

Asp Tyr Arg His Leu Pro Gln Cys Pro Ala Asn Phe  
 1 5 10

&lt;210&gt; 133

&lt;211&gt; 91

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

Asp Leu Gly Ser Glu Gly Ser Arg Glu Arg Phe Arg Gly Phe Arg Tyr  
 1 5 10 15

Pro Glu Ala Ala Gly Pro Arg Glu Ala Leu Ser Arg Leu Arg Glu Leu  
 20 25 30

Cys Arg Gln Trp Leu Gln Pro Glu Met His Ser Lys Glu Gln Ile Leu  
 35 40 45

Glu Leu Leu Val Leu Glu Gln Phe Leu Thr Ile Leu Pro Gly Asn Leu  
 50 55 60

Gln Ser Trp Val Arg Glu Gln His Pro Glu Ser Gly Glu Glu Val Val  
 65 70 75 80

Val Leu Leu Glu Tyr Leu Glu Arg Gln Leu Asp  
 85 90

&lt;210&gt; 134

&lt;211&gt; 91

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 134

Asn Leu Gly Pro Glu Ser Ala Cys Arg His Phe Trp Ser Phe Arg Tyr  
 1 5 10 15

His Glu Ala Thr Gly Pro Leu Glu Thr Ile Ser Gln Leu Gln Lys Leu  
 20 25 30

Cys His Gln Trp Leu Arg Pro Glu Ile His Ser Lys Glu Gln Ile Leu  
 35 40 45

Glu Met Leu Val Leu Glu Gln Phe Leu Ser Ile Leu Pro Lys Glu Thr  
 50 55 60

Gln Asn Trp Val Gln Lys His His Pro Gln Asn Val Lys Gln Ala Leu  
 65 70 75 80

Val Leu Val Glu Phe Leu Gln Arg Glu Pro Asp  
 85 90

&lt;210&gt; 135

&lt;211&gt; 240

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Gly Ser Thr Leu Ala Val Met Lys Lys Ser Ser Lys Phe Leu Pro Val  
 1 5 10 15

Ile Gly Trp Ser Met Trp Phe Ala Glu Tyr Leu Phe Leu Glu Arg Ser  
 20 25 30

Trp Ala Lys Asp Glu Lys Thr Leu Lys Trp Gly Leu Gln Arg Leu Lys  
 35 40 45

Asp Phe Pro Arg Pro Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg  
 50 55 60

Phe Thr Pro Ala Lys Leu Leu Ala Ala Gln Glu Tyr Ala Ala Ser Gln  
 65 70 75 80

Gly Leu Pro Ala Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe  
 85 90 95

Val Ser Ala Val Ser Ile Met Arg Asp Phe Val Pro Ala Ile Tyr Asp  
 100 105 110

Thr Thr Val Ile Val Pro Lys Asp Ser Pro Gln Pro Thr Met Leu Arg  
 115 120 125

Ile Leu Lys Gly Gln Ser Ser Val Ile His Val Arg Met Lys Arg His  
 130 135 140

Ala Met Ser Glu Met Pro Lys Ser Asp Glu Asp Val Ser Lys Trp Cys  
 145 150 155 160

Lys Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Leu Ala  
 165 170 175

Thr Gly Thr Phe Asp Glu Glu Ile Arg Pro Ile Gly Arg Pro Val Lys  
 180 185 190

Ser Leu Leu Val Thr Leu Phe Trp Ser Cys Leu Leu Leu Phe Gly Ala  
 195 200 205

Ile Glu Phe Phe Lys Trp Thr Gln Leu Leu Ser Thr Trp Arg Gly Val  
 210 215 220

Ala Phe Thr Ala Ala Gly Met Ala Leu Val Thr Gly Val Met His Val  
 225 230 235 240



<210> 136  
 <211> 234  
 <212> PRT  
 <213> Homo sapiens

<400> 136  
 Gly Ser Lys Val Leu Ala Lys Lys Glu Leu Ala Tyr Val Pro Ile Ile  
     1                    5                    10                    15  
 Gly Trp Met Trp Tyr Phe Thr Glu Met Val Phe Cys Ser Arg Lys Trp  
             20                    25                    30  
 Glu Gln Asp Arg Lys Thr Val Ala Thr Ser Leu Gln His Leu Arg Asp  
             35                    40                    45  
 Tyr Pro Glu Lys Tyr Phe Phe Leu Ile His Cys Glu Gly Thr Arg Phe  
             50                    55                    60  
 Thr Glu Lys Lys His Glu Ile Ser Met Gln Val Ala Arg Ala Lys Gly  
             65                    70                    75                    80  
 Leu Pro Arg Leu Lys His His Leu Leu Pro Arg Thr Lys Gly Phe Ala  
                     85                    90                    95  
 Ile Thr Val Arg Ser Leu Arg Asn Val Val Ser Ala Val Tyr Asp Cys  
                     100                    105                    110  
 Thr Leu Asn Phe Arg Asn Asn Glu Asn Pro Thr Leu Leu Gly Val Leu  
             115                    120                    125  
 Asn Gly Lys Lys Tyr His Ala Asp Leu Tyr Val Arg Arg Ile Pro Leu  
             130                    135                    140  
 Glu Asp Ile Pro Glu Asp Asp Asp Glu Cys Ser Ala Trp Leu His Lys  
             145                    150                    155                    160  
 Leu Tyr Gln Glu Lys Asp Ala Phe Gln Glu Glu Tyr Tyr Arg Thr Gly  
                     165                    170                    175  
 Thr Phe Pro Glu Thr Pro Met Val Pro Pro Arg Arg Pro Trp Thr Leu  
             180                    185                    190  
 Val Asn Trp Leu Phe Trp Ala Ser Leu Val Leu Tyr Pro Phe Phe Gln  
             195                    200                    205  
 Phe Leu Val Ser Met Ile Arg Ser Gly Ser Ser Leu Thr Leu Ala Ser  
             210                    215                    220  
 Phe Ile Leu Val Phe Phe Val Ala Ser Val  
             225                    230

<210> 137

<211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 137  
 Phe Lys Leu Tyr Tyr Lys Ala Thr Val Thr Lys Thr Val Trp Tyr Trp  
   1                  5                  10                  15  
 Tyr Gln Asn Arg His Ile Asp Gln Trp Asn Arg Thr Glu Pro Ser Glu  
                   20                  25                  30  
 Ile Thr Pro His Ile Tyr Asn Tyr Leu Ile Phe Asp Lys Pro Glu Lys  
                   35                  40                  45  
 Asn Lys Gln  
           50

<210> 138  
 <211> 44  
 <212> PRT  
 <213> Homo sapiens

<400> 138  
 Phe Lys Leu Tyr Tyr Lys Ala Ile Val Thr Lys Thr Thr Trp Tyr Trp  
   1                  5                  10                  15  
 Tyr Gln Asn Arg Tyr Val Asp Gln Trp Asn Arg Thr Lys Ala Ser Glu  
                   20                  25                  30  
 Ile Met Thr Phe Met Gln Pro Thr Lys Lys Lys Lys  
           35                  40

<210> 139  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 139  
 Phe Asn Lys Trp Cys Trp Glu Asn Trp Leu Ala Ile Cys Lys Lys Leu  
   1                  5                  10                  15  
 Lys Leu Asp Pro Phe Leu Thr Pro Tyr Thr Lys Ile Asn Ser Arg Trp  
                   20                  25                  30  
 Ile Lys Asp Leu Asn Val Arg Leu Lys Thr Ile Lys Thr Ile Glu Glu  
           35                  40                  45  
 Asn Leu Gly Ile Thr Ile Gln Asp Ile Gly Met Gly Lys Asp Phe Met  
   50                  55                  60  
 Ser Lys Thr Pro Lys Ala Met Ala Thr Lys Ala Lys Ile Asp Lys Trp  
   65                  70                  75                  80

Asp Leu Ile Lys Leu Lys Ser Phe Cys Thr Ala Lys Gln Thr Thr Ile  
                   85                                  90                                  95

Arg Val

---

<210> 140  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (4)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (73)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (83)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 140  
 Phe Asn Lys Xaa Cys Trp Asp Thr Trp Thr Ala Lys Cys Lys Arg Met  
   1                  5                                  10                                  15

Met Phe Asp Ser Asp Phe Thr Ser Tyr Thr Lys Val Lys Ser Lys Ile  
                   20                                  25                                  30

Leu Met Ala Gln Arg Pro Tyr Val Ile Ala Lys Thr Ile Lys Phe Leu  
                   35                                  40                                  45

Glu Glu Asn Ile Gly Val Asn Leu His Asp Leu Gly Phe Gly Ser Gly  
                   50                                  55                                  60

Phe Leu Asp Ala Thr Pro Lys Ala Xaa Ala Thr Lys Glu Lys Cys Arg  
   65                                  70                                  75                                  80

Tyr Ile Xaa Leu His Lys Asn Leu Lys Leu Cys Val Leu Lys Asp Thr  
                                   85                                  90                                  95

Thr Lys Glu Val  
                   100

<210> 141  
 <211> 167  
 <212> PRT

<213> Homo sapiens

<400> 141

```

Leu Pro Gln Arg Asp Leu Arg Pro Phe Thr Arg Val Thr Val His Trp
 1             5             10             15

Gly Lys Gly Asn Asn Gln Thr Phe Arg Gly Leu Leu Asp Thr Gly Ser
          20             25             30

Glu Leu Thr Leu Ile Pro Gly Asp Pro Lys Lys His Cys Gly Pro Pro
          35             40             45

Val Lys Val Gly Ala Tyr Gly Gly Gln Val Ile Asn Gly Val Leu Thr
          50             55             60

Asp Val Arg Leu Thr Val Gly Pro Val Gly Pro Arg Thr His Pro Val
          65             70             75             80

Val Ile Ser Pro Val Pro Glu Cys Ile Ile Gly Ile Asp Ile Leu Arg
          85             90             95

Asn Trp Gln Asn Ser His Ile Gly Ser Leu Asn Cys Arg Val Arg Ala
          100            105            110

Ile Met Val Gly Lys Ala Lys Trp Ile Pro Leu Glu Leu Pro Leu Pro
          115            120            125

Lys Lys Ile Val Asn Gln Lys Gln Tyr Cys Ile Pro Gly Glu Ile Ala
          130            135            140

Glu Ile Thr Ala Thr Ile Lys Asp Leu Lys Asp Ala Gly Val Val Val
          145            150            155            160

Pro Thr Thr Ser Pro Phe Asn
          165

```

<210> 142

<211> 155

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

&lt;222&gt; (40)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (48)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (70)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (77)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (153)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 142

Leu	Pro	Gln	Arg	Pro	Phe	Thr	Arg	Val	Thr	Thr	Asp	Xaa	Arg	Lys	Gly
1				5					10					15	

Asn	Thr	Gln	Thr	Phe	Arg	Asp	Tyr	Xaa	Phe	Leu	Gly	Thr	Gln	Asn	Ala
		20						25					30		

Thr	Val	Ala	Tyr	Gln	Ser	Lys	Xaa	Val	Leu	Thr	Val	Val	Arg	Xaa	Xaa
		35					40						45		

Met	Lys	Cys	Leu	Ala	Gln	Val	His	Leu	Thr	Val	Asp	Pro	Ile	Val	Gln
	50					55					60				

Trp	Ala	Tyr	Phe	Val	Xaa	Ile	Ser	Ser	Val	Pro	Glu	Xaa	Ile	Leu	Gly
65					70					75				80	

Thr	Asp	Ile	Leu	Asp	Tyr	Trp	Gln	Ser	Ser	His	Ile	Gly	Phe	Leu	Thr
			85						90					95	

Gln	Leu	Ile	Arg	Val	Ile	Leu	Ile	Val	Arg	Ala	Lys	Trp	Lys	Pro	Leu
		100						105					110		

Glu	Leu	Thr	Leu	Pro	Thr	Lys	Ile	Leu	Ser	Gln	Lys	Gln	Tyr	His	Ile
		115					120					125			

Ser	Arg	Ile	Lys	Glu	Leu	Asn	Val	Thr	Ile	Lys	Arg	Leu	Glu	Arg	Asn
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

130 135 140

Arg Val Val Ile Pro Ile Ile Ser Xaa Phe Asn  
 145 150 155

<210> 143  
 <211> 144  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Thr Ile Asn Val Ser Asn Phe Thr Val Ser Arg Ser His Ala His Glu  
 1 5 10 15  
 Ala Phe Asn Thr Ala Phe Thr Thr Leu Ala Ala Cys Val Ala Ser Ile  
 20 25 30  
 Val Leu Val Leu Leu Tyr Leu Tyr Leu Thr Pro Cys Pro Cys Lys Cys  
 35 40 45  
 Lys Thr Lys Arg Gln Lys Asn Met Leu His Gln Ser Asn Ala His Ser  
 50 55 60  
 Ser Ile Leu Ser Pro Gly Pro Ala Ser Asp Ala Ser Ala Asp Glu Arg  
 65 70 75 80  
 Lys Ala Gly Ala Gly Lys Arg Val Val Phe Leu Glu Pro Leu Lys Asp  
 85 90 95  
 Thr Ala Ala Gly Gln Asn Gly Lys Val Arg Leu Phe Pro Ser Glu Ala  
 100 105 110  
 Val Ile Ala Glu Gly Ile Leu Lys Ser Thr Arg Gly Lys Ser Asp Ser  
 115 120 125  
 Asp Ser Val Asn Ser Val Phe Ser Asp Thr Pro Phe Val Ala Ser Thr  
 130 135 140

<210> 144  
 <211> 144  
 <212> PRT  
 <213> Homo sapiens

<400> 144  
 Thr Ile Asn Val Ser Asn Phe Thr Val Ser Arg Ser His Ala His Glu  
 1 5 10 15  
 Ala Phe Asn Thr Ala Phe Thr Thr Leu Ala Ala Cys Val Ala Ser Ile  
 20 25 30

Val Leu Val Leu Leu Tyr Leu Tyr Leu Thr Pro Cys Pro Cys Lys Cys  
35 40 45

Lys Thr Lys Arg Gln Lys Asn Met Leu His Gln Ser Asn Ala His Ser  
50 55 60

Ser Ile Leu Ser Pro Gly Pro Ala Ser Asp Ala Ser Ala Asp Glu Arg  
65 70 75 80

Lys Ala Gly Ala Gly Lys Arg Val Val Phe Leu Glu Pro Leu Lys Asp  
85 90 95

Thr Ala Ala Gly Gln Asn Gly Lys Val Arg Leu Phe Pro Ser Glu Ala  
100 105 110

Val Ile Ala Glu Gly Ile Leu Lys Ser Thr Arg Gly Lys Ser Asp Ser  
115 120 125

Asp Ser Val Asn Ser Val Phe Ser Asp Thr Pro Phe Val Ala Ser Thr  
130 135 140

<210> 145

<211> 88

<212> PRT

<213> Homo sapiens

<400> 145

Asn Gly Tyr Met Glu Lys Ser Thr Pro Tyr Glu Cys Gly Phe Asp Pro  
1 5 10 15

Met Ser Pro Ala Arg Val Pro Phe Ser Met Lys Phe Phe Leu Val Ala  
20 25 30

Ile Thr Phe Leu Leu Phe Asp Leu Glu Ile Ala Leu Leu Leu Pro Leu  
35 40 45

Pro Trp Ala Leu Gln Thr Thr Asn Leu Pro Leu Met Val Met Ser Ser  
50 55 60

Leu Leu Leu Ile Ile Ile Leu Ala Leu Ser Leu Ala Tyr Glu Trp Leu  
65 70 75 80

Gln Lys Gly Leu Asp Trp Thr Glu  
85

<210> 146

<211> 88

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (86)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 146

Asn Gly Tyr Ile Glu Lys Ser Thr Pro Tyr Glu Cys Gly Phe Asp Pro  
1 5 10 15

Ile Ser Pro Ala Arg Val Pro Phe Ser Ile Lys Phe Phe Leu Val Ala  
20 25 30

Ile Thr Phe Leu Leu Phe Asp Leu Glu Ile Ala Leu Leu Leu Pro Leu  
35 40 45

Pro Xaa Ala Leu Gln Thr Thr Asn Leu Pro Leu Ile Val Met Ser Ser  
50 55 60

Leu Leu Leu Ile Ile Ile Leu Ala Leu Ser Leu Ala Tyr Glu Xaa Leu  
65 70 75 80

Gln Lys Gly Leu Asp Xaa Thr Glu  
85

<210> 147

<211> 131

<212> PRT

<213> Homo sapiens

<400> 147

Glu Glu Glu Leu Gln Val Ile Gln Pro Asp Lys Ser Val Ser Val Ala  
1 5 10 15

Ala Gly Glu Ser Ala Ile Leu His Cys Thr Val Thr Ser Leu Ile Pro  
20 25 30

Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Ala Arg Glu Leu  
35 40 45

Ile Tyr Asn Gln Lys Glu Gly His Phe Pro Arg Val Thr Thr Val Ser  
50 55 60



95

Glu Ser Thr Lys Arg Glu Asn Met Asp Phe Ser Ile Ser Ile Ser Asn  
65 70 75 80

Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Arg Lys  
85 90 95

Gly Ser Pro Asp Thr Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu Ser  
100 105 110

Val Arg Ala Lys Pro Ser Ala Pro Val Val Ser Gly Pro Ala Ala Arg  
115 120 125

Ala Thr Pro  
130

<210> 148

<211> 130

<212> PRT

<213> Homo sapiens

<400> 148

Glu Pro Asp Leu Trp Ile Ile Gln Pro Gln Glu Leu Val Leu Gly Thr  
1 5 10 15

Thr Gly Asp Thr Val Phe Leu Asn Cys Thr Val Leu Gly Asp Gly Pro  
20 25 30

Pro Gly Pro Ile Arg Trp Phe Gln Gly Ala Gly Leu Ser Arg Glu Ala  
35 40 45

Ile Tyr Asn Phe Gly Gly Ile Ser His Pro Lys Ala Thr Ala Val Gln  
50 55 60

Ala Ser Asn Asn Asp Phe Ser Ile Leu Leu Gln Asn Val Ser Ser Glu  
65 70 75 80

Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Gln Arg Lys Pro Asn Arg  
85 90 95

Gln Tyr Leu Ser Gly Gln Gly Thr Ser Leu Lys Val Lys Ala Lys Ser  
100 105 110

Thr Ser Ser Lys Glu Ala Glu Phe Thr Ser Glu Pro Ala Thr Glu Met  
115 120 125

Ser Pro  
130

<210> 149

<211> 86

<212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 149

Leu Asp Lys Val Thr Met Gln Gln Val Ala Arg Thr Val Ala Lys Val  
 1 5 10 15

Glu Leu Ser Asp His Val Cys Asp Val Val Phe Ala Leu Phe Asp Cys  
 20 25 30

Asp Gly Asn Gly Glu Leu Ser Asn Lys Glu Phe Val Ser Ile Met Lys  
 35 40 45

Gln Arg Leu Met Arg Gly Leu Glu Lys Pro Lys Asp Met Gly Phe Thr  
 50 55 60

Arg Leu Met Gln Ala Met Trp Lys Cys Ala Gln Glu Thr Ala Trp Asp  
 65 70 75 80

Phe Ala Leu Pro Lys Gln  
 85

&lt;210&gt; 150

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 150

Leu Phe Ser Val Thr Met Gln Gln Val Ala Arg Thr Val Ala Lys Val  
 1 5 10 15

Glu Leu Ser Asp His Val Cys Asp Val Val Phe Ala Leu Phe Asp Cys  
 20 25 30

Asp Gly Asn Gly Glu Leu Ser Asn Lys Glu Phe Val Ser Ile Met Lys  
 35 40 45

Gln Arg Leu Met Arg Gly Leu Glu Lys Pro Lys Asp Met Gly Phe Thr  
 50 55 60

Arg Leu Met Gln Ala Met Trp Lys Cys Ala Gln Glu Thr Ala Trp Asp  
 65 70 75 80

Phe Ala Leu Pro Lys Gln  
 85

&lt;210&gt; 151

&lt;211&gt; 537

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

Thr Tyr Asn Tyr Tyr Ser Leu Pro Phe Cys Arg Pro Ser Gly Asn Asn

1	5	10	15
Val His Lys Trp Gly Gly Leu Gly Glu Val Leu Gly Gly Asn Glu Leu	20	25	30
Ile Asp Ser Glu Ile Ala Ile Lys Phe Met Lys Asn Val Glu Arg Ser	35	40	45
Val Ile Cys Pro Leu Glu Leu Asp Glu Ala Lys Val Lys His Phe Lys	50	55	60
Asp Ala Ile Glu Ser Ser Tyr Trp Phe Glu Phe Phe Met Gly Met Phe	65	70	75
His Val Cys Cys Phe Val Gly Glu Leu His Pro Asp Lys Asn Ser Glu	85	90	95
Asn Gly Lys His Val Leu Tyr Thr His Lys Asn Ile Val Val Lys Tyr	100	105	110
Asn Lys Asp Gln Ile Ile His Val Asn Leu Thr Gln Asp Asn Pro Arg	115	120	125
Pro Leu Glu Ala Gly Lys Lys Met Asp Leu Thr Tyr Ser Val Gln Trp	130	135	140
Ile Pro Thr Asn Val Thr Phe Ala Arg Arg Phe Asp Val Tyr Leu Asp	145	150	155
Tyr Pro Phe Phe Glu His Gln Ile His Trp Phe Ser Ile Phe Asn Ser	165	170	175
Phe Met Met Val Ile Phe Leu Thr Gly Leu Val Ser Met Ile Leu Met	180	185	190
Arg Thr Leu Arg Asn Asp Tyr Ala Lys Tyr Ala Arg Glu Asp Asp Asp	195	200	205
Leu Glu Ser Leu Glu Arg Asp Val Ser Glu Glu Ser Gly Trp Lys Leu	210	215	220
Val His Gly Asp Val Phe Arg Pro Ala Ser Ser Leu Val Leu Leu Ser	225	230	235
Ala Val Val Gly Thr Gly Ala Gln Leu Ala Leu Leu Val Leu Leu Val	245	250	255
Ile Leu Met Ala Ile Val Gly Thr Leu Tyr Val Gly Arg Gly Ala Ile	260	265	270
Val Thr Thr Phe Ile Val Cys Tyr Ala Leu Thr Ser Phe Val Ser Gly	275	280	285
Tyr Val Ser Gly Gly Met Tyr Ser Arg Ser Gly Gly Lys His Trp Ile			

290	295	300
Lys Cys Met Val Leu Thr Ala Ser Leu Phe Pro Phe Leu Cys Phe Gly 305	310	315 320
Ile Gly Phe Leu Leu Asn Thr Ile Ala Ile Phe Tyr Gly Ser Leu Ala 325	330	335
Ala Ile Pro Phe Gly Thr Met Val Val Val Phe Val Ile Trp Gly Phe 340	345	350
Ile Ser Phe Pro Leu Ala Leu Leu Gly Thr Val Val Gly Arg Asn Trp 355	360	365
Ser Gly Ala Pro Asn Asn Pro Cys Arg Val Lys Thr Ile Pro Arg Pro 370	375	380
Ile Pro Glu Lys Lys Trp Tyr Leu Thr Pro Ser Val Val Ser Leu Met 385	390	395 400
Gly Gly Leu Leu Pro Phe Gly Ser Ile Phe Ile Glu Met Tyr Phe Val 405	410	415
Phe Thr Ser Phe Trp Asn Tyr Lys Val Tyr Tyr Val Tyr Gly Phe Met 420	425	430
Leu Leu Val Phe Val Ile Leu Val Ile Val Thr Val Cys Val Thr Ile 435	440	445
Val Gly Thr Tyr Phe Leu Leu Asn Ala Glu Asn Tyr His Trp Gln Trp 450	455	460
Thr Ser Phe Phe Ser Ala Ala Ser Thr Ala Val Tyr Val Tyr Leu Tyr 465	470	475 480
Ser Ile Tyr Tyr Tyr Tyr Val Lys Thr Lys Met Ser Gly Phe Phe Gln 485	490	495
Thr Ser Phe Tyr Phe Gly Tyr Thr Met Met Phe Cys Leu Gly Leu Gly 500	505	510
Ile Leu Cys Gly Ala Val Gly Tyr Leu Gly Ser Asn Leu Phe Val Arg 515	520	525
Arg Ile Tyr Arg Asn Ile Lys Cys Asp 530	535	

&lt;210&gt; 152

&lt;211&gt; 530

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 152

Thr	Phe	His	Phe	His	Ser	Val	Trp	Gly	Gln	Lys	Lys	Ser	Ile	Ser	His
1				5					10					15	
Tyr	His	Glu	Thr	Leu	Gly	Glu	Ala	Leu	Gln	Gly	Val	Glu	Leu	Glu	Phe
			20					25					30		
Ser	Gly	Leu	Asp	Ile	Lys	Phe	Lys	Asp	Asp	Val	Met	Pro	Ala	Thr	Tyr
		35					40					45			
Cys	Glu	Ile	Asp	Leu	Asp	Lys	Glu	Lys	Arg	Asp	Ala	Phe	Val	Tyr	Ala
	50					55					60				
Ile	Lys	Asn	His	Tyr	Trp	Tyr	Gln	Met	Tyr	Ile	Asp	Asp	Leu	Pro	Ile
65					70					75					80
Trp	Gly	Ile	Val	Gly	Glu	Ala	Asp	Glu	Asn	Gly	Glu	Asp	Tyr	Tyr	Leu
				85					90						95
Trp	Thr	Tyr	Lys	Lys	Leu	Glu	Ile	Gly	Phe	Asn	Gly	Asn	Arg	Ile	Val
			100					105						110	
Asp	Val	Asn	Leu	Thr	Ser	Glu	Gly	Lys	Val	Lys	Leu	Val	Pro	Asn	Thr
		115					120					125			
Lys	Ile	Gln	Met	Ser	Tyr	Ser	Val	Lys	Trp	Lys	Lys	Ser	Asp	Val	Lys
	130					135					140				
Phe	Glu	Asp	Arg	Phe	Asp	Lys	Tyr	Leu	Asp	Pro	Ser	Phe	Phe	Gln	His
145					150					155					160
Arg	Ile	His	Trp	Phe	Ser	Ile	Phe	Asn	Ser	Phe	Met	Met	Val	Ile	Phe
				165					170					175	
Leu	Val	Gly	Leu	Val	Ser	Met	Ile	Leu	Met	Arg	Thr	Leu	Arg	Lys	Asp
		180						185					190		
Tyr	Ala	Arg	Tyr	Ser	Lys	Glu	Glu	Glu	Met	Asp	Asp	Met	Asp	Arg	Asp
		195					200					205			
Leu	Gly	Asp	Glu	Tyr	Gly	Trp	Lys	Gln	Val	His	Gly	Asp	Val	Phe	Arg
	210					215					220				
Pro	Ser	Ser	His	Pro	Leu	Ile	Phe	Ser	Ser	Leu	Ile	Gly	Ser	Gly	Cys
225					230					235					240
Gln	Ile	Phe	Ala	Val	Ser	Leu	Ile	Val	Ile	Ile	Val	Ala	Met	Ile	Glu
				245					250					255	
Asp	Leu	Tyr	Thr	Glu	Arg	Gly	Ser	Met	Leu	Ser	Thr	Ala	Ile	Phe	Val
			260					265					270		
Tyr	Ala	Ala	Thr	Ser	Pro	Val	Asn	Gly	Tyr	Phe	Gly	Gly	Ser	Leu	Tyr
		275					280					285			

100

Ala Arg Gln Gly Gly Arg Arg Trp Ile Lys Gln Met Phe Ile Gly Ala  
 290 295 300  
 Phe Leu Ile Pro Ala Met Val Cys Gly Thr Ala Phe Phe Ile Asn Phe  
 305 310 315 320  
 Ile Ala Ile Tyr Tyr His Ala Ser Arg Ala Ile Pro Phe Gly Thr Met  
 325 330 335  
 Val Ala Val Cys Cys Ile Cys Phe Phe Val Ile Leu Pro Leu Asn Leu  
 340 345 350  
 Val Gly Thr Ile Leu Gly Arg Asn Leu Ser Gly Gln Pro Asn Phe Pro  
 355 360 365  
 Cys Arg Val Asn Ala Val Pro Arg Pro Ile Pro Glu Lys Lys Trp Phe  
 370 375 380  
 Met Glu Pro Ala Val Ile Val Cys Leu Gly Gly Ile Leu Pro Phe Gly  
 385 390 395 400  
 Ser Ile Phe Ile Glu Met Tyr Phe Ile Phe Thr Ser Phe Trp Ala Tyr  
 405 410 415  
 Lys Ile Tyr Tyr Val Tyr Gly Phe Met Met Leu Val Leu Val Ile Leu  
 420 425 430  
 Cys Ile Val Thr Val Cys Val Thr Ile Val Cys Thr Tyr Phe Leu Leu  
 435 440 445  
 Asn Ala Glu Asp Tyr Arg Trp Gln Trp Thr Ser Phe Leu Ser Ala Ala  
 450 455 460  
 Ser Thr Ala Ile Tyr Val Tyr Met Tyr Ser Phe Tyr Tyr Tyr Phe Phe  
 465 470 475 480  
 Lys Thr Lys Met Tyr Gly Leu Phe Gln Thr Ser Phe Tyr Phe Gly Tyr  
 485 490 495  
 Met Ala Val Phe Ser Thr Ala Leu Gly Ile Met Cys Gly Ala Ile Gly  
 500 505 510  
 Tyr Met Gly Thr Ser Ala Phe Val Arg Lys Ile Tyr Thr Asn Val Lys  
 515 520 525  
 Ile Asp  
 530

&lt;210&gt; 153

&lt;211&gt; 194

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

101

&lt;400&gt; 153

Leu Asp Pro Phe Leu Thr Pro Tyr Thr Lys Ile Asn Ser Arg Trp Ile  
 1 5 10 15

Lys Asp Leu Asn Val Lys Pro Lys Thr Ile Lys Thr Leu Glu Glu Asn  
 20 25 30

Leu Gly Ile Thr Ile Gln Asp Ile Gly Val Gly Lys Asp Phe Met Ser  
 35 40 45

Lys Thr Pro Lys Ala Met Ala Thr Lys Asp Lys Ile Asp Lys Trp Asp  
 50 55 60

Leu Ile Lys Leu Lys Ser Phe Cys Thr Ala Lys Glu Thr Thr Ile Arg  
 65 70 75 80

Val Asn Arg Gln Pro Thr Thr Trp Glu Lys Ile Phe Ala Thr Tyr Ser  
 85 90 95

Ser Asp Lys Gly Leu Ile Ser Arg Ile Tyr Asn Glu Leu Lys Gln Ile  
 100 105 110

Tyr Lys Lys Lys Thr Asn Asn Pro Ile Lys Lys Trp Ala Lys Asp Met  
 115 120 125

Asn Arg His Phe Ser Lys Glu Asp Ile Tyr Ala Ala Lys Lys His Met  
 130 135 140

Lys Lys Cys Ser Ser Ser Leu Ala Ile Arg Glu Met Gln Ile Lys Thr  
 145 150 155 160

Thr Met Arg Tyr His Leu Thr Pro Val Arg Met Ala Ile Ile Lys Lys  
 165 170 175

Ser Gly Asn Asn Arg Cys Trp Arg Gly Cys Gly Glu Ile Gly Thr Leu  
 180 185 190

Val His

&lt;210&gt; 154

&lt;211&gt; 181

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (75)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (89)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (102)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (140)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (171)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 154

Leu	Asp	Pro	Tyr	Phe	Thr	Pro	Tyr	Asn	Ser	Lys	Tyr	Met	Leu	Asp	Leu
1				5					10				15		

Asp	Val	Lys	Leu	Lys	Pro	Leu	Glu	Glu	Asn	Thr	Gly	Lys	Asn	His	Cys
		20						25					30		

Asn	Leu	Trp	Leu	Gly	Lys	Asp	Phe	Leu	Asp	Thr	Ala	Leu	Lys	Ala	Gln
	35						40						45		

Pro	Arg	Asn	Glu	Gln	Met	Glu	Arg	Thr	Asp	Phe	Ile	Lys	Ile	Ser	Ser
	50					55					60				

Ser	Val	Leu	Gln	Lys	Thr	Leu	Leu	Arg	Glu	Xaa	Lys	Asp	Asn	Pro	Glu
	65				70					75					80

Thr	Gly	Arg	Lys	Pro	Leu	Gln	Gly	Xaa	Trp	Thr	Asp	Ser	Glu	Val	Thr
			85						90					95	

Pro	Arg	Ile	Tyr	Phe	Xaa	Lys	Leu	Ser	Val	Leu	Asn	Asn	Lys	Lys	Thr
		100					105						110		

Gln	Ile	Thr	Gln	Leu	Ile	Met	Gly	Lys	Arg	Phe	Lys	Gln	Thr	Xaa	His
		115					120					125			

Gln	Arg	Phe	Ser	Ile	Lys	Asp	Asp	Gln	Tyr	Tyr	Xaa	Ser	Leu	Gly	Gln
	130					135					140				

Cys	Lys	Leu	Ile	Ser	Gln	Tyr	Asn	Phe	Thr	Cys	Thr	Arg	Ile	Ala	Ile
	145				150					155					160

Ile	Lys	Lys	Thr	Asn	Asn	Asn	Lys	Ser	Trp	Xaa	Gly	Cys	Gly	Glu	Thr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----



103

165

170

175

Gly Asn Leu Ile His  
180

&lt;210&gt; 155

&lt;211&gt; 419

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Ser His Leu Glu Asp Ala Ser Gly Glu Ile His Pro Pro Lys Leu Val  
1 5 10 15

Leu Lys Lys Ile Asn Ser Lys Arg Ser Leu Lys Gln Pro Leu Glu Gln  
20 25 30

Asn Gln Thr Ile Ser Pro Leu Ser Thr Tyr Glu Glu Ser Lys Val Ser  
35 40 45

Lys Tyr Ala Phe Glu Leu Val Asp Lys Gln Ala Leu Leu Asp Ser Glu  
50 55 60

Gly Asn Ala Asp Ile Asp Gln Val Asp Asn Leu Gln Glu Gly Pro Ser  
65 70 75 80

Lys Pro Val His Ser Ser Thr Asn Tyr Asp Asp Ala Met Gln Phe Leu  
85 90 95

Lys Lys Lys Arg Tyr Leu Gln Ala Ala Ser Asn Asn Ser Arg Glu Tyr  
100 105 110

Ala Leu Asn Val Gly Thr Ile Ala Ser Gln Pro Ser Val Thr Gln Ala  
115 120 125

Ala Val Ala Ser Val Ile Asp Glu Ser Thr Thr Ala Ser Ile Leu Glu  
130 135 140

Ser Gln Ala Leu Asn Val Glu Ile Lys Ser Asn His Asp Lys Asn Val  
145 150 155 160

Ile Pro Asp Glu Val Leu Gln Thr Leu Leu Asp His Tyr Ser His Lys  
165 170 175

Ala Asn Gly Gln His Glu Ile Ser Phe Ser Val Ala Asp Thr Glu Val  
180 185 190

Thr Ser Ser Ile Ser Ile Asn Ser Ser Glu Val Pro Glu Val Thr Pro  
195 200 205

Ser Glu Asn Val Gly Ser Ser Ser Gln Ala Ser Ser Ser Asp Lys Ala  
210 215 220

Asn Met Leu Gln Glu Tyr Ser Lys Phe Leu Gln Gln Ala Leu Asp Arg  
 225 230 235 240  
 Thr Ser Gln Asn Asp Ala Tyr Leu Asn Ser Pro Ser Leu Asn Phe Val  
 245 250 255  
 Thr Asp Asn Gln Thr Leu Pro Asn Gln Pro Ala Phe Ser Ser Ile Asp  
 260 265 270  
 Lys Gln Val Tyr Ala Thr Met Pro Ile Asn Ser Phe Arg Ser Gly Met  
 275 280 285  
 Asn Ser Pro Leu Arg Thr Thr Pro Asp Lys Ser His Phe Gly Leu Ile  
 290 295 300  
 Val Gly Asp Ser Gln His Ser Phe Pro Phe Ser Gly Asp Glu Thr Asn  
 305 310 315 320  
 His Ala Ser Ala Thr Ser Thr Gln Asp Phe Leu Asp Gln Val Thr Ser  
 325 330 335  
 Gln Lys Lys Ala Glu Ala Gln Pro Val His Gln Ala Tyr Gln Met Ser  
 340 345 350  
 Ser Phe Glu Gln Pro Phe Arg Ala Pro Tyr His Gly Ser Arg Ala Gly  
 355 360 365  
 Ile Ala Thr Gln Phe Ser Thr Ala Asn Gly Gln Val Asn Leu Arg Gly  
 370 375 380  
 Pro Gly Thr Ser Ala Glu Phe Ser Glu Phe Pro Leu Val Asn Val Asn  
 385 390 395 400  
 Asp Asn Arg Ala Gly Met Thr Ser Ser Pro Asp Ala Thr Thr Gly Gln  
 405 410 415  
 Thr Phe Gly

<210> 156  
 <211> 419  
 <212> PRT  
 <213> Homo sapiens

<400> 156  
 Ser His Leu Glu Asp Ala Ser Gly Glu Ile His Pro Pro Lys Leu Val  
 1 5 10 15  
 Leu Lys Lys Ile Asn Ser Lys Arg Ser Leu Lys Gln Pro Leu Glu Gln  
 20 25 30  
 Asn Gln Thr Ile Ser Pro Leu Ser Thr Tyr Glu Glu Ser Lys Val Ser  
 35 40 45

Lys Tyr Ala Phe Glu Leu Val Asp Lys Gln Ala Leu Leu Asp Ser Glu  
50 55 60

Gly Asn Ala Asp Ile Asp Gln Val Asp Asn Leu Gln Glu Gly Pro Ser  
65 70 75 80

Lys Pro Val His Ser Ser Thr Asn Tyr Asp Asp Ala Met Gln Phe Leu  
85 90 95

Lys Lys Lys Arg Tyr Leu Gln Ala Ala Ser Thr Thr Ser Arg Glu Tyr  
100 105 110

Ala Leu Asn Val Gly Thr Ile Ala Ser Gln Pro Ser Val Thr Gln Ala  
115 120 125

Ala Val Ala Ser Val Ile Asp Glu Ser Thr Thr Ala Ser Ile Leu Glu  
130 135 140

Ser Gln Ala Leu Asn Val Glu Ile Lys Ser Asn His Asp Lys Asn Val  
145 150 155 160

Ile Pro Asp Glu Val Leu Gln Thr Leu Leu Asp His Tyr Ser His Lys  
165 170 175

Ala Asn Gly Gln His Glu Ile Ser Phe Ser Val Ala Asp Thr Glu Val  
180 185 190

Thr Ser Ser Ile Ser Ile Asn Ser Ser Glu Val Pro Glu Val Thr Pro  
195 200 205

Ser Glu Asn Val Gly Ser Ser Ser Gln Ala Ser Ser Ser Asp Lys Ala  
210 215 220

Asn Met Leu Gln Glu Tyr Ser Lys Phe Leu Gln Gln Ala Leu Asp Arg  
225 230 235 240

Thr Ser Gln Asn Asp Ala Tyr Leu Asn Ser Pro Ser Leu Asn Phe Val  
245 250 255

Thr Asp Asn Gln Thr Leu Pro Asn Gln Pro Ala Phe Ser Ser Ile Asp  
260 265 270

Lys Gln Val Tyr Ala Thr Met Pro Ile Asn Ser Phe Arg Ser Gly Met  
275 280 285

Asn Ser Pro Leu Arg Thr Thr Pro Asp Lys Ser His Phe Gly Leu Ile  
290 295 300

Val Gly Asp Ser Gln His Ser Phe Pro Phe Ser Gly Asp Glu Thr Asn  
305 310 315 320

His Ala Ser Ala Thr Ser Thr Gln Asp Phe Leu Asp Gln Val Thr Ser  
325 330 335

Gln Lys Lys Ala Glu Ala Gln Pro Val His Gln Ala Tyr Gln Met Ser  
 340 345 350

Ser Phe Glu Gln Pro Phe Arg Ala Pro Tyr His Gly Ser Arg Ala Gly  
 355 360 365

Ile Ala Thr Gln Phe Ser Thr Ala Asn Gly Gln Val Asn Leu Arg Gly  
 370 375 380

Pro Gly Thr Ser Ala Glu Phe Ser Glu Phe Pro Leu Val Asn Val Asn  
 385 390 395 400

Asp Asn Arg Ala Gly Met Thr Ser Ser Pro Asp Ala Thr Thr Gly Gln  
 405 410 415

Thr Phe Gly

<210> 157

<211> 203

<212> PRT

<213> Homo sapiens

<400> 157

Arg Asp Val Thr Arg Glu Ser Thr Tyr Gln Gly His His Thr Pro Pro  
 1 5 10 15

Val Gln Lys Gly Leu Arg Tyr Gly Met Ile Leu Phe Ile Thr Ser Glu  
 20 25 30

Val Phe Phe Phe Ala Gly Phe Phe Trp Ala Phe Tyr His Ser Ser Leu  
 35 40 45

Ala Pro Thr Pro Gln Leu Gly Gly His Trp Pro Pro Thr Gly Ile Thr  
 50 55 60

Pro Leu Asn Pro Leu Glu Val Pro Leu Leu Asn Thr Ser Val Leu Leu  
 65 70 75 80

Ala Ser Gly Val Ser Ile Thr Trp Ala His His Ser Leu Met Glu Asn  
 85 90 95

Asn Arg Asn Gln Met Ile Gln Ala Leu Leu Ile Thr Ile Leu Leu Gly  
 100 105 110

Leu Tyr Phe Thr Leu Leu Gln Ala Ser Glu Tyr Phe Glu Ser Pro Phe  
 115 120 125

Thr Ile Ser Asp Gly Ile Tyr Gly Ser Thr Phe Phe Val Ala Thr Gly  
 130 135 140

Phe His Gly Leu His Val Ile Ile Gly Ser Thr Phe Leu Thr Ile Cys

107

145	150	155	160
Phe Ile Arg Gln Leu Met Phe His Phe Thr Ser Lys His His Phe Gly			
	165	170	175

---

Phe Glu Ala Ala Ala Trp Tyr Trp His Phe Val Asp Val Val Trp Leu
180 185 190

Phe Leu Tyr Val Ser Ile Tyr Trp Trp Gly Ser
195 200

&lt;210&gt; 158

&lt;211&gt; 203

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (41)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (88)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (182)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (191)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (200)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (201)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 158

Arg Asp Val Thr Arg Glu Ser Thr Tyr Gln Gly His His Thr Pro Pro
1 5 10 15

Val Gln Lys Gly Leu Arg Tyr Gly Ile Ile Leu Phe Ile Thr Ser Glu
20 25 30

```
<210> 159
<211> 139
<212> PRT
<213> Homo sapiens
```

```

<400> 159
Lys Leu Tyr Ser Lys Val Trp Lys Met Ile Glu Thr Leu His Phe Phe
  1             5             10             15

Thr Thr Arg Gly Trp Ser Phe Asn Ala Arg Gly Leu Pro Glu Phe Phe
          20             25             30

Glu Lys Met Thr Pro Ala Asp Gln Lys Glu Tyr Asn Phe Asp Val Arg
          35             40             45

Gln Val Asp Trp Asn Ser Tyr Leu Phe Asp Tyr Val Met Gly Ile Lys
          50             55             60

Lys Phe Leu Leu Lys Glu Asn Leu Glu Asn Leu Asn Arg Ser Arg Ala
  65             70             75             80

```

His Leu Leu Lys Met Arg Ile Arg Arg Gln Val Ile Ala Ala Ile Val  
85 90 95

Tyr Ala Gly Phe Ile Ser Thr Ile Gly Arg Lys Trp Lys Lys Thr Thr  
100 105 110

Gln Tyr Leu Thr Trp Phe Gly Ala Met Leu Ala Thr Tyr Thr Tyr Thr  
115 120 125

Glu Val Ser Phe Arg Arg His Ile Pro Leu Lys  
130 135

<210> 160

<211> 136

<212> PRT

<213> Homo sapiens

<400> 160

Lys Leu Met Asn Arg Leu Leu Arg Thr Val Ser Met Leu Glu Tyr Phe  
1 5 10 15

Ile Asn Arg Ser Trp Glu Trp Ser Thr Tyr Asn Thr Glu Met Leu Met  
20 25 30

Ser Glu Leu Ser Pro Glu Asp Gln Arg Val Phe Asn Phe Asp Val Arg  
35 40 45

Gln Leu Asn Trp Leu Glu Tyr Ile Glu Asn Tyr Val Leu Gly Val Lys  
50 55 60

Lys Tyr Leu Leu Lys Glu Asp Met Ala Gly Ile Pro Lys Ala Lys Gln  
65 70 75 80

Arg Leu Lys Arg Leu Arg Asn Ile His Tyr Leu Phe Asn Thr Ala Leu  
85 90 95

Phe Leu Ile Ala Trp Arg Leu Leu Ile Ala Arg Ser Gln Met Ala Arg  
100 105 110

Asn Val Trp Phe Phe Ile Val Ser Phe Cys Tyr Lys Phe Leu Ser Tyr  
115 120 125

Phe Arg Ala Ser Ser Thr Leu Lys  
130 135

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/14973

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) :C07K 2/00; C07H 21/00; C12N 15/12; C12P 19/34 US CL :530/350; 536/22.1; 435/91.1, 69.1 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/350; 536/22.1; 435/91.1, 69.1  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Genembl, Genbank, Swiss-Prot		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	GENEMBL Accession number AL080121, especially bases 6-2153. 16 June 1999.	1-10, 21
X, P	GENEMBL Accession Number AC009675, especially bases 150598-151904. 28 August 1999.	1-10, 21
X	WO 9845437 A2 (AGOSTINO et al.) 15 October 1998, page 321.	1-10, 21
X	EST Accession number AA780275, especially bases 1-622. 18 December 1997.	1-10, 21
X	EST Accession number Q9Y4S1, especially bases 1-243. June 1999.	14-16
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the invention but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family
Date of the actual completion of the international search 05 SEPTEMBER 2000		Date of mailing of the international search report 20 SEP 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer MARJORIE MORAN Telephone No. (703) 308-1235



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/14973

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-12, 14-16, 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/14973

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-12, 14-16, 21, drawn to isolated polynucleotides, a vector and host comprising the polynucleotides, a method of making the host cell, polypeptides encoded by the polynucleotides, and a method of making the polypeptides.

Group II, claim(s) 13, drawn to an antibody.

Group III, claim(s) 17, drawn to a method of treating or preventing a condition using the polynucleotides or polypeptides of Group I.

Group IV, claim(s) 18-19, drawn to methods of diagnosis using the polypeptides and polynucleotides of Group I.

Group V, claim(s) 20 and 23, drawn to a method of identifying a binding partner for the polypeptides of Group I.

Group VI, claim(s) 22, drawn to a method of identifying biological activity using the polynucleotides of Group I.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: SEQ ID NO. 11 is known in the prior art, therefore the claims do not recite a special technical feature and are not linked by a single inventive concept. In addition, under Unity of Invention rules, applicant is allowed one method of making and one method of use with a product. A method of use for both polynucleotides and polypeptides is included in Group I. Groups II-VI recite additional methods of use.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows: each nucleotide sequence and the polypeptide sequence encoded thereby (i.e. each sequence represented by SEQ ID Y and its corresponding SEQ ID X) is considered a separate species.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each sequence represents a unique chemical entity. In addition, SEQ ID NO. 11 is known, therefore the nucleotide sequences claimed do not relate to a single inventive concept.